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INTRODUCTION 
 
Content 
 
The purpose of this report is to provide an estimate of cancer incidence for each of the 351 cities 
and towns of Massachusetts for the five-year time period 2011 through 2015.  For each city and 
town, Standardized Incidence Ratios (SIRs) are presented for twenty-three types of invasive 
cancer and for all invasive cancer types combined.  These ratios compare the cancer incidence 
experience of each city or town with the cancer experience of the state as a whole.  The method 
involves comparing the number of cases that were observed for a city or town to the number of 
cases that would be expected if the city or town had the same cancer rates as the state as whole.  
The report is organized into the following sections: 
 
METHODS provides a detailed explanation of the data collection, data processing, and 
statistical techniques employed in this report. 
 
TABLES present data for selected types of cancer by city/town and sex. 
 
APPENDIX I provides a listing of International Classification of Diseases for Oncology 
codes used in the preparation of this report. 
 
APPENDIX II provides selected resources for information on cancer. 
 
APPENDIX III describes the Massachusetts Department of Public Health’s current cancer 
control initiatives, and provides links to bureaus within the department that address some 
aspect of cancer.  Links to resources for publications are also provided. 
 
Comparison with Previous Reports 
 
This report updates previous annual reports published by the Massachusetts Cancer Registry 
(MCR).   It is available on line at http://www.mass.gov/dph/mcr.  For questions about the report, 
contact the MCR at: 
  
 Massachusetts Cancer Registry 
 Office of Data Management and Outcomes Assessment 
Office of Population Health 
 Massachusetts Department of Public Health 
 250 Washington Street, 6
th
 floor 
 Boston, MA 02108-4619 
telephone 617-624-5642; fax 617-624-5695  
 
The preceding report, Cancer Incidence in Massachusetts 2010-2014:  City and Town 
Supplement, included data for diagnosis years 2010 through 2014.  This report contains data for 
the diagnosis years 2011 through 2015.  There have been no changes in this report’s format from 
the previous report.   
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METHODS 
 
Data Sources 
 
Cancer Incidence 
 
The MCR collects reports of newly diagnosed cancer cases from health care facilities and 
practitioners throughout Massachusetts. Facilities that  reported the 2011-2015 diagnoses that 
comprise this report  include 69 Massachusetts  acute care hospitals, 20 independent laboratories, 
10 surgical centers, 5  radiation/oncology centers, 10 medical practice associations, 4 endoscopy 
centers, and approximately 500 private practice physicians. The MCR signed the modified 
National Data Exchange Agreement on March 28, 2013. This is a single agreement that allows 
participating states to exchange data on cases diagnosed or treated in other areas.  Together with 
states participating in the agreement, and states with individual agreements, the MCR now has 
reciprocal reporting agreements with 42 states and with the District of Columbia, the Virgin 
Islands, Puerto Rico and Guam to obtain data on Massachusetts residents diagnosed out of state. 
Currently the MCR collects information on in situ and invasive cancers and benign tumors of the 
brain and associated tissues. The MCR does not collect information on basal and squamous cell 
carcinomas of the skin. 
 
The MCR also collects information from reporting hospitals on cases diagnosed and treated in 
staff physician offices when this information is available. Not all hospitals report this type of 
case, however, some hospitals report such cases as if the patients had been diagnosed and treated 
by the hospital directly. Collecting these types of data makes the MCR’s overall case 
ascertainment more complete. Some cancer types that may be reported to the MCR in this manner 
are melanoma, prostate, colon/rectum, and oral cancers. 
 
In addition, the MCR identifies previously unreported cancer cases through review of death 
certificate data to further improve case completeness. This process is referred to as death 
clearance and identifies cancers mentioned on death certificates that were not previously reported 
to the MCR. In some instances, the MCR obtains additional information on these cases through 
follow-up activities with hospitals, nursing homes, hospice residences, and physicians’ offices. In 
other instances, a cancer-related cause of death recorded on a Massachusetts death certificate is 
the only source of information for a cancer case. Thus these “death certificate only” cancer 
diagnoses are poorly documented and have not been confirmed by review of clinical and 
pathological information. Such cases are included in this report, but they comprise less than 3% 
of all cancer cases. 
 
All case reports that provided the basis for this report were coded following the International 
Classification of Diseases for Oncology, Third Edition (ICD-O-3), which was implemented in 
North America with cases diagnosed as of January 1, 2001. (1)  Please see Appendix A for the 
classification of cancers by ICD-O3 codes. 
 
Each year, the North American Association of Central Cancer Registries (NAACCR) reviews 
cancer registry data for quality, completeness, and timeliness.  For 2011-2015, the MCR’s annual 
case count was estimated by NAACCR to be more than 95% complete for each year. The MCR 
has achieved the gold standard for this certification element as well as for six other certification 
elements for each case year since 1997.  
 
The Massachusetts cancer cases presented in this report are primary cases of cancer diagnosed 
among Massachusetts residents during 2011-2015 and reported to the MCR as of June 26, 2018.  
These data include some additional cases diagnosed in 2010-2014 that were not counted in the 
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previous report,   Cancer Incidence in Massachusetts 2010-2014:  City and Town Supplement.   
The lag time between this report and the annual statewide report of 2011-2015 cancer cases is due 
to the fact that data for this city and town report needed to be cleaned for accuracy of residence 
within Massachusetts.  The statewide report presented data at the state level and did not require 
such accuracy of city and town of residence.  The numbers presented in this report may change 
slightly in future reports, reflecting late reported cases or corrections based on subsequent details 
from the reporting facilities.  Such changes might result in slight differences in numbers and rates 
in future reports of MCR data, reflecting the nature of population-based cancer registries that 
receive case reports on an ongoing basis. 
Massachusetts cancer cases presented in this report are primary cases of cancer diagnosed among 
Massachusetts residents during 2011-2015.  The Massachusetts data presented include invasive 
cancers only (except cancer of the urinary bladder, where in situ cancers are also included).  
Invasive cancers have spread beyond the layer of cells where they started and have the potential 
to spread to other parts of the body.  In situ cancers are neoplasms diagnosed at the earliest stage, 
before they have spread, when they are limited to a small number of cells and have not invaded 
the organ itself.  Typically, published incidence rates do not combine invasive and in situ cancers 
due to differences in the biologic significance, survival prognosis and types of treatment of the 
tumors.  Cancer of the urinary bladder is the only exception, due to the specific nature of the 
diagnostic techniques and treatment patterns. 
  
Presentation of Data 
 
Each city and town in Massachusetts is listed alphabetically in the TABLES section.  The 
observed number of cases, the expected number of cases, the standardized incidence ratios, and 
95% confidence intervals are presented for twenty-three main types of cancer and for all cancer 
types combined.  The “all cancers combined” category includes the twenty-three main types 
presented in this report and other malignant neoplasms.  This category is meant to provide a 
summary of the total cancer experience in a community.  As different cancers have different 
causes, this category does not reflect any specific risk factor that may be important for this 
community. 
 
Observed and Expected Case Counts 
 
The observed case count (Obs) for a particular type of cancer in a city/town is the actual number 
of newly diagnosed cases among residents of that city/town for a given time period.  
 
A city/town’s expected case count (Exp) for a certain type of cancer for this time period is a 
calculated number based on that city/town’s population distribution2 (by sex and among eighteen 
age groups) for the time period 2011-2015, and the corresponding statewide average annual age-
specific incidence rates.  The source of the city and town population data for the 2011-2015 
period was the US Census American Community Survey (ACS), an ongoing national survey that 
provides demographic estimates on a yearly basis.
2
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Standardized Incidence Ratios 
 
A Standardized Incidence Ratio (SIR) is an indirect method of adjustment for age and sex that 
describes in numerical terms how a city/town’s cancer experience in a given time period 
compares with that of the state as a whole. 
 An SIR of exactly 100 indicates that a city/town’s incidence of a certain type of cancer is 
equal to that expected based on statewide average age-specific incidence rates. 
 An SIR of more than 100 indicates that a city/town’s incidence of a certain type of cancer 
is higher than expected for that type of cancer based on statewide average annual age-
specific incidence rates.  For example, an SIR of 105 indicates that a city/town’s cancer 
incidence is 5% higher than expected based on statewide average annual age-specific 
incidence rates. 
 An SIR of less than 100 indicates that a city/town’s incidence of a certain type of cancer is 
lower than expected based on statewide average age-specific incidence rates.  For 
example, an SIR of 85 indicates that a city/town’s cancer incidence is 15% lower than 
expected based on statewide average annual age-specific incidence rates.  
 
Statistical Significance and Interpretation of SIRs 
 
The interpretation of the SIR depends on both how large it is and how stable it is.  Stability in this 
context refers to how much the SIR changes when there are small increases or decreases in the 
observed or expected number of cases.  Two SIRs may have the same size but not the same 
stability.  For example, an SIR of 150 may represent 6 observed cases and 4 expected cases, or 
600 observed cases and 400 expected cases.  Both represent a 50 percent excess of observed 
cases.  However, in the first instance, one or two fewer cases would change the SIR a great deal, 
whereas in the second instance, even if there were several fewer cases, the SIR would only 
change minimally.  When the observed and expected numbers of cases are relatively small, their 
ratio is easily affected by one or two cases.  Conversely, when the observed and expected 
numbers of cases are relatively large, the value of the SIR is stable. 
 
A 95 percent confidence interval (CI) has been presented for each SIR in this report (when the 
observed number of cases is at least 5), to indicate if the observed number of cases is significantly 
different from the expected number, or if the difference is most likely due to chance.  A 
confidence interval is a range of values around a measurement that indicates the precision of the 
measurement.  In this report, the 95% confidence interval is the range of estimated SIR values 
that has a 95% probability of including the true SIR for a specific city or town.  If the 95% 
confidence interval range does not include the value 100.0, then the number of observed cases is 
significantly different from the expected number of cases.  “Significantly different” means there 
is at most a 5% chance that the difference between the number of observed and expected cancer 
cases is due solely to chance alone.  If the confidence interval does contain the value 100.0, there 
is no significant difference between the observed and expected numbers.  Statistically, the width 
of the interval reflects the size of the population and the number of events; smaller populations 
and smaller observed numbers of cases yield less precise estimates that have wider confidence 
intervals.  Wide confidence intervals indicate instability, meaning that small changes in the 
observed or expected number of cases would change the SIR a great deal. 
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Examples: 
 SIR = 137.0; 95% CI (101.6 - 180.6) – the confidence interval does not include 100.0 and the 
interval is above 100.0, indicating that the number of observed cases is statistically 
significantly higher than the expected number. 
 
 SIR = 71.0; 95% CI (56.2 – 88.4) – the confidence interval does not include 100.0 and the 
interval is below 100.0, indicating that the number of observed cases is statistically 
significantly lower than the expected number. 
 
 SIR = 108.8 95% CI (71.0-159.4) – the confidence interval DOES include 100.0 indicating 
that the number of observed cases is NOT statistically significantly different from what is 
expected, and the difference is likely due to chance.  When the interval includes 100.0, then 
the true SIR may be 100.0. 
 
Example of Calculation of an SIR and Its Significance 
 
 
SIR = 
OBSERVED CASES 
X 100 
 EXPECTED CASES 
 
The following example illustrates the method of calculation for a hypothetical town for one type 
of cancer and one sex for the years 2007-2011: 
 
 
 Town X State Town X Town X 
 Age  Age-Specific Expected Observed 
 Group Population Incidence Rate Cases Cases 
 (A) (B) (C) = (A) x (B) (D) 
 00-04 74,657 0.0001 7.47 11 
 05-09 134,957 0.0002 26.99 25 
 10-14 54,463 0.0005 27.23 30 
 15-19 25,136 0.0015 37.70 40 
 20-24 17,012 0.0018 30.62 30 
    UP TO 
 85+ 6,337 0.0010 6.34 8 
  Total:     136.35 144 
 
 
SIR = 
Observed Cases 
X 100 = 
(column D total) 
X 100 = 
144 
X 100 ≈ 106 
Expected Cases (column C total) 136.35 
 
Thus the SIR for this type of cancer in Town X is 106, indicating that the incidence of this cancer 
in Town X is 6% higher than the corresponding statewide average incidence for this cancer.  
However, the range for the 95% confidence interval (89.1-124.3) (calculation not shown) 
indicates that the true value may be as low as 89.1 or as high as 124.3  Also, since the range 
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includes the value 100, it means that the observed number of cases is not statistically significantly 
higher or lower than what is expected. 
 
Whenever the number of observed cases is less than five, the corresponding SIR is neither 
calculated nor tested for statistical significance. This is indicated with an (nc) (“not calculated”).  
However, the number of observed and expected cases is shown in these circumstances. 
 
Notes about Data Interpretation 
 
The SIR is a useful indication of the disease categories that have relatively high or low rates for a 
given community.  These statistics, however, should be used with care.  Such statistics provide a 
starting point for further research and investigation into a possible health problem, but they do not 
by themselves confirm or deny the existence of a particular health problem.  Many factors 
unrelated to disease causation may contribute to an elevated SIR, including demographic factors, 
changes in diagnostic techniques, and changes in data collection or recording methods over time, 
as well as the natural variation in disease occurrence.   
 
When reviewing the data tables, it is important to keep in mind that an SIR compares the 
observed cancer incidence in a particular community with the expected incidence based on 
statewide average annual age-specific incidence rates.  This means that valid comparisons can 
only be made between a community and the state as a whole.  SIRs for different cities and towns 
CANNOT and SHOULD NOT be compared to each other.  (Comparisons between two communities 
would be valid only if there were no differences in the age and sex distributions of the two 
communities’ populations.) 
 
Another point to keep in mind when reviewing these data is the large number of statistical tests 
being performed in this report.  For each of the 351 cities and towns, we evaluate 18 types of 
cancer that can occur in both males and females, 3 types that occur only in females and 2 types 
that occur only in males, resulting in 41 gender/cancer categories.  This results in 14,391 possible 
calculations (351 cities and towns x 41 gender cancer categories).  Note that gender/cancer 
categories with less than 5 observed cases are not evaluated for statistical significance, so the 
actual numbers of tests is slightly lower than 14,391. This is important for the reader because 
when multiple significance tests are performed, some will result in a significant finding due to 
chance alone. Based on the number of calculations in this report, we expect 720 significant 
findings to be due to chance alone.  Half of these would be significant excesses (360) and half 
would be significant deficits (360).  There are statistical techniques that can be used to reduce this 
number, however use of these techniques leads to the opposite problem – true significant 
differences that may be missed.  We choose to err on the side of caution and identify more 
significant results, knowing that some will be due to chance alone.   
 
Data Limitations 
 
It should be emphasized that apparent increases or decreases in cancer incidence over time might 
reflect changes in diagnostic methods or case reporting rather than true changes in cancer 
incidence.  Four other limitations must be considered when interpreting cancer incidence data for 
Massachusetts cities and towns:  under-reporting in areas close to neighboring states; under-
reporting for cancers that may not be diagnosed in hospitals; cases being assigned to incorrect 
cities/towns; and standardized incidence ratios based on small numbers of cases. 
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Border Areas and Neighboring States 
 
Some areas of Massachusetts appear to have low cancer incidence, but this may be due to loss of 
Massachusetts resident cases who are diagnosed in neighboring or other states and not reported to 
the MCR. The MCR has reciprocal reporting agreements with 42 states and with the District of 
Columbia, the Virgin Islands, Puerto Rico, and Guam. 
 
Cases Diagnosed in Non-Hospital Settings 
 
During the time period covered by this report, the MCR’s primary information source for most 
newly diagnosed cases of cancer was hospitals. In addition the MCR collected information from 
reporting hospitals on cases diagnosed and treated in staff physician offices, when this 
information was available. Other reporting sources include dermatologists and dermatopathology 
laboratories, urologists’ offices and a general laboratory. Some types of cancer in this report may 
be under-reported because they are diagnosed primarily by private physicians, private 
laboratories, health maintenance organizations, radiotherapy centers that escape identification 
systems used by hospitals.  The most common types of cancer diagnosed or treated outside of the 
hospital include melanoma and prostate cancer.   The exact extent of this under-reporting has not 
been determined, but cases included in this report represent the great majority of cases statewide 
and provide an essential basis for evaluating statewide cancer incidence patterns. 
 
 
City/Town Misassignment 
 
In accordance with standard central cancer registry procedures, each case reported to the MCR 
ideally should be assigned to the city/town in which the patient lived at the time of diagnosis, 
based on the address provided by the reporting hospital.  In practice, however, a patient may 
provide the hospital with his/her mailing address (e.g., a post office box located outside the 
patient’s city/town of residence); a business address; a temporary address (e.g., the patient is 
staying with a relative while receiving treatment and reports the relative’s address as his/her 
own); or a locality or post office name (e.g., “Chestnut Hill” rather than “Boston,” “Brookline,” 
or “Newton”).  In addition, if a patient has moved since being diagnosed, the hospital may report 
the patient’s current address.  Because of the large number of cases reported to the MCR, and 
because data are reported to the MCR via electronic media, most city/town case assignments are 
performed by an automated computer process.  This simplified matching process may misassign 
some cases based on the reported locality name.  When MCR staff become aware of such 
misassignments, they manually correct the errors.  Furthermore, in order to minimize such errors, 
cases from fifty geographic localities prone to city/town misassignment are reviewed manually. 
 
Small Numbers of Cases 
 
Standardized incidence ratios based on small numbers of cases result in estimates that are very 
unstable.  This situation is common when the population of a city or town is small or if the 
particular cancer type is rare.  SIRs and statistical significance are not calculated when the 
number of observed cases for a specific category is less than five.  In these instances, the 
observed and expected cases are presented in the tables for qualitative comparison only. 
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APPENDIX I:  INTERNATIONAL CLASSIFICATION OF DISEASES FOR ONCOLOGY (THIRD 
EDITION) 
CODES USED FOR THIS REPORT 
1 
Cancer Site/Type
2 
ICD-O-3
 
Brain & Other  
Nervous System 
C70.0-C72.9 
except 9050-9055, 9140,  
9590-9992 
 
Breast 
 (includes in situ) 
C50.0 – C50.9 
except 9050-9055, 9140,  
9590-9992 
 
Bronchus & Lung C34.0 – C34.9  
except 9050-9055, 9140,  
9590-9992 
 
Cervix Uteri C53.0 – C53.9 
except 9050-9055, 9140,  
9590-9992 
 
Colon/ Rectum C18.0-C18.9, 
C19.9, C20.9, 
C26.0 
except 9050-9055, 9140,  
9590-9992 
 
Corpus Uteri  
& Uterus, NOS 
C54.0 – C54.9, 
C55.9 
except 9050-9055, 9140,  
9590-9992 
 
Esophagus C15.0-C15.9 
except 9050-9055, 9140,  
9590-9992 
 
Hodgkin Lymphoma C00.00 – C80.9  
(includes 9650-9667) 
 
Kidney &  
Renal Pelvis
3 
C64.9, C65.9 
except 9050-9055, 9140,  
9590-9992 
Larynx C32.0 – C32.9 
except 9050-9055, 9140,  
9590-9992 
Leukemia 
 
 
 
 
 
 
 
C00.0 – C80.9 
(includes 9733, 9742, 
9800-9801, 9805-9809, 9820, 9826, 9831-9836, 9840, 9860-9861, 
9863, 9865-9867, 9869-9876, 9891, 9895-9898, 9910-9911, 9920, 
9930-9931, 9940, 9945-9946, 9948, 9963-9964) 
 
C42.0, C42.1, C42.4 
(includes 9811-9818, 9823, 9827, 9837) 
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Liver and Intrahepatic 
Bile Ducts 
C22.0, C22.1 
except 9050-9055, 9140,  
9590-9992 
Melanoma of Skin C44.0 – C44.9 
(includes 8720-8790) 
Multiple Myeloma C00.0-C80.9 
(includes 9731, 9732, 
9734) 
 
Non – Hodgkin  
Lymphoma 
C02.4, C098, C099, C111, C142, C379, C422, C770-C779 
(includes 9590-9597, 9670-9671, 9673, 9675, 9678-9680, 
9684, 9687-9691, 9695, 9698-9702, 9705, 9708-9709, 9712, 
9714-9719, 9724-9729, 9735, 9737-9738, 9811-9818, 9823, 
9827, 9837) 
 
All sites except C02.4, C90.8-C09.9, C11.1, C14.2, C37.9, 
C42.2, C77.0-C77.9 (includes  9590-9597, 9670-9671, 9673, 
9675, 9678-9680, 9684, 9687, 9688, 9689-9691, 9695, 9698-
9702, 9705, 9708-9709, 9712, 9714-9719, 9724-9729, 9735, 
9737, 9738) 
 
All sites except C02.4, c09.8-C09.9, C11.1, C14.2, C37.9, 
C42.0-C42.2, c42.4, C77.0-C77.9 (includes 9811-9818, 
9823, 9827, 9837) 
  
 
Oral Cavity  
& Pharynx 
C00.0 – C14.8 
except 9050-9055, 9140,  
9590-9992 
 
Ovary C56.9 
except 9050-9055, 9140,  
9590-9992 
 
Pancreas C25.0 – C25.9 
except 9050-9055, 9140,  
9590-9992 
 
Prostate 
 
 
C61.9 
except 9050-9055, 9140,  
9590-9992 
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Stomach 
 
C16.0 – C16.9 
except 9050-9055, 9140,  
9590-9992 
 
Testis C62.0 – C62.9 
except 9050-9055, 9140,  
9590-9992 
 
Thyroid C73.9 
except 9050-9055, 9140,  
9590-9992 
 
Urinary Bladder 
(includes in situ) 
C67.0 – C67.9 
except 9050-9055, 9140,  
9590-9992 
 
 
 
1International Classification of Diseases for Oncology, 3d Ed. (includes codes added since publication) 
2 Only invasive cancers (those with invasive behaviors) are included in this publication except Bladder, Urinary, which 
includes invasive and in situ behaviors.  Non-invasive (in situ) cancers are not included. 
3 Massachusetts hospital coding conventions may have assigned some cases to a “not otherwise specified” site category 
that is not included in this cancer type. 
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APPENDIX II:  SELECTED RESOURCES FOR 
INFORMATION ON CANCER 
 
This Appendix contains a listing of selected resources for additional information on cancer. 
Cancers are complex diseases, many of which have multiple factors that may contribute to their 
development.   
 
For information on cancer risk factors or prevention, you may wish to contact the following: 
Cancer Information Service (National Cancer Institute): 1-800-4-CANCER (1-800-422-6237) 
Cancer Response Line (American Cancer Society): 1-800-ACS-2345 (1-800-227-2345) 
 
In addition, the following selected Internet websites provide information on cancer.  Many of 
these also provide links to other sites (not listed) which may be of interest. 
Massachusetts Department of Public Health:  http://www.mass.gov/dph 
 
American Cancer Society:  http://www.cancer.org 
 
Centers for Disease Control and Prevention 
 Home Page:  http://www.cdc.gov 
 Cancer Prevention and Control Program:  http://www.cdc.gov/cancer 
Fruits and Veggies More Matters™ Campaign (nutrition – formerly 5-A-Day Program):   
http://www.fruitsandveggiesmorematters.org/ 
 
National Cancer Institute 
 Information:  http://www.cancer.gov 
 Cancer Literature in PubMed:  
https://www.ncbi.nlm.nih.gov/pubmed?cmd_current=Limits&pmfilter_Subsets=Cancer 
 Surveillance, Epidemiology, and End Results (SEER) Program data:  http://seer.cancer.gov 
 
Your Cancer Risk (Siteman Cancer Center at Barnes-Jewish Hospital and Washington 
University School of Medicine; formerly at Harvard Center for Cancer Prevention):  
http://www.yourdiseaserisk.wustl.edu 
 
OncoLink (Abramson Cancer Center of the University of Pennsylvania): 
http://www.oncolink.org 
 
Cancerquest (Emory University – Winship Cancer Institute):  www.cancerquest.org 
 
National Coalition for Cancer Survivorship:  http://www.canceradvocacy.org 
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APPENDIX III:  MDPH CANCER PREVENTION AND CONTROL INITIATIVES  
 
The Massachusetts Department of Public Health is working to reduce the incidence and mortality 
of cancer in the Commonwealth.  Partnerships between MDPH programs, researchers, healthcare 
providers and nonprofit organizations collect information about cancer, lead quality improvement 
projects, coordinate evidenced-based workshops for managing living with chronic disease 
(including cancer), provide education for health professionals and bring shared messages to the 
public. Our collaborated efforts focus on reducing cancer risk, incidence and mortality through 
healthy lifestyles, early diagnosis, and increased access to care. The Department’s programs 
address the impact of tobacco, alcohol, nutrition, and physical activity on cancer prevention, 
along with environmental and occupational hazards for cancer. Throughout all of our efforts there 
is an emphasis on reducing disparate health outcomes and unequal access to cancer care. 
 
MDPH Bureaus and Programs:  
Bureau of Environmental Health, www.mass.gov/dph/environmental_health  
Bureau of Substance Abuse Services, www.mass.gov/dph/bsas 
Comprehensive Cancer Prevention and Control Program, www.mass.gov/compcancer 
Men’s Health/Women’s Health/Care Coordination Program 
Tobacco Cessation and Prevention Program, www.mass.gov/dph/mtcp  
Occupational Health Surveillance Program, www.mass.gov/dph/ohsp 
Office of Elder Affairs www.mass.gov/elders/ 
Oral Health Program, www.mass.gov/dph/oralhealth  
Division of Prevention and Wellness www.mass.gov/dph/healthpromotion 
 
MDPH publications on cancer prevention and screening are available at the Massachusetts Health 
Promotion Clearinghouse, www.maclearinghouse.com.  
 
Massachusetts Cancer Registry Publications are available through the Massachusetts Cancer 
Registry, telephone: 617-624-5642 and on the web at www.mass.gov/dph/mcr. 
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Abington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 14.4 97.5 (53.3-163.6)   Male 12 9.9 121.0 (62.5-211.4) 
Female 7 5.9 119.1 (47.7-245.4)   Female 8 8.8 91.0 (39.2-179.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 3.0 nc (nc-nc)   Male 7 3.2 220.2 (88.2-453.8) 
Female 1 3.0 nc (nc-nc)   Female 3 2.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.5 nc (nc-nc)   Male 4 8.7 nc (nc-nc) 
Female 59 72.4 81.5 (62.0-105.1)   Female 6 8.4 71.6 (26.2-155.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 7.8 89.2 (35.7-183.7) 
Female 3 2.4 nc (nc-nc)   Female 8 3.9 206.9 (89.1-407.6) 
Colon / Rectum            Ovary     
Male 22 15.9 138.1 (86.5-209.1)             
Female 20 16.7 120.0 (73.3-185.4)   Female 5 6.2 80.8 (26.1-188.7) 
Esophagus            Pancreas     
Male 6 4.0 151.7 (55.4-330.2)   Male 7 5.6 125.3 (50.2-258.2) 
Female 0 1.2 nc (nc-nc)   Female 3 6.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.3 nc (nc-nc)   Male 42 48.8 86.1 (62.1-116.4) 
Female 2 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 17 9.4 181.2 (105.5-290.1)   Male 4 3.5 nc (nc-nc) 
Female 7 5.7 123.4 (49.4-254.3)   Female 4 2.4 nc (nc-nc) 
Larynx            Testis     
Male 3 2.4 nc (nc-nc)   Male 2 2.5 nc (nc-nc) 
Female 6 0.8 741.1 (270.6-1613.1)             
Leukemia            Thyroid     
Male 5 6.0 83.2 (26.8-194.1)   Male 3 4.4 nc (nc-nc) 
Female 6 4.9 121.7 (44.4-264.8)   Female 16 13.9 115.4 (65.9-187.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 5.7 105.4 (38.5-229.4)             
Female 2 2.1 nc (nc-nc)   Female 18 17.2 104.7 (62.0-165.5) 
Lung and Bronchus            All Sites / Types     
Male 35 26.5 132.3 (92.2-184.0)   Male 216 198.1 109.0 (95.0-124.6) 
Female 41 32.0 128.3 (92.0-174.0)   Female 245 235.5 104.0 (91.4-117.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
10 
Acton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 19 21.6 87.9 (52.9-137.3)   Male 17 15.1 112.3 (65.4-179.8) 
Female 4 7.9 nc (nc-nc)   Female 16 12.4 128.9 (73.6-209.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 4.7 128.4 (46.9-279.5)   Male 3 4.8 nc (nc-nc) 
Female 3 3.9 nc (nc-nc)   Female 4 3.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.8 nc (nc-nc)   Male 16 13.4 119.8 (68.5-194.6) 
Female 118 103.5 114.1 (94.4-136.6)   Female 8 11.6 69.2 (29.8-136.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 12.2 81.8 (39.2-150.5) 
Female 3 3.6 nc (nc-nc)   Female 5 5.3 94.9 (30.6-221.5) 
Colon / Rectum            Ovary     
Male 24 25.1 95.5 (61.2-142.1)             
Female 20 24.2 82.8 (50.5-127.8)   Female 8 8.6 93.0 (40.0-183.2) 
Esophagus            Pancreas     
Male 6 6.0 100.8 (36.8-219.4)   Male 7 8.5 82.6 (33.1-170.2) 
Female 3 1.6 nc (nc-nc)   Female 8 8.2 97.2 (41.9-191.6) 
Hodgkin Lymphoma            Prostate     
Male 1 1.8 nc (nc-nc)   Male 79 72.3 109.3 (86.5-136.2) 
Female 1 1.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 14.5 48.4 (19.4-99.8)   Male 3 5.4 nc (nc-nc) 
Female 10 7.8 127.9 (61.2-235.2)   Female 1 3.3 nc (nc-nc) 
Larynx            Testis     
Male 3 3.5 nc (nc-nc)   Male 3 3.5 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 9.2 86.7 (37.4-170.9)   Male 7 7.0 100.7 (40.3-207.4) 
Female 9 6.7 134.3 (61.3-255.0)   Female 20 20.3 98.5 (60.1-152.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 8.7 68.7 (25.1-149.6)             
Female 2 2.7 nc (nc-nc)   Female 14 22.7 61.6 (33.7-103.4) 
Lung and Bronchus            All Sites / Types     
Male 18 38.9 46.3 (27.4-73.1)   Male 257 299.7 85.7 (75.6-96.9) 
Female 27 42.2 64.0 (42.2-93.1)   Female 307 327.4 93.8 (83.6-104.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
11 
Acushnet 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 20 13.4 148.8 (90.9-229.9)   Male 4 8.5 nc (nc-nc) 
Female 4 4.3 nc (nc-nc)   Female 5 5.8 86.3 (27.8-201.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.4 nc (nc-nc)   Male 3 2.7 nc (nc-nc) 
Female 2 1.9 nc (nc-nc)   Female 4 2.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.4 nc (nc-nc)   Male 9 7.4 121.0 (55.2-229.7) 
Female 50 47.8 104.6 (77.6-137.9)   Female 13 5.9 221.2 (117.7-378.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 6.0 nc (nc-nc) 
Female 0 1.5 nc (nc-nc)   Female 1 2.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 18 13.7 131.5 (77.9-207.9)             
Female 13 12.0 108.0 (57.4-184.7)   Female 5 4.1 123.3 (39.7-287.6) 
Esophagus            Pancreas     
Male 4 3.2 nc (nc-nc)   Male 4 4.9 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 7 4.5 155.3 (62.2-319.9) 
Hodgkin Lymphoma            Prostate     
Male 2 0.9 nc (nc-nc)   Male 44 36.5 120.6 (87.6-162.0) 
Female 0 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 7.3 68.4 (22.1-159.7)   Male 1 3.1 nc (nc-nc) 
Female 4 3.8 nc (nc-nc)   Female 0 1.7 nc (nc-nc) 
Larynx            Testis     
Male 3 1.8 nc (nc-nc)   Male 1 1.7 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 5.4 nc (nc-nc)   Male 1 3.3 nc (nc-nc) 
Female 8 3.3 240.9 (103.7-474.7)   Female 8 8.3 96.0 (41.3-189.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 4.5 nc (nc-nc)             
Female 1 1.4 nc (nc-nc)   Female 6 11.0 54.5 (19.9-118.6) 
Lung and Bronchus            All Sites / Types     
Male 30 22.8 131.3 (88.6-187.5)   Male 178 163.8 108.7 (93.3-125.9) 
Female 22 23.2 95.0 (59.5-143.9)   Female 165 159.9 103.2 (88.0-120.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
12 
Adams 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 9.9 70.8 (28.4-145.9)   Male 5 6.1 81.6 (26.3-190.5) 
Female 3 3.8 nc (nc-nc)   Female 3 5.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.8 nc (nc-nc)   Male 2 2.0 nc (nc-nc) 
Female 3 1.6 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 6 5.4 110.7 (40.4-240.9) 
Female 35 41.8 83.8 (58.4-116.6)   Female 7 5.1 136.2 (54.6-280.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 4.5 112.0 (36.1-261.4) 
Female 1 1.3 nc (nc-nc)   Female 0 2.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 13 10.0 129.8 (69.1-222.0)             
Female 8 10.7 75.0 (32.3-147.7)   Female 1 3.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 2.4 nc (nc-nc)   Male 6 3.6 167.0 (61.0-363.6) 
Female 0 0.7 nc (nc-nc)   Female 7 3.9 178.9 (71.7-368.7) 
Hodgkin Lymphoma            Prostate     
Male 2 0.7 nc (nc-nc)   Male 22 29.6 74.3 (46.6-112.5) 
Female 2 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 5.5 109.9 (40.1-239.3)   Male 2 2.3 nc (nc-nc) 
Female 2 3.4 nc (nc-nc)   Female 3 1.5 nc (nc-nc) 
Larynx            Testis     
Male 2 1.4 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 3.9 154.7 (56.5-336.6)   Male 3 2.3 nc (nc-nc) 
Female 2 3.0 nc (nc-nc)   Female 6 7.3 81.7 (29.8-177.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 3.4 nc (nc-nc)             
Female 0 1.3 nc (nc-nc)   Female 6 9.5 63.2 (23.1-137.5) 
Lung and Bronchus            All Sites / Types     
Male 20 17.1 116.7 (71.3-180.2)   Male 125 123.1 101.6 (84.5-121.0) 
Female 20 20.0 100.1 (61.1-154.7)   Female 118 139.8 84.4 (69.9-101.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
13 
Agawam 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 34 35.2 96.7 (66.9-135.1)   Male 20 22.1 90.6 (55.3-140.0) 
Female 8 13.7 58.6 (25.2-115.4)   Female 15 18.0 83.5 (46.7-137.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 6.3 78.8 (25.4-183.8)   Male 10 7.1 139.9 (67.0-257.3) 
Female 5 5.7 87.2 (28.1-203.4)   Female 7 6.3 111.2 (44.5-229.1) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.2 nc (nc-nc)   Male 20 19.5 102.5 (62.6-158.4) 
Female 141 143.2 98.4 (82.9-116.1)   Female 20 18.3 109.4 (66.8-169.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 24 16.3 147.2 (94.3-219.0) 
Female 6 4.5 132.5 (48.4-288.4)   Female 12 8.0 149.6 (77.2-261.3) 
Colon / Rectum            Ovary     
Male 38 36.1 105.2 (74.5-144.5)             
Female 34 38.8 87.7 (60.7-122.5)   Female 7 12.5 56.1 (22.5-115.6) 
Esophagus            Pancreas     
Male 3 8.8 nc (nc-nc)   Male 8 12.9 61.9 (26.6-121.9) 
Female 4 2.6 nc (nc-nc)   Female 17 14.4 118.2 (68.8-189.2) 
Hodgkin Lymphoma            Prostate     
Male 3 2.3 nc (nc-nc)   Male 87 106.1 82.0 (65.7-101.2) 
Female 2 2.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 28 19.8 141.2 (93.8-204.0)   Male 8 8.2 97.9 (42.2-192.9) 
Female 11 11.6 94.7 (47.2-169.5)   Female 4 5.5 nc (nc-nc) 
Larynx            Testis     
Male 7 5.1 136.7 (54.8-281.7)   Male 1 4.0 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 16 13.8 115.7 (66.1-188.0)   Male 3 8.4 nc (nc-nc) 
Female 7 10.7 65.3 (26.1-134.5)   Female 20 25.0 80.0 (48.8-123.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 13 12.3 106.1 (56.4-181.5)             
Female 5 4.5 111.3 (35.9-259.8)   Female 27 32.6 82.8 (54.5-120.4) 
Lung and Bronchus            All Sites / Types     
Male 72 61.5 117.0 (91.5-147.3)   Male 432 442.0 97.7 (88.7-107.4) 
Female 88 69.7 126.3 (101.3-155.6)   Female 481 490.0 98.2 (89.6-107.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
14 
Alford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 1.1 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 5 3.3 150.6 (48.5-351.4)   Female 0 0.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 1.0 nc (nc-nc)             
Female 1 0.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 0 3.3 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.6 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 2 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.3 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 1.9 nc (nc-nc)   Male 3 12.8 nc (nc-nc) 
Female 0 1.7 nc (nc-nc)   Female 8 11.0 72.7 (31.3-143.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
15 
Amesbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 15 16.3 92.1 (51.5-151.9)   Male 6 11.1 53.9 (19.7-117.4) 
Female 11 6.8 160.9 (80.2-287.9)   Female 4 9.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 3.4 145.2 (46.8-339.0)   Male 2 3.5 nc (nc-nc) 
Female 4 3.1 nc (nc-nc)   Female 0 3.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.6 nc (nc-nc)   Male 17 9.8 172.9 (100.6-276.8) 
Female 78 81.0 96.3 (76.1-120.2)   Female 11 9.6 114.9 (57.3-205.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 8.7 114.3 (54.7-210.3) 
Female 1 2.7 nc (nc-nc)   Female 3 4.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 16 18.0 88.9 (50.8-144.4)             
Female 20 19.6 101.9 (62.2-157.5)   Female 6 6.9 87.3 (31.9-190.1) 
Esophagus            Pancreas     
Male 4 4.4 nc (nc-nc)   Male 7 6.3 111.4 (44.6-229.5) 
Female 2 1.4 nc (nc-nc)   Female 4 7.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 3 1.4 nc (nc-nc)   Male 70 53.8 130.0 (101.4-164.3) 
Female 0 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 10.5 nc (nc-nc)   Male 5 4.0 125.5 (40.5-293.0) 
Female 7 6.4 110.2 (44.1-227.0)   Female 1 2.8 nc (nc-nc) 
Larynx            Testis     
Male 2 2.6 nc (nc-nc)   Male 2 2.7 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 7.0 129.0 (58.9-245.0)   Male 7 5.0 139.6 (55.9-287.7) 
Female 5 5.4 91.9 (29.6-214.5)   Female 18 15.1 119.5 (70.8-188.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 8 6.4 124.8 (53.7-245.8)             
Female 0 2.3 nc (nc-nc)   Female 18 18.6 96.6 (57.2-152.7) 
Lung and Bronchus            All Sites / Types     
Male 29 29.1 99.7 (66.8-143.3)   Male 234 221.7 105.6 (92.5-120.0) 
Female 43 36.6 117.5 (85.1-158.3)   Female 248 265.2 93.5 (82.3-105.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
16 
Amherst 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 17 19.8 85.8 (50.0-137.4)   Male 11 12.7 86.7 (43.2-155.1) 
Female 3 7.6 nc (nc-nc)   Female 12 10.3 116.0 (59.9-202.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 5.2 nc (nc-nc)   Male 4 4.0 nc (nc-nc) 
Female 1 5.0 nc (nc-nc)   Female 1 3.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.7 nc (nc-nc)   Male 9 12.0 74.8 (34.1-142.0) 
Female 78 79.7 97.8 (77.3-122.1)   Female 8 10.7 74.9 (32.3-147.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 9.5 84.5 (36.4-166.6) 
Female 2 2.5 nc (nc-nc)   Female 4 4.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 18 20.5 87.7 (52.0-138.7)             
Female 23 21.1 108.8 (69.0-163.3)   Female 12 7.4 161.4 (83.3-282.0) 
Esophagus            Pancreas     
Male 2 5.0 nc (nc-nc)   Male 11 7.3 150.5 (75.0-269.3) 
Female 0 1.4 nc (nc-nc)   Female 8 7.8 103.0 (44.4-203.0) 
Hodgkin Lymphoma            Prostate     
Male 0 2.6 nc (nc-nc)   Male 43 60.1 71.5 (51.8-96.4) 
Female 0 2.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 11.4 nc (nc-nc)   Male 1 4.6 nc (nc-nc) 
Female 7 6.6 106.1 (42.5-218.6)   Female 0 3.0 nc (nc-nc) 
Larynx            Testis     
Male 2 2.9 nc (nc-nc)   Male 0 3.6 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 9.8 71.1 (28.5-146.5)   Male 5 5.3 94.7 (30.5-221.0) 
Female 2 6.8 nc (nc-nc)   Female 4 15.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 7.1 nc (nc-nc)             
Female 0 2.6 nc (nc-nc)   Female 17 18.5 91.8 (53.4-146.9) 
Lung and Bronchus            All Sites / Types     
Male 14 35.0 40.0 (21.8-67.1)   Male 171 261.4 65.4 (56.0-76.0) 
Female 19 38.8 49.0 (29.5-76.5)   Female 219 281.4 77.8 (67.8-88.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
17 
Andover 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 29 39.6 73.3 (49.0-105.2)   Male 27 25.4 106.2 (70.0-154.5) 
Female 12 12.5 95.8 (49.4-167.4)   Female 25 18.8 132.9 (86.0-196.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 7.4 107.4 (46.3-211.7)   Male 5 8.3 60.5 (19.5-141.3) 
Female 5 6.1 81.4 (26.2-189.9)   Female 13 6.0 216.7 (115.3-370.6) 
Breast            Non-Hodgkin Lymphoma     
Male 4 1.4 nc (nc-nc)   Male 30 22.5 133.5 (90.0-190.5) 
Female 170 156.3 108.7 (93.0-126.4)   Female 16 17.9 89.2 (51.0-144.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 17 19.1 88.9 (51.7-142.3) 
Female 3 5.3 nc (nc-nc)   Female 3 8.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 28 42.0 66.6 (44.2-96.3)             
Female 38 37.3 101.9 (72.1-139.9)   Female 11 13.1 84.2 (42.0-150.7) 
Esophagus            Pancreas     
Male 8 10.1 79.3 (34.1-156.2)   Male 14 14.7 95.3 (52.1-159.9) 
Female 7 2.5 280.6 (112.4-578.2)   Female 11 13.1 83.9 (41.8-150.2) 
Hodgkin Lymphoma            Prostate     
Male 1 2.6 nc (nc-nc)   Male 104 119.8 86.8 (71.0-105.2) 
Female 1 2.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 22 23.2 94.7 (59.3-143.4)   Male 6 9.3 64.2 (23.4-139.7) 
Female 11 12.0 91.5 (45.6-163.7)   Female 4 5.2 nc (nc-nc) 
Larynx            Testis     
Male 3 5.9 nc (nc-nc)   Male 8 4.6 173.1 (74.5-341.1) 
Female 2 1.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 18 15.8 114.0 (67.5-180.1)   Male 18 10.1 178.8 (105.9-282.6) 
Female 11 10.5 104.6 (52.1-187.2)   Female 45 29.7 151.4 (110.4-202.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 14.0 50.1 (20.1-103.2)             
Female 2 4.3 nc (nc-nc)   Female 22 34.7 63.4 (39.7-96.0) 
Lung and Bronchus            All Sites / Types     
Male 38 69.7 54.5 (38.6-74.8)   Male 429 505.3 84.9 (77.1-93.3) 
Female 41 67.0 61.2 (43.9-83.1)   Female 482 502.8 95.9 (87.5-104.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
18 
Aquinnah 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 4 2.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 0.4 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.1 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 0.6 nc (nc-nc)   Male 3 5.0 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 5 6.6 75.2 (24.2-175.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
19 
Arlington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 48 47.6 100.9 (74.4-133.8)   Male 24 30.3 79.2 (50.7-117.8) 
Female 14 19.7 71.0 (38.8-119.1)   Female 29 26.8 108.1 (72.4-155.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 12 8.9 135.3 (69.8-236.3)   Male 10 9.6 104.6 (50.1-192.4) 
Female 11 8.5 129.8 (64.7-232.2)   Female 4 9.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.6 nc (nc-nc)   Male 24 26.9 89.3 (57.2-132.8) 
Female 206 207.3 99.4 (86.3-113.9)   Female 34 26.6 127.9 (88.6-178.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 16 21.8 73.6 (42.0-119.5) 
Female 5 6.9 72.5 (23.4-169.2)   Female 14 11.6 120.2 (65.7-201.7) 
Colon / Rectum            Ovary     
Male 45 50.0 90.0 (65.7-120.5)             
Female 56 57.0 98.3 (74.2-127.6)   Female 23 18.3 126.0 (79.9-189.1) 
Esophagus            Pancreas     
Male 9 11.5 77.9 (35.6-148.0)   Male 18 17.4 103.6 (61.4-163.8) 
Female 4 3.8 nc (nc-nc)   Female 18 20.8 86.3 (51.1-136.5) 
Hodgkin Lymphoma            Prostate     
Male 5 3.4 145.1 (46.8-338.6)   Male 141 134.1 105.2 (88.5-124.0) 
Female 5 3.3 153.8 (49.6-358.9)             
Kidney & Renal Pelvis            Stomach     
Male 27 26.7 101.3 (66.7-147.4)   Male 13 11.1 117.5 (62.5-200.9) 
Female 14 16.9 82.9 (45.3-139.1)   Female 9 8.0 112.2 (51.2-213.1) 
Larynx            Testis     
Male 6 6.7 89.6 (32.7-195.0)   Male 9 7.0 128.6 (58.7-244.2) 
Female 3 2.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 21 19.1 110.1 (68.1-168.3)   Male 15 12.3 122.2 (68.3-201.5) 
Female 11 16.0 68.6 (34.2-122.8)   Female 44 38.4 114.5 (83.2-153.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 15 16.1 93.2 (52.1-153.7)             
Female 4 6.5 nc (nc-nc)   Female 48 46.8 102.5 (75.6-135.9) 
Lung and Bronchus            All Sites / Types     
Male 66 81.0 81.5 (63.0-103.6)   Male 573 591.6 96.9 (89.1-105.1) 
Female 84 99.4 84.5 (67.4-104.6)   Female 693 713.9 97.1 (90.0-104.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
20 
Ashburnham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 5.3 112.9 (41.2-245.8)   Male 3 3.9 nc (nc-nc) 
Female 0 2.1 nc (nc-nc)   Female 3 3.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 1.3 nc (nc-nc)   Male 2 1.3 nc (nc-nc) 
Female 2 1.1 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.2 nc (nc-nc)   Male 2 3.5 nc (nc-nc) 
Female 18 29.2 61.7 (36.6-97.6)   Female 0 3.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 3.5 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 6.3 nc (nc-nc)             
Female 8 6.2 129.2 (55.6-254.7)   Female 3 2.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.7 nc (nc-nc)   Male 5 2.2 224.4 (72.3-523.7) 
Female 1 0.4 nc (nc-nc)   Female 1 2.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.5 nc (nc-nc)   Male 19 22.1 85.9 (51.7-134.2) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 4.0 nc (nc-nc)   Male 2 1.4 nc (nc-nc) 
Female 2 2.2 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Larynx            Testis     
Male 1 1.0 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 2.4 210.3 (67.8-490.7)   Male 1 1.9 nc (nc-nc) 
Female 3 1.7 nc (nc-nc)   Female 5 5.6 89.3 (28.8-208.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.4 nc (nc-nc)             
Female 0 0.8 nc (nc-nc)   Female 5 6.9 72.9 (23.5-170.1) 
Lung and Bronchus            All Sites / Types     
Male 6 10.1 59.3 (21.6-129.0)   Male 79 81.5 97.0 (76.8-120.8) 
Female 4 11.9 nc (nc-nc)   Female 63 90.6 69.6 (53.4-89.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
21 
Ashby 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 3.7 nc (nc-nc)   Male 4 2.4 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 4 1.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 0.7 nc (nc-nc)   Male 2 0.8 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 2.1 nc (nc-nc) 
Female 13 14.6 88.9 (47.3-152.0)   Female 0 1.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 1.9 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 2 0.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 4.1 nc (nc-nc)             
Female 2 3.3 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 0.9 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.3 nc (nc-nc)   Male 7 11.5 60.8 (24.4-125.3) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 2.2 nc (nc-nc)   Male 3 0.9 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Larynx            Testis     
Male 1 0.6 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.5 nc (nc-nc)   Male 2 1.0 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 4 2.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.4 nc (nc-nc)             
Female 1 0.4 nc (nc-nc)   Female 3 3.4 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 6.3 nc (nc-nc)   Male 44 48.1 91.4 (66.4-122.7) 
Female 4 6.3 nc (nc-nc)   Female 45 46.5 96.7 (70.5-129.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
22 
Ashfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 1.8 nc (nc-nc)   Male 2 1.2 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 5 9.3 53.9 (17.4-125.7)   Female 0 1.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.0 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 2.0 nc (nc-nc)             
Female 2 2.2 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.5 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 4 6.9 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.2 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 1 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.8 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.8 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 4 2.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 3.4 nc (nc-nc)   Male 21 25.8 81.4 (50.4-124.4) 
Female 1 4.3 nc (nc-nc)   Female 18 30.1 59.7 (35.4-94.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
23 
Ashland 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 17 15.4 110.3 (64.2-176.6)   Male 7 10.6 66.2 (26.5-136.3) 
Female 4 5.9 nc (nc-nc)   Female 5 9.2 54.1 (17.4-126.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 3.4 nc (nc-nc)   Male 3 3.4 nc (nc-nc) 
Female 3 3.0 nc (nc-nc)   Female 3 2.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.6 nc (nc-nc)   Male 8 9.4 85.4 (36.8-168.2) 
Female 80 76.1 105.2 (83.4-130.9)   Female 8 8.6 93.2 (40.1-183.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 8.4 71.7 (26.2-156.1) 
Female 1 2.6 nc (nc-nc)   Female 5 3.9 126.8 (40.9-295.8) 
Colon / Rectum            Ovary     
Male 12 17.3 69.5 (35.9-121.5)             
Female 21 17.2 121.8 (75.3-186.2)   Female 8 6.4 125.5 (54.0-247.2) 
Esophagus            Pancreas     
Male 7 4.2 168.3 (67.4-346.8)   Male 3 6.0 nc (nc-nc) 
Female 3 1.2 nc (nc-nc)   Female 6 6.1 98.4 (35.9-214.1) 
Hodgkin Lymphoma            Prostate     
Male 1 1.3 nc (nc-nc)   Male 44 51.5 85.4 (62.0-114.6) 
Female 2 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 10.1 nc (nc-nc)   Male 4 3.8 nc (nc-nc) 
Female 1 5.8 nc (nc-nc)   Female 3 2.4 nc (nc-nc) 
Larynx            Testis     
Male 1 2.5 nc (nc-nc)   Male 2 2.6 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 6.7 74.9 (24.2-174.9)   Male 3 4.8 nc (nc-nc) 
Female 6 5.1 118.3 (43.2-257.6)   Female 16 15.0 106.5 (60.8-173.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 6.0 82.8 (26.7-193.3)             
Female 3 2.1 nc (nc-nc)   Female 15 17.6 85.5 (47.8-141.0) 
Lung and Bronchus            All Sites / Types     
Male 19 27.8 68.2 (41.1-106.6)   Male 162 211.6 76.6 (65.2-89.3) 
Female 36 32.0 112.6 (78.9-156.0)   Female 238 243.2 97.9 (85.8-111.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
24 
Athol 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 20 14.9 134.2 (82.0-207.3)   Male 7 9.5 73.3 (29.4-151.1) 
Female 1 4.6 nc (nc-nc)   Female 4 6.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 2.7 nc (nc-nc)   Male 2 3.1 nc (nc-nc) 
Female 0 2.1 nc (nc-nc)   Female 0 2.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 3 8.4 nc (nc-nc) 
Female 43 52.5 81.9 (59.3-110.3)   Female 6 6.4 93.7 (34.2-203.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 7.2 83.2 (30.4-181.2) 
Female 2 1.7 nc (nc-nc)   Female 2 2.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 18 15.2 118.5 (70.2-187.3)             
Female 16 13.5 118.3 (67.6-192.2)   Female 4 4.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 6 3.9 154.4 (56.4-336.0)   Male 5 5.6 89.6 (28.9-209.1) 
Female 0 0.9 nc (nc-nc)   Female 6 4.9 123.4 (45.1-268.6) 
Hodgkin Lymphoma            Prostate     
Male 1 1.0 nc (nc-nc)   Male 30 47.4 63.2 (42.7-90.3) 
Female 1 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 13 8.7 149.8 (79.7-256.2)   Male 2 3.5 nc (nc-nc) 
Female 4 4.2 nc (nc-nc)   Female 1 1.9 nc (nc-nc) 
Larynx            Testis     
Male 2 2.3 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 5.9 nc (nc-nc)   Male 4 3.7 nc (nc-nc) 
Female 6 3.8 158.1 (57.7-344.1)   Female 9 9.6 94.1 (42.9-178.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 5.5 109.2 (39.9-237.7)             
Female 2 1.6 nc (nc-nc)   Female 19 11.9 159.1 (95.7-248.5) 
Lung and Bronchus            All Sites / Types     
Male 33 26.9 122.6 (84.4-172.2)   Male 180 192.3 93.6 (80.4-108.3) 
Female 32 23.9 134.1 (91.7-189.4)   Female 174 174.9 99.5 (85.2-115.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
25 
Attleboro 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 43 42.0 102.4 (74.1-138.0)   Male 29 28.3 102.6 (68.7-147.3) 
Female 19 15.1 126.2 (76.0-197.1)   Female 23 22.8 101.0 (64.0-151.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 10 8.8 113.9 (54.5-209.4)   Male 5 9.0 55.7 (17.9-130.0) 
Female 4 7.4 nc (nc-nc)   Female 7 7.2 97.4 (39.0-200.7) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.5 nc (nc-nc)   Male 15 25.0 59.9 (33.5-98.8) 
Female 197 183.1 107.6 (93.1-123.7)   Female 19 21.5 88.4 (53.2-138.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 22 21.6 101.8 (63.8-154.2) 
Female 3 6.4 nc (nc-nc)   Female 8 9.7 82.6 (35.6-162.7) 
Colon / Rectum            Ovary     
Male 51 46.1 110.5 (82.3-145.3)             
Female 42 44.2 95.1 (68.5-128.5)   Female 18 15.5 115.8 (68.6-183.0) 
Esophagus            Pancreas     
Male 14 11.0 127.4 (69.6-213.7)   Male 23 15.9 144.6 (91.6-216.9) 
Female 4 3.0 nc (nc-nc)   Female 18 15.7 114.9 (68.0-181.6) 
Hodgkin Lymphoma            Prostate     
Male 8 3.5 226.6 (97.6-446.5)   Male 133 131.0 101.5 (85.0-120.3) 
Female 2 3.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 21 26.3 79.9 (49.5-122.2)   Male 7 10.2 68.9 (27.6-142.0) 
Female 9 14.3 63.0 (28.7-119.5)   Female 10 6.2 160.4 (76.8-294.9) 
Larynx            Testis     
Male 11 6.4 171.3 (85.4-306.5)   Male 11 7.0 156.6 (78.1-280.3) 
Female 3 2.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 16 17.8 89.9 (51.3-145.9)   Male 13 12.6 103.5 (55.1-177.1) 
Female 10 12.7 78.7 (37.7-144.8)   Female 26 36.5 71.2 (46.5-104.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 11 15.4 71.2 (35.5-127.4)             
Female 9 5.1 174.9 (79.8-332.0)   Female 45 41.1 109.4 (79.8-146.4) 
Lung and Bronchus            All Sites / Types     
Male 94 74.7 125.9 (101.7-154.1)   Male 577 557.8 103.4 (95.2-112.2) 
Female 86 80.2 107.3 (85.8-132.5)   Female 623 598.8 104.0 (96.0-112.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
26 
Auburn 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 27 20.3 133.1 (87.7-193.6)   Male 19 12.6 151.0 (90.9-235.8) 
Female 11 8.3 133.2 (66.4-238.4)   Female 11 10.5 104.5 (52.1-186.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 3.5 141.3 (45.5-329.8)   Male 4 4.1 nc (nc-nc) 
Female 6 3.4 177.8 (64.9-387.0)   Female 8 3.8 213.0 (91.7-419.7) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.7 nc (nc-nc)   Male 11 11.2 98.5 (49.1-176.2) 
Female 86 84.3 102.0 (81.6-125.9)   Female 12 11.0 109.2 (56.4-190.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 8.9 112.0 (53.6-206.0) 
Female 0 2.6 nc (nc-nc)   Female 1 4.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 19 20.9 90.9 (54.7-142.0)             
Female 21 23.2 90.5 (56.0-138.3)   Female 7 7.3 95.7 (38.4-197.3) 
Esophagus            Pancreas     
Male 5 4.9 102.2 (32.9-238.5)   Male 6 7.3 81.7 (29.8-177.9) 
Female 2 1.6 nc (nc-nc)   Female 6 8.6 69.6 (25.4-151.4) 
Hodgkin Lymphoma            Prostate     
Male 0 1.2 nc (nc-nc)   Male 57 56.4 101.1 (76.6-131.0) 
Female 2 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 11.0 72.8 (31.3-143.4)   Male 2 4.7 nc (nc-nc) 
Female 5 6.9 72.7 (23.4-169.7)   Female 4 3.3 nc (nc-nc) 
Larynx            Testis     
Male 8 2.9 280.5 (120.8-552.8)   Male 1 2.3 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 7.8 nc (nc-nc)   Male 5 4.7 106.5 (34.3-248.4) 
Female 10 6.3 158.3 (75.8-291.2)   Female 9 14.2 63.4 (28.9-120.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 6.7 104.8 (42.0-216.0)             
Female 0 2.7 nc (nc-nc)   Female 17 19.0 89.6 (52.2-143.5) 
Lung and Bronchus            All Sites / Types     
Male 32 34.8 92.0 (62.9-129.9)   Male 253 247.0 102.4 (90.2-115.8) 
Female 49 42.1 116.3 (86.0-153.7)   Female 290 290.0 100.0 (88.8-112.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
27 
Avon 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 5.9 135.5 (58.3-266.9)   Male 4 3.6 nc (nc-nc) 
Female 1 2.1 nc (nc-nc)   Female 2 2.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.0 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 2 1.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.2 nc (nc-nc)   Male 9 3.2 281.3 (128.4-534.1) 
Female 24 22.1 108.6 (69.6-161.6)   Female 2 2.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 2.6 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 6.0 116.1 (46.5-239.2)             
Female 5 5.7 87.1 (28.1-203.2)   Female 2 1.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.4 nc (nc-nc)   Male 2 2.1 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 2 2.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.4 nc (nc-nc)   Male 9 16.7 53.8 (24.5-102.1) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 3.2 nc (nc-nc)   Male 2 1.3 nc (nc-nc) 
Female 1 1.8 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Larynx            Testis     
Male 1 0.8 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 2.3 nc (nc-nc)   Male 4 1.3 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)   Female 3 3.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 1.9 nc (nc-nc)             
Female 0 0.7 nc (nc-nc)   Female 3 5.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 12 10.0 120.2 (62.0-209.9)   Male 71 71.7 99.0 (77.3-124.8) 
Female 14 11.4 122.5 (66.9-205.5)   Female 69 75.7 91.2 (71.0-115.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
28 
Ayer 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 9 7.1 127.4 (58.1-241.9)   Male 4 5.1 nc (nc-nc) 
Female 3 2.5 nc (nc-nc)   Female 4 3.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.6 nc (nc-nc)   Male 2 1.6 nc (nc-nc) 
Female 2 1.2 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 1 4.5 nc (nc-nc) 
Female 37 29.8 124.2 (87.4-171.2)   Female 3 3.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 4.0 nc (nc-nc) 
Female 2 1.1 nc (nc-nc)   Female 2 1.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 8.0 125.7 (60.2-231.2)             
Female 14 7.4 189.7 (103.6-318.2)   Female 3 2.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 6 2.0 301.0 (109.9-655.1)   Male 5 2.8 178.2 (57.4-415.9) 
Female 0 0.5 nc (nc-nc)   Female 6 2.6 233.9 (85.4-509.1) 
Hodgkin Lymphoma            Prostate     
Male 0 0.7 nc (nc-nc)   Male 24 23.9 100.2 (64.2-149.2) 
Female 1 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 4.8 nc (nc-nc)   Male 1 1.8 nc (nc-nc) 
Female 4 2.3 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Larynx            Testis     
Male 1 1.2 nc (nc-nc)   Male 0 1.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 3.1 nc (nc-nc)   Male 1 2.4 nc (nc-nc) 
Female 0 2.1 nc (nc-nc)   Female 4 6.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 2.9 nc (nc-nc)             
Female 0 0.8 nc (nc-nc)   Female 13 6.4 201.8 (107.4-345.2) 
Lung and Bronchus            All Sites / Types     
Male 19 13.2 144.4 (86.9-225.4)   Male 104 99.6 104.4 (85.3-126.5) 
Female 19 13.1 145.4 (87.5-227.0)   Female 125 98.5 126.9 (105.6-151.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
29 
Barnstable 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 90 73.2 122.9 (98.8-151.0)   Male 69 43.7 157.9 (122.9-199.9) 
Female 28 24.0 116.6 (77.5-168.5)   Female 40 29.8 134.1 (95.8-182.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 16 11.6 137.4 (78.5-223.2)   Male 10 14.3 69.9 (33.5-128.5) 
Female 10 9.6 104.3 (49.9-191.8)   Female 14 10.9 128.5 (70.2-215.6) 
Breast            Non-Hodgkin Lymphoma     
Male 5 2.4 206.9 (66.7-482.7)   Male 44 38.4 114.7 (83.3-154.0) 
Female 310 246.8 125.6 (112.0-140.4)   Female 42 31.4 133.6 (96.3-180.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 34 30.7 110.9 (76.8-155.0) 
Female 6 7.1 84.9 (31.0-184.8)   Female 15 13.8 108.8 (60.9-179.5) 
Colon / Rectum            Ovary     
Male 56 70.8 79.1 (59.8-102.8)             
Female 60 64.6 92.9 (70.9-119.6)   Female 20 21.4 93.3 (57.0-144.2) 
Esophagus            Pancreas     
Male 24 17.6 136.2 (87.2-202.6)   Male 29 26.1 111.1 (74.4-159.5) 
Female 3 4.7 nc (nc-nc)   Female 18 24.7 72.8 (43.1-115.1) 
Hodgkin Lymphoma            Prostate     
Male 3 3.8 nc (nc-nc)   Male 195 206.6 94.4 (81.6-108.6) 
Female 0 3.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 32 37.5 85.3 (58.3-120.4)   Male 15 16.4 91.3 (51.1-150.6) 
Female 15 20.4 73.6 (41.1-121.3)   Female 13 9.1 142.1 (75.6-243.1) 
Larynx            Testis     
Male 5 10.1 49.5 (15.9-115.4)   Male 4 5.9 nc (nc-nc) 
Female 0 2.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 33 27.1 121.8 (83.8-171.0)   Male 12 14.4 83.2 (43.0-145.4) 
Female 29 18.0 161.5 (108.1-231.9)   Female 26 38.8 66.9 (43.7-98.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 31 23.9 129.6 (88.1-184.0)             
Female 7 7.9 89.0 (35.7-183.5)   Female 45 58.1 77.5 (56.5-103.7) 
Lung and Bronchus            All Sites / Types     
Male 95 126.7 75.0 (60.6-91.6)   Male 884 871.9 101.4 (94.8-108.3) 
Female 107 127.6 83.9 (68.7-101.3)   Female 872 842.9 103.4 (96.7-110.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
30 
Barre 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 5.7 87.3 (28.1-203.7)   Male 1 3.7 nc (nc-nc) 
Female 2 2.2 nc (nc-nc)   Female 6 3.2 190.0 (69.4-413.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.2 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 2 1.0 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 3 3.4 nc (nc-nc) 
Female 19 25.5 74.4 (44.8-116.2)   Female 1 3.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 2.9 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 6.1 163.0 (78.0-299.7)             
Female 1 6.7 nc (nc-nc)   Female 3 2.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.5 nc (nc-nc)   Male 2 2.2 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 1 2.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 13 18.5 70.2 (37.3-120.0) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 3.4 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 3 2.0 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Larynx            Testis     
Male 0 0.9 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 2.4 nc (nc-nc)   Male 2 1.5 nc (nc-nc) 
Female 2 1.8 nc (nc-nc)   Female 0 4.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.2 nc (nc-nc)             
Female 0 0.8 nc (nc-nc)   Female 6 5.8 103.8 (37.9-225.9) 
Lung and Bronchus            All Sites / Types     
Male 7 10.0 69.9 (28.0-144.0)   Male 55 75.4 72.9 (54.9-94.9) 
Female 6 11.2 53.5 (19.5-116.4)   Female 60 84.9 70.7 (53.9-91.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
31 
Becket 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 3.1 162.7 (52.4-379.7)   Male 1 1.9 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.5 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 8 10.2 78.5 (33.8-154.7)   Female 2 1.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 1.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 3.0 nc (nc-nc)             
Female 2 2.5 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 0.8 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 2 0.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 5 9.5 52.5 (16.9-122.5) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.7 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Larynx            Testis     
Male 0 0.5 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.1 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.1 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 5 2.4 206.9 (66.7-482.8) 
Lung and Bronchus            All Sites / Types     
Male 3 5.6 nc (nc-nc)   Male 33 38.3 86.0 (59.2-120.9) 
Female 4 5.0 nc (nc-nc)   Female 27 33.6 80.3 (52.9-116.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
32 
Bedford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 23 19.6 117.3 (74.3-176.0)   Male 14 12.0 116.3 (63.5-195.1) 
Female 6 5.9 101.3 (37.0-220.4)   Female 11 8.1 136.5 (68.1-244.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 3.3 153.0 (49.3-357.1)   Male 6 3.8 159.6 (58.3-347.4) 
Female 0 2.6 nc (nc-nc)   Female 2 2.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.6 nc (nc-nc)   Male 15 10.5 143.3 (80.1-236.3) 
Female 71 64.1 110.8 (86.5-139.8)   Female 7 8.0 87.6 (35.1-180.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 8.1 86.2 (34.5-177.6) 
Female 0 2.1 nc (nc-nc)   Female 3 3.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 16 19.9 80.5 (46.0-130.7)             
Female 14 17.2 81.3 (44.4-136.5)   Female 5 5.5 90.4 (29.1-211.0) 
Esophagus            Pancreas     
Male 4 4.5 nc (nc-nc)   Male 8 6.9 115.9 (49.9-228.5) 
Female 2 1.1 nc (nc-nc)   Female 5 6.2 81.0 (26.1-189.0) 
Hodgkin Lymphoma            Prostate     
Male 1 1.1 nc (nc-nc)   Male 58 47.8 121.4 (92.2-156.9) 
Female 0 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 10.0 69.9 (28.0-144.0)   Male 6 4.4 135.8 (49.6-295.5) 
Female 1 5.2 nc (nc-nc)   Female 3 2.4 nc (nc-nc) 
Larynx            Testis     
Male 1 2.5 nc (nc-nc)   Male 2 2.1 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 7.5 92.8 (37.2-191.2)   Male 2 4.3 nc (nc-nc) 
Female 5 4.8 104.8 (33.8-244.6)   Female 10 11.8 84.9 (40.7-156.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 6.1 98.7 (36.0-214.8)             
Female 1 1.9 nc (nc-nc)   Female 6 13.8 43.4 (15.9-94.5) 
Lung and Bronchus            All Sites / Types     
Male 24 33.1 72.6 (46.5-108.0)   Male 224 227.9 98.3 (85.8-112.0) 
Female 27 30.4 88.9 (58.6-129.3)   Female 189 216.6 87.3 (75.3-100.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
33 
Belchertown 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 14.4 48.8 (19.5-100.5)   Male 6 9.9 60.5 (22.1-131.6) 
Female 3 5.0 nc (nc-nc)   Female 6 7.9 76.0 (27.8-165.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 3.1 195.4 (71.4-425.4)   Male 5 3.2 157.1 (50.6-366.5) 
Female 0 2.6 nc (nc-nc)   Female 4 2.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.5 nc (nc-nc)   Male 7 8.7 80.3 (32.2-165.5) 
Female 70 65.4 107.0 (83.4-135.2)   Female 14 7.3 190.9 (104.3-320.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 8.1 74.4 (27.2-162.0) 
Female 0 2.3 nc (nc-nc)   Female 5 3.3 149.4 (48.1-348.6) 
Colon / Rectum            Ovary     
Male 15 16.1 93.3 (52.2-153.9)             
Female 14 14.9 94.3 (51.5-158.2)   Female 4 5.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 4.0 nc (nc-nc)   Male 4 5.7 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 10 5.2 192.4 (92.1-353.9) 
Hodgkin Lymphoma            Prostate     
Male 0 1.1 nc (nc-nc)   Male 51 50.5 101.0 (75.2-132.9) 
Female 0 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 9.6 73.0 (29.2-150.4)   Male 3 3.6 nc (nc-nc) 
Female 3 5.0 nc (nc-nc)   Female 4 2.1 nc (nc-nc) 
Larynx            Testis     
Male 2 2.4 nc (nc-nc)   Male 2 2.0 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 6.1 81.4 (26.2-190.0)   Male 1 4.3 nc (nc-nc) 
Female 3 4.3 nc (nc-nc)   Female 9 12.9 69.7 (31.8-132.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 5.8 nc (nc-nc)             
Female 1 1.8 nc (nc-nc)   Female 22 14.7 149.3 (93.5-226.1) 
Lung and Bronchus            All Sites / Types     
Male 13 26.7 48.7 (25.9-83.3)   Male 155 200.4 77.3 (65.6-90.5) 
Female 20 27.5 72.7 (44.4-112.3)   Female 207 208.2 99.4 (86.3-113.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
34 
Bellingham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 14.4 97.5 (53.3-163.6)   Male 11 9.9 110.9 (55.3-198.4) 
Female 3 5.0 nc (nc-nc)   Female 9 7.9 114.0 (52.0-216.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 3.1 nc (nc-nc)   Male 8 3.2 251.3 (108.2-495.2) 
Female 5 2.6 195.7 (63.1-456.8)   Female 1 2.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.5 nc (nc-nc)   Male 19 8.7 218.0 (131.2-340.4) 
Female 74 65.4 113.1 (88.8-142.0)   Female 10 7.3 136.4 (65.3-250.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 8.1 86.8 (34.8-178.9) 
Female 1 2.3 nc (nc-nc)   Female 1 3.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 21 16.1 130.6 (80.8-199.6)             
Female 17 14.9 114.5 (66.6-183.3)   Female 4 5.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 4.0 nc (nc-nc)   Male 8 5.7 141.4 (60.9-278.6) 
Female 2 1.0 nc (nc-nc)   Female 13 5.2 250.1 (133.0-427.7) 
Hodgkin Lymphoma            Prostate     
Male 1 1.1 nc (nc-nc)   Male 74 50.5 146.6 (115.1-184.1) 
Female 1 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 9.6 104.3 (49.9-191.8)   Male 5 3.6 140.4 (45.2-327.6) 
Female 5 5.0 99.9 (32.2-233.0)   Female 1 2.1 nc (nc-nc) 
Larynx            Testis     
Male 0 2.4 nc (nc-nc)   Male 3 2.0 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 6.1 81.4 (26.2-190.0)   Male 5 4.3 115.4 (37.2-269.2) 
Female 7 4.3 164.5 (65.9-338.9)   Female 17 12.9 131.7 (76.7-210.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 5.8 85.8 (27.7-200.2)             
Female 0 1.8 nc (nc-nc)   Female 16 14.7 108.6 (62.0-176.4) 
Lung and Bronchus            All Sites / Types     
Male 30 26.7 112.4 (75.8-160.5)   Male 250 200.4 124.7 (109.7-141.2) 
Female 27 27.5 98.1 (64.6-142.8)   Female 226 208.2 108.6 (94.9-123.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
35 
Belmont 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 24 29.3 81.9 (52.5-121.9)   Male 18 18.3 98.4 (58.3-155.5) 
Female 4 10.5 nc (nc-nc)   Female 7 14.8 47.4 (19.0-97.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 5.2 114.5 (41.8-249.2)   Male 3 5.9 nc (nc-nc) 
Female 2 4.8 nc (nc-nc)   Female 4 4.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 5 1.0 498.5 (160.7-1163.4)   Male 17 16.2 104.9 (61.1-168.0) 
Female 129 118.2 109.1 (91.1-129.7)   Female 9 14.5 62.3 (28.4-118.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 13.0 38.4 (12.4-89.6) 
Female 3 4.0 nc (nc-nc)   Female 9 6.4 141.3 (64.5-268.3) 
Colon / Rectum            Ovary     
Male 24 30.1 79.6 (51.0-118.5)             
Female 25 30.5 81.9 (53.0-121.0)   Female 14 10.1 138.3 (75.5-232.0) 
Esophagus            Pancreas     
Male 4 7.1 nc (nc-nc)   Male 11 10.6 103.7 (51.7-185.6) 
Female 5 2.0 244.0 (78.6-569.4)   Female 11 11.0 99.8 (49.7-178.5) 
Hodgkin Lymphoma            Prostate     
Male 2 1.9 nc (nc-nc)   Male 77 82.2 93.7 (73.9-117.1) 
Female 1 1.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 12 16.0 74.8 (38.6-130.7)   Male 5 6.8 74.1 (23.9-172.8) 
Female 7 9.4 74.4 (29.8-153.2)   Female 6 4.3 140.4 (51.3-305.5) 
Larynx            Testis     
Male 2 4.1 nc (nc-nc)   Male 7 3.7 188.1 (75.4-387.6) 
Female 0 1.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 11.5 43.6 (14.0-101.7)   Male 6 7.1 84.8 (30.9-184.5) 
Female 5 8.6 58.1 (18.7-135.6)   Female 25 22.1 113.0 (73.1-166.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 9.7 51.8 (16.7-120.8)             
Female 1 3.5 nc (nc-nc)   Female 24 26.2 91.7 (58.7-136.5) 
Lung and Bronchus            All Sites / Types     
Male 39 50.1 77.9 (55.4-106.5)   Male 300 359.2 83.5 (74.3-93.5) 
Female 41 54.9 74.6 (53.6-101.3)   Female 354 395.4 89.5 (80.4-99.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
36 
Berkley 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 7.2 nc (nc-nc)   Male 5 4.8 104.9 (33.8-244.7) 
Female 0 1.6 nc (nc-nc)   Female 5 3.0 164.2 (52.9-383.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.5 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 2 1.0 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 0 4.2 nc (nc-nc) 
Female 24 25.8 93.0 (59.6-138.4)   Female 6 2.6 227.6 (83.1-495.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 3.7 nc (nc-nc) 
Female 2 1.0 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 7.6 131.9 (63.2-242.7)             
Female 7 5.1 137.4 (55.0-283.0)   Female 0 2.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.9 nc (nc-nc)   Male 1 2.7 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 1.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 15 23.5 63.8 (35.7-105.2) 
Female 1 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 4.5 nc (nc-nc)   Male 1 1.7 nc (nc-nc) 
Female 2 1.9 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Larynx            Testis     
Male 1 1.1 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 3.0 nc (nc-nc)   Male 4 1.9 nc (nc-nc) 
Female 3 1.5 nc (nc-nc)   Female 4 5.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 2.7 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 8 5.7 140.4 (60.5-276.7) 
Lung and Bronchus            All Sites / Types     
Male 13 13.3 97.5 (51.9-166.7)   Male 73 95.9 76.1 (59.7-95.7) 
Female 4 9.4 nc (nc-nc)   Female 77 77.9 98.9 (78.0-123.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
37 
Berlin 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 4.8 nc (nc-nc)   Male 6 2.9 210.1 (76.7-457.3) 
Female 1 1.3 nc (nc-nc)   Female 2 1.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.8 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.2 nc (nc-nc)   Male 0 2.5 nc (nc-nc) 
Female 16 15.0 107.0 (61.1-173.8)   Female 1 1.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 2.0 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 4.8 nc (nc-nc)             
Female 3 3.5 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 1.1 nc (nc-nc)   Male 1 1.7 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.3 nc (nc-nc)   Male 11 13.1 84.1 (41.9-150.5) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 2.4 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Larynx            Testis     
Male 0 0.6 nc (nc-nc)   Male 2 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.8 nc (nc-nc)   Male 2 1.0 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 2 2.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.5 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 4 3.5 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 8 8.1 99.0 (42.6-195.0)   Male 54 56.6 95.4 (71.6-124.4) 
Female 5 6.8 73.0 (23.5-170.4)   Female 40 48.4 82.6 (59.0-112.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
38 
Bernardston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 3.8 nc (nc-nc)   Male 3 2.2 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 2 1.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.6 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 5 2.0 255.4 (82.3-596.1) 
Female 14 12.3 113.7 (62.1-190.8)   Female 3 1.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.5 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 3.7 134.8 (43.5-314.7)             
Female 3 3.0 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.9 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 10 10.2 98.2 (47.0-180.6) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.9 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 2 1.0 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Larynx            Testis     
Male 1 0.5 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.4 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 1 2.0 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.2 nc (nc-nc)             
Female 1 0.4 nc (nc-nc)   Female 3 2.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 5 6.3 79.5 (25.6-185.5)   Male 35 43.8 79.8 (55.6-111.0) 
Female 5 5.8 85.5 (27.6-199.6)   Female 42 40.5 103.8 (74.8-140.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
39 
Beverly 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 49 42.2 116.1 (85.9-153.5)   Male 38 26.9 141.3 (100.0-193.9) 
Female 19 16.7 114.1 (68.6-178.1)   Female 27 23.0 117.1 (77.2-170.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 10 8.0 125.2 (59.9-230.2)   Male 10 8.6 116.7 (55.8-214.5) 
Female 5 7.6 65.7 (21.2-153.4)   Female 6 7.7 77.5 (28.3-168.7) 
Breast            Non-Hodgkin Lymphoma     
Male 4 1.5 nc (nc-nc)   Male 26 23.8 109.2 (71.3-160.0) 
Female 177 183.9 96.2 (82.6-111.5)   Female 19 22.7 83.6 (50.3-130.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 26 19.9 130.5 (85.2-191.2) 
Female 6 6.0 100.8 (36.8-219.4)   Female 12 10.2 117.7 (60.8-205.7) 
Colon / Rectum            Ovary     
Male 37 43.8 84.5 (59.5-116.5)             
Female 51 47.5 107.3 (79.9-141.1)   Female 12 15.9 75.3 (38.9-131.6) 
Esophagus            Pancreas     
Male 10 10.6 94.0 (45.0-172.8)   Male 18 15.6 115.5 (68.4-182.6) 
Female 4 3.3 nc (nc-nc)   Female 19 17.6 108.0 (65.0-168.7) 
Hodgkin Lymphoma            Prostate     
Male 1 3.1 nc (nc-nc)   Male 137 128.5 106.6 (89.5-126.1) 
Female 2 3.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 29 24.2 119.9 (80.3-172.3)   Male 4 9.9 nc (nc-nc) 
Female 13 14.7 88.5 (47.1-151.3)   Female 3 6.7 nc (nc-nc) 
Larynx            Testis     
Male 6 6.2 97.5 (35.6-212.2)   Male 7 5.8 121.6 (48.7-250.5) 
Female 2 2.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 24 17.0 140.8 (90.2-209.5)   Male 20 10.8 185.5 (113.3-286.5) 
Female 21 13.4 156.2 (96.7-238.9)   Female 35 33.8 103.5 (72.1-143.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 12 14.9 80.7 (41.6-140.9)             
Female 6 5.5 108.4 (39.6-236.0)   Female 33 42.3 78.0 (53.7-109.5) 
Lung and Bronchus            All Sites / Types     
Male 80 73.6 108.8 (86.2-135.4)   Male 604 537.3 112.4 (103.6-121.8) 
Female 95 86.4 109.9 (88.9-134.4)   Female 633 620.7 102.0 (94.2-110.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
40 
Billerica 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 52 42.3 122.8 (91.7-161.1)   Male 26 28.4 91.7 (59.9-134.4) 
Female 18 15.4 117.1 (69.4-185.1)   Female 27 22.0 122.9 (81.0-178.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 10 8.7 114.7 (54.9-211.0)   Male 8 9.1 88.2 (38.0-173.8) 
Female 5 7.2 69.3 (22.3-161.7)   Female 9 7.2 125.5 (57.3-238.3) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.5 nc (nc-nc)   Male 29 25.1 115.6 (77.4-166.0) 
Female 195 177.5 109.8 (95.0-126.4)   Female 22 21.3 103.2 (64.6-156.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 19 22.0 86.4 (52.0-134.9) 
Female 6 5.9 100.9 (36.8-219.6)   Female 8 9.5 84.0 (36.2-165.6) 
Colon / Rectum            Ovary     
Male 37 46.6 79.4 (55.9-109.4)             
Female 59 43.9 134.5 (102.4-173.5)   Female 11 15.1 72.8 (36.3-130.2) 
Esophagus            Pancreas     
Male 14 11.2 125.0 (68.3-209.7)   Male 11 16.1 68.5 (34.1-122.5) 
Female 1 3.0 nc (nc-nc)   Female 12 16.0 75.0 (38.7-131.0) 
Hodgkin Lymphoma            Prostate     
Male 6 3.5 170.8 (62.4-371.7)   Male 129 135.9 94.9 (79.2-112.8) 
Female 2 2.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 33 26.5 124.5 (85.7-174.9)   Male 7 10.2 68.3 (27.4-140.7) 
Female 7 14.1 49.7 (19.9-102.5)   Female 8 6.2 129.9 (55.9-255.9) 
Larynx            Testis     
Male 3 6.5 nc (nc-nc)   Male 5 6.9 72.8 (23.5-170.0) 
Female 0 2.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 24 17.7 135.8 (87.0-202.1)   Male 16 12.4 129.0 (73.7-209.6) 
Female 20 12.6 159.2 (97.2-245.9)   Female 40 33.7 118.7 (84.8-161.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 12 15.9 75.6 (39.0-132.0)             
Female 3 5.1 nc (nc-nc)   Female 43 40.3 106.7 (77.2-143.8) 
Lung and Bronchus            All Sites / Types     
Male 82 75.3 108.9 (86.6-135.1)   Male 567 565.4 100.3 (92.2-108.9) 
Female 108 82.0 131.8 (108.1-159.1)   Female 644 588.8 109.4 (101.1-118.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
41 
Blackstone 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 8.0 137.8 (68.7-246.6)   Male 6 5.6 107.9 (39.4-234.9) 
Female 4 3.1 nc (nc-nc)   Female 6 5.0 119.1 (43.5-259.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 1.7 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)   Female 2 1.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.3 nc (nc-nc)   Male 4 4.9 nc (nc-nc) 
Female 30 41.7 72.0 (48.6-102.8)   Female 3 4.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 4.6 nc (nc-nc) 
Female 0 1.5 nc (nc-nc)   Female 5 2.1 232.7 (75.0-543.1) 
Colon / Rectum            Ovary     
Male 9 9.1 99.1 (45.2-188.1)             
Female 7 9.5 73.8 (29.5-152.0)   Female 6 3.5 173.0 (63.2-376.6) 
Esophagus            Pancreas     
Male 4 2.2 nc (nc-nc)   Male 1 3.2 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 3 3.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.6 nc (nc-nc)   Male 31 27.9 110.9 (75.4-157.5) 
Female 2 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 5.3 nc (nc-nc)   Male 2 2.0 nc (nc-nc) 
Female 4 3.1 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Larynx            Testis     
Male 1 1.3 nc (nc-nc)   Male 3 1.2 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 3.4 nc (nc-nc)   Male 1 2.5 nc (nc-nc) 
Female 7 2.7 262.8 (105.3-541.6)   Female 4 8.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 3.4 nc (nc-nc)             
Female 0 1.1 nc (nc-nc)   Female 5 9.5 52.8 (17.0-123.3) 
Lung and Bronchus            All Sites / Types     
Male 20 14.6 137.1 (83.7-211.8)   Male 122 112.0 109.0 (90.5-130.1) 
Female 14 16.9 83.0 (45.3-139.2)   Female 124 131.9 94.0 (78.2-112.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
42 
Blandford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 1.4 nc (nc-nc)   Male 3 1.0 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 7 5.7 123.8 (49.6-255.2)   Female 0 0.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 0.8 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 1.6 nc (nc-nc)             
Female 2 1.3 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.4 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 0.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 3 5.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.0 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 1 0.2 nc (nc-nc) 
Larynx            Testis     
Male 1 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 0.6 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.6 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 2.6 nc (nc-nc)   Male 17 20.6 82.5 (48.1-132.2) 
Female 4 2.4 nc (nc-nc)   Female 22 17.8 123.6 (77.4-187.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
43 
Bolton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 4.9 nc (nc-nc)   Male 2 3.4 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)   Female 2 2.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.0 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 2 0.8 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 7 3.0 235.8 (94.5-485.9) 
Female 29 21.2 137.0 (91.7-196.7)   Female 2 2.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 2.7 184.6 (59.5-430.7) 
Female 0 0.8 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 5.6 nc (nc-nc)             
Female 8 4.3 186.6 (80.4-367.8)   Female 2 1.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.3 nc (nc-nc)   Male 3 1.9 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 3 1.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.4 nc (nc-nc)   Male 15 16.0 94.0 (52.6-155.1) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 3.2 155.1 (50.0-362.0)   Male 0 1.2 nc (nc-nc) 
Female 0 1.6 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Larynx            Testis     
Male 1 0.8 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 2.1 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 3 4.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.9 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 4 4.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 8.7 nc (nc-nc)   Male 60 66.5 90.2 (68.8-116.1) 
Female 3 7.9 nc (nc-nc)   Female 64 64.3 99.6 (76.7-127.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
44 
Boston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 359 478.0 75.1 (67.5-83.3)   Male 238 320.2 74.3 (65.2-84.4) 
Female 146 184.8 79.0 (66.7-92.9)   Female 223 281.6 79.2 (69.1-90.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 84 108.4 77.5 (61.8-95.9)   Male 113 99.9 113.1 (93.2-135.9) 
Female 74 98.2 75.4 (59.2-94.6)   Female 128 86.3 148.3 (123.7-176.4) 
Breast            Non-Hodgkin Lymphoma     
Male 20 17.0 117.5 (71.7-181.5)   Male 264 289.1 91.3 (80.6-103.0) 
Female 1951 2117.3 92.1 (88.1-96.3)   Female 258 262.3 98.4 (86.7-111.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 271 237.4 114.2 (101.0-128.6) 
Female 95 75.4 126.0 (101.9-154.0)   Female 107 116.2 92.1 (75.4-111.2) 
Colon / Rectum            Ovary     
Male 555 513.5 108.1 (99.3-117.5)             
Female 545 534.1 102.0 (93.7-111.0)   Female 181 187.1 96.7 (83.1-111.9) 
Esophagus            Pancreas     
Male 122 122.7 99.4 (82.6-118.7)   Male 174 178.5 97.5 (83.5-113.1) 
Female 26 36.1 72.1 (47.1-105.6)   Female 187 191.6 97.6 (84.1-112.6) 
Hodgkin Lymphoma            Prostate     
Male 49 54.9 89.2 (66.0-118.0)   Male 1737 1459.5 119.0 (113.5-124.7) 
Female 39 52.1 74.9 (53.3-102.4)             
Kidney & Renal Pelvis            Stomach     
Male 255 288.7 88.3 (77.8-99.8)   Male 170 114.0 149.2 (127.6-173.4) 
Female 167 170.1 98.2 (83.9-114.3)   Female 123 75.6 162.7 (135.2-194.1) 
Larynx            Testis     
Male 90 71.5 125.8 (101.2-154.7)   Male 95 110.4 86.0 (69.6-105.1) 
Female 21 23.0 91.1 (56.4-139.3)             
Leukemia            Thyroid     
Male 185 212.0 87.3 (75.1-100.8)   Male 140 146.8 95.4 (80.2-112.6) 
Female 151 162.4 93.0 (78.7-109.0)   Female 436 462.7 94.2 (85.6-103.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 254 173.3 146.5 (129.1-165.7)             
Female 99 63.1 157.0 (127.6-191.1)   Female 447 478.2 93.5 (85.0-102.5) 
Lung and Bronchus            All Sites / Types     
Male 872 839.4 103.9 (97.1-111.0)   Male 6566 6345.0 103.5 (101.0-106.0) 
Female 880 968.2 90.9 (85.0-97.1)   Female 6881 7198.6 95.6 (93.3-97.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
45 
Bourne 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 41 28.4 144.6 (103.7-196.1)   Male 32 17.2 185.8 (127.1-262.3) 
Female 10 10.4 95.9 (45.9-176.3)   Female 16 13.0 123.3 (70.4-200.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 4.7 nc (nc-nc)   Male 8 5.6 142.4 (61.3-280.7) 
Female 3 4.1 nc (nc-nc)   Female 3 4.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.0 nc (nc-nc)   Male 12 15.3 78.6 (40.6-137.4) 
Female 87 105.8 82.3 (65.9-101.5)   Female 10 13.7 73.1 (35.0-134.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 17 12.1 141.0 (82.1-225.7) 
Female 2 3.1 nc (nc-nc)   Female 7 6.0 117.2 (47.0-241.6) 
Colon / Rectum            Ovary     
Male 28 28.1 99.5 (66.1-143.8)             
Female 29 28.9 100.2 (67.1-144.0)   Female 12 9.2 130.4 (67.3-227.8) 
Esophagus            Pancreas     
Male 8 6.8 117.4 (50.6-231.4)   Male 8 10.2 78.5 (33.8-154.7) 
Female 2 2.0 nc (nc-nc)   Female 12 11.0 109.5 (56.5-191.3) 
Hodgkin Lymphoma            Prostate     
Male 0 1.6 nc (nc-nc)   Male 82 78.9 103.9 (82.7-129.0) 
Female 0 1.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 13 14.8 87.6 (46.6-149.8)   Male 9 6.4 139.7 (63.8-265.3) 
Female 10 8.7 115.4 (55.2-212.2)   Female 6 4.1 146.8 (53.6-319.4) 
Larynx            Testis     
Male 11 4.0 276.7 (138.0-495.2)   Male 3 2.6 nc (nc-nc) 
Female 4 1.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 10.7 65.3 (26.2-134.6)   Male 5 6.0 83.6 (26.9-195.1) 
Female 6 7.9 76.4 (27.9-166.3)   Female 23 16.9 136.1 (86.2-204.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 8 9.3 85.8 (36.9-169.0)             
Female 3 3.4 nc (nc-nc)   Female 22 24.4 90.1 (56.4-136.4) 
Lung and Bronchus            All Sites / Types     
Male 54 49.1 110.0 (82.6-143.5)   Male 378 340.7 111.0 (100.0-122.7) 
Female 56 53.8 104.2 (78.7-135.3)   Female 345 363.8 94.8 (85.1-105.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
46 
Boxborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 4.9 nc (nc-nc)   Male 2 3.4 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 4 2.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.0 nc (nc-nc)   Male 3 1.1 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.2 nc (nc-nc)   Male 5 3.0 167.5 (54.0-391.0) 
Female 22 21.2 103.6 (64.9-156.9)   Female 1 2.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 2.8 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 5.7 nc (nc-nc)             
Female 5 4.3 117.1 (37.7-273.2)   Female 0 1.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.4 nc (nc-nc)   Male 2 1.9 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 3 1.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 16 17.5 91.7 (52.4-148.9) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 3.3 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 0 1.5 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Larynx            Testis     
Male 0 0.8 nc (nc-nc)   Male 2 0.7 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 2.1 nc (nc-nc)   Male 3 1.5 nc (nc-nc) 
Female 4 1.2 nc (nc-nc)   Female 4 4.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.0 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 2 4.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 6 8.8 68.1 (24.9-148.3)   Male 60 68.6 87.5 (66.8-112.7) 
Female 8 7.7 103.7 (44.7-204.4)   Female 64 63.8 100.3 (77.2-128.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
47 
Boxford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 9.8 82.0 (35.3-161.5)   Male 10 6.6 150.9 (72.3-277.6) 
Female 2 3.3 nc (nc-nc)   Female 11 4.7 233.9 (116.6-418.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.9 nc (nc-nc)   Male 3 2.1 nc (nc-nc) 
Female 2 1.5 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 4 5.8 nc (nc-nc) 
Female 34 39.7 85.7 (59.3-119.7)   Female 5 4.6 109.8 (35.4-256.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 5.2 nc (nc-nc) 
Female 0 1.3 nc (nc-nc)   Female 3 2.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 10.7 nc (nc-nc)             
Female 8 9.2 86.5 (37.3-170.5)   Female 1 3.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 2.6 nc (nc-nc)   Male 3 3.8 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 4 3.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.6 nc (nc-nc)   Male 36 32.4 111.0 (77.8-153.7) 
Female 2 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 6.3 nc (nc-nc)   Male 2 2.4 nc (nc-nc) 
Female 2 3.1 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Larynx            Testis     
Male 2 1.6 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 3.9 127.1 (41.0-296.7)   Male 2 2.8 nc (nc-nc) 
Female 3 2.6 nc (nc-nc)   Female 10 7.3 137.3 (65.7-252.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 3.8 nc (nc-nc)             
Female 0 1.1 nc (nc-nc)   Female 7 9.2 76.0 (30.4-156.5) 
Lung and Bronchus            All Sites / Types     
Male 8 17.9 44.8 (19.3-88.2)   Male 99 131.8 75.1 (61.0-91.4) 
Female 13 17.7 73.2 (39.0-125.3)   Female 120 128.4 93.5 (77.5-111.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
48 
Boylston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 5.6 nc (nc-nc)   Male 4 3.5 nc (nc-nc) 
Female 2 1.8 nc (nc-nc)   Female 6 2.6 231.9 (84.7-504.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.0 nc (nc-nc)   Male 2 1.1 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 3 3.1 nc (nc-nc) 
Female 26 20.7 125.8 (82.1-184.3)   Female 0 2.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 2.6 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 5.9 85.0 (27.4-198.3)             
Female 8 5.4 149.1 (64.2-293.7)   Female 1 1.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.4 nc (nc-nc)   Male 3 2.0 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 2 1.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.4 nc (nc-nc)   Male 16 16.4 97.3 (55.6-158.0) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 3.2 nc (nc-nc)   Male 2 1.3 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)   Female 3 0.7 nc (nc-nc) 
Larynx            Testis     
Male 0 0.8 nc (nc-nc)   Male 2 0.6 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 2.2 nc (nc-nc)   Male 3 1.4 nc (nc-nc) 
Female 1 1.5 nc (nc-nc)   Female 3 3.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.0 nc (nc-nc)             
Female 1 0.6 nc (nc-nc)   Female 4 4.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 5 9.6 52.1 (16.8-121.6)   Male 63 69.9 90.1 (69.3-115.3) 
Female 6 9.2 65.6 (23.9-142.7)   Female 71 68.7 103.4 (80.7-130.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
49 
Braintree 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 41 40.5 101.3 (72.7-137.5)   Male 26 25.6 101.5 (66.3-148.8) 
Female 17 17.3 98.5 (57.4-157.8)   Female 23 22.5 102.4 (64.9-153.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 7.5 66.5 (21.4-155.2)   Male 7 8.2 85.6 (34.3-176.4) 
Female 7 7.2 96.8 (38.8-199.5)   Female 3 7.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.4 nc (nc-nc)   Male 21 22.7 92.6 (57.3-141.6) 
Female 194 175.3 110.6 (95.6-127.4)   Female 20 22.9 87.4 (53.4-135.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 20 18.4 108.6 (66.3-167.7) 
Female 6 5.7 105.7 (38.6-230.0)   Female 10 9.8 101.6 (48.6-186.8) 
Colon / Rectum            Ovary     
Male 46 41.8 109.9 (80.5-146.6)             
Female 64 49.2 130.1 (100.2-166.2)   Female 16 15.3 104.3 (59.6-169.5) 
Esophagus            Pancreas     
Male 9 9.9 90.7 (41.4-172.2)   Male 14 14.7 95.2 (52.0-159.7) 
Female 6 3.3 182.3 (66.6-396.8)   Female 19 18.2 104.6 (62.9-163.3) 
Hodgkin Lymphoma            Prostate     
Male 6 2.9 207.7 (75.8-452.0)   Male 120 114.1 105.2 (87.2-125.8) 
Female 4 2.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 25 22.5 111.3 (72.0-164.3)   Male 9 9.4 96.1 (43.9-182.5) 
Female 12 14.4 83.6 (43.2-146.1)   Female 7 7.0 100.5 (40.2-207.0) 
Larynx            Testis     
Male 4 5.7 nc (nc-nc)   Male 6 5.5 109.8 (40.1-239.1) 
Female 4 2.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 16.2 49.5 (21.3-97.4)   Male 10 10.1 99.4 (47.6-182.8) 
Female 17 13.7 124.1 (72.3-198.8)   Female 29 31.2 93.0 (62.2-133.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 16 13.8 116.2 (66.4-188.7)             
Female 4 5.5 nc (nc-nc)   Female 48 38.7 123.9 (91.4-164.3) 
Lung and Bronchus            All Sites / Types     
Male 66 69.5 95.0 (73.5-120.9)   Male 500 501.4 99.7 (91.2-108.9) 
Female 88 86.9 101.3 (81.3-124.8)   Female 651 608.0 107.1 (99.0-115.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
50 
Brewster 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 16 19.7 81.4 (46.5-132.2)   Male 18 11.6 155.0 (91.8-244.9) 
Female 6 7.1 84.3 (30.8-183.4)   Female 8 8.1 98.4 (42.4-193.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.9 nc (nc-nc)   Male 3 3.9 nc (nc-nc) 
Female 1 2.5 nc (nc-nc)   Female 1 3.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.7 nc (nc-nc)   Male 12 10.1 119.2 (61.5-208.2) 
Female 96 67.9 141.3 (114.5-172.6)   Female 17 9.0 189.0 (110.1-302.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 8.1 61.7 (19.9-144.0) 
Female 0 1.8 nc (nc-nc)   Female 5 3.9 127.0 (40.9-296.4) 
Colon / Rectum            Ovary     
Male 10 18.7 53.6 (25.7-98.6)             
Female 15 19.1 78.7 (44.0-129.8)   Female 7 5.9 117.9 (47.2-242.8) 
Esophagus            Pancreas     
Male 5 4.8 104.6 (33.7-244.1)   Male 4 7.0 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 3 7.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.8 nc (nc-nc)   Male 55 55.6 98.9 (74.5-128.7) 
Female 0 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 10.0 nc (nc-nc)   Male 1 4.4 nc (nc-nc) 
Female 6 5.7 105.4 (38.5-229.5)   Female 1 2.7 nc (nc-nc) 
Larynx            Testis     
Male 1 2.8 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 2 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 7.0 128.7 (58.7-244.4)   Male 2 3.6 nc (nc-nc) 
Female 7 5.1 136.5 (54.7-281.3)   Female 5 9.3 54.0 (17.4-126.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 8 6.3 126.4 (54.4-249.1)             
Female 0 2.2 nc (nc-nc)   Female 16 16.2 98.6 (56.3-160.2) 
Lung and Bronchus            All Sites / Types     
Male 31 35.0 88.6 (60.2-125.7)   Male 205 232.3 88.3 (76.6-101.2) 
Female 26 36.9 70.4 (46.0-103.2)   Female 239 237.3 100.7 (88.3-114.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
51 
Bridgewater 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 26 27.6 94.1 (61.5-137.9)   Male 16 17.9 89.3 (51.0-145.1) 
Female 11 8.0 136.7 (68.1-244.6)   Female 21 11.8 178.2 (110.2-272.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 5.5 nc (nc-nc)   Male 3 5.7 nc (nc-nc) 
Female 6 4.1 145.5 (53.1-316.7)   Female 3 3.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.0 nc (nc-nc)   Male 10 16.1 61.9 (29.6-113.9) 
Female 87 96.3 90.3 (72.4-111.4)   Female 11 11.4 96.2 (48.0-172.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 13 13.5 96.1 (51.1-164.4) 
Female 4 3.2 nc (nc-nc)   Female 4 5.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 35 29.6 118.4 (82.5-164.7)             
Female 23 23.1 99.4 (63.0-149.1)   Female 9 8.2 109.5 (49.9-207.8) 
Esophagus            Pancreas     
Male 6 7.0 85.5 (31.2-186.1)   Male 12 10.3 116.3 (60.0-203.1) 
Female 0 1.6 nc (nc-nc)   Female 9 8.3 107.8 (49.2-204.7) 
Hodgkin Lymphoma            Prostate     
Male 2 2.3 nc (nc-nc)   Male 74 84.7 87.4 (68.6-109.7) 
Female 0 1.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 13 16.4 79.5 (42.3-136.0)   Male 5 6.5 76.6 (24.7-178.7) 
Female 8 7.5 106.2 (45.7-209.2)   Female 2 3.3 nc (nc-nc) 
Larynx            Testis     
Male 2 4.1 nc (nc-nc)   Male 2 4.2 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 11.6 69.2 (29.8-136.3)   Male 9 7.6 118.8 (54.2-225.5) 
Female 4 6.7 nc (nc-nc)   Female 28 18.3 153.1 (101.7-221.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 14 9.9 141.1 (77.1-236.8)             
Female 1 2.8 nc (nc-nc)   Female 26 22.2 117.1 (76.4-171.5) 
Lung and Bronchus            All Sites / Types     
Male 55 47.6 115.6 (87.1-150.5)   Male 333 357.7 93.1 (83.4-103.6) 
Female 43 42.9 100.2 (72.5-135.0)   Female 319 316.1 100.9 (90.1-112.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
52 
Brimfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 4.0 nc (nc-nc)   Male 2 2.8 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)   Female 1 2.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.8 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 4 2.4 nc (nc-nc) 
Female 15 18.2 82.6 (46.2-136.2)   Female 5 2.0 247.1 (79.6-576.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 2.4 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 4.5 nc (nc-nc)             
Female 2 3.9 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.2 nc (nc-nc)   Male 2 1.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.3 nc (nc-nc)   Male 8 15.0 53.4 (23.0-105.2) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 2.7 219.2 (80.0-477.1)   Male 2 1.0 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Larynx            Testis     
Male 0 0.7 nc (nc-nc)   Male 2 0.6 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 1.7 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 1 3.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.7 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 3 4.4 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 6 7.5 79.8 (29.1-173.7)   Male 51 57.1 89.3 (66.5-117.4) 
Female 5 7.9 63.0 (20.3-147.0)   Female 41 57.5 71.3 (51.1-96.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
53 
Brockton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 85 86.8 98.0 (78.3-121.2)   Male 27 57.0 47.3 (31.2-68.9) 
Female 32 33.0 96.8 (66.2-136.7)   Female 30 48.0 62.5 (42.1-89.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 16 18.0 89.1 (50.9-144.8)   Male 14 18.2 77.0 (42.1-129.2) 
Female 21 15.9 131.8 (81.6-201.5)   Female 17 15.4 110.5 (64.4-177.0) 
Breast            Non-Hodgkin Lymphoma     
Male 2 3.1 nc (nc-nc)   Male 45 50.9 88.4 (64.5-118.3) 
Female 325 379.4 85.7 (76.6-95.5)   Female 40 45.9 87.1 (62.2-118.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 41 43.2 94.9 (68.1-128.7) 
Female 28 12.9 216.5 (143.8-312.8)   Female 25 20.4 122.4 (79.2-180.7) 
Colon / Rectum            Ovary     
Male 111 93.4 118.8 (97.7-143.1)             
Female 98 95.6 102.5 (83.2-125.0)   Female 40 32.8 122.1 (87.2-166.3) 
Esophagus            Pancreas     
Male 25 22.3 112.1 (72.5-165.5)   Male 38 32.6 116.5 (82.5-159.9) 
Female 8 6.5 123.9 (53.3-244.1)   Female 52 34.4 151.3 (113.0-198.4) 
Hodgkin Lymphoma            Prostate     
Male 8 7.2 111.7 (48.1-220.1)   Male 265 265.8 99.7 (88.1-112.5) 
Female 6 6.6 91.3 (33.3-198.7)             
Kidney & Renal Pelvis            Stomach     
Male 72 52.1 138.1 (108.1-173.9)   Male 26 20.7 125.8 (82.2-184.4) 
Female 30 30.3 99.1 (66.9-141.5)   Female 13 13.4 96.8 (51.5-165.5) 
Larynx            Testis     
Male 17 13.0 131.1 (76.3-209.9)   Male 13 13.7 94.8 (50.4-162.1) 
Female 6 4.2 144.2 (52.7-314.0)             
Leukemia            Thyroid     
Male 26 36.9 70.5 (46.1-103.4)   Male 26 24.3 107.1 (69.9-156.9) 
Female 18 27.8 64.7 (38.3-102.3)   Female 86 74.7 115.1 (92.1-142.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 46 31.6 145.6 (106.6-194.2)             
Female 15 11.1 135.6 (75.8-223.6)   Female 88 84.6 104.0 (83.4-128.1) 
Lung and Bronchus            All Sites / Types     
Male 182 151.0 120.5 (103.7-139.4)   Male 1185 1132.3 104.7 (98.8-110.8) 
Female 205 174.1 117.8 (102.2-135.1)   Female 1291 1267.6 101.8 (96.4-107.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
54 
Brookfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 3.8 132.8 (42.8-309.9)   Male 3 2.5 nc (nc-nc) 
Female 2 1.4 nc (nc-nc)   Female 3 2.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.8 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 2.2 nc (nc-nc) 
Female 12 16.0 74.9 (38.7-130.9)   Female 4 2.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.9 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 2 0.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 3.9 nc (nc-nc)             
Female 4 4.0 nc (nc-nc)   Female 2 1.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.0 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.3 nc (nc-nc)   Male 15 13.0 115.5 (64.6-190.5) 
Female 1 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 2.4 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Larynx            Testis     
Male 0 0.6 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.5 nc (nc-nc)   Male 4 1.1 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 4 2.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.5 nc (nc-nc)             
Female 2 0.5 nc (nc-nc)   Female 2 3.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 10 7.0 143.0 (68.5-263.1)   Male 51 51.0 100.1 (74.5-131.6) 
Female 18 7.6 235.4 (139.4-372.0)   Female 63 53.6 117.6 (90.4-150.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
55 
Brookline 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 47 55.9 84.1 (61.8-111.8)   Male 51 35.5 143.6 (106.9-188.8) 
Female 16 22.4 71.3 (40.7-115.8)   Female 32 31.2 102.7 (70.2-145.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 10.8 74.3 (32.0-146.3)   Male 9 11.4 79.0 (36.1-150.0) 
Female 14 10.7 131.4 (71.8-220.6)   Female 7 10.3 67.9 (27.2-139.9) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.9 nc (nc-nc)   Male 35 31.5 111.0 (77.3-154.3) 
Female 222 242.6 91.5 (79.9-104.4)   Female 36 30.5 118.1 (82.7-163.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 29 25.9 112.0 (75.0-160.9) 
Female 3 7.9 nc (nc-nc)   Female 7 13.6 51.5 (20.6-106.2) 
Colon / Rectum            Ovary     
Male 30 56.9 52.8 (35.6-75.3)             
Female 41 62.4 65.7 (47.2-89.2)   Female 31 21.3 145.4 (98.8-206.4) 
Esophagus            Pancreas     
Male 4 14.1 nc (nc-nc)   Male 18 20.5 87.6 (51.9-138.5) 
Female 3 4.5 nc (nc-nc)   Female 26 23.5 110.6 (72.2-162.1) 
Hodgkin Lymphoma            Prostate     
Male 6 4.6 129.6 (47.3-282.0)   Male 155 169.7 91.3 (77.5-106.9) 
Female 7 5.0 139.0 (55.7-286.5)             
Kidney & Renal Pelvis            Stomach     
Male 31 31.7 97.7 (66.4-138.7)   Male 10 13.0 76.9 (36.8-141.5) 
Female 16 19.8 81.0 (46.2-131.5)   Female 6 8.9 67.7 (24.7-147.3) 
Larynx            Testis     
Male 2 8.2 nc (nc-nc)   Male 12 8.7 137.2 (70.8-239.7) 
Female 2 2.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 33 22.6 145.8 (100.4-204.8)   Male 16 14.3 112.1 (64.0-182.0) 
Female 22 18.6 118.6 (74.3-179.5)   Female 46 46.9 98.2 (71.9-131.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 12 19.2 62.4 (32.2-108.9)             
Female 3 7.4 nc (nc-nc)   Female 46 56.4 81.5 (59.7-108.8) 
Lung and Bronchus            All Sites / Types     
Male 47 98.6 47.7 (35.0-63.4)   Male 607 711.1 85.4 (78.7-92.4) 
Female 74 118.3 62.5 (49.1-78.5)   Female 740 832.1 88.9 (82.6-95.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
56 
Buckland 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 2.5 nc (nc-nc)   Male 2 1.5 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 0.4 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 4 10.5 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.1 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 2.5 nc (nc-nc)             
Female 4 2.5 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.6 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 7 7.6 91.6 (36.7-188.8) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 1.4 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Larynx            Testis     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.0 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.9 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 0 2.5 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 4.4 nc (nc-nc)   Male 24 31.1 77.3 (49.5-115.0) 
Female 7 5.1 137.8 (55.2-284.0)   Female 24 34.8 69.0 (44.2-102.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
57 
Burlington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 27 33.5 80.7 (53.2-117.4)   Male 19 20.4 93.3 (56.1-145.6) 
Female 8 11.3 70.8 (30.5-139.6)   Female 11 15.0 73.2 (36.5-131.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 5.7 88.5 (28.5-206.4)   Male 6 6.5 92.5 (33.8-201.2) 
Female 5 4.9 102.4 (33.0-238.9)   Female 4 5.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.1 nc (nc-nc)   Male 24 17.9 134.0 (85.8-199.3) 
Female 131 123.6 105.9 (88.6-125.7)   Female 13 15.1 85.9 (45.7-146.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 13.6 73.4 (35.1-135.0) 
Female 2 3.9 nc (nc-nc)   Female 5 6.7 74.8 (24.1-174.6) 
Colon / Rectum            Ovary     
Male 27 33.1 81.7 (53.8-118.8)             
Female 30 31.4 95.6 (64.5-136.5)   Female 9 10.5 85.6 (39.1-162.6) 
Esophagus            Pancreas     
Male 3 7.7 nc (nc-nc)   Male 19 11.7 161.8 (97.3-252.6) 
Female 1 2.2 nc (nc-nc)   Female 7 11.7 60.0 (24.0-123.5) 
Hodgkin Lymphoma            Prostate     
Male 1 2.1 nc (nc-nc)   Male 75 83.9 89.4 (70.3-112.0) 
Female 2 1.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 16 16.9 94.6 (54.1-153.7)   Male 6 7.5 79.9 (29.2-174.0) 
Female 5 10.0 49.9 (16.1-116.6)   Female 3 4.4 nc (nc-nc) 
Larynx            Testis     
Male 2 4.4 nc (nc-nc)   Male 3 3.9 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 16 12.8 125.1 (71.5-203.2)   Male 8 7.3 110.3 (47.5-217.4) 
Female 5 8.8 56.7 (18.3-132.4)   Female 31 22.0 141.0 (95.8-200.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 8 10.5 76.4 (32.9-150.6)             
Female 3 3.6 nc (nc-nc)   Female 34 27.6 123.1 (85.2-172.0) 
Lung and Bronchus            All Sites / Types     
Male 39 56.9 68.6 (48.8-93.8)   Male 352 390.9 90.0 (80.9-100.0) 
Female 60 61.1 98.3 (75.0-126.5)   Female 395 415.1 95.2 (86.0-105.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
58 
Cambridge 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 52 77.2 67.4 (50.3-88.4)   Male 52 50.3 103.4 (77.2-135.6) 
Female 16 29.9 53.6 (30.6-87.0)   Female 52 44.6 116.6 (87.1-153.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 20 17.5 114.5 (69.9-176.8)   Male 15 15.7 95.6 (53.4-157.6) 
Female 15 15.9 94.1 (52.6-155.2)   Female 9 13.8 65.1 (29.7-123.6) 
Breast            Non-Hodgkin Lymphoma     
Male 3 2.7 nc (nc-nc)   Male 47 45.8 102.6 (75.4-136.4) 
Female 326 328.6 99.2 (88.7-110.6)   Female 49 41.9 116.9 (86.5-154.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 40 35.7 112.1 (80.1-152.6) 
Female 6 11.5 52.3 (19.1-113.9)   Female 18 18.5 97.3 (57.7-153.8) 
Colon / Rectum            Ovary     
Male 70 79.1 88.5 (69.0-111.9)             
Female 64 83.7 76.5 (58.9-97.6)   Female 31 29.5 105.2 (71.4-149.3) 
Esophagus            Pancreas     
Male 16 19.3 83.0 (47.4-134.8)   Male 28 28.1 99.7 (66.2-144.1) 
Female 10 5.9 170.6 (81.7-313.8)   Female 26 30.9 84.2 (55.0-123.4) 
Hodgkin Lymphoma            Prostate     
Male 11 9.8 112.7 (56.2-201.6)   Male 255 227.4 112.1 (98.8-126.8) 
Female 4 9.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 33 43.8 75.3 (51.8-105.7)   Male 12 17.9 66.9 (34.5-116.9) 
Female 17 26.9 63.2 (36.8-101.2)   Female 10 12.0 83.5 (40.0-153.6) 
Larynx            Testis     
Male 5 11.1 44.9 (14.5-104.7)   Male 24 19.5 122.9 (78.7-182.9) 
Female 0 3.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 32 34.0 94.1 (64.4-132.9)   Male 25 22.5 111.0 (71.8-163.9) 
Female 16 26.0 61.5 (35.1-99.8)   Female 84 72.4 116.0 (92.5-143.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 19 26.6 71.3 (42.9-111.4)             
Female 10 10.1 98.9 (47.4-182.0)   Female 67 76.0 88.1 (68.3-111.9) 
Lung and Bronchus            All Sites / Types     
Male 99 134.8 73.4 (59.7-89.4)   Male 928 1000.3 92.8 (86.9-98.9) 
Female 112 157.4 71.2 (58.6-85.6)   Female 1020 1139.5 89.5 (84.1-95.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
59 
Canton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 19 27.1 70.2 (42.2-109.6)   Male 21 16.9 124.1 (76.8-189.7) 
Female 5 9.5 52.5 (16.9-122.6)   Female 15 13.1 114.5 (64.1-188.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 4.8 145.4 (58.2-299.5)   Male 13 5.4 240.2 (127.8-410.8) 
Female 6 4.2 142.4 (52.0-309.9)   Female 5 4.4 114.4 (36.9-266.9) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.9 nc (nc-nc)   Male 13 15.0 86.8 (46.2-148.4) 
Female 113 104.6 108.0 (89.0-129.9)   Female 15 12.9 116.2 (65.0-191.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 12.0 92.0 (45.9-164.6) 
Female 5 3.5 143.2 (46.2-334.2)   Female 5 5.7 88.0 (28.4-205.4) 
Colon / Rectum            Ovary     
Male 34 27.4 123.9 (85.8-173.2)             
Female 30 27.3 109.8 (74.1-156.8)   Female 9 9.0 100.2 (45.7-190.3) 
Esophagus            Pancreas     
Male 6 6.5 91.6 (33.5-199.4)   Male 11 9.8 112.0 (55.9-200.5) 
Female 0 1.9 nc (nc-nc)   Female 8 10.0 80.2 (34.5-158.0) 
Hodgkin Lymphoma            Prostate     
Male 2 1.8 nc (nc-nc)   Male 87 76.0 114.5 (91.7-141.3) 
Female 1 1.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 9 14.8 60.9 (27.8-115.7)   Male 8 6.2 128.7 (55.4-253.6) 
Female 7 8.4 83.6 (33.5-172.2)   Female 3 3.8 nc (nc-nc) 
Larynx            Testis     
Male 3 3.8 nc (nc-nc)   Male 3 3.3 nc (nc-nc) 
Female 3 1.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 16 10.6 151.1 (86.3-245.3)   Male 11 6.4 170.8 (85.1-305.6) 
Female 6 7.7 78.0 (28.5-169.7)   Female 31 19.4 159.5 (108.4-226.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 9.0 nc (nc-nc)             
Female 0 3.1 nc (nc-nc)   Female 25 23.2 107.9 (69.8-159.3) 
Lung and Bronchus            All Sites / Types     
Male 46 46.9 98.2 (71.9-131.0)   Male 360 331.6 108.6 (97.6-120.4) 
Female 55 49.4 111.4 (83.9-145.0)   Female 380 352.3 107.9 (97.3-119.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
60 
Carlisle 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 7.2 69.5 (22.4-162.2)   Male 7 4.7 149.5 (59.9-308.0) 
Female 1 2.2 nc (nc-nc)   Female 7 3.2 220.8 (88.4-454.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.3 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 3 1.0 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 4 4.0 nc (nc-nc) 
Female 32 27.3 117.2 (80.1-165.4)   Female 5 3.1 159.9 (51.5-373.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 3.7 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 7.6 nc (nc-nc)             
Female 3 6.5 nc (nc-nc)   Female 4 2.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.9 nc (nc-nc)   Male 2 2.7 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 3 2.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 24 23.9 100.4 (64.3-149.5) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 4.4 nc (nc-nc)   Male 1 1.7 nc (nc-nc) 
Female 1 2.1 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Larynx            Testis     
Male 1 1.1 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 2.8 215.6 (78.7-469.2)   Male 2 1.8 nc (nc-nc) 
Female 1 1.8 nc (nc-nc)   Female 2 4.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 2.8 nc (nc-nc)             
Female 1 0.8 nc (nc-nc)   Female 10 6.1 163.9 (78.5-301.5) 
Lung and Bronchus            All Sites / Types     
Male 6 13.3 45.3 (16.5-98.5)   Male 69 94.6 72.9 (56.7-92.3) 
Female 1 11.9 nc (nc-nc)   Female 82 87.0 94.2 (74.9-116.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
61 
Carver 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 22 14.9 147.5 (92.4-223.4)   Male 11 9.3 118.2 (58.9-211.5) 
Female 9 5.4 165.7 (75.6-314.6)   Female 11 7.3 150.0 (74.8-268.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 2.6 nc (nc-nc)   Male 6 3.0 199.4 (72.8-434.0) 
Female 0 2.4 nc (nc-nc)   Female 1 2.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 3 8.2 nc (nc-nc) 
Female 48 61.8 77.7 (57.3-103.0)   Female 7 7.5 93.8 (37.6-193.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 6.8 103.5 (41.5-213.3) 
Female 2 1.9 nc (nc-nc)   Female 2 3.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 16 15.2 105.4 (60.2-171.2)             
Female 15 15.2 98.5 (55.1-162.4)   Female 1 5.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 6 3.7 162.5 (59.4-353.8)   Male 7 5.5 128.3 (51.4-264.3) 
Female 1 1.1 nc (nc-nc)   Female 2 5.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.9 nc (nc-nc)   Male 28 44.0 63.6 (42.3-92.0) 
Female 0 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 8.3 nc (nc-nc)   Male 2 3.5 nc (nc-nc) 
Female 6 4.9 122.6 (44.8-266.9)   Female 0 2.1 nc (nc-nc) 
Larynx            Testis     
Male 1 2.2 nc (nc-nc)   Male 2 1.6 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 5.7 nc (nc-nc)   Male 5 3.5 143.9 (46.4-335.8) 
Female 3 4.3 nc (nc-nc)   Female 6 10.5 57.3 (20.9-124.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 5.1 nc (nc-nc)             
Female 1 1.8 nc (nc-nc)   Female 18 14.4 125.2 (74.2-197.9) 
Lung and Bronchus            All Sites / Types     
Male 33 26.2 126.2 (86.8-177.2)   Male 170 185.1 91.8 (78.5-106.7) 
Female 44 28.9 152.0 (110.5-204.1)   Female 192 203.8 94.2 (81.4-108.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
62 
Charlemont 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 1.8 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 2 0.6 nc (nc-nc)   Female 2 0.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 9 6.3 142.4 (65.0-270.3)   Female 1 0.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 0.8 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 1.8 nc (nc-nc)             
Female 0 1.6 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.4 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 5 5.3 94.7 (30.5-221.0) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.0 nc (nc-nc)   Male 2 0.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 0.2 nc (nc-nc) 
Larynx            Testis     
Male 1 0.3 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.7 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.6 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 3 1.5 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 3.2 nc (nc-nc)   Male 26 22.0 118.1 (77.1-173.1) 
Female 2 3.2 nc (nc-nc)   Female 26 21.4 121.5 (79.4-178.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
63 
Charlton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 19 13.4 142.3 (85.6-222.2)   Male 6 8.9 67.5 (24.6-146.9) 
Female 5 4.5 111.7 (36.0-260.6)   Female 4 7.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 2.7 nc (nc-nc)   Male 2 2.8 nc (nc-nc) 
Female 1 2.3 nc (nc-nc)   Female 4 2.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 9 7.9 114.1 (52.1-216.6) 
Female 50 57.9 86.3 (64.1-113.8)   Female 7 6.6 106.0 (42.5-218.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 6.9 nc (nc-nc) 
Female 2 2.0 nc (nc-nc)   Female 3 3.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 14.9 46.9 (18.8-96.6)             
Female 16 13.7 116.9 (66.8-189.8)   Female 5 4.9 101.6 (32.7-237.0) 
Esophagus            Pancreas     
Male 2 3.5 nc (nc-nc)   Male 9 5.1 177.1 (80.8-336.3) 
Female 0 0.9 nc (nc-nc)   Female 4 4.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.0 nc (nc-nc)   Male 33 42.0 78.7 (54.1-110.5) 
Female 1 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 12 8.3 144.8 (74.7-253.0)   Male 0 3.2 nc (nc-nc) 
Female 3 4.4 nc (nc-nc)   Female 1 1.9 nc (nc-nc) 
Larynx            Testis     
Male 2 2.0 nc (nc-nc)   Male 1 2.0 nc (nc-nc) 
Female 3 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 5.6 125.6 (50.3-258.9)   Male 3 3.9 nc (nc-nc) 
Female 3 3.9 nc (nc-nc)   Female 17 11.5 147.4 (85.8-236.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 5.0 nc (nc-nc)             
Female 1 1.6 nc (nc-nc)   Female 9 13.3 67.9 (31.0-128.9) 
Lung and Bronchus            All Sites / Types     
Male 21 23.1 90.9 (56.3-139.0)   Male 153 176.5 86.7 (73.5-101.6) 
Female 22 23.3 94.6 (59.2-143.2)   Female 177 185.5 95.4 (81.9-110.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
64 
Chatham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 15.3 71.9 (35.8-128.7)   Male 25 8.7 288.1 (186.4-425.4) 
Female 11 4.8 228.7 (114.0-409.2)   Female 15 5.2 288.5 (161.4-475.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.1 nc (nc-nc)   Male 1 2.9 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)   Female 2 2.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 11 7.6 144.5 (72.0-258.6) 
Female 40 43.5 92.0 (65.8-125.3)   Female 6 5.9 101.4 (37.0-220.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 5.7 140.8 (60.6-277.5) 
Female 2 1.1 nc (nc-nc)   Female 1 2.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 18 14.0 128.4 (76.0-202.9)             
Female 11 12.5 88.3 (44.0-158.0)   Female 4 3.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 3.5 nc (nc-nc)   Male 6 5.3 113.4 (41.4-246.9) 
Female 1 0.9 nc (nc-nc)   Female 5 5.0 99.9 (32.2-233.2) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 39 39.8 98.0 (69.7-134.0) 
Female 1 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 7.2 83.7 (30.6-182.1)   Male 1 3.3 nc (nc-nc) 
Female 3 3.7 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Larynx            Testis     
Male 0 2.0 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 5.3 170.1 (77.6-322.9)   Male 2 2.4 nc (nc-nc) 
Female 4 3.4 nc (nc-nc)   Female 2 5.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 4.5 nc (nc-nc)             
Female 3 1.5 nc (nc-nc)   Female 9 10.3 87.7 (40.0-166.5) 
Lung and Bronchus            All Sites / Types     
Male 17 26.4 64.5 (37.5-103.2)   Male 175 172.0 101.7 (87.2-118.0) 
Female 26 25.4 102.5 (66.9-150.2)   Female 164 154.8 105.9 (90.4-123.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
65 
Chelmsford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 52 40.8 127.4 (95.1-167.0)   Male 21 26.4 79.6 (49.3-121.7) 
Female 15 15.8 94.7 (52.9-156.2)   Female 22 21.3 103.4 (64.8-156.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 12 7.6 158.2 (81.6-276.4)   Male 7 8.4 83.2 (33.3-171.5) 
Female 5 6.8 73.3 (23.6-171.1)   Female 9 7.4 122.4 (55.8-232.3) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.4 nc (nc-nc)   Male 27 23.2 116.5 (76.8-169.5) 
Female 179 174.6 102.5 (88.1-118.7)   Female 10 21.5 46.5 (22.3-85.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 22 19.5 112.9 (70.8-171.0) 
Female 5 5.5 90.6 (29.2-211.5)   Female 7 9.4 74.1 (29.7-152.7) 
Colon / Rectum            Ovary     
Male 39 42.9 91.0 (64.7-124.4)             
Female 51 44.1 115.5 (86.0-151.9)   Female 23 14.9 154.5 (97.9-231.9) 
Esophagus            Pancreas     
Male 9 10.3 87.3 (39.9-165.8)   Male 19 15.2 125.4 (75.4-195.8) 
Female 2 3.1 nc (nc-nc)   Female 24 16.4 146.7 (94.0-218.3) 
Hodgkin Lymphoma            Prostate     
Male 1 2.8 nc (nc-nc)   Male 129 121.7 106.0 (88.5-125.9) 
Female 3 2.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 22 23.6 93.0 (58.3-140.9)   Male 5 9.6 52.0 (16.8-121.4) 
Female 13 14.1 92.3 (49.1-157.9)   Female 3 6.2 nc (nc-nc) 
Larynx            Testis     
Male 4 6.0 nc (nc-nc)   Male 7 5.4 130.4 (52.2-268.7) 
Female 1 2.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 16 16.3 98.1 (56.1-159.4)   Male 11 10.5 104.3 (52.0-186.7) 
Female 23 12.4 186.0 (117.9-279.1)   Female 33 30.5 108.1 (74.4-151.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 15 14.5 103.6 (57.9-170.8)             
Female 2 5.2 nc (nc-nc)   Female 47 39.8 118.2 (86.8-157.1) 
Lung and Bronchus            All Sites / Types     
Male 60 71.9 83.4 (63.7-107.4)   Male 531 519.3 102.2 (93.7-111.3) 
Female 71 84.8 83.7 (65.4-105.6)   Female 608 584.3 104.1 (96.0-112.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
66 
Chelsea 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 18 24.4 73.7 (43.6-116.4)   Male 8 17.2 46.4 (20.0-91.4) 
Female 9 8.8 101.7 (46.4-193.1)   Female 11 14.7 74.9 (37.3-134.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 6.2 96.4 (35.2-209.8)   Male 8 5.2 153.1 (65.9-301.6) 
Female 6 5.1 117.0 (42.7-254.7)   Female 3 4.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.9 nc (nc-nc)   Male 14 15.7 89.4 (48.8-149.9) 
Female 99 109.3 90.5 (73.6-110.2)   Female 19 13.0 146.0 (87.9-228.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 12.8 54.5 (21.8-112.3) 
Female 9 4.3 209.9 (95.8-398.4)   Female 9 5.8 155.5 (71.0-295.2) 
Colon / Rectum            Ovary     
Male 33 28.3 116.6 (80.2-163.7)             
Female 12 26.6 45.1 (23.3-78.8)   Female 5 9.4 53.1 (17.1-123.9) 
Esophagus            Pancreas     
Male 4 6.2 nc (nc-nc)   Male 9 9.2 97.5 (44.5-185.0) 
Female 1 1.8 nc (nc-nc)   Female 16 9.3 172.4 (98.5-280.0) 
Hodgkin Lymphoma            Prostate     
Male 3 3.2 nc (nc-nc)   Male 52 71.5 72.7 (54.3-95.3) 
Female 2 2.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 15.8 44.3 (17.7-91.2)   Male 8 6.0 133.6 (57.5-263.3) 
Female 12 8.6 139.3 (71.9-243.3)   Female 4 3.8 nc (nc-nc) 
Larynx            Testis     
Male 1 3.6 nc (nc-nc)   Male 4 7.1 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 11.7 85.6 (41.0-157.5)   Male 13 8.9 145.5 (77.4-248.9) 
Female 12 8.4 142.0 (73.3-248.1)   Female 43 25.9 166.3 (120.3-224.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 12 8.8 136.1 (70.2-237.7)             
Female 12 3.0 396.7 (204.7-692.9)   Female 16 23.6 67.8 (38.7-110.1) 
Lung and Bronchus            All Sites / Types     
Male 53 41.6 127.5 (95.5-166.8)   Male 301 332.2 90.6 (80.7-101.4) 
Female 65 46.5 139.8 (107.9-178.1)   Female 396 364.7 108.6 (98.2-119.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
67 
Cheshire 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 5.2 96.0 (30.9-224.0)   Male 6 3.2 189.7 (69.3-412.9) 
Female 2 1.5 nc (nc-nc)   Female 1 2.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.8 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.2 nc (nc-nc)   Male 1 2.8 nc (nc-nc) 
Female 18 17.3 104.0 (61.6-164.3)   Female 4 2.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 2.3 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 5.1 117.8 (43.0-256.3)             
Female 2 4.1 nc (nc-nc)   Female 3 1.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.3 nc (nc-nc)   Male 1 1.9 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.3 nc (nc-nc)   Male 13 15.7 83.0 (44.1-141.9) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 2.8 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 2 1.4 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Larynx            Testis     
Male 0 0.7 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.9 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 1 3.0 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 1.8 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 5 4.1 122.7 (39.5-286.2) 
Lung and Bronchus            All Sites / Types     
Male 12 9.2 130.0 (67.1-227.1)   Male 55 63.7 86.3 (65.0-112.3) 
Female 6 8.5 71.0 (25.9-154.5)   Female 49 57.3 85.5 (63.3-113.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Chester 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 1.5 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 5 5.5 91.6 (29.5-213.7)   Female 1 0.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.9 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 1.7 289.7 (93.3-675.9)             
Female 1 1.2 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.4 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 5 5.3 94.3 (30.4-220.2) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 1.0 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.6 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.6 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 2.7 nc (nc-nc)   Male 20 21.2 94.2 (57.5-145.6) 
Female 4 1.9 nc (nc-nc)   Female 15 16.7 89.7 (50.2-147.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Chesterfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.2 nc (nc-nc)   Male 2 0.9 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 6.1 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.8 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 1.5 nc (nc-nc)             
Female 0 1.4 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.4 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 1 0.1 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 6 4.8 125.9 (46.0-273.9) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.9 nc (nc-nc)   Male 3 0.3 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 1 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.5 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.6 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 2 1.5 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 2.2 nc (nc-nc)   Male 22 18.0 122.2 (76.6-185.1) 
Female 2 2.5 nc (nc-nc)   Female 11 19.3 57.1 (28.5-102.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Chicopee 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 57 65.0 87.6 (66.4-113.5)   Male 21 40.9 51.3 (31.7-78.4) 
Female 21 24.1 87.0 (53.8-133.0)   Female 20 31.9 62.7 (38.3-96.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 12.1 58.0 (23.2-119.5)   Male 11 13.2 83.3 (41.6-149.1) 
Female 11 10.4 106.0 (52.8-189.6)   Female 6 11.1 54.1 (19.8-117.8) 
Breast            Non-Hodgkin Lymphoma     
Male 3 2.3 nc (nc-nc)   Male 30 36.3 82.7 (55.8-118.1) 
Female 260 254.6 102.1 (90.1-115.3)   Female 39 32.4 120.4 (85.6-164.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 30 29.6 101.4 (68.4-144.8) 
Female 11 7.9 139.7 (69.6-249.9)   Female 22 14.2 155.0 (97.1-234.6) 
Colon / Rectum            Ovary     
Male 95 66.5 142.8 (115.5-174.5)             
Female 60 67.7 88.7 (67.7-114.1)   Female 28 22.3 125.6 (83.4-181.5) 
Esophagus            Pancreas     
Male 16 16.1 99.1 (56.6-161.0)   Male 19 23.8 80.0 (48.1-124.9) 
Female 6 4.7 128.5 (46.9-279.7)   Female 24 25.2 95.3 (61.0-141.8) 
Hodgkin Lymphoma            Prostate     
Male 4 4.7 nc (nc-nc)   Male 121 189.5 63.8 (53.0-76.3) 
Female 1 4.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 43 36.2 118.8 (85.9-160.0)   Male 11 15.1 73.1 (36.4-130.7) 
Female 28 20.7 135.0 (89.7-195.2)   Female 9 9.5 94.4 (43.1-179.2) 
Larynx            Testis     
Male 11 9.4 117.6 (58.6-210.4)   Male 10 8.6 116.0 (55.5-213.3) 
Female 2 2.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 23 25.9 88.9 (56.3-133.4)   Male 13 15.8 82.1 (43.7-140.5) 
Female 10 19.0 52.7 (25.2-96.9)   Female 34 44.8 75.9 (52.5-106.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 13 22.1 58.7 (31.2-100.4)             
Female 7 7.9 88.5 (35.5-182.4)   Female 54 58.5 92.3 (69.3-120.5) 
Lung and Bronchus            All Sites / Types     
Male 135 113.3 119.2 (99.9-141.1)   Male 722 811.6 89.0 (82.6-95.7) 
Female 136 125.6 108.3 (90.8-128.1)   Female 866 870.7 99.5 (92.9-106.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
71 
Chilmark 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 1.6 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 2 6.2 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.7 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 1.5 nc (nc-nc)             
Female 0 1.4 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.4 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 2 4.9 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.9 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 0.6 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.6 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 2.7 nc (nc-nc)   Male 14 19.6 71.6 (39.1-120.1) 
Female 2 2.8 nc (nc-nc)   Female 11 19.8 55.5 (27.7-99.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Clarksburg 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 2.8 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 2 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 2 1.5 nc (nc-nc) 
Female 5 8.8 57.0 (18.4-132.9)   Female 1 1.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 1.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 2.8 nc (nc-nc)             
Female 3 2.2 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 0.7 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 8 7.6 105.5 (45.4-207.8) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.4 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.0 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.9 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 1 2.1 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 5 4.9 101.3 (32.6-236.3)   Male 28 33.4 83.9 (55.8-121.3) 
Female 5 4.3 115.5 (37.2-269.5)   Female 23 29.2 78.9 (50.0-118.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Clinton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 27 12.4 217.5 (143.3-316.5)   Male 10 8.3 120.5 (57.7-221.6) 
Female 5 5.1 98.4 (31.7-229.6)   Female 12 7.3 165.5 (85.4-289.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.6 nc (nc-nc)   Male 3 2.6 nc (nc-nc) 
Female 3 2.4 nc (nc-nc)   Female 2 2.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 5 7.4 67.6 (21.8-157.9) 
Female 56 57.4 97.6 (73.7-126.7)   Female 9 7.0 127.7 (58.3-242.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 6.2 80.0 (25.8-186.7) 
Female 3 1.9 nc (nc-nc)   Female 5 3.1 159.5 (51.4-372.2) 
Colon / Rectum            Ovary     
Male 20 13.5 148.1 (90.5-228.8)             
Female 12 14.7 81.6 (42.1-142.6)   Female 7 5.0 140.8 (56.4-290.1) 
Esophagus            Pancreas     
Male 4 3.2 nc (nc-nc)   Male 3 4.7 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 4 5.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 1.1 nc (nc-nc)   Male 56 39.0 143.7 (108.6-186.7) 
Female 0 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 13 7.6 170.2 (90.5-291.0)   Male 4 3.0 nc (nc-nc) 
Female 6 4.6 131.0 (47.9-285.2)   Female 2 2.1 nc (nc-nc) 
Larynx            Testis     
Male 1 1.9 nc (nc-nc)   Male 1 2.3 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 5.3 151.0 (65.0-297.5)   Male 3 3.8 nc (nc-nc) 
Female 7 4.2 165.8 (66.4-341.6)   Female 14 11.1 126.5 (69.1-212.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 11 4.5 242.5 (120.9-433.9)             
Female 0 1.7 nc (nc-nc)   Female 16 13.0 123.0 (70.2-199.7) 
Lung and Bronchus            All Sites / Types     
Male 29 21.8 133.1 (89.1-191.2)   Male 216 164.7 131.1 (114.2-149.9) 
Female 31 26.3 117.9 (80.1-167.3)   Female 216 192.7 112.1 (97.7-128.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Cohasset 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 9 9.0 100.1 (45.7-190.0)   Male 4 6.0 nc (nc-nc) 
Female 6 3.4 179.0 (65.4-389.5)   Female 15 4.8 314.7 (176.0-519.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.7 nc (nc-nc)   Male 1 1.9 nc (nc-nc) 
Female 2 1.6 nc (nc-nc)   Female 0 1.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 6 5.2 114.4 (41.8-249.1) 
Female 44 39.4 111.6 (81.1-149.8)   Female 2 4.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 4.4 137.3 (50.1-298.8) 
Female 0 1.3 nc (nc-nc)   Female 1 2.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 9.5 105.5 (50.5-194.0)             
Female 4 9.5 nc (nc-nc)   Female 5 3.3 151.6 (48.8-353.7) 
Esophagus            Pancreas     
Male 2 2.3 nc (nc-nc)   Male 3 3.4 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 2 3.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 28 26.4 105.9 (70.3-153.0) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 5.3 113.5 (41.5-247.1)   Male 1 2.1 nc (nc-nc) 
Female 4 3.1 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Larynx            Testis     
Male 1 1.4 nc (nc-nc)   Male 2 1.2 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 3.7 nc (nc-nc)   Male 2 2.4 nc (nc-nc) 
Female 5 2.7 183.6 (59.2-428.5)   Female 10 7.3 136.6 (65.4-251.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 3.3 nc (nc-nc)             
Female 1 1.1 nc (nc-nc)   Female 7 8.5 82.1 (32.9-169.2) 
Lung and Bronchus            All Sites / Types     
Male 11 16.0 68.9 (34.3-123.2)   Male 105 115.5 90.9 (74.4-110.1) 
Female 12 18.1 66.4 (34.3-116.0)   Female 132 128.7 102.6 (85.8-121.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Colrain 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 2.6 nc (nc-nc)   Male 0 1.6 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 13 8.5 153.6 (81.7-262.7)   Female 0 1.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.2 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 2.6 nc (nc-nc)             
Female 4 2.0 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.6 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 4 7.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.4 nc (nc-nc)   Male 2 0.6 nc (nc-nc) 
Female 2 0.7 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.4 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.0 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.9 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 4 2.1 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 4 4.4 nc (nc-nc)   Male 19 31.8 59.8 (36.0-93.4) 
Female 4 3.8 nc (nc-nc)   Female 34 27.5 123.8 (85.7-173.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Concord 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 32 27.4 117.0 (80.0-165.1)   Male 27 17.4 155.5 (102.4-226.2) 
Female 11 9.7 113.8 (56.7-203.6)   Female 30 12.2 246.4 (166.2-351.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 4.9 103.0 (33.2-240.3)   Male 5 5.6 88.5 (28.5-206.6) 
Female 4 3.8 nc (nc-nc)   Female 4 4.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.0 nc (nc-nc)   Male 15 15.3 98.0 (54.8-161.6) 
Female 130 99.3 130.9 (109.3-155.4)   Female 10 12.8 78.1 (37.4-143.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 12.9 85.6 (42.7-153.1) 
Female 2 3.0 nc (nc-nc)   Female 8 5.6 143.8 (61.9-283.3) 
Colon / Rectum            Ovary     
Male 17 28.6 59.5 (34.6-95.2)             
Female 30 27.2 110.1 (74.3-157.2)   Female 16 8.6 185.4 (105.9-301.1) 
Esophagus            Pancreas     
Male 1 6.9 nc (nc-nc)   Male 8 10.1 79.3 (34.2-156.3) 
Female 0 1.9 nc (nc-nc)   Female 8 10.2 78.7 (33.9-155.2) 
Hodgkin Lymphoma            Prostate     
Male 1 1.7 nc (nc-nc)   Male 82 81.0 101.2 (80.5-125.6) 
Female 1 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 15.7 38.3 (14.0-83.4)   Male 4 6.4 nc (nc-nc) 
Female 11 8.1 136.3 (67.9-243.9)   Female 0 3.8 nc (nc-nc) 
Larynx            Testis     
Male 1 4.0 nc (nc-nc)   Male 3 3.1 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 10.6 94.0 (45.0-172.8)   Male 6 6.8 88.4 (32.3-192.4) 
Female 3 7.3 nc (nc-nc)   Female 17 15.9 106.8 (62.2-171.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 9.5 74.0 (29.6-152.4)             
Female 3 3.1 nc (nc-nc)   Female 26 22.8 114.2 (74.6-167.4) 
Lung and Bronchus            All Sites / Types     
Male 18 47.7 37.8 (22.4-59.7)   Male 285 343.6 82.9 (73.6-93.2) 
Female 29 49.2 59.0 (39.5-84.7)   Female 377 339.5 111.0 (100.1-122.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Conway 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 2.6 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 2 0.5 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.4 nc (nc-nc) 
Female 7 10.3 68.0 (27.2-140.0)   Female 0 1.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 2.8 nc (nc-nc)             
Female 2 2.2 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.7 nc (nc-nc)   Male 2 1.0 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 3 8.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 1.5 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 1 0.4 nc (nc-nc)   Male 1 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.0 nc (nc-nc)   Male 2 0.6 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 1.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.9 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 3 2.5 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 4.5 nc (nc-nc)   Male 27 33.1 81.5 (53.7-118.6) 
Female 1 4.3 nc (nc-nc)   Female 18 32.1 56.2 (33.3-88.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
78 
Cummington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.3 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 2 0.7 nc (nc-nc) 
Female 9 5.1 177.0 (80.8-336.1)   Female 1 0.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.6 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 1.4 nc (nc-nc)             
Female 5 1.4 367.6 (118.5-857.8)   Female 0 0.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.3 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 1 3.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.7 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 1 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.5 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.4 nc (nc-nc)             
Female 1 0.2 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 2.2 nc (nc-nc)   Male 15 15.4 97.3 (54.4-160.6) 
Female 1 2.4 nc (nc-nc)   Female 21 17.2 122.1 (75.5-186.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Dalton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 10.2 78.1 (33.6-154.0)   Male 6 6.2 97.4 (35.6-211.9) 
Female 4 3.5 nc (nc-nc)   Female 4 4.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.7 nc (nc-nc)   Male 2 2.0 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 3 5.4 nc (nc-nc) 
Female 24 36.2 66.2 (42.4-98.5)   Female 2 4.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 4.2 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 2 2.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 10.2 68.8 (27.6-141.7)             
Female 8 9.9 80.8 (34.8-159.2)   Female 3 3.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 2.4 nc (nc-nc)   Male 1 3.6 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 2 3.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.6 nc (nc-nc)   Male 22 26.1 84.4 (52.9-127.8) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 5.2 nc (nc-nc)   Male 1 2.3 nc (nc-nc) 
Female 3 3.0 nc (nc-nc)   Female 2 1.4 nc (nc-nc) 
Larynx            Testis     
Male 0 1.3 nc (nc-nc)   Male 2 1.0 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 3.8 nc (nc-nc)   Male 2 2.1 nc (nc-nc) 
Female 3 2.7 nc (nc-nc)   Female 0 5.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 3.2 nc (nc-nc)             
Female 0 1.1 nc (nc-nc)   Female 7 8.2 85.6 (34.3-176.3) 
Lung and Bronchus            All Sites / Types     
Male 18 17.3 104.2 (61.7-164.7)   Male 91 119.1 76.4 (61.5-93.8) 
Female 15 18.3 82.2 (46.0-135.5)   Female 90 123.8 72.7 (58.5-89.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
80 
Danvers 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 33 37.2 88.6 (61.0-124.5)   Male 15 22.8 65.9 (36.8-108.7) 
Female 18 13.7 131.8 (78.1-208.3)   Female 15 17.3 86.7 (48.5-143.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 12 6.2 192.3 (99.3-336.0)   Male 2 7.3 nc (nc-nc) 
Female 5 5.5 90.5 (29.2-211.3)   Female 3 6.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.2 nc (nc-nc)   Male 16 20.1 79.6 (45.5-129.3) 
Female 150 136.9 109.6 (92.7-128.6)   Female 21 17.9 117.4 (72.6-179.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 20 15.8 126.9 (77.5-195.9) 
Female 3 4.3 nc (nc-nc)   Female 9 7.7 116.5 (53.2-221.2) 
Colon / Rectum            Ovary     
Male 34 37.3 91.2 (63.1-127.4)             
Female 36 38.7 93.0 (65.2-128.8)   Female 13 11.9 108.9 (57.9-186.2) 
Esophagus            Pancreas     
Male 10 8.8 113.4 (54.3-208.5)   Male 15 13.3 112.8 (63.1-186.0) 
Female 3 2.6 nc (nc-nc)   Female 12 14.4 83.2 (42.9-145.3) 
Hodgkin Lymphoma            Prostate     
Male 2 2.2 nc (nc-nc)   Male 97 100.1 96.9 (78.6-118.3) 
Female 3 1.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 20 19.5 102.6 (62.7-158.5)   Male 6 8.4 71.1 (25.9-154.7) 
Female 16 11.2 142.4 (81.3-231.2)   Female 6 5.5 109.6 (40.0-238.6) 
Larynx            Testis     
Male 4 5.1 nc (nc-nc)   Male 7 4.0 173.9 (69.7-358.3) 
Female 1 1.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 14.2 63.3 (28.9-120.2)   Male 9 8.3 108.6 (49.5-206.1) 
Female 13 10.7 121.7 (64.7-208.1)   Female 31 23.1 134.0 (91.1-190.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 11.9 58.6 (23.5-120.8)             
Female 2 4.4 nc (nc-nc)   Female 41 30.4 134.9 (96.8-183.0) 
Lung and Bronchus            All Sites / Types     
Male 63 63.3 99.5 (76.4-127.3)   Male 424 444.2 95.5 (86.6-105.0) 
Female 65 68.8 94.5 (72.9-120.4)   Female 505 475.2 106.3 (97.2-116.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
81 
Dartmouth 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 53 42.2 125.6 (94.0-164.2)   Male 23 25.8 89.2 (56.5-133.9) 
Female 17 15.5 110.0 (64.0-176.1)   Female 11 19.5 56.5 (28.2-101.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 7.4 94.5 (37.8-194.6)   Male 5 8.3 60.4 (19.5-140.9) 
Female 6 6.5 92.7 (33.8-201.7)   Female 7 7.0 99.9 (40.0-205.9) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.4 nc (nc-nc)   Male 22 22.9 96.1 (60.2-145.5) 
Female 134 155.4 86.2 (72.3-102.1)   Female 17 20.3 83.9 (48.8-134.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 18 18.1 99.2 (58.8-156.8) 
Female 4 4.8 nc (nc-nc)   Female 6 8.9 67.7 (24.7-147.4) 
Colon / Rectum            Ovary     
Male 38 42.3 89.8 (63.5-123.2)             
Female 48 43.6 110.1 (81.2-146.0)   Female 9 13.6 66.1 (30.2-125.6) 
Esophagus            Pancreas     
Male 13 10.1 128.8 (68.5-220.3)   Male 15 15.1 99.4 (55.6-164.0) 
Female 2 3.0 nc (nc-nc)   Female 7 16.4 42.6 (17.0-87.7) 
Hodgkin Lymphoma            Prostate     
Male 3 2.9 nc (nc-nc)   Male 127 117.2 108.3 (90.3-128.9) 
Female 2 2.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 21 22.3 94.1 (58.2-143.9)   Male 13 9.6 135.7 (72.2-232.0) 
Female 15 12.7 117.9 (65.9-194.5)   Female 12 6.1 195.5 (100.9-341.5) 
Larynx            Testis     
Male 8 5.8 138.3 (59.5-272.5)   Male 4 4.8 nc (nc-nc) 
Female 1 1.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 15 16.4 91.5 (51.2-150.9)   Male 10 9.4 106.2 (50.8-195.3) 
Female 9 12.0 74.8 (34.1-142.0)   Female 36 25.9 138.8 (97.2-192.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 14 13.6 102.7 (56.1-172.4)             
Female 1 4.9 nc (nc-nc)   Female 27 35.3 76.5 (50.4-111.3) 
Lung and Bronchus            All Sites / Types     
Male 72 72.4 99.4 (77.8-125.2)   Male 511 510.0 100.2 (91.7-109.3) 
Female 50 78.3 63.9 (47.4-84.2)   Female 450 539.7 83.4 (75.9-91.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
82 
Dedham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 32 31.2 102.7 (70.2-145.0)   Male 25 18.9 132.1 (85.5-195.0) 
Female 15 12.9 116.3 (65.0-191.8)   Female 21 15.8 132.5 (82.0-202.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 5.4 148.3 (63.9-292.3)   Male 7 6.1 115.6 (46.3-238.2) 
Female 6 5.1 117.6 (43.0-256.0)   Female 4 5.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.0 nc (nc-nc)   Male 24 16.9 142.3 (91.2-211.8) 
Female 152 123.0 123.6 (104.7-144.9)   Female 18 16.6 108.1 (64.1-170.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 19 12.9 147.1 (88.5-229.8) 
Female 2 3.8 nc (nc-nc)   Female 11 7.1 155.2 (77.4-277.7) 
Colon / Rectum            Ovary     
Male 29 31.2 93.0 (62.3-133.5)             
Female 35 36.5 95.9 (66.8-133.4)   Female 6 11.0 54.7 (20.0-119.1) 
Esophagus            Pancreas     
Male 4 7.3 nc (nc-nc)   Male 17 11.0 153.9 (89.6-246.4) 
Female 3 2.4 nc (nc-nc)   Female 17 13.6 125.0 (72.8-200.2) 
Hodgkin Lymphoma            Prostate     
Male 0 2.0 nc (nc-nc)   Male 89 82.8 107.5 (86.4-132.3) 
Female 4 1.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 25 16.1 155.3 (100.4-229.2)   Male 8 7.0 113.7 (49.0-224.1) 
Female 14 10.3 135.5 (74.0-227.3)   Female 7 5.1 136.8 (54.8-282.0) 
Larynx            Testis     
Male 5 4.2 119.8 (38.6-279.5)   Male 6 3.9 154.9 (56.6-337.2) 
Female 1 1.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 12 12.1 99.5 (51.4-173.8)   Male 6 7.0 86.0 (31.4-187.2) 
Female 8 10.1 79.5 (34.2-156.6)   Female 25 20.6 121.1 (78.3-178.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 11 9.8 112.4 (56.0-201.1)             
Female 5 4.1 122.7 (39.5-286.3)   Female 27 27.1 99.7 (65.7-145.0) 
Lung and Bronchus            All Sites / Types     
Male 49 52.4 93.5 (69.2-123.6)   Male 419 370.3 113.2 (102.6-124.5) 
Female 81 64.2 126.1 (100.2-156.8)   Female 494 436.5 113.2 (103.4-123.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
83 
Deerfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 4.6 nc (nc-nc)   Male 6 3.3 179.7 (65.6-391.1) 
Female 3 2.3 nc (nc-nc)   Female 5 3.2 156.6 (50.5-365.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.0 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 3 2.9 nc (nc-nc) 
Female 19 26.4 72.0 (43.3-112.4)   Female 2 3.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 2.8 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 8 5.4 148.3 (63.8-292.2)             
Female 7 6.5 108.0 (43.3-222.6)   Female 1 2.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.3 nc (nc-nc)   Male 3 1.9 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 3 2.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.4 nc (nc-nc)   Male 16 17.0 94.1 (53.7-152.8) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 3.3 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 2.1 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Larynx            Testis     
Male 0 0.8 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.9 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 1 1.8 nc (nc-nc)   Female 1 4.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.0 nc (nc-nc)             
Female 0 0.8 nc (nc-nc)   Female 9 6.2 145.4 (66.3-276.0) 
Lung and Bronchus            All Sites / Types     
Male 4 8.6 nc (nc-nc)   Male 60 66.8 89.8 (68.5-115.6) 
Female 9 12.1 74.2 (33.8-140.8)   Female 71 86.8 81.8 (63.9-103.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
84 
Dennis 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 51 32.0 159.6 (118.8-209.9)   Male 37 18.0 205.5 (144.7-283.3) 
Female 16 11.6 138.4 (79.1-224.8)   Female 27 12.7 213.3 (140.5-310.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 4.4 nc (nc-nc)   Male 11 6.0 183.2 (91.3-327.9) 
Female 1 4.0 nc (nc-nc)   Female 5 5.1 97.5 (31.4-227.4) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.0 nc (nc-nc)   Male 13 15.7 82.7 (44.0-141.4) 
Female 116 107.3 108.1 (89.3-129.7)   Female 12 14.4 83.1 (42.9-145.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 14 11.6 120.6 (65.9-202.3) 
Female 4 2.6 nc (nc-nc)   Female 3 6.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 23 28.7 80.0 (50.7-120.1)             
Female 25 29.5 84.8 (54.8-125.1)   Female 19 9.4 203.1 (122.2-317.1) 
Esophagus            Pancreas     
Male 12 7.3 164.4 (84.9-287.3)   Male 9 11.0 81.8 (37.3-155.3) 
Female 6 2.2 267.4 (97.7-582.1)   Female 12 11.9 100.7 (52.0-175.9) 
Hodgkin Lymphoma            Prostate     
Male 1 1.2 nc (nc-nc)   Male 100 83.5 119.7 (97.4-145.6) 
Female 1 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 14.8 40.5 (14.8-88.1)   Male 2 6.9 nc (nc-nc) 
Female 7 9.2 76.4 (30.6-157.4)   Female 2 4.2 nc (nc-nc) 
Larynx            Testis     
Male 3 4.2 nc (nc-nc)   Male 2 1.5 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 11.1 90.2 (43.2-165.9)   Male 3 4.9 nc (nc-nc) 
Female 7 8.0 87.4 (35.0-180.2)   Female 13 13.8 94.1 (50.1-160.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 8 9.3 85.9 (37.0-169.2)             
Female 2 3.6 nc (nc-nc)   Female 22 25.8 85.1 (53.3-128.9) 
Lung and Bronchus            All Sites / Types     
Male 48 55.9 85.9 (63.4-113.9)   Male 391 358.5 109.1 (98.5-120.4) 
Female 63 61.9 101.8 (78.2-130.2)   Female 394 377.3 104.4 (94.4-115.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
85 
Dighton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 10 7.9 126.3 (60.5-232.4)   Male 8 5.3 149.8 (64.5-295.2) 
Female 0 2.9 nc (nc-nc)   Female 3 3.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 1.6 nc (nc-nc)   Male 1 1.7 nc (nc-nc) 
Female 0 1.3 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 5 4.7 106.8 (34.4-249.3) 
Female 26 31.4 82.8 (54.1-121.4)   Female 4 3.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 4.1 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 2 1.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 11 8.8 124.4 (62.0-222.7)             
Female 8 8.2 97.3 (41.9-191.7)   Female 3 2.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.1 nc (nc-nc)   Male 4 3.0 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 3 3.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.6 nc (nc-nc)   Male 21 24.4 86.1 (53.3-131.6) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 4.9 101.3 (32.6-236.3)   Male 2 1.9 nc (nc-nc) 
Female 4 2.6 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Larynx            Testis     
Male 1 1.2 nc (nc-nc)   Male 2 1.2 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 3.2 nc (nc-nc)   Male 4 2.3 nc (nc-nc) 
Female 0 2.4 nc (nc-nc)   Female 4 5.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 3.0 nc (nc-nc)             
Female 2 1.0 nc (nc-nc)   Female 9 7.1 127.2 (58.0-241.4) 
Lung and Bronchus            All Sites / Types     
Male 10 14.1 70.9 (33.9-130.3)   Male 110 104.6 105.1 (86.4-126.7) 
Female 15 15.2 98.9 (55.3-163.2)   Female 91 106.3 85.6 (68.9-105.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
86 
Douglas 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 8.2 134.8 (67.2-241.2)   Male 12 5.7 211.0 (108.9-368.6) 
Female 6 2.3 263.7 (96.3-574.0)   Female 2 4.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.8 nc (nc-nc)   Male 5 1.9 268.8 (86.6-627.2) 
Female 1 1.3 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 5 5.0 99.1 (31.9-231.3) 
Female 33 35.3 93.6 (64.4-131.4)   Female 1 3.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 4.5 132.7 (48.5-288.9) 
Female 2 1.3 nc (nc-nc)   Female 2 1.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 8 9.1 87.4 (37.7-172.3)             
Female 9 7.0 128.6 (58.7-244.1)   Female 3 2.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 2.3 nc (nc-nc)   Male 0 3.2 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 0 2.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.7 nc (nc-nc)   Male 25 27.5 90.9 (58.8-134.2) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 5.4 111.4 (40.7-242.4)   Male 2 2.0 nc (nc-nc) 
Female 3 2.6 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Larynx            Testis     
Male 1 1.4 nc (nc-nc)   Male 3 1.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 3.5 nc (nc-nc)   Male 5 2.5 196.1 (63.2-457.6) 
Female 2 2.0 nc (nc-nc)   Female 8 7.5 107.3 (46.2-211.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 3.3 nc (nc-nc)             
Female 0 0.9 nc (nc-nc)   Female 6 7.9 75.5 (27.6-164.3) 
Lung and Bronchus            All Sites / Types     
Male 16 15.0 106.4 (60.8-172.7)   Male 123 113.1 108.7 (90.4-129.7) 
Female 13 13.2 98.4 (52.3-168.2)   Female 104 106.5 97.7 (79.8-118.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
87 
Dover 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 8.0 nc (nc-nc)   Male 10 4.9 202.3 (96.9-372.1) 
Female 2 2.1 nc (nc-nc)   Female 3 3.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.4 nc (nc-nc)   Male 2 1.6 nc (nc-nc) 
Female 2 1.0 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.3 nc (nc-nc)   Male 7 4.3 161.2 (64.6-332.2) 
Female 31 27.7 111.8 (76.0-158.7)   Female 3 3.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 3.5 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 8.2 85.7 (34.3-176.5)             
Female 2 6.2 nc (nc-nc)   Female 2 2.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.9 nc (nc-nc)   Male 2 2.9 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 2 2.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 22 22.2 99.1 (62.1-150.0) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 4.3 115.2 (37.1-268.9)   Male 0 1.8 nc (nc-nc) 
Female 2 2.1 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Larynx            Testis     
Male 0 1.1 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 3.1 nc (nc-nc)   Male 4 1.8 nc (nc-nc) 
Female 0 1.7 nc (nc-nc)   Female 6 5.2 116.0 (42.3-252.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 2.6 nc (nc-nc)             
Female 0 0.7 nc (nc-nc)   Female 5 6.2 81.3 (26.2-189.7) 
Lung and Bronchus            All Sites / Types     
Male 8 13.9 57.7 (24.8-113.6)   Male 88 96.9 90.8 (72.8-111.9) 
Female 6 11.4 52.8 (19.3-114.9)   Female 72 86.4 83.4 (65.2-105.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
88 
Dracut 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 35 30.5 114.9 (80.0-159.8)   Male 15 20.3 73.8 (41.3-121.7) 
Female 17 10.6 160.5 (93.4-256.9)   Female 17 16.0 106.4 (61.9-170.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 9 6.3 142.3 (64.9-270.1)   Male 9 6.5 138.6 (63.3-263.2) 
Female 3 5.2 nc (nc-nc)   Female 4 5.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.1 nc (nc-nc)   Male 12 17.9 67.1 (34.6-117.2) 
Female 137 129.2 106.1 (89.0-125.4)   Female 12 15.1 79.2 (40.9-138.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 16 15.7 101.6 (58.1-165.1) 
Female 3 4.4 nc (nc-nc)   Female 10 6.9 146.0 (69.9-268.4) 
Colon / Rectum            Ovary     
Male 36 32.6 110.4 (77.3-152.9)             
Female 44 30.6 143.7 (104.4-192.9)   Female 11 11.1 99.2 (49.4-177.4) 
Esophagus            Pancreas     
Male 13 8.1 160.4 (85.3-274.3)   Male 9 11.6 77.8 (35.5-147.8) 
Female 4 2.1 nc (nc-nc)   Female 12 10.9 110.2 (56.9-192.5) 
Hodgkin Lymphoma            Prostate     
Male 0 2.6 nc (nc-nc)   Male 82 99.2 82.7 (65.8-102.6) 
Female 3 2.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 20 18.9 105.9 (64.6-163.5)   Male 11 7.3 150.2 (74.9-268.7) 
Female 16 10.2 157.4 (89.9-255.6)   Female 5 4.3 116.2 (37.4-271.2) 
Larynx            Testis     
Male 8 4.7 168.9 (72.7-332.8)   Male 5 4.9 101.8 (32.8-237.5) 
Female 0 1.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 16 12.8 124.9 (71.3-202.8)   Male 8 8.7 92.3 (39.8-181.9) 
Female 5 8.9 56.4 (18.2-131.7)   Female 24 25.4 94.5 (60.5-140.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 12 11.6 103.6 (53.4-180.9)             
Female 4 3.7 nc (nc-nc)   Female 27 29.7 90.8 (59.8-132.1) 
Lung and Bronchus            All Sites / Types     
Male 81 55.1 147.1 (116.8-182.8)   Male 445 407.5 109.2 (99.3-119.8) 
Female 75 57.3 130.9 (103.0-164.1)   Female 472 422.1 111.8 (102.0-122.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
89 
Dudley 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 11.4 105.0 (54.2-183.4)   Male 5 7.6 65.7 (21.2-153.4) 
Female 3 3.3 nc (nc-nc)   Female 7 5.2 133.4 (53.4-274.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 2.4 nc (nc-nc)   Male 4 2.5 nc (nc-nc) 
Female 2 1.8 nc (nc-nc)   Female 2 1.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 5 6.8 73.6 (23.7-171.7) 
Female 46 42.8 107.6 (78.8-143.5)   Female 5 4.8 103.9 (33.5-242.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 5.7 nc (nc-nc) 
Female 2 1.5 nc (nc-nc)   Female 3 2.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 11 12.2 90.4 (45.1-161.8)             
Female 11 9.9 111.2 (55.4-199.0)   Female 3 3.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 3.0 nc (nc-nc)   Male 4 4.3 nc (nc-nc) 
Female 3 0.7 nc (nc-nc)   Female 2 3.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.9 nc (nc-nc)   Male 34 35.1 96.8 (67.0-135.3) 
Female 2 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 16 6.9 232.1 (132.6-377.0)   Male 3 2.7 nc (nc-nc) 
Female 7 3.3 214.8 (86.0-442.5)   Female 0 1.4 nc (nc-nc) 
Larynx            Testis     
Male 1 1.8 nc (nc-nc)   Male 1 1.7 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 4.8 186.8 (85.2-354.6)   Male 2 3.2 nc (nc-nc) 
Female 6 2.9 206.9 (75.6-450.4)   Female 11 8.8 124.5 (62.1-222.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 4.3 nc (nc-nc)             
Female 1 1.2 nc (nc-nc)   Female 16 9.7 165.5 (94.6-268.8) 
Lung and Bronchus            All Sites / Types     
Male 20 20.5 97.4 (59.5-150.5)   Male 155 150.2 103.2 (87.6-120.8) 
Female 26 17.4 149.3 (97.5-218.8)   Female 172 137.1 125.4 (107.4-145.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
90 
Dunstable 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 3.5 nc (nc-nc)   Male 4 2.3 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 2 2.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 0.7 nc (nc-nc)   Male 2 0.8 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 2 2.1 nc (nc-nc) 
Female 14 16.7 83.8 (45.8-140.6)   Female 2 1.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.9 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 2 0.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 3.9 129.5 (41.7-302.3)             
Female 1 3.8 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 0.9 nc (nc-nc)   Male 0 1.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 10 11.4 87.6 (41.9-161.1) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 2.2 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Larynx            Testis     
Male 1 0.6 nc (nc-nc)   Male 3 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.4 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 2 3.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.3 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 5 3.7 136.0 (43.8-317.4) 
Lung and Bronchus            All Sites / Types     
Male 3 6.2 nc (nc-nc)   Male 42 46.7 89.9 (64.8-121.5) 
Female 8 6.5 122.8 (52.9-242.0)   Female 45 51.9 86.8 (63.3-116.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
91 
Duxbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 26 19.3 134.5 (87.8-197.0)   Male 31 12.3 251.8 (171.0-357.4) 
Female 2 6.4 nc (nc-nc)   Female 12 9.2 131.0 (67.6-228.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 3.5 141.2 (45.5-329.6)   Male 9 4.1 221.5 (101.1-420.5) 
Female 1 2.9 nc (nc-nc)   Female 2 3.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.7 nc (nc-nc)   Male 18 10.9 164.9 (97.7-260.6) 
Female 85 77.2 110.1 (88.0-136.2)   Female 6 8.9 67.2 (24.5-146.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 9.6 52.3 (16.9-122.0) 
Female 2 2.5 nc (nc-nc)   Female 4 4.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 20.3 nc (nc-nc)             
Female 12 19.0 63.0 (32.5-110.1)   Female 9 6.5 138.5 (63.2-263.0) 
Esophagus            Pancreas     
Male 3 5.1 nc (nc-nc)   Male 4 7.3 nc (nc-nc) 
Female 2 1.3 nc (nc-nc)   Female 8 6.8 118.1 (50.8-232.7) 
Hodgkin Lymphoma            Prostate     
Male 1 1.1 nc (nc-nc)   Male 74 62.9 117.6 (92.3-147.6) 
Female 0 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 16 11.5 138.7 (79.2-225.2)   Male 2 4.6 nc (nc-nc) 
Female 3 5.9 nc (nc-nc)   Female 0 2.6 nc (nc-nc) 
Larynx            Testis     
Male 1 2.9 nc (nc-nc)   Male 2 1.9 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 7.6 104.7 (45.1-206.4)   Male 2 4.8 nc (nc-nc) 
Female 7 5.2 134.8 (54.0-277.7)   Female 8 13.6 58.7 (25.3-115.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 7.1 nc (nc-nc)             
Female 0 2.2 nc (nc-nc)   Female 11 17.5 63.0 (31.4-112.7) 
Lung and Bronchus            All Sites / Types     
Male 27 34.3 78.7 (51.9-114.6)   Male 252 251.0 100.4 (88.4-113.6) 
Female 22 33.4 65.8 (41.2-99.7)   Female 216 249.5 86.6 (75.4-98.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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East Bridgewater 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 16 14.1 113.8 (65.0-184.8)   Male 12 9.3 129.0 (66.6-225.3) 
Female 2 6.3 nc (nc-nc)   Female 10 8.6 116.5 (55.8-214.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.8 nc (nc-nc)   Male 1 3.0 nc (nc-nc) 
Female 3 2.8 nc (nc-nc)   Female 1 2.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 9 8.2 109.1 (49.8-207.2) 
Female 53 71.1 74.5 (55.8-97.5)   Female 11 8.5 128.8 (64.2-230.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 7.0 128.8 (58.8-244.5) 
Female 2 2.2 nc (nc-nc)   Female 1 3.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 19 15.1 125.9 (75.8-196.6)             
Female 10 17.6 56.9 (27.2-104.6)   Female 7 6.1 115.2 (46.2-237.4) 
Esophagus            Pancreas     
Male 6 3.6 165.2 (60.3-359.6)   Male 3 5.3 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 7 6.5 108.4 (43.4-223.3) 
Hodgkin Lymphoma            Prostate     
Male 0 1.1 nc (nc-nc)   Male 51 43.6 117.0 (87.1-153.8) 
Female 1 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 15 8.6 175.3 (98.1-289.2)   Male 0 3.4 nc (nc-nc) 
Female 5 5.7 87.6 (28.2-204.5)   Female 3 2.5 nc (nc-nc) 
Larynx            Testis     
Male 3 2.1 nc (nc-nc)   Male 3 2.1 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 5.8 nc (nc-nc)   Male 2 4.0 nc (nc-nc) 
Female 4 5.0 nc (nc-nc)   Female 11 12.7 86.9 (43.3-155.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 5.1 nc (nc-nc)             
Female 1 2.1 nc (nc-nc)   Female 10 16.2 61.9 (29.6-113.9) 
Lung and Bronchus            All Sites / Types     
Male 24 25.1 95.5 (61.2-142.1)   Male 199 184.0 108.2 (93.7-124.3) 
Female 22 34.0 64.7 (40.5-98.0)   Female 179 235.8 75.9 (65.2-87.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
93 
East Brookfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 3.4 nc (nc-nc)   Male 1 2.0 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 0.5 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 2 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 6 9.8 61.3 (22.4-133.4)   Female 0 1.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 3.4 nc (nc-nc)             
Female 0 2.2 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 0.8 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 10 9.4 106.4 (50.9-195.6) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 1.7 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 1 0.5 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.2 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 2 1.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 1.0 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 5 2.3 214.8 (69.2-501.2) 
Lung and Bronchus            All Sites / Types     
Male 5 5.6 89.3 (28.8-208.4)   Male 40 39.7 100.8 (72.0-137.3) 
Female 7 4.2 166.7 (66.8-343.5)   Female 29 31.3 92.7 (62.1-133.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
94 
East Longmeadow 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 23.0 60.9 (33.3-102.2)   Male 13 13.7 94.9 (50.5-162.3) 
Female 5 8.6 58.1 (18.7-135.6)   Female 11 10.9 101.2 (50.5-181.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 3.7 nc (nc-nc)   Male 4 4.4 nc (nc-nc) 
Female 4 3.5 nc (nc-nc)   Female 4 3.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.8 nc (nc-nc)   Male 14 12.1 115.3 (63.0-193.5) 
Female 80 86.0 93.0 (73.8-115.8)   Female 11 11.3 97.0 (48.3-173.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 9.7 103.6 (49.6-190.6) 
Female 0 2.6 nc (nc-nc)   Female 3 4.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 25 22.9 108.9 (70.5-160.8)             
Female 33 24.2 136.4 (93.8-191.5)   Female 11 7.5 145.9 (72.8-261.1) 
Esophagus            Pancreas     
Male 3 5.4 nc (nc-nc)   Male 7 8.2 85.9 (34.4-176.9) 
Female 2 1.6 nc (nc-nc)   Female 7 9.0 77.4 (31.0-159.6) 
Hodgkin Lymphoma            Prostate     
Male 1 1.3 nc (nc-nc)   Male 52 62.8 82.8 (61.9-108.6) 
Female 0 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 14 11.8 118.7 (64.9-199.2)   Male 4 5.2 nc (nc-nc) 
Female 5 7.1 70.8 (22.8-165.2)   Female 6 3.4 174.4 (63.7-379.6) 
Larynx            Testis     
Male 2 3.1 nc (nc-nc)   Male 2 2.1 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 8.7 nc (nc-nc)   Male 3 4.8 nc (nc-nc) 
Female 3 6.7 nc (nc-nc)   Female 12 14.3 83.7 (43.2-146.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 7.3 nc (nc-nc)             
Female 1 2.8 nc (nc-nc)   Female 22 19.3 113.8 (71.3-172.2) 
Lung and Bronchus            All Sites / Types     
Male 37 38.3 96.7 (68.1-133.2)   Male 231 271.7 85.0 (74.4-96.7) 
Female 45 43.4 103.7 (75.6-138.7)   Female 288 298.6 96.5 (85.6-108.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
95 
Eastham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 10.9 128.7 (70.3-216.0)   Male 13 6.1 211.5 (112.5-361.7) 
Female 1 3.5 nc (nc-nc)   Female 6 4.0 148.8 (54.3-323.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 1.5 nc (nc-nc)   Male 2 2.0 nc (nc-nc) 
Female 0 1.3 nc (nc-nc)   Female 3 1.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 5 5.3 93.5 (30.1-218.2) 
Female 50 34.2 146.2 (108.5-192.7)   Female 6 4.5 133.7 (48.8-291.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 4.2 168.3 (67.4-346.8) 
Female 1 0.9 nc (nc-nc)   Female 3 2.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 14 10.0 140.5 (76.7-235.7)             
Female 9 9.2 97.8 (44.6-185.7)   Female 3 3.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.5 nc (nc-nc)   Male 4 3.8 nc (nc-nc) 
Female 2 0.7 nc (nc-nc)   Female 7 3.6 192.8 (77.2-397.2) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 32 29.7 107.6 (73.6-151.9) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 5.2 97.0 (31.3-226.4)   Male 0 2.4 nc (nc-nc) 
Female 2 2.9 nc (nc-nc)   Female 3 1.3 nc (nc-nc) 
Larynx            Testis     
Male 2 1.4 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 3.8 185.0 (74.1-381.3)   Male 2 1.7 nc (nc-nc) 
Female 1 2.5 nc (nc-nc)   Female 2 4.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.3 nc (nc-nc)             
Female 1 1.1 nc (nc-nc)   Female 3 8.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 28 18.7 149.5 (99.3-216.1)   Male 156 123.9 125.9 (106.9-147.3) 
Female 14 19.0 73.7 (40.3-123.7)   Female 127 118.8 106.9 (89.1-127.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Easthampton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 19.4 61.7 (31.8-107.8)   Male 10 12.6 79.6 (38.1-146.4) 
Female 5 6.8 73.6 (23.7-171.7)   Female 4 9.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 3.6 nc (nc-nc)   Male 2 4.0 nc (nc-nc) 
Female 3 3.0 nc (nc-nc)   Female 3 3.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.7 nc (nc-nc)   Male 15 11.1 135.6 (75.8-223.6) 
Female 75 76.2 98.4 (77.4-123.4)   Female 7 9.4 74.4 (29.8-153.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 9.3 107.1 (51.3-196.9) 
Female 1 2.4 nc (nc-nc)   Female 4 4.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 26 20.3 127.9 (83.6-187.5)             
Female 18 19.3 93.1 (55.1-147.1)   Female 1 6.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 4.9 nc (nc-nc)   Male 7 7.3 96.5 (38.7-198.8) 
Female 1 1.3 nc (nc-nc)   Female 11 7.0 156.2 (77.9-279.5) 
Hodgkin Lymphoma            Prostate     
Male 2 1.4 nc (nc-nc)   Male 45 59.5 75.6 (55.2-101.2) 
Female 0 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 14 11.3 123.8 (67.6-207.8)   Male 6 4.6 130.9 (47.8-284.8) 
Female 6 6.1 98.4 (35.9-214.1)   Female 2 2.7 nc (nc-nc) 
Larynx            Testis     
Male 3 2.9 nc (nc-nc)   Male 1 2.6 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 7.6 65.4 (21.1-152.6)   Male 1 5.0 nc (nc-nc) 
Female 4 5.4 nc (nc-nc)   Female 8 14.0 57.1 (24.6-112.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 7.0 nc (nc-nc)             
Female 5 2.3 215.5 (69.5-503.0)   Female 23 17.7 130.0 (82.4-195.1) 
Lung and Bronchus            All Sites / Types     
Male 26 34.7 74.9 (48.9-109.8)   Male 207 249.3 83.0 (72.1-95.1) 
Female 43 35.7 120.5 (87.2-162.3)   Female 244 255.3 95.6 (83.9-108.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
97 
Easton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 28 21.9 128.1 (85.1-185.1)   Male 23 14.6 157.8 (100.0-236.8) 
Female 12 7.9 151.3 (78.1-264.3)   Female 10 11.9 84.1 (40.3-154.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 4.6 130.4 (47.6-283.8)   Male 4 4.7 nc (nc-nc) 
Female 4 4.0 nc (nc-nc)   Female 7 3.8 184.1 (73.8-379.3) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.8 nc (nc-nc)   Male 10 13.0 77.1 (36.9-141.9) 
Female 113 98.7 114.5 (94.3-137.6)   Female 12 11.4 105.3 (54.3-183.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 11.4 87.8 (42.0-161.5) 
Female 3 3.3 nc (nc-nc)   Female 5 5.1 97.2 (31.3-226.8) 
Colon / Rectum            Ovary     
Male 14 23.7 59.1 (32.3-99.2)             
Female 26 22.9 113.5 (74.1-166.4)   Female 11 8.3 132.9 (66.3-237.9) 
Esophagus            Pancreas     
Male 4 5.9 nc (nc-nc)   Male 12 8.3 144.2 (74.4-251.9) 
Female 2 1.6 nc (nc-nc)   Female 12 8.2 147.1 (75.9-256.9) 
Hodgkin Lymphoma            Prostate     
Male 3 1.8 nc (nc-nc)   Male 94 71.8 130.8 (105.7-160.1) 
Female 0 1.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 17 13.8 123.4 (71.8-197.5)   Male 3 5.3 nc (nc-nc) 
Female 5 7.6 65.4 (21.1-152.5)   Female 3 3.2 nc (nc-nc) 
Larynx            Testis     
Male 2 3.4 nc (nc-nc)   Male 1 3.2 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 16 9.2 173.0 (98.8-280.9)   Male 6 6.2 96.6 (35.3-210.2) 
Female 3 6.6 nc (nc-nc)   Female 20 19.1 104.7 (64.0-161.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 10 8.3 120.6 (57.7-221.8)             
Female 5 2.7 182.3 (58.8-425.4)   Female 21 22.3 94.0 (58.2-143.7) 
Lung and Bronchus            All Sites / Types     
Male 34 39.7 85.6 (59.3-119.7)   Male 324 293.9 110.2 (98.6-122.9) 
Female 50 43.1 115.9 (86.0-152.8)   Female 354 318.7 111.1 (99.8-123.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
98 
Edgartown 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 6.8 87.9 (32.1-191.3)   Male 18 4.3 415.6 (246.2-656.8) 
Female 2 1.8 nc (nc-nc)   Female 3 2.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.2 nc (nc-nc)   Male 2 1.4 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 5 3.8 130.8 (42.1-305.2) 
Female 29 19.9 146.0 (97.8-209.8)   Female 1 2.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 3.4 178.4 (65.1-388.3) 
Female 0 0.6 nc (nc-nc)   Female 3 1.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 7.1 140.1 (67.1-257.7)             
Female 4 5.1 nc (nc-nc)   Female 0 1.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.8 nc (nc-nc)   Male 0 2.5 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 3 1.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 24 21.7 110.7 (70.9-164.8) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 4.0 nc (nc-nc)   Male 2 1.6 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Larynx            Testis     
Male 1 1.0 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 2.7 nc (nc-nc)   Male 3 1.7 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)   Female 6 3.2 185.5 (67.8-403.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 2.5 nc (nc-nc)             
Female 1 0.6 nc (nc-nc)   Female 1 4.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 13 11.7 110.6 (58.9-189.2)   Male 101 87.5 115.4 (94.0-140.2) 
Female 9 9.6 93.5 (42.7-177.6)   Female 72 66.4 108.5 (84.9-136.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Egremont 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 2.7 nc (nc-nc)   Male 0 1.6 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 2 0.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.4 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.4 nc (nc-nc) 
Female 6 7.4 81.5 (29.8-177.4)   Female 1 1.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.1 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 2.6 194.2 (62.6-453.3)             
Female 1 2.1 nc (nc-nc)   Female 2 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.6 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 6 7.7 77.9 (28.5-169.7) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.4 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.4 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.9 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.9 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 2 1.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 4.6 nc (nc-nc)   Male 22 31.7 69.5 (43.5-105.2) 
Female 3 4.0 nc (nc-nc)   Female 25 25.8 96.9 (62.7-143.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Erving 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 2.0 nc (nc-nc)   Male 0 1.3 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 4 8.7 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.0 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 2.2 nc (nc-nc)             
Female 1 2.1 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.5 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 2 0.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 1 6.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.2 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.8 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.8 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 4 1.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 5 3.6 140.3 (45.2-327.3)   Male 18 26.7 67.3 (39.9-106.4) 
Female 3 4.1 nc (nc-nc)   Female 21 28.7 73.2 (45.3-111.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Essex 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 5.1 nc (nc-nc)   Male 7 3.2 220.2 (88.2-453.8) 
Female 1 1.4 nc (nc-nc)   Female 2 2.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.9 nc (nc-nc)   Male 2 1.1 nc (nc-nc) 
Female 3 0.7 nc (nc-nc)   Female 2 0.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 3 2.8 nc (nc-nc) 
Female 18 17.5 102.8 (60.9-162.5)   Female 3 2.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 2.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 5.2 nc (nc-nc)             
Female 4 4.0 nc (nc-nc)   Female 4 1.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.3 nc (nc-nc)   Male 3 1.9 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 2 1.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 9 16.2 55.6 (25.4-105.6) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 2.9 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Larynx            Testis     
Male 0 0.8 nc (nc-nc)   Male 2 0.5 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 2.0 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 2 3.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.8 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 2 4.1 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 10 8.9 112.3 (53.7-206.5)   Male 58 64.8 89.5 (68.0-115.7) 
Female 9 8.0 112.8 (51.5-214.2)   Female 59 56.5 104.5 (79.5-134.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
102 
Everett 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 32 37.4 85.6 (58.5-120.8)   Male 22 25.0 88.1 (55.2-133.5) 
Female 12 13.6 88.0 (45.4-153.7)   Female 9 20.9 43.0 (19.6-81.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 8.0 nc (nc-nc)   Male 9 7.8 114.7 (52.3-217.7) 
Female 4 7.0 nc (nc-nc)   Female 2 6.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.3 nc (nc-nc)   Male 22 22.2 99.0 (62.0-150.0) 
Female 146 161.2 90.6 (76.5-106.5)   Female 17 19.5 87.2 (50.8-139.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 18 18.4 98.0 (58.1-154.9) 
Female 13 5.9 219.1 (116.5-374.7)   Female 11 8.6 127.7 (63.7-228.5) 
Colon / Rectum            Ovary     
Male 40 40.0 99.9 (71.4-136.0)             
Female 27 40.4 66.8 (44.0-97.2)   Female 12 13.9 86.4 (44.6-150.9) 
Esophagus            Pancreas     
Male 11 9.5 115.4 (57.5-206.6)   Male 15 13.9 107.8 (60.3-177.8) 
Female 2 2.7 nc (nc-nc)   Female 13 14.2 91.3 (48.6-156.2) 
Hodgkin Lymphoma            Prostate     
Male 2 3.5 nc (nc-nc)   Male 88 111.1 79.2 (63.5-97.6) 
Female 2 3.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 26 22.5 115.3 (75.3-169.0)   Male 16 8.9 179.6 (102.6-291.6) 
Female 15 12.7 118.0 (66.0-194.6)   Female 7 5.7 123.5 (49.5-254.5) 
Larynx            Testis     
Male 8 5.6 143.8 (61.9-283.4)   Male 7 7.1 98.6 (39.5-203.1) 
Female 5 1.7 294.3 (94.8-686.7)             
Leukemia            Thyroid     
Male 17 16.1 105.7 (61.5-169.3)   Male 13 11.0 118.0 (62.8-201.8) 
Female 11 11.8 92.9 (46.3-166.2)   Female 29 34.3 84.7 (56.7-121.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 22 13.4 164.3 (102.9-248.7)             
Female 6 4.6 130.1 (47.5-283.1)   Female 27 35.6 75.9 (50.0-110.5) 
Lung and Bronchus            All Sites / Types     
Male 69 66.3 104.0 (80.9-131.6)   Male 470 488.5 96.2 (87.7-105.3) 
Female 73 71.0 102.8 (80.6-129.3)   Female 478 537.3 89.0 (81.2-97.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
103 
Fairhaven 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 24 22.5 106.8 (68.4-158.9)   Male 8 13.8 58.0 (25.0-114.2) 
Female 20 8.6 232.5 (142.0-359.1)   Female 5 10.7 46.5 (15.0-108.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 3.8 nc (nc-nc)   Male 7 4.4 157.5 (63.1-324.5) 
Female 3 3.4 nc (nc-nc)   Female 4 3.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.8 nc (nc-nc)   Male 11 12.1 90.6 (45.2-162.2) 
Female 80 85.7 93.4 (74.1-116.2)   Female 15 11.2 134.4 (75.1-221.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 9.9 50.3 (16.2-117.4) 
Female 4 2.6 nc (nc-nc)   Female 3 4.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 17 22.7 74.8 (43.6-119.8)             
Female 22 24.0 91.8 (57.5-139.0)   Female 14 7.6 184.5 (100.8-309.5) 
Esophagus            Pancreas     
Male 2 5.5 nc (nc-nc)   Male 6 8.1 73.9 (27.0-160.8) 
Female 2 1.6 nc (nc-nc)   Female 7 9.0 77.6 (31.1-159.9) 
Hodgkin Lymphoma            Prostate     
Male 0 1.3 nc (nc-nc)   Male 62 64.9 95.5 (73.2-122.4) 
Female 2 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 17 12.1 140.2 (81.6-224.5)   Male 3 5.1 nc (nc-nc) 
Female 7 7.1 98.4 (39.4-202.8)   Female 3 3.4 nc (nc-nc) 
Larynx            Testis     
Male 5 3.1 159.3 (51.3-371.7)   Male 4 2.4 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 8.5 70.2 (25.6-152.8)   Male 3 5.1 nc (nc-nc) 
Female 10 6.5 153.1 (73.3-281.7)   Female 14 14.0 99.7 (54.5-167.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 7.5 nc (nc-nc)             
Female 1 2.8 nc (nc-nc)   Female 18 19.7 91.4 (54.2-144.5) 
Lung and Bronchus            All Sites / Types     
Male 39 38.6 101.1 (71.9-138.2)   Male 245 274.5 89.3 (78.4-101.2) 
Female 36 44.2 81.5 (57.1-112.8)   Female 286 297.9 96.0 (85.2-107.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
104 
Fall River 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 101 87.6 115.3 (93.9-140.1)   Male 26 56.4 46.1 (30.1-67.6) 
Female 37 38.3 96.7 (68.0-133.2)   Female 24 51.4 46.7 (29.9-69.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 17 17.2 99.1 (57.7-158.7)   Male 12 17.9 66.9 (34.5-116.9) 
Female 14 16.7 83.6 (45.7-140.3)   Female 13 17.5 74.1 (39.4-126.7) 
Breast            Non-Hodgkin Lymphoma     
Male 3 3.1 nc (nc-nc)   Male 48 50.1 95.8 (70.6-127.0) 
Female 317 403.6 78.5 (70.1-87.7)   Female 38 51.5 73.7 (52.2-101.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 38 41.6 91.4 (64.7-125.5) 
Female 19 13.0 145.7 (87.7-227.5)   Female 22 22.4 98.0 (61.4-148.4) 
Colon / Rectum            Ovary     
Male 108 92.0 117.4 (96.3-141.7)             
Female 115 109.0 105.6 (87.1-126.7)   Female 18 35.3 51.0 (30.2-80.7) 
Esophagus            Pancreas     
Male 18 22.0 81.9 (48.5-129.4)   Male 35 32.4 108.1 (75.3-150.3) 
Female 4 7.4 nc (nc-nc)   Female 42 40.1 104.7 (75.4-141.5) 
Hodgkin Lymphoma            Prostate     
Male 10 7.0 143.8 (68.8-264.5)   Male 278 262.7 105.8 (93.8-119.0) 
Female 7 6.7 104.2 (41.8-214.7)             
Kidney & Renal Pelvis            Stomach     
Male 56 50.8 110.2 (83.3-143.1)   Male 34 20.6 165.4 (114.5-231.1) 
Female 35 32.9 106.5 (74.2-148.1)   Female 28 15.3 182.5 (121.2-263.8) 
Larynx            Testis     
Male 17 12.8 132.7 (77.3-212.6)   Male 12 13.4 89.9 (46.4-157.0) 
Female 8 4.6 175.2 (75.4-345.2)             
Leukemia            Thyroid     
Male 35 35.9 97.4 (67.9-135.5)   Male 16 23.1 69.2 (39.5-112.4) 
Female 34 30.7 110.7 (76.6-154.6)   Female 91 73.9 123.2 (99.2-151.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 36 30.5 117.9 (82.5-163.2)             
Female 10 12.4 80.8 (38.7-148.6)   Female 93 90.4 102.9 (83.0-126.0) 
Lung and Bronchus            All Sites / Types     
Male 258 153.3 168.3 (148.4-190.2)   Male 1256 1119.3 112.2 (106.1-118.6) 
Female 200 197.5 101.3 (87.7-116.3)   Female 1277 1384.9 92.2 (87.2-97.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
105 
Falmouth 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 47 57.2 82.1 (60.3-109.2)   Male 36 33.5 107.4 (75.2-148.7) 
Female 13 20.9 62.1 (33.0-106.2)   Female 33 24.2 136.5 (93.9-191.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 14 8.6 162.2 (88.6-272.2)   Male 8 11.0 73.0 (31.4-143.9) 
Female 10 7.6 131.2 (62.8-241.3)   Female 10 9.3 107.1 (51.3-197.0) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.9 nc (nc-nc)   Male 32 29.3 109.1 (74.6-154.1) 
Female 204 199.8 102.1 (88.6-117.1)   Female 13 26.5 49.1 (26.1-84.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 28 23.0 121.8 (80.9-176.1) 
Female 2 5.3 nc (nc-nc)   Female 11 11.5 96.0 (47.9-171.8) 
Colon / Rectum            Ovary     
Male 52 54.6 95.2 (71.1-124.8)             
Female 52 55.8 93.2 (69.6-122.2)   Female 22 17.5 125.5 (78.6-190.0) 
Esophagus            Pancreas     
Male 12 13.4 89.5 (46.2-156.4)   Male 14 20.2 69.3 (37.9-116.4) 
Female 5 4.0 124.6 (40.1-290.7)   Female 14 21.8 64.2 (35.1-107.8) 
Hodgkin Lymphoma            Prostate     
Male 2 2.6 nc (nc-nc)   Male 183 157.1 116.5 (100.2-134.6) 
Female 2 2.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 29 28.6 101.5 (68.0-145.8)   Male 10 12.7 78.7 (37.7-144.7) 
Female 15 16.9 88.9 (49.7-146.7)   Female 3 7.9 nc (nc-nc) 
Larynx            Testis     
Male 13 7.7 168.3 (89.5-287.8)   Male 4 3.8 nc (nc-nc) 
Female 2 2.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 29 20.7 140.4 (94.0-201.6)   Male 8 10.5 76.5 (32.9-150.7) 
Female 6 15.1 39.6 (14.5-86.3)   Female 15 28.8 52.1 (29.1-85.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 17 17.7 96.1 (56.0-153.9)             
Female 3 6.5 nc (nc-nc)   Female 33 46.5 70.9 (48.8-99.6) 
Lung and Bronchus            All Sites / Types     
Male 74 99.3 74.5 (58.5-93.5)   Male 665 667.4 99.6 (92.2-107.5) 
Female 118 110.2 107.1 (88.6-128.2)   Female 644 699.6 92.1 (85.1-99.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
106 
Fitchburg 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 52 39.9 130.4 (97.4-171.0)   Male 17 25.8 66.0 (38.4-105.6) 
Female 20 13.8 145.1 (88.6-224.1)   Female 15 19.2 78.2 (43.7-129.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 8.0 nc (nc-nc)   Male 4 8.2 nc (nc-nc) 
Female 13 6.6 198.4 (105.5-339.2)   Female 6 6.3 94.8 (34.6-206.4) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.4 nc (nc-nc)   Male 13 22.9 56.8 (30.2-97.2) 
Female 147 151.5 97.0 (82.0-114.1)   Female 15 18.7 80.1 (44.8-132.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 22 18.7 117.5 (73.6-178.0) 
Female 8 5.0 160.1 (68.9-315.5)   Female 8 8.3 96.5 (41.6-190.2) 
Colon / Rectum            Ovary     
Male 40 41.8 95.6 (68.3-130.2)             
Female 45 39.5 114.0 (83.1-152.5)   Female 12 13.2 90.7 (46.8-158.5) 
Esophagus            Pancreas     
Male 6 9.9 60.4 (22.0-131.4)   Male 17 14.7 115.9 (67.5-185.6) 
Female 2 2.6 nc (nc-nc)   Female 9 14.3 62.8 (28.6-119.2) 
Hodgkin Lymphoma            Prostate     
Male 2 3.3 nc (nc-nc)   Male 84 115.1 73.0 (58.2-90.3) 
Female 1 2.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 27 22.9 117.9 (77.7-171.6)   Male 12 9.3 128.4 (66.2-224.2) 
Female 16 12.3 129.8 (74.2-210.9)   Female 6 5.5 108.6 (39.7-236.5) 
Larynx            Testis     
Male 4 5.8 nc (nc-nc)   Male 6 6.2 96.0 (35.1-209.0) 
Female 2 1.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 14 16.6 84.4 (46.1-141.5)   Male 8 10.5 75.9 (32.7-149.5) 
Female 17 11.6 147.0 (85.6-235.4)   Female 32 29.1 110.1 (75.3-155.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 16 13.8 115.9 (66.2-188.3)             
Female 6 4.5 133.5 (48.7-290.5)   Female 29 33.5 86.5 (57.9-124.2) 
Lung and Bronchus            All Sites / Types     
Male 86 69.8 123.1 (98.5-152.1)   Male 478 505.9 94.5 (86.2-103.3) 
Female 76 72.7 104.6 (82.4-130.9)   Female 534 514.3 103.8 (95.2-113.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Florida 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 0.8 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 3 3.9 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 0.9 nc (nc-nc)             
Female 0 0.9 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.2 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 1 2.8 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.5 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 1 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.3 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 1.5 nc (nc-nc)   Male 10 10.9 92.1 (44.1-169.5) 
Female 2 1.8 nc (nc-nc)   Female 8 12.6 63.5 (27.3-125.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Foxborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 16 21.3 75.1 (42.9-121.9)   Male 24 13.2 182.3 (116.7-271.2) 
Female 1 7.2 nc (nc-nc)   Female 11 9.9 111.1 (55.4-198.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 3.7 216.7 (93.3-427.0)   Male 2 4.2 nc (nc-nc) 
Female 3 3.2 nc (nc-nc)   Female 3 3.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.7 nc (nc-nc)   Male 11 11.7 93.9 (46.8-168.0) 
Female 98 80.1 122.3 (99.3-149.1)   Female 7 9.8 71.2 (28.5-146.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 9.4 85.4 (36.8-168.4) 
Female 1 2.6 nc (nc-nc)   Female 2 4.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 20 22.0 91.1 (55.6-140.7)             
Female 20 20.4 98.0 (59.8-151.4)   Female 6 6.9 87.1 (31.8-189.6) 
Esophagus            Pancreas     
Male 6 5.1 116.9 (42.7-254.4)   Male 4 7.7 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)   Female 6 7.5 80.3 (29.3-174.8) 
Hodgkin Lymphoma            Prostate     
Male 5 1.4 364.5 (117.5-850.5)   Male 63 58.3 108.1 (83.0-138.2) 
Female 0 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 19 11.4 166.7 (100.3-260.3)   Male 8 4.9 163.8 (70.5-322.8) 
Female 8 6.4 124.6 (53.7-245.6)   Female 3 2.9 nc (nc-nc) 
Larynx            Testis     
Male 1 2.9 nc (nc-nc)   Male 3 2.6 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 8.3 121.2 (58.0-222.9)   Male 7 5.0 139.2 (55.8-286.8) 
Female 6 5.8 103.6 (37.8-225.6)   Female 20 14.5 137.5 (84.0-212.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 7.0 nc (nc-nc)             
Female 1 2.4 nc (nc-nc)   Female 18 18.2 98.8 (58.5-156.2) 
Lung and Bronchus            All Sites / Types     
Male 34 35.6 95.6 (66.2-133.5)   Male 274 257.9 106.3 (94.1-119.6) 
Female 42 37.8 111.2 (80.1-150.3)   Female 278 268.2 103.6 (91.8-116.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
109 
Framingham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 65 67.5 96.2 (74.3-122.7)   Male 48 44.0 109.1 (80.4-144.6) 
Female 26 26.1 99.8 (65.2-146.2)   Female 29 36.9 78.5 (52.6-112.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 13.5 59.2 (25.5-116.6)   Male 12 13.9 86.4 (44.6-151.0) 
Female 8 12.3 65.1 (28.0-128.3)   Female 6 12.1 49.5 (18.1-107.8) 
Breast            Non-Hodgkin Lymphoma     
Male 2 2.4 nc (nc-nc)   Male 40 39.1 102.3 (73.1-139.3) 
Female 280 287.4 97.4 (86.4-109.5)   Female 28 35.8 78.2 (51.9-113.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 31 32.4 95.7 (65.0-135.8) 
Female 22 9.8 223.5 (140.0-338.3)   Female 10 15.8 63.1 (30.2-116.0) 
Colon / Rectum            Ovary     
Male 61 71.3 85.5 (65.4-109.8)             
Female 82 75.8 108.2 (86.0-134.3)   Female 26 25.1 103.7 (67.7-152.0) 
Esophagus            Pancreas     
Male 10 17.0 58.8 (28.1-108.1)   Male 30 25.1 119.6 (80.7-170.8) 
Female 4 5.0 nc (nc-nc)   Female 30 27.4 109.4 (73.8-156.1) 
Hodgkin Lymphoma            Prostate     
Male 3 5.6 nc (nc-nc)   Male 194 201.5 96.3 (83.2-110.8) 
Female 8 5.1 156.1 (67.2-307.6)             
Kidney & Renal Pelvis            Stomach     
Male 55 39.4 139.5 (105.1-181.6)   Male 22 15.9 138.2 (86.6-209.3) 
Female 20 23.1 86.4 (52.8-133.5)   Female 6 10.7 56.2 (20.5-122.4) 
Larynx            Testis     
Male 4 9.9 nc (nc-nc)   Male 9 11.2 80.4 (36.7-152.6) 
Female 4 3.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 20 28.1 71.2 (43.5-110.0)   Male 22 18.6 118.4 (74.2-179.2) 
Female 19 22.0 86.5 (52.0-135.0)   Female 70 56.3 124.4 (97.0-157.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 29 24.0 121.0 (81.0-173.8)             
Female 8 8.7 92.1 (39.7-181.5)   Female 63 64.1 98.2 (75.5-125.7) 
Lung and Bronchus            All Sites / Types     
Male 101 117.3 86.1 (70.1-104.6)   Male 816 867.7 94.0 (87.7-100.7) 
Female 124 133.6 92.8 (77.2-110.7)   Female 955 976.6 97.8 (91.7-104.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Franklin 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 28 29.5 94.8 (63.0-137.1)   Male 22 20.0 109.8 (68.8-166.2) 
Female 9 10.8 83.6 (38.2-158.7)   Female 19 16.6 114.1 (68.7-178.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 6.3 79.9 (25.8-186.5)   Male 10 6.3 157.8 (75.5-290.2) 
Female 5 5.5 90.9 (29.3-212.2)   Female 6 5.1 117.7 (43.0-256.3) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.1 nc (nc-nc)   Male 19 17.7 107.0 (64.4-167.2) 
Female 148 135.3 109.4 (92.5-128.5)   Female 15 15.5 96.7 (54.1-159.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 18 15.5 115.9 (68.7-183.2) 
Female 8 4.9 164.3 (70.8-323.8)   Female 4 7.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 30 32.7 91.7 (61.8-130.8)             
Female 23 32.4 71.1 (45.0-106.6)   Female 15 11.3 132.4 (74.0-218.4) 
Esophagus            Pancreas     
Male 8 7.8 102.7 (44.2-202.4)   Male 15 11.3 132.9 (74.3-219.2) 
Female 2 2.1 nc (nc-nc)   Female 7 11.2 62.6 (25.1-129.1) 
Hodgkin Lymphoma            Prostate     
Male 3 2.4 nc (nc-nc)   Male 96 93.9 102.3 (82.8-124.9) 
Female 4 2.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 15 18.8 79.8 (44.6-131.7)   Male 12 7.2 167.1 (86.2-291.8) 
Female 18 10.4 173.3 (102.7-274.0)   Female 5 4.6 109.8 (35.4-256.2) 
Larynx            Testis     
Male 7 4.6 153.8 (61.6-316.8)   Male 11 4.7 234.8 (117.0-420.1) 
Female 0 1.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 15 12.7 118.3 (66.2-195.2)   Male 16 9.0 178.7 (102.1-290.2) 
Female 4 9.3 nc (nc-nc)   Female 40 27.6 145.2 (103.7-197.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 11.1 53.9 (19.7-117.3)             
Female 0 3.7 nc (nc-nc)   Female 43 29.4 146.4 (105.9-197.2) 
Lung and Bronchus            All Sites / Types     
Male 38 52.6 72.3 (51.1-99.2)   Male 407 396.1 102.8 (93.0-113.2) 
Female 38 56.8 66.9 (47.3-91.8)   Female 436 436.4 99.9 (90.7-109.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Freetown 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 9 11.5 78.4 (35.8-148.8)   Male 4 7.3 nc (nc-nc) 
Female 1 3.1 nc (nc-nc)   Female 4 4.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.1 nc (nc-nc)   Male 1 2.4 nc (nc-nc) 
Female 1 1.5 nc (nc-nc)   Female 3 1.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 4 6.5 nc (nc-nc) 
Female 48 39.2 122.4 (90.3-162.3)   Female 4 4.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 5.5 126.3 (50.6-260.3) 
Female 2 1.3 nc (nc-nc)   Female 2 2.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 12.2 57.4 (23.0-118.2)             
Female 4 8.9 nc (nc-nc)   Female 2 3.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 2.9 nc (nc-nc)   Male 0 4.2 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 6 3.2 188.8 (69.0-411.0) 
Hodgkin Lymphoma            Prostate     
Male 1 0.8 nc (nc-nc)   Male 38 34.4 110.5 (78.2-151.7) 
Female 0 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 6.7 nc (nc-nc)   Male 2 2.7 nc (nc-nc) 
Female 2 3.0 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Larynx            Testis     
Male 1 1.6 nc (nc-nc)   Male 0 1.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 4.6 nc (nc-nc)   Male 4 3.0 nc (nc-nc) 
Female 2 2.5 nc (nc-nc)   Female 9 7.5 119.8 (54.7-227.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 4.0 nc (nc-nc)             
Female 1 1.1 nc (nc-nc)   Female 10 9.0 110.9 (53.1-204.0) 
Lung and Bronchus            All Sites / Types     
Male 16 19.6 81.5 (46.6-132.4)   Male 117 145.4 80.4 (66.5-96.4) 
Female 23 17.2 133.7 (84.7-200.7)   Female 147 125.7 116.9 (98.8-137.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Gardner 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 13 23.4 55.5 (29.5-94.9)   Male 4 14.8 nc (nc-nc) 
Female 11 8.6 127.3 (63.5-227.8)   Female 11 11.3 97.0 (48.3-173.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 4.4 114.9 (37.0-268.1)   Male 3 4.8 nc (nc-nc) 
Female 5 3.7 135.4 (43.6-316.0)   Female 2 4.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.8 nc (nc-nc)   Male 11 13.2 83.4 (41.6-149.2) 
Female 59 89.7 65.8 (50.1-84.9)   Female 9 11.6 77.7 (35.5-147.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 10.6 103.7 (51.7-185.6) 
Female 0 2.8 nc (nc-nc)   Female 5 5.0 99.7 (32.1-232.6) 
Colon / Rectum            Ovary     
Male 30 24.3 123.3 (83.1-176.0)             
Female 25 24.2 103.1 (66.7-152.2)   Female 9 7.9 114.1 (52.1-216.6) 
Esophagus            Pancreas     
Male 11 5.8 190.9 (95.2-341.6)   Male 8 8.5 93.7 (40.4-184.7) 
Female 0 1.7 nc (nc-nc)   Female 5 9.0 55.6 (17.9-129.7) 
Hodgkin Lymphoma            Prostate     
Male 2 1.7 nc (nc-nc)   Male 43 65.7 65.5 (47.4-88.2) 
Female 3 1.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 15 13.0 115.5 (64.6-190.5)   Male 2 5.4 nc (nc-nc) 
Female 9 7.4 122.3 (55.8-232.1)   Female 6 3.4 175.5 (64.1-382.0) 
Larynx            Testis     
Male 3 3.3 nc (nc-nc)   Male 3 3.3 nc (nc-nc) 
Female 2 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 13 9.3 139.3 (74.1-238.2)   Male 2 5.9 nc (nc-nc) 
Female 12 6.9 174.2 (89.9-304.3)   Female 11 15.9 69.4 (34.6-124.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 11 7.9 139.3 (69.4-249.3)             
Female 4 2.9 nc (nc-nc)   Female 21 20.5 102.3 (63.3-156.4) 
Lung and Bronchus            All Sites / Types     
Male 60 40.2 149.4 (114.0-192.3)   Male 269 290.2 92.7 (81.9-104.5) 
Female 53 44.3 119.6 (89.6-156.4)   Female 290 308.7 93.9 (83.4-105.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Georgetown 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 8.7 69.0 (25.2-150.3)   Male 6 5.8 103.6 (37.8-225.5) 
Female 2 2.9 nc (nc-nc)   Female 4 4.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.8 nc (nc-nc)   Male 0 1.9 nc (nc-nc) 
Female 1 1.5 nc (nc-nc)   Female 2 1.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 7 5.1 136.8 (54.8-281.8) 
Female 31 38.9 79.6 (54.1-113.0)   Female 2 4.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 4.5 nc (nc-nc) 
Female 0 1.3 nc (nc-nc)   Female 2 2.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 9.6 62.6 (22.8-136.2)             
Female 6 8.6 69.5 (25.4-151.3)   Female 0 3.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 2.3 nc (nc-nc)   Male 5 3.3 151.7 (48.9-354.0) 
Female 1 0.6 nc (nc-nc)   Female 3 3.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.7 nc (nc-nc)   Male 32 28.3 113.2 (77.4-159.8) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 5.5 nc (nc-nc)   Male 2 2.1 nc (nc-nc) 
Female 2 3.0 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Larynx            Testis     
Male 1 1.3 nc (nc-nc)   Male 2 1.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 3.6 nc (nc-nc)   Male 3 2.5 nc (nc-nc) 
Female 2 2.5 nc (nc-nc)   Female 5 7.3 68.5 (22.1-160.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.2 nc (nc-nc)             
Female 1 1.0 nc (nc-nc)   Female 10 9.0 110.9 (53.1-203.9) 
Lung and Bronchus            All Sites / Types     
Male 7 15.7 44.7 (17.9-92.0)   Male 98 116.1 84.4 (68.5-102.9) 
Female 11 16.2 68.0 (33.9-121.6)   Female 97 122.4 79.3 (64.3-96.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
114 
Gill 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 2.2 nc (nc-nc)   Male 0 1.4 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.4 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 6 7.6 78.5 (28.7-170.8)   Female 1 0.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.1 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 2.3 nc (nc-nc)             
Female 0 1.7 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.6 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.2 nc (nc-nc)   Male 4 7.0 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.3 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.8 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.8 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 2 1.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 10 3.9 256.8 (123.0-472.4)   Male 23 28.5 80.7 (51.1-121.0) 
Female 4 3.3 nc (nc-nc)   Female 22 24.6 89.4 (56.0-135.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Gloucester 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 43 40.0 107.6 (77.9-144.9)   Male 26 24.8 104.9 (68.5-153.7) 
Female 27 14.8 182.5 (120.2-265.5)   Female 28 19.5 143.9 (95.6-207.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 6.9 nc (nc-nc)   Male 9 8.2 110.2 (50.3-209.2) 
Female 4 6.3 nc (nc-nc)   Female 3 6.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.4 nc (nc-nc)   Male 26 22.0 118.4 (77.3-173.5) 
Female 175 161.3 108.5 (93.0-125.8)   Female 24 20.0 120.0 (76.9-178.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 27 18.9 142.9 (94.1-207.8) 
Female 4 4.8 nc (nc-nc)   Female 9 8.9 101.3 (46.2-192.4) 
Colon / Rectum            Ovary     
Male 37 40.4 91.6 (64.5-126.3)             
Female 51 41.4 123.3 (91.8-162.1)   Female 22 13.9 158.6 (99.3-240.1) 
Esophagus            Pancreas     
Male 12 10.3 116.7 (60.2-203.9)   Male 27 14.8 182.0 (119.9-264.8) 
Female 1 2.9 nc (nc-nc)   Female 12 15.5 77.6 (40.1-135.6) 
Hodgkin Lymphoma            Prostate     
Male 4 2.4 nc (nc-nc)   Male 115 128.6 89.4 (73.8-107.3) 
Female 3 2.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 27 22.6 119.5 (78.7-173.9)   Male 9 9.3 97.2 (44.3-184.4) 
Female 15 13.0 115.6 (64.7-190.7)   Female 2 5.8 nc (nc-nc) 
Larynx            Testis     
Male 8 6.0 134.2 (57.8-264.4)   Male 5 3.8 131.6 (42.4-307.0) 
Female 3 1.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 20 15.3 130.3 (79.6-201.2)   Male 11 9.0 122.2 (60.9-218.6) 
Female 13 11.5 113.0 (60.1-193.3)   Female 32 26.7 119.7 (81.8-168.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 9 14.5 62.0 (28.3-117.8)             
Female 5 4.9 101.2 (32.6-236.2)   Female 27 37.8 71.4 (47.1-103.9) 
Lung and Bronchus            All Sites / Types     
Male 90 70.4 127.8 (102.8-157.1)   Male 553 508.4 108.8 (99.9-118.2) 
Female 95 77.8 122.0 (98.7-149.2)   Female 606 541.0 112.0 (103.3-121.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Goshen 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 1.3 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 5 5.8 86.8 (28.0-202.5)   Female 0 0.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 0.8 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 1.5 nc (nc-nc)             
Female 1 1.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.4 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 3 4.8 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.9 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 1 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.5 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.5 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 2.4 nc (nc-nc)   Male 12 18.3 65.5 (33.8-114.5) 
Female 0 2.3 nc (nc-nc)   Female 10 18.2 54.8 (26.2-100.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Gosnold 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.0 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 0.1 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.0 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.1 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Larynx            Testis     
Male 0 0.0 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.0 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.0 nc (nc-nc)             
Female 0 0.0 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 0.2 nc (nc-nc)   Male 0 1.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 2.3 nc (nc-nc) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Grafton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 21 16.1 130.1 (80.5-198.8)   Male 11 11.2 98.4 (49.1-176.1) 
Female 4 5.8 nc (nc-nc)   Female 11 9.1 120.3 (60.0-215.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 3.5 199.2 (79.8-410.5)   Male 2 3.5 nc (nc-nc) 
Female 5 3.0 168.4 (54.3-392.9)   Female 3 2.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.6 nc (nc-nc)   Male 7 9.9 70.5 (28.3-145.3) 
Female 74 74.4 99.5 (78.1-124.9)   Female 7 8.4 83.4 (33.4-171.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 15 8.8 171.3 (95.8-282.6) 
Female 3 2.7 nc (nc-nc)   Female 5 3.8 130.9 (42.2-305.5) 
Colon / Rectum            Ovary     
Male 7 18.4 38.0 (15.2-78.3)             
Female 18 17.0 105.9 (62.8-167.4)   Female 2 6.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 4.3 nc (nc-nc)   Male 3 6.3 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 2 5.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 1.4 nc (nc-nc)   Male 63 51.9 121.4 (93.3-155.4) 
Female 1 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 14 10.5 133.2 (72.8-223.5)   Male 1 4.0 nc (nc-nc) 
Female 5 5.7 87.3 (28.1-203.7)   Female 2 2.4 nc (nc-nc) 
Larynx            Testis     
Male 9 2.5 356.6 (162.7-676.9)   Male 1 3.0 nc (nc-nc) 
Female 2 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 7.0 127.7 (58.3-242.4)   Male 5 5.2 95.8 (30.9-223.5) 
Female 12 4.9 243.7 (125.8-425.7)   Female 15 15.4 97.6 (54.6-161.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 6.2 nc (nc-nc)             
Female 1 2.0 nc (nc-nc)   Female 14 16.5 84.8 (46.3-142.2) 
Lung and Bronchus            All Sites / Types     
Male 31 28.4 109.0 (74.1-154.7)   Male 226 220.0 102.7 (89.7-117.0) 
Female 31 31.7 97.9 (66.5-138.9)   Female 237 238.5 99.4 (87.1-112.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Granby 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 6.1 nc (nc-nc)   Male 2 4.3 nc (nc-nc) 
Female 4 2.5 nc (nc-nc)   Female 3 3.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.3 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 2 1.2 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 5 3.7 133.9 (43.2-312.6) 
Female 23 29.0 79.3 (50.2-118.9)   Female 3 3.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 3.6 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 0 1.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 6.8 147.6 (70.6-271.4)             
Female 8 7.2 110.7 (47.7-218.2)   Female 2 2.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 1.8 nc (nc-nc)   Male 2 2.5 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 2.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.5 nc (nc-nc)   Male 19 22.6 84.2 (50.7-131.5) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 4.1 nc (nc-nc)   Male 2 1.5 nc (nc-nc) 
Female 8 2.3 350.9 (151.1-691.4)   Female 0 1.0 nc (nc-nc) 
Larynx            Testis     
Male 0 1.1 nc (nc-nc)   Male 2 0.8 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 2.6 nc (nc-nc)   Male 1 1.9 nc (nc-nc) 
Female 1 2.1 nc (nc-nc)   Female 1 5.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 2.7 nc (nc-nc)             
Female 2 0.8 nc (nc-nc)   Female 6 6.7 89.2 (32.6-194.2) 
Lung and Bronchus            All Sites / Types     
Male 14 11.5 121.9 (66.6-204.5)   Male 89 87.2 102.1 (82.0-125.6) 
Female 12 12.8 93.6 (48.3-163.6)   Female 82 96.3 85.1 (67.7-105.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Granville 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 2.3 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 2 0.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 4 1.3 nc (nc-nc) 
Female 7 7.4 94.4 (37.8-194.5)   Female 0 0.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.1 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 2.3 nc (nc-nc)             
Female 2 1.7 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.6 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 8 7.2 111.3 (47.9-219.2) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 1.3 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.9 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 2 1.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.8 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 6 1.7 350.8 (128.1-763.6) 
Lung and Bronchus            All Sites / Types     
Male 3 4.0 nc (nc-nc)   Male 27 29.0 93.0 (61.2-135.3) 
Female 4 3.1 nc (nc-nc)   Female 28 23.3 120.0 (79.7-173.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Great Barrington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 9.2 119.6 (59.6-214.0)   Male 9 5.7 159.1 (72.6-301.9) 
Female 5 3.9 128.8 (41.5-300.5)   Female 3 4.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.6 nc (nc-nc)   Male 4 1.8 nc (nc-nc) 
Female 5 1.5 333.0 (107.3-777.0)   Female 2 1.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.3 nc (nc-nc)   Male 5 5.0 100.0 (32.2-233.5) 
Female 45 37.7 119.5 (87.2-159.9)   Female 3 5.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 4.1 123.1 (39.7-287.2) 
Female 2 1.1 nc (nc-nc)   Female 2 2.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 9.1 76.6 (30.7-157.7)             
Female 9 10.6 85.1 (38.8-161.6)   Female 3 3.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.3 nc (nc-nc)   Male 3 3.3 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 4 4.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 27 26.6 101.4 (66.8-147.5) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 5.0 nc (nc-nc)   Male 2 2.1 nc (nc-nc) 
Female 2 3.1 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Larynx            Testis     
Male 3 1.3 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 3.6 nc (nc-nc)   Male 1 2.1 nc (nc-nc) 
Female 3 2.9 nc (nc-nc)   Female 6 5.6 106.4 (38.9-231.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.1 nc (nc-nc)             
Female 1 1.2 nc (nc-nc)   Female 6 8.9 67.2 (24.5-146.2) 
Lung and Bronchus            All Sites / Types     
Male 14 16.0 87.8 (47.9-147.3)   Male 115 112.8 102.0 (84.2-122.4) 
Female 23 19.7 116.8 (74.0-175.2)   Female 134 131.7 101.7 (85.2-120.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Greenfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 15 21.8 68.7 (38.4-113.2)   Male 10 13.7 72.8 (34.8-133.8) 
Female 7 8.1 86.6 (34.7-178.4)   Female 7 10.6 66.1 (26.5-136.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 4.0 151.4 (55.3-329.5)   Male 5 4.5 111.9 (36.1-261.2) 
Female 5 3.4 146.6 (47.3-342.2)   Female 4 3.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.8 nc (nc-nc)   Male 6 12.2 49.2 (18.0-107.0) 
Female 66 83.6 79.0 (61.1-100.5)   Female 7 10.8 64.7 (25.9-133.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 13 10.2 127.8 (68.0-218.6) 
Female 3 2.6 nc (nc-nc)   Female 6 4.7 126.9 (46.3-276.2) 
Colon / Rectum            Ovary     
Male 25 22.1 113.1 (73.1-166.9)             
Female 27 22.9 118.1 (77.8-171.8)   Female 6 7.3 81.8 (29.9-178.1) 
Esophagus            Pancreas     
Male 4 5.6 nc (nc-nc)   Male 8 8.1 98.6 (42.5-194.4) 
Female 3 1.6 nc (nc-nc)   Female 9 8.5 105.3 (48.0-199.9) 
Hodgkin Lymphoma            Prostate     
Male 5 1.5 343.2 (110.6-801.0)   Male 40 67.7 59.1 (42.2-80.4) 
Female 2 1.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 9 12.3 73.0 (33.3-138.5)   Male 3 5.1 nc (nc-nc) 
Female 7 6.8 102.7 (41.1-211.6)   Female 2 3.2 nc (nc-nc) 
Larynx            Testis     
Male 1 3.3 nc (nc-nc)   Male 2 2.6 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 8.6 81.3 (32.6-167.6)   Male 4 5.2 nc (nc-nc) 
Female 5 6.4 77.9 (25.1-181.8)   Female 3 14.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 7.8 76.9 (28.1-167.4)             
Female 5 2.7 187.2 (60.3-436.9)   Female 23 19.3 119.2 (75.5-178.8) 
Lung and Bronchus            All Sites / Types     
Male 34 38.5 88.4 (61.2-123.5)   Male 227 277.2 81.9 (71.6-93.3) 
Female 49 40.9 119.9 (88.7-158.5)   Female 276 288.2 95.8 (84.8-107.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Groton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 10 11.5 86.8 (41.6-159.7)   Male 5 7.8 64.0 (20.6-149.4) 
Female 2 3.9 nc (nc-nc)   Female 5 6.1 82.0 (26.4-191.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.3 nc (nc-nc)   Male 1 2.5 nc (nc-nc) 
Female 0 1.9 nc (nc-nc)   Female 1 1.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.4 nc (nc-nc)   Male 4 6.9 nc (nc-nc) 
Female 45 50.8 88.5 (64.6-118.5)   Female 7 5.7 122.7 (49.2-252.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 6.3 79.4 (25.6-185.2) 
Female 2 1.8 nc (nc-nc)   Female 1 2.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 15 13.1 114.7 (64.1-189.2)             
Female 12 11.8 101.8 (52.5-177.9)   Female 2 4.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 3.1 nc (nc-nc)   Male 3 4.5 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 3 4.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.8 nc (nc-nc)   Male 29 38.4 75.5 (50.6-108.4) 
Female 0 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 7.5 93.7 (37.6-193.1)   Male 2 2.8 nc (nc-nc) 
Female 3 3.9 nc (nc-nc)   Female 2 1.6 nc (nc-nc) 
Larynx            Testis     
Male 0 1.8 nc (nc-nc)   Male 5 1.5 326.7 (105.3-762.3) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 4.8 nc (nc-nc)   Male 6 3.4 175.1 (63.9-381.1) 
Female 0 3.3 nc (nc-nc)   Female 9 9.8 91.5 (41.8-173.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 4.5 nc (nc-nc)             
Female 1 1.4 nc (nc-nc)   Female 10 11.4 87.5 (41.9-160.9) 
Lung and Bronchus            All Sites / Types     
Male 9 20.4 44.1 (20.1-83.8)   Male 123 156.5 78.6 (65.3-93.8) 
Female 13 21.1 61.7 (32.8-105.5)   Female 128 161.5 79.3 (66.1-94.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Groveland 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 9.3 64.7 (23.6-140.8)   Male 5 5.8 86.7 (27.9-202.3) 
Female 3 2.9 nc (nc-nc)   Female 12 3.9 304.8 (157.3-532.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.6 nc (nc-nc)   Male 0 1.9 nc (nc-nc) 
Female 0 1.3 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 9 5.1 176.0 (80.3-334.2) 
Female 34 34.2 99.4 (68.8-138.9)   Female 4 3.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 4.1 nc (nc-nc) 
Female 2 1.0 nc (nc-nc)   Female 2 1.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 9.4 nc (nc-nc)             
Female 5 8.0 62.6 (20.2-146.2)   Female 3 2.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 2.3 nc (nc-nc)   Male 5 3.4 147.3 (47.5-343.7) 
Female 1 0.6 nc (nc-nc)   Female 3 3.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 30 27.1 110.6 (74.6-157.9) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 5.1 nc (nc-nc)   Male 3 2.1 nc (nc-nc) 
Female 3 2.7 nc (nc-nc)   Female 4 1.1 nc (nc-nc) 
Larynx            Testis     
Male 1 1.4 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 3.6 nc (nc-nc)   Male 6 2.1 285.9 (104.4-622.2) 
Female 2 2.2 nc (nc-nc)   Female 5 5.7 87.7 (28.3-204.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 3.1 nc (nc-nc)             
Female 1 1.0 nc (nc-nc)   Female 6 8.1 74.2 (27.1-161.5) 
Lung and Bronchus            All Sites / Types     
Male 8 16.5 48.5 (20.9-95.6)   Male 94 114.8 81.9 (66.2-100.2) 
Female 16 15.8 101.1 (57.7-164.2)   Female 113 110.6 102.2 (84.2-122.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hadley 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 7.2 83.3 (30.4-181.4)   Male 2 4.2 nc (nc-nc) 
Female 1 3.4 nc (nc-nc)   Female 1 4.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.1 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 0 1.3 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 2 3.7 nc (nc-nc) 
Female 28 32.4 86.4 (57.4-124.9)   Female 4 4.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 2.9 273.6 (117.8-539.2) 
Female 1 1.0 nc (nc-nc)   Female 0 1.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 7.0 85.7 (31.3-186.6)             
Female 8 9.4 85.4 (36.8-168.2)   Female 3 2.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.7 nc (nc-nc)   Male 2 2.5 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 1 3.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 19 19.5 97.5 (58.7-152.3) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 3.6 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 3 2.7 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.9 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 2.6 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 3 2.6 nc (nc-nc)   Female 3 5.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.2 nc (nc-nc)             
Female 1 1.1 nc (nc-nc)   Female 12 7.5 159.3 (82.2-278.2) 
Lung and Bronchus            All Sites / Types     
Male 7 12.2 57.5 (23.0-118.5)   Male 69 84.1 82.1 (63.8-103.8) 
Female 7 17.0 41.1 (16.5-84.7)   Female 81 114.8 70.6 (56.0-87.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Halifax 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 8.2 72.8 (26.6-158.4)   Male 4 5.4 nc (nc-nc) 
Female 1 3.1 nc (nc-nc)   Female 5 4.3 115.4 (37.2-269.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.6 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 2 1.4 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 5 4.8 104.0 (33.5-242.8) 
Female 40 35.4 112.8 (80.6-153.7)   Female 6 4.3 138.5 (50.6-301.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 3.9 127.2 (41.0-296.9) 
Female 1 1.2 nc (nc-nc)   Female 2 1.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 15 8.8 170.3 (95.3-281.0)             
Female 11 8.9 124.0 (61.8-221.9)   Female 2 3.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.1 nc (nc-nc)   Male 7 3.1 229.2 (91.8-472.3) 
Female 1 0.6 nc (nc-nc)   Female 3 3.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 28 23.6 118.5 (78.7-171.3) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 9 4.9 185.3 (84.5-351.8)   Male 1 2.0 nc (nc-nc) 
Female 5 2.8 177.9 (57.3-415.1)   Female 2 1.2 nc (nc-nc) 
Larynx            Testis     
Male 1 1.2 nc (nc-nc)   Male 3 1.2 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 3.3 nc (nc-nc)   Male 3 2.2 nc (nc-nc) 
Female 2 2.5 nc (nc-nc)   Female 12 6.5 183.4 (94.7-320.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 2.9 173.8 (56.0-405.6)             
Female 3 1.0 nc (nc-nc)   Female 17 7.7 220.8 (128.6-353.6) 
Lung and Bronchus            All Sites / Types     
Male 19 14.6 129.8 (78.1-202.7)   Male 130 104.9 123.9 (103.6-147.2) 
Female 17 16.4 103.4 (60.2-165.5)   Female 144 116.9 123.1 (103.9-145.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hamilton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 8.8 nc (nc-nc)   Male 5 5.8 86.6 (27.9-202.0) 
Female 5 3.0 167.2 (53.9-390.3)   Female 9 4.3 210.9 (96.3-400.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.8 nc (nc-nc)   Male 2 1.9 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 2 5.1 nc (nc-nc) 
Female 41 35.2 116.4 (83.5-158.0)   Female 10 4.1 241.7 (115.7-444.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 4.3 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 0 1.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 9.5 nc (nc-nc)             
Female 11 8.7 126.5 (63.1-226.4)   Female 1 3.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 2.3 nc (nc-nc)   Male 1 3.3 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 1 3.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.7 nc (nc-nc)   Male 24 26.7 90.0 (57.7-134.0) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 5.3 113.3 (41.4-246.7)   Male 1 2.1 nc (nc-nc) 
Female 3 2.8 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Larynx            Testis     
Male 0 1.3 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 3.6 nc (nc-nc)   Male 5 2.4 208.6 (67.2-486.9) 
Female 3 2.4 nc (nc-nc)   Female 7 6.4 109.8 (44.0-226.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 3.1 nc (nc-nc)             
Female 0 1.0 nc (nc-nc)   Female 6 8.0 75.1 (27.4-163.5) 
Lung and Bronchus            All Sites / Types     
Male 8 15.6 51.2 (22.0-100.8)   Male 79 114.2 69.2 (54.8-86.2) 
Female 13 16.0 81.3 (43.2-139.0)   Female 125 115.3 108.4 (90.2-129.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hampden 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 8.8 68.5 (25.0-149.1)   Male 1 5.3 nc (nc-nc) 
Female 0 2.6 nc (nc-nc)   Female 1 3.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.4 nc (nc-nc)   Male 1 1.8 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 7 4.7 149.5 (59.9-308.1) 
Female 26 27.9 93.2 (60.9-136.6)   Female 2 3.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 3.7 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 2 1.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 8.5 nc (nc-nc)             
Female 5 7.3 68.1 (21.9-158.9)   Female 2 2.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 2.1 nc (nc-nc)   Male 2 3.2 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 3 2.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 22 25.0 87.9 (55.1-133.1) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 4.6 108.7 (35.0-253.6)   Male 0 2.0 nc (nc-nc) 
Female 0 2.2 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Larynx            Testis     
Male 0 1.3 nc (nc-nc)   Male 6 0.6 1007.6 (367.9-2193.2) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 3.2 nc (nc-nc)   Male 1 1.7 nc (nc-nc) 
Female 1 2.0 nc (nc-nc)   Female 5 4.7 106.3 (34.3-248.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 2.9 nc (nc-nc)             
Female 0 0.8 nc (nc-nc)   Female 5 6.3 79.2 (25.5-184.9) 
Lung and Bronchus            All Sites / Types     
Male 6 15.6 38.5 (14.0-83.7)   Male 70 105.6 66.3 (51.7-83.8) 
Female 9 13.3 67.6 (30.8-128.3)   Female 69 93.4 73.8 (57.5-93.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
129 
Hancock 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 1.0 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 2 3.5 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 1.0 nc (nc-nc)             
Female 0 0.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 3 3.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.6 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 1 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.4 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.4 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 2 0.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 1.8 nc (nc-nc)   Male 9 12.7 71.1 (32.5-135.1) 
Female 3 1.6 nc (nc-nc)   Female 11 11.4 96.5 (48.1-172.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hanover 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 17 13.1 129.4 (75.4-207.2)   Male 23 8.9 259.5 (164.5-389.5) 
Female 6 5.4 111.9 (40.8-243.5)   Female 6 7.8 77.0 (28.1-167.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 2.8 nc (nc-nc)   Male 2 2.8 nc (nc-nc) 
Female 2 2.6 nc (nc-nc)   Female 4 2.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 4 7.9 nc (nc-nc) 
Female 82 64.1 128.0 (101.8-158.9)   Female 8 7.5 106.2 (45.7-209.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 6.8 87.6 (32.0-190.7) 
Female 0 2.2 nc (nc-nc)   Female 2 3.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 18 14.2 126.4 (74.9-199.8)             
Female 16 15.4 104.2 (59.5-169.2)   Female 6 5.4 111.9 (40.9-243.5) 
Esophagus            Pancreas     
Male 5 3.5 141.4 (45.6-330.1)   Male 1 5.0 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 2 5.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.0 nc (nc-nc)   Male 53 42.9 123.5 (92.5-161.6) 
Female 0 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 8.4 nc (nc-nc)   Male 1 3.2 nc (nc-nc) 
Female 5 5.0 99.9 (32.2-233.0)   Female 0 2.2 nc (nc-nc) 
Larynx            Testis     
Male 2 2.0 nc (nc-nc)   Male 2 2.1 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 5.7 176.6 (84.6-324.8)   Male 6 4.0 151.0 (55.1-328.6) 
Female 2 4.4 nc (nc-nc)   Female 13 12.1 107.1 (57.0-183.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 5.0 nc (nc-nc)             
Female 0 1.8 nc (nc-nc)   Female 18 14.5 123.9 (73.4-195.7) 
Lung and Bronchus            All Sites / Types     
Male 17 23.6 72.1 (42.0-115.5)   Male 184 177.1 103.9 (89.4-120.1) 
Female 31 28.7 108.1 (73.4-153.4)   Female 214 209.5 102.1 (88.9-116.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hanson 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 10 10.7 93.2 (44.6-171.5)   Male 6 7.3 82.6 (30.2-179.7) 
Female 4 3.3 nc (nc-nc)   Female 4 5.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.2 nc (nc-nc)   Male 1 2.4 nc (nc-nc) 
Female 0 1.7 nc (nc-nc)   Female 2 1.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 2 6.4 nc (nc-nc) 
Female 37 44.6 83.0 (58.4-114.4)   Female 3 4.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 5.8 189.3 (94.3-338.7) 
Female 0 1.5 nc (nc-nc)   Female 4 2.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 13 11.7 111.5 (59.3-190.7)             
Female 9 9.5 95.0 (43.3-180.3)   Female 4 3.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 3.0 nc (nc-nc)   Male 4 4.2 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 1 3.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.8 nc (nc-nc)   Male 31 37.4 83.0 (56.4-117.8) 
Female 0 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 7.0 nc (nc-nc)   Male 1 2.6 nc (nc-nc) 
Female 8 3.4 236.2 (101.7-465.4)   Female 0 1.4 nc (nc-nc) 
Larynx            Testis     
Male 0 1.8 nc (nc-nc)   Male 3 1.5 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 4.5 nc (nc-nc)   Male 2 3.1 nc (nc-nc) 
Female 4 2.8 nc (nc-nc)   Female 6 8.7 69.3 (25.3-150.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 4.3 nc (nc-nc)             
Female 2 1.2 nc (nc-nc)   Female 9 10.2 87.8 (40.1-166.7) 
Lung and Bronchus            All Sites / Types     
Male 25 19.9 125.7 (81.3-185.6)   Male 137 147.7 92.7 (77.9-109.6) 
Female 26 18.9 137.7 (89.9-201.8)   Female 137 140.0 97.9 (82.2-115.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hardwick 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 4.9 nc (nc-nc)   Male 4 3.1 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.9 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 2 0.5 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 2 2.7 nc (nc-nc) 
Female 13 13.3 97.8 (52.0-167.3)   Female 1 1.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 2.3 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 4.9 101.8 (32.8-237.5)             
Female 3 2.9 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.3 nc (nc-nc)   Male 3 1.8 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 6 16.3 36.8 (13.4-80.2) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 2.9 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Larynx            Testis     
Male 0 0.8 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.9 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 2 0.8 nc (nc-nc)   Female 1 2.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 1.8 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 4 3.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 10 9.0 110.6 (53.0-203.5)   Male 44 63.3 69.5 (50.5-93.3) 
Female 9 5.8 156.2 (71.3-296.6)   Female 43 42.2 101.8 (73.7-137.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Harvard 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 9.1 54.9 (17.7-128.1)   Male 3 6.1 nc (nc-nc) 
Female 0 1.8 nc (nc-nc)   Female 3 2.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.8 nc (nc-nc)   Male 4 2.0 nc (nc-nc) 
Female 3 0.9 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.3 nc (nc-nc)   Male 7 5.3 130.9 (52.4-269.8) 
Female 28 24.7 113.5 (75.4-164.1)   Female 3 2.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 4.8 104.0 (33.5-242.6) 
Female 0 0.8 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 9.9 nc (nc-nc)             
Female 10 5.4 184.9 (88.5-340.1)   Female 2 2.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.5 nc (nc-nc)   Male 3 3.5 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 1 1.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 22 31.0 70.9 (44.4-107.4) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 5.8 nc (nc-nc)   Male 2 2.2 nc (nc-nc) 
Female 1 1.9 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Larynx            Testis     
Male 1 1.5 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 3.6 nc (nc-nc)   Male 2 2.6 nc (nc-nc) 
Female 1 1.5 nc (nc-nc)   Female 4 4.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 3.5 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 4 5.6 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 5 16.5 30.3 (9.8-70.8)   Male 87 123.0 70.7 (56.7-87.3) 
Female 8 10.0 80.1 (34.5-157.8)   Female 76 76.8 99.0 (78.0-123.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Harwich 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 29 23.3 124.5 (83.4-178.9)   Male 26 13.3 194.8 (127.2-285.4) 
Female 7 8.5 82.4 (33.0-169.8)   Female 17 9.8 173.8 (101.2-278.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 3.4 nc (nc-nc)   Male 8 4.4 180.8 (77.9-356.3) 
Female 5 3.1 158.9 (51.2-370.9)   Female 7 3.8 184.0 (73.7-379.2) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.8 nc (nc-nc)   Male 18 11.7 153.3 (90.8-242.3) 
Female 109 81.7 133.4 (109.5-160.9)   Female 7 10.8 64.6 (25.9-133.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 8.8 90.4 (38.9-178.2) 
Female 0 2.2 nc (nc-nc)   Female 5 4.6 107.7 (34.7-251.3) 
Colon / Rectum            Ovary     
Male 25 21.5 116.0 (75.1-171.3)             
Female 37 22.3 165.8 (116.7-228.6)   Female 4 7.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 6 5.4 111.4 (40.7-242.5)   Male 6 8.1 74.2 (27.1-161.5) 
Female 0 1.6 nc (nc-nc)   Female 8 8.8 91.2 (39.3-179.7) 
Hodgkin Lymphoma            Prostate     
Male 3 1.0 nc (nc-nc)   Male 90 62.1 144.8 (116.5-178.0) 
Female 0 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 12 11.2 107.2 (55.3-187.3)   Male 7 5.1 137.3 (55.0-282.9) 
Female 5 6.9 72.7 (23.4-169.7)   Female 1 3.2 nc (nc-nc) 
Larynx            Testis     
Male 3 3.1 nc (nc-nc)   Male 0 1.5 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 8.3 120.9 (57.9-222.3)   Male 7 4.0 174.1 (69.8-358.8) 
Female 7 6.1 113.9 (45.6-234.8)   Female 5 11.5 43.3 (14.0-101.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 6.9 86.4 (31.5-188.0)             
Female 3 2.7 nc (nc-nc)   Female 20 19.2 104.0 (63.5-160.6) 
Lung and Bronchus            All Sites / Types     
Male 44 40.1 109.6 (79.6-147.2)   Male 336 266.0 126.3 (113.2-140.6) 
Female 46 44.8 102.7 (75.1-136.9)   Female 327 284.5 114.9 (102.8-128.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
135 
Hatfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 5.3 94.2 (30.4-219.9)   Male 4 3.3 nc (nc-nc) 
Female 3 1.6 nc (nc-nc)   Female 1 2.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 0.9 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 2 0.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 1 2.9 nc (nc-nc) 
Female 21 18.9 111.3 (68.9-170.1)   Female 3 2.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 2.4 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 5.3 94.9 (30.6-221.5)             
Female 9 4.5 200.5 (91.5-380.6)   Female 3 1.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.3 nc (nc-nc)   Male 4 1.9 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.3 nc (nc-nc)   Male 16 16.3 98.1 (56.0-159.3) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 3.0 201.9 (73.7-439.5)   Male 3 1.2 nc (nc-nc) 
Female 6 1.5 400.0 (146.1-870.7)   Female 0 0.6 nc (nc-nc) 
Larynx            Testis     
Male 0 0.8 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 2.0 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 2 3.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.9 nc (nc-nc)             
Female 1 0.5 nc (nc-nc)   Female 5 4.3 115.4 (37.2-269.3) 
Lung and Bronchus            All Sites / Types     
Male 9 9.8 92.2 (42.1-175.0)   Male 63 66.5 94.8 (72.8-121.2) 
Female 8 9.0 88.8 (38.2-174.9)   Female 72 61.4 117.4 (91.8-147.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Haverhill 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 54 61.0 88.5 (66.5-115.5)   Male 29 39.9 72.7 (48.7-104.5) 
Female 33 21.5 153.6 (105.7-215.7)   Female 17 32.2 52.8 (30.7-84.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 14 12.1 115.4 (63.0-193.6)   Male 8 12.6 63.5 (27.3-125.0) 
Female 16 10.5 152.1 (86.9-247.0)   Female 10 10.2 98.2 (47.0-180.7) 
Breast            Non-Hodgkin Lymphoma     
Male 3 2.1 nc (nc-nc)   Male 36 35.6 101.2 (70.9-140.2) 
Female 242 255.2 94.8 (83.3-107.6)   Female 39 30.4 128.5 (91.4-175.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 27 30.0 90.0 (59.3-131.0) 
Female 9 8.8 102.1 (46.6-193.8)   Female 12 13.7 87.7 (45.3-153.3) 
Colon / Rectum            Ovary     
Male 64 65.9 97.2 (74.8-124.1)             
Female 71 63.5 111.8 (87.3-141.0)   Female 18 22.0 81.9 (48.5-129.4) 
Esophagus            Pancreas     
Male 13 15.5 84.1 (44.7-143.8)   Male 23 22.8 101.1 (64.1-151.7) 
Female 8 4.2 188.9 (81.3-372.3)   Female 28 22.5 124.2 (82.5-179.6) 
Hodgkin Lymphoma            Prostate     
Male 6 5.0 120.5 (44.0-262.3)   Male 156 183.1 85.2 (72.4-99.7) 
Female 4 4.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 36 35.9 100.2 (70.1-138.7)   Male 18 14.5 124.5 (73.7-196.8) 
Female 23 20.1 114.4 (72.5-171.7)   Female 7 8.9 79.0 (31.7-162.8) 
Larynx            Testis     
Male 12 8.9 134.4 (69.4-234.7)   Male 7 9.8 71.3 (28.6-146.9) 
Female 5 2.8 179.0 (57.7-417.8)             
Leukemia            Thyroid     
Male 22 25.4 86.8 (54.4-131.4)   Male 16 17.0 94.3 (53.9-153.2) 
Female 22 18.4 119.6 (74.9-181.1)   Female 61 50.6 120.5 (92.1-154.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 16 22.2 72.2 (41.3-117.3)             
Female 6 7.4 81.6 (29.8-177.6)   Female 69 57.6 119.8 (93.2-151.6) 
Lung and Bronchus            All Sites / Types     
Male 116 104.3 111.2 (91.9-133.4)   Male 723 787.2 91.8 (85.3-98.8) 
Female 134 112.5 119.1 (99.8-141.1)   Female 895 843.6 106.1 (99.2-113.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hawley 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 0.7 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.1 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 3 2.0 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 0.7 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.2 nc (nc-nc)   Male 2 0.3 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 1 2.3 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.2 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 1.4 nc (nc-nc)   Male 6 9.2 65.5 (23.9-142.6) 
Female 0 0.9 nc (nc-nc)   Female 3 6.3 nc (nc-nc) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Heath 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 1.1 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 1 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 2 3.6 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 1.1 nc (nc-nc)             
Female 0 0.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 2 3.6 nc (nc-nc) 
Female 1 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.6 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.4 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.4 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 3 0.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 1.9 nc (nc-nc)   Male 12 14.0 85.9 (44.4-150.1) 
Female 1 1.7 nc (nc-nc)   Female 11 11.5 95.4 (47.5-170.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hingham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 32 31.5 101.6 (69.5-143.4)   Male 34 19.1 178.4 (123.5-249.3) 
Female 12 11.8 101.6 (52.4-177.5)   Female 31 14.8 208.9 (141.9-296.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 5.2 154.0 (66.3-303.6)   Male 7 6.1 115.5 (46.3-238.0) 
Female 5 4.7 105.7 (34.1-246.7)   Female 5 5.4 92.4 (29.8-215.6) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.0 nc (nc-nc)   Male 14 16.7 83.6 (45.7-140.3) 
Female 108 119.5 90.4 (74.1-109.1)   Female 21 15.5 135.5 (83.8-207.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 14 13.3 105.4 (57.6-176.9) 
Female 3 3.6 nc (nc-nc)   Female 6 6.8 88.8 (32.4-193.3) 
Colon / Rectum            Ovary     
Male 35 31.8 110.2 (76.7-153.2)             
Female 36 33.8 106.6 (74.6-147.5)   Female 9 10.5 85.8 (39.2-163.0) 
Esophagus            Pancreas     
Male 2 7.3 nc (nc-nc)   Male 9 11.2 80.4 (36.7-152.7) 
Female 7 2.3 311.1 (124.6-640.9)   Female 14 12.6 111.4 (60.8-186.8) 
Hodgkin Lymphoma            Prostate     
Male 2 1.7 nc (nc-nc)   Male 93 83.8 110.9 (89.5-135.9) 
Female 1 1.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 16 16.3 97.9 (55.9-159.0)   Male 12 7.1 168.6 (87.0-294.5) 
Female 7 9.8 71.5 (28.6-147.3)   Female 1 4.7 nc (nc-nc) 
Larynx            Testis     
Male 2 4.2 nc (nc-nc)   Male 6 3.1 193.1 (70.5-420.2) 
Female 0 1.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 14 12.0 116.6 (63.7-195.6)   Male 4 6.8 nc (nc-nc) 
Female 14 9.3 151.3 (82.6-253.9)   Female 22 19.4 113.3 (71.0-171.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 9.9 nc (nc-nc)             
Female 1 3.8 nc (nc-nc)   Female 19 26.9 70.6 (42.5-110.2) 
Lung and Bronchus            All Sites / Types     
Male 28 52.9 52.9 (35.2-76.5)   Male 368 372.3 98.8 (89.0-109.5) 
Female 46 59.6 77.2 (56.5-103.0)   Female 395 412.8 95.7 (86.5-105.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hinsdale 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 2.7 nc (nc-nc)   Male 0 1.8 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.5 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 3 1.6 nc (nc-nc) 
Female 15 9.9 152.0 (85.0-250.8)   Female 2 1.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 3.0 nc (nc-nc)             
Female 4 2.4 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.7 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 10 8.8 113.0 (54.1-207.8) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 1.7 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.4 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.1 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 4 1.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.1 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 2 2.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 5 4.8 103.6 (33.4-241.9)   Male 34 36.2 93.9 (65.0-131.3) 
Female 6 4.4 136.5 (49.8-297.1)   Female 41 31.9 128.6 (92.3-174.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Holbrook 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 17 13.6 125.2 (72.9-200.5)   Male 5 8.6 57.9 (18.7-135.1) 
Female 7 4.7 148.2 (59.4-305.4)   Female 1 6.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 2.5 nc (nc-nc)   Male 4 2.8 nc (nc-nc) 
Female 4 2.1 nc (nc-nc)   Female 6 2.2 275.6 (100.6-599.9) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 10 7.6 131.8 (63.1-242.3) 
Female 55 54.3 101.3 (76.3-131.9)   Female 10 6.4 155.1 (74.2-285.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 6.2 96.8 (35.3-210.7) 
Female 4 1.7 nc (nc-nc)   Female 2 2.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 18 14.1 127.5 (75.5-201.5)             
Female 19 13.3 143.3 (86.2-223.7)   Female 10 4.6 216.4 (103.6-397.9) 
Esophagus            Pancreas     
Male 7 3.3 210.4 (84.3-433.4)   Male 3 4.9 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 5 4.8 103.8 (33.4-242.2) 
Hodgkin Lymphoma            Prostate     
Male 1 1.0 nc (nc-nc)   Male 41 37.8 108.4 (77.8-147.1) 
Female 1 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 12 7.5 159.5 (82.3-278.6)   Male 3 3.2 nc (nc-nc) 
Female 4 4.3 nc (nc-nc)   Female 1 1.9 nc (nc-nc) 
Larynx            Testis     
Male 1 1.9 nc (nc-nc)   Male 1 1.8 nc (nc-nc) 
Female 2 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 5.3 93.5 (30.1-218.1)   Male 1 3.3 nc (nc-nc) 
Female 6 3.6 165.1 (60.3-359.5)   Female 6 9.9 60.7 (22.2-132.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 4.6 129.0 (47.1-280.9)             
Female 1 1.6 nc (nc-nc)   Female 10 12.3 81.4 (39.0-149.7) 
Lung and Bronchus            All Sites / Types     
Male 20 23.5 85.0 (51.9-131.2)   Male 177 167.9 105.5 (90.5-122.2) 
Female 32 25.7 124.4 (85.1-175.7)   Female 195 178.8 109.0 (94.3-125.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Holden 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 19.8 70.7 (38.6-118.7)   Male 19 12.9 147.2 (88.6-229.9) 
Female 14 6.8 206.3 (112.7-346.1)   Female 13 9.9 130.8 (69.6-223.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 3.9 nc (nc-nc)   Male 7 4.2 168.3 (67.4-346.9) 
Female 4 3.2 nc (nc-nc)   Female 3 3.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.7 nc (nc-nc)   Male 11 11.4 96.2 (47.9-172.1) 
Female 93 80.4 115.7 (93.4-141.8)   Female 8 9.6 83.6 (36.0-164.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 14 9.9 141.6 (77.3-237.6) 
Female 1 2.7 nc (nc-nc)   Female 6 4.3 140.0 (51.1-304.7) 
Colon / Rectum            Ovary     
Male 18 21.2 84.8 (50.2-134.0)             
Female 14 19.8 70.7 (38.6-118.6)   Female 7 6.9 101.9 (40.8-210.0) 
Esophagus            Pancreas     
Male 7 5.1 136.6 (54.7-281.4)   Male 12 7.5 161.0 (83.1-281.2) 
Female 2 1.3 nc (nc-nc)   Female 8 7.1 113.0 (48.7-222.8) 
Hodgkin Lymphoma            Prostate     
Male 0 1.4 nc (nc-nc)   Male 65 61.7 105.4 (81.3-134.3) 
Female 1 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 11.8 67.7 (29.1-133.3)   Male 1 4.7 nc (nc-nc) 
Female 5 6.3 79.4 (25.6-185.4)   Female 5 2.8 179.6 (57.9-419.0) 
Larynx            Testis     
Male 3 3.0 nc (nc-nc)   Male 3 2.6 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 8.1 86.6 (34.7-178.4)   Male 7 5.3 133.1 (53.3-274.3) 
Female 7 5.6 125.4 (50.2-258.3)   Female 11 15.2 72.2 (36.0-129.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 7.3 95.3 (38.2-196.4)             
Female 3 2.3 nc (nc-nc)   Female 32 18.2 175.5 (120.1-247.8) 
Lung and Bronchus            All Sites / Types     
Male 22 34.7 63.3 (39.7-95.9)   Male 252 257.5 97.9 (86.1-110.7) 
Female 36 35.8 100.6 (70.5-139.3)   Female 296 264.0 112.1 (99.7-125.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Holland 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 3.0 nc (nc-nc)   Male 2 2.1 nc (nc-nc) 
Female 2 0.8 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.6 nc (nc-nc)   Male 2 0.7 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.8 nc (nc-nc) 
Female 9 10.6 84.6 (38.6-160.7)   Female 2 1.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.6 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 2 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 3.3 nc (nc-nc)             
Female 1 2.4 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.8 nc (nc-nc)   Male 2 1.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.2 nc (nc-nc)   Male 5 10.3 48.4 (15.6-113.1) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 2.0 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.5 nc (nc-nc)   Male 2 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.2 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 3 0.7 nc (nc-nc)   Female 4 2.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.2 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 3 2.4 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 6 5.7 105.6 (38.6-229.9)   Male 35 41.4 84.6 (58.9-117.7) 
Female 6 4.3 139.4 (50.9-303.4)   Female 35 33.3 105.0 (73.1-146.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Holliston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 22 14.7 150.1 (94.0-227.3)   Male 11 9.8 112.4 (56.0-201.1) 
Female 2 5.1 nc (nc-nc)   Female 12 7.7 155.7 (80.4-272.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 2.9 204.0 (74.5-444.1)   Male 6 3.1 191.1 (69.8-416.1) 
Female 3 2.5 nc (nc-nc)   Female 0 2.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 12 8.7 138.6 (71.5-242.0) 
Female 68 64.0 106.3 (82.5-134.7)   Female 8 7.2 110.4 (47.5-217.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 7.8 77.3 (28.2-168.3) 
Female 2 2.2 nc (nc-nc)   Female 5 3.3 149.7 (48.2-349.4) 
Colon / Rectum            Ovary     
Male 15 16.1 93.0 (52.0-153.5)             
Female 14 15.1 92.7 (50.6-155.5)   Female 4 5.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 3.9 nc (nc-nc)   Male 5 5.6 88.5 (28.5-206.5) 
Female 2 1.0 nc (nc-nc)   Female 4 5.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 1.1 nc (nc-nc)   Male 49 49.0 100.0 (74.0-132.3) 
Female 0 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 12 9.3 129.3 (66.8-225.9)   Male 0 3.6 nc (nc-nc) 
Female 5 4.9 101.7 (32.8-237.4)   Female 1 2.1 nc (nc-nc) 
Larynx            Testis     
Male 2 2.3 nc (nc-nc)   Male 4 2.0 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 6.1 131.7 (56.7-259.5)   Male 3 4.2 nc (nc-nc) 
Female 4 4.3 nc (nc-nc)   Female 14 12.3 113.9 (62.2-191.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 5.6 nc (nc-nc)             
Female 4 1.8 nc (nc-nc)   Female 20 14.5 138.2 (84.4-213.4) 
Lung and Bronchus            All Sites / Types     
Male 19 26.1 72.8 (43.8-113.7)   Male 203 197.3 102.9 (89.2-118.0) 
Female 19 27.0 70.3 (42.3-109.7)   Female 205 205.3 99.9 (86.7-114.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Holyoke 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 29 39.2 74.0 (49.5-106.2)   Male 13 24.7 52.7 (28.0-90.1) 
Female 10 15.6 64.2 (30.7-118.0)   Female 13 21.2 61.5 (32.7-105.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 7.6 105.6 (45.5-208.0)   Male 3 7.7 nc (nc-nc) 
Female 5 7.0 71.8 (23.1-167.6)   Female 4 7.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.3 nc (nc-nc)   Male 17 22.1 77.0 (44.8-123.3) 
Female 136 162.6 83.6 (70.2-98.9)   Female 19 20.8 91.4 (55.0-142.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 21 17.4 120.7 (74.7-184.6) 
Female 6 5.5 109.5 (40.0-238.4)   Female 10 9.1 110.0 (52.7-202.3) 
Colon / Rectum            Ovary     
Male 40 40.9 97.9 (69.9-133.3)             
Female 43 44.9 95.8 (69.3-129.0)   Female 14 14.3 97.8 (53.4-164.2) 
Esophagus            Pancreas     
Male 5 9.3 53.9 (17.4-125.9)   Male 14 14.1 99.2 (54.2-166.5) 
Female 0 3.0 nc (nc-nc)   Female 20 16.4 121.9 (74.4-188.2) 
Hodgkin Lymphoma            Prostate     
Male 5 3.1 163.5 (52.7-381.5)   Male 96 103.6 92.6 (75.0-113.1) 
Female 6 2.9 206.6 (75.4-449.6)             
Kidney & Renal Pelvis            Stomach     
Male 24 21.3 112.9 (72.3-168.0)   Male 8 9.0 88.9 (38.3-175.3) 
Female 12 13.3 90.1 (46.5-157.3)   Female 9 6.3 143.0 (65.2-271.4) 
Larynx            Testis     
Male 9 5.3 169.7 (77.4-322.1)   Male 3 5.8 nc (nc-nc) 
Female 3 1.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 16.3 61.3 (29.4-112.8)   Male 1 9.7 nc (nc-nc) 
Female 11 12.8 85.6 (42.7-153.2)   Female 27 31.3 86.4 (56.9-125.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 19 12.9 147.1 (88.5-229.8)             
Female 4 5.0 nc (nc-nc)   Female 42 35.6 118.0 (85.1-159.5) 
Lung and Bronchus            All Sites / Types     
Male 69 65.7 105.0 (81.7-132.9)   Male 444 478.1 92.9 (84.4-101.9) 
Female 73 79.4 92.0 (72.1-115.7)   Female 523 563.1 92.9 (85.1-101.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hopedale 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 6.2 113.4 (45.4-233.7)   Male 2 3.8 nc (nc-nc) 
Female 3 2.4 nc (nc-nc)   Female 4 3.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.1 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 2 1.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 3 3.4 nc (nc-nc) 
Female 27 26.1 103.3 (68.1-150.4)   Female 1 3.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 2.7 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 6.7 104.9 (42.0-216.2)             
Female 9 7.1 127.3 (58.1-241.6)   Female 1 2.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.4 nc (nc-nc)   Male 2 2.2 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 2.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 22 15.7 140.0 (87.7-212.0) 
Female 1 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 3.3 nc (nc-nc)   Male 3 1.4 nc (nc-nc) 
Female 2 2.1 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Larynx            Testis     
Male 1 0.8 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 2.5 nc (nc-nc)   Male 2 1.5 nc (nc-nc) 
Female 1 2.0 nc (nc-nc)   Female 7 5.0 139.4 (55.9-287.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 2.0 nc (nc-nc)             
Female 0 0.8 nc (nc-nc)   Female 7 5.6 124.6 (49.9-256.7) 
Lung and Bronchus            All Sites / Types     
Male 16 9.6 166.6 (95.1-270.5)   Male 86 73.7 116.7 (93.4-144.2) 
Female 13 11.9 109.0 (58.0-186.3)   Female 89 88.3 100.8 (80.9-124.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hopkinton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 12.2 114.8 (62.7-192.7)   Male 9 8.8 102.0 (46.5-193.6) 
Female 11 4.6 240.3 (119.8-430.0)   Female 10 7.9 126.6 (60.6-232.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 2.9 nc (nc-nc)   Male 1 2.8 nc (nc-nc) 
Female 4 2.6 nc (nc-nc)   Female 0 2.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.5 nc (nc-nc)   Male 7 7.8 89.3 (35.8-183.9) 
Female 67 65.1 102.9 (79.8-130.7)   Female 5 7.0 71.3 (23.0-166.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 7.2 138.5 (66.3-254.7) 
Female 4 2.5 nc (nc-nc)   Female 2 3.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 18 14.6 123.1 (72.9-194.5)             
Female 12 14.5 82.9 (42.8-144.8)   Female 4 5.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 3.4 nc (nc-nc)   Male 4 4.8 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 8 4.8 168.2 (72.4-331.5) 
Hodgkin Lymphoma            Prostate     
Male 0 1.1 nc (nc-nc)   Male 59 41.7 141.6 (107.8-182.7) 
Female 3 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 8.6 nc (nc-nc)   Male 2 3.1 nc (nc-nc) 
Female 1 4.8 nc (nc-nc)   Female 1 2.0 nc (nc-nc) 
Larynx            Testis     
Male 2 2.0 nc (nc-nc)   Male 4 2.4 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 5.5 nc (nc-nc)   Male 9 4.4 205.6 (93.8-390.2) 
Female 1 4.2 nc (nc-nc)   Female 13 13.9 93.2 (49.6-159.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 5.1 nc (nc-nc)             
Female 0 1.6 nc (nc-nc)   Female 10 14.0 71.6 (34.3-131.7) 
Lung and Bronchus            All Sites / Types     
Male 14 21.9 63.8 (34.9-107.1)   Male 177 174.2 101.6 (87.2-117.7) 
Female 23 24.6 93.7 (59.4-140.6)   Female 188 202.0 93.1 (80.2-107.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hubbardston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 4.5 nc (nc-nc)   Male 1 3.0 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 1 2.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.9 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 2 0.7 nc (nc-nc)   Female 2 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 5 2.7 185.3 (59.7-432.5) 
Female 13 18.6 70.0 (37.2-119.6)   Female 2 2.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 2.4 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 5 0.9 547.4 (176.4-1277.5) 
Colon / Rectum            Ovary     
Male 0 5.1 nc (nc-nc)             
Female 4 3.9 nc (nc-nc)   Female 3 1.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.2 nc (nc-nc)   Male 1 1.7 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 2 1.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 13 14.2 91.8 (48.9-157.1) 
Female 1 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 2.8 nc (nc-nc)   Male 2 1.1 nc (nc-nc) 
Female 2 1.4 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Larynx            Testis     
Male 0 0.7 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 1.9 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 5 3.9 129.0 (41.6-301.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.7 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 3 4.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 6 7.8 77.0 (28.1-167.5)   Male 46 59.8 76.9 (56.3-102.6) 
Female 9 6.9 130.9 (59.7-248.4)   Female 61 56.7 107.6 (82.3-138.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hudson 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 21 21.5 97.8 (60.5-149.4)   Male 13 14.0 92.9 (49.4-158.9) 
Female 8 8.4 95.8 (41.2-188.7)   Female 7 11.5 60.6 (24.3-124.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 4.2 142.7 (52.1-310.7)   Male 4 4.5 nc (nc-nc) 
Female 5 3.7 133.4 (43.0-311.2)   Female 4 3.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.8 nc (nc-nc)   Male 6 12.3 48.7 (17.8-105.9) 
Female 96 95.9 100.1 (81.1-122.3)   Female 10 11.4 87.8 (42.0-161.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 14 10.5 132.8 (72.6-222.9) 
Female 2 3.1 nc (nc-nc)   Female 6 5.1 117.4 (42.9-255.5) 
Colon / Rectum            Ovary     
Male 26 22.6 115.3 (75.3-168.9)             
Female 34 23.1 147.0 (101.8-205.4)   Female 9 8.1 111.1 (50.7-211.0) 
Esophagus            Pancreas     
Male 2 5.6 nc (nc-nc)   Male 3 8.1 nc (nc-nc) 
Female 0 1.7 nc (nc-nc)   Female 4 8.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.6 nc (nc-nc)   Male 66 69.0 95.7 (74.0-121.8) 
Female 2 1.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 11 13.0 84.7 (42.2-151.5)   Male 2 5.1 nc (nc-nc) 
Female 9 7.6 117.7 (53.7-223.4)   Female 6 3.3 183.1 (66.9-398.7) 
Larynx            Testis     
Male 2 3.3 nc (nc-nc)   Male 2 3.0 nc (nc-nc) 
Female 2 1.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 8.7 80.4 (32.2-165.7)   Male 7 5.8 121.4 (48.7-250.2) 
Female 2 6.6 nc (nc-nc)   Female 29 17.4 166.9 (111.8-239.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 7.7 nc (nc-nc)             
Female 3 2.8 nc (nc-nc)   Female 23 22.0 104.7 (66.4-157.2) 
Lung and Bronchus            All Sites / Types     
Male 33 39.0 84.6 (58.2-118.8)   Male 256 281.3 91.0 (80.2-102.9) 
Female 35 45.6 76.8 (53.5-106.8)   Female 320 316.4 101.1 (90.4-112.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Hull 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 15 15.3 98.1 (54.9-161.9)   Male 14 9.6 145.7 (79.6-244.6) 
Female 8 5.9 136.6 (58.8-269.2)   Female 14 7.7 181.1 (98.9-303.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.6 nc (nc-nc)   Male 4 3.2 nc (nc-nc) 
Female 4 2.4 nc (nc-nc)   Female 2 2.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.5 nc (nc-nc)   Male 3 8.4 nc (nc-nc) 
Female 61 65.3 93.4 (71.5-120.0)   Female 11 7.9 138.6 (69.1-247.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 7.3 123.8 (56.5-235.1) 
Female 2 1.9 nc (nc-nc)   Female 5 3.6 140.8 (45.4-328.6) 
Colon / Rectum            Ovary     
Male 17 15.3 110.8 (64.5-177.5)             
Female 17 15.9 107.1 (62.3-171.4)   Female 5 5.6 88.9 (28.6-207.4) 
Esophagus            Pancreas     
Male 4 4.0 nc (nc-nc)   Male 7 5.7 122.7 (49.1-252.8) 
Female 0 1.2 nc (nc-nc)   Female 8 6.0 134.1 (57.8-264.3) 
Hodgkin Lymphoma            Prostate     
Male 4 0.8 nc (nc-nc)   Male 36 49.2 73.2 (51.3-101.4) 
Female 1 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 13 8.7 148.7 (79.1-254.3)   Male 3 3.6 nc (nc-nc) 
Female 5 5.3 94.9 (30.6-221.5)   Female 1 2.2 nc (nc-nc) 
Larynx            Testis     
Male 3 2.4 nc (nc-nc)   Male 4 1.3 nc (nc-nc) 
Female 4 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 5.8 nc (nc-nc)   Male 3 3.4 nc (nc-nc) 
Female 2 4.4 nc (nc-nc)   Female 7 10.6 65.9 (26.4-135.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 11 5.7 194.2 (96.8-347.6)             
Female 0 2.0 nc (nc-nc)   Female 20 15.7 127.5 (77.8-196.9) 
Lung and Bronchus            All Sites / Types     
Male 21 27.8 75.5 (46.7-115.4)   Male 193 195.3 98.8 (85.4-113.8) 
Female 36 31.9 112.7 (78.9-156.0)   Female 225 216.4 104.0 (90.8-118.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
151 
Huntington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 2.4 nc (nc-nc)   Male 2 1.6 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.5 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 2 1.4 nc (nc-nc) 
Female 10 9.5 104.9 (50.2-192.9)   Female 4 1.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.3 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 2.5 nc (nc-nc)             
Female 3 2.0 nc (nc-nc)   Female 2 0.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 0.7 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.2 nc (nc-nc)   Male 4 8.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 1.5 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 3 0.4 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.0 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 2 1.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.9 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 1 2.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 7 4.3 162.0 (64.9-333.9)   Male 37 32.1 115.3 (81.2-158.9) 
Female 5 4.1 122.0 (39.3-284.7)   Female 33 29.8 110.9 (76.3-155.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
152 
Ipswich 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 20 17.5 114.1 (69.7-176.3)   Male 20 11.4 175.9 (107.4-271.7) 
Female 10 6.8 146.6 (70.2-269.6)   Female 9 8.9 101.0 (46.1-191.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 3.2 nc (nc-nc)   Male 1 3.7 nc (nc-nc) 
Female 2 2.8 nc (nc-nc)   Female 1 3.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.6 nc (nc-nc)   Male 15 10.0 149.8 (83.8-247.2) 
Female 91 73.0 124.6 (100.3-153.0)   Female 11 9.2 119.6 (59.6-214.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 8.8 79.7 (31.9-164.2) 
Female 3 2.2 nc (nc-nc)   Female 4 4.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 17 18.6 91.4 (53.2-146.4)             
Female 15 19.3 77.6 (43.4-127.9)   Female 3 6.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 9 4.6 196.5 (89.7-373.1)   Male 7 6.6 105.4 (42.2-217.2) 
Female 2 1.3 nc (nc-nc)   Female 5 7.2 69.6 (22.4-162.4) 
Hodgkin Lymphoma            Prostate     
Male 0 1.1 nc (nc-nc)   Male 62 56.7 109.3 (83.8-140.1) 
Female 2 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 10.6 47.4 (15.3-110.5)   Male 1 4.2 nc (nc-nc) 
Female 7 5.8 119.7 (48.0-246.6)   Female 5 2.7 183.3 (59.1-427.9) 
Larynx            Testis     
Male 2 2.7 nc (nc-nc)   Male 5 2.0 247.1 (79.6-576.7) 
Female 0 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 6.9 72.3 (23.3-168.8)   Male 3 4.5 nc (nc-nc) 
Female 2 5.2 nc (nc-nc)   Female 15 11.9 125.6 (70.3-207.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 6.5 93.0 (34.0-202.5)             
Female 2 2.3 nc (nc-nc)   Female 15 17.0 88.4 (49.5-145.9) 
Lung and Bronchus            All Sites / Types     
Male 21 31.4 66.8 (41.4-102.2)   Male 235 229.1 102.6 (89.9-116.6) 
Female 25 35.0 71.5 (46.2-105.5)   Female 246 246.2 99.9 (87.8-113.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
153 
Kingston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 14.3 97.7 (53.4-164.0)   Male 20 9.1 218.8 (133.6-337.9) 
Female 6 5.6 108.0 (39.4-235.1)   Female 12 7.6 156.9 (81.0-274.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 2.6 nc (nc-nc)   Male 4 2.9 nc (nc-nc) 
Female 6 2.5 244.0 (89.1-531.1)   Female 2 2.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 8 8.1 98.9 (42.6-194.9) 
Female 54 60.9 88.6 (66.6-115.7)   Female 6 7.6 79.4 (29.0-172.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 6.7 nc (nc-nc) 
Female 5 2.1 235.3 (75.8-549.2)   Female 3 3.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 12 15.1 79.6 (41.1-139.1)             
Female 9 16.4 54.8 (25.0-104.0)   Female 2 5.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 3.5 nc (nc-nc)   Male 8 5.3 151.0 (65.0-297.6) 
Female 4 1.1 nc (nc-nc)   Female 9 5.9 153.2 (69.9-290.9) 
Hodgkin Lymphoma            Prostate     
Male 0 0.9 nc (nc-nc)   Male 44 40.9 107.6 (78.2-144.5) 
Female 2 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 8.1 123.8 (59.3-227.6)   Male 3 3.3 nc (nc-nc) 
Female 2 4.8 nc (nc-nc)   Female 1 2.3 nc (nc-nc) 
Larynx            Testis     
Male 2 2.1 nc (nc-nc)   Male 4 1.7 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 5.7 157.5 (71.9-299.0)   Male 6 3.5 169.1 (61.7-368.0) 
Female 3 4.5 nc (nc-nc)   Female 12 11.5 104.5 (53.9-182.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 5.0 nc (nc-nc)             
Female 1 1.8 nc (nc-nc)   Female 16 13.1 122.4 (69.9-198.8) 
Lung and Bronchus            All Sites / Types     
Male 29 24.7 117.6 (78.7-168.9)   Male 198 178.8 110.8 (95.9-127.3) 
Female 28 28.1 99.7 (66.2-144.1)   Female 205 205.2 99.9 (86.7-114.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
154 
Lakeville 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 15 12.1 124.0 (69.4-204.6)   Male 9 8.2 110.0 (50.2-208.8) 
Female 5 3.9 129.0 (41.6-301.0)   Female 5 6.1 82.2 (26.5-191.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 2.4 nc (nc-nc)   Male 3 2.6 nc (nc-nc) 
Female 2 2.0 nc (nc-nc)   Female 2 1.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 4 7.2 nc (nc-nc) 
Female 47 51.6 91.1 (67.0-121.2)   Female 5 5.7 87.3 (28.1-203.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 6.6 91.5 (33.4-199.1) 
Female 1 1.7 nc (nc-nc)   Female 2 2.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 13.3 67.9 (31.0-128.9)             
Female 11 11.4 96.3 (48.0-172.2)   Female 3 4.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 3.3 nc (nc-nc)   Male 2 4.7 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 4 4.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.9 nc (nc-nc)   Male 38 41.6 91.4 (64.7-125.4) 
Female 1 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 7.8 64.1 (20.7-149.7)   Male 2 3.0 nc (nc-nc) 
Female 2 3.9 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Larynx            Testis     
Male 2 1.9 nc (nc-nc)   Male 2 1.6 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 5.0 nc (nc-nc)   Male 5 3.5 142.4 (45.9-332.4) 
Female 2 3.3 nc (nc-nc)   Female 18 9.8 184.1 (109.1-291.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 4.8 104.4 (33.6-243.5)             
Female 3 1.4 nc (nc-nc)   Female 13 12.0 108.1 (57.5-184.9) 
Lung and Bronchus            All Sites / Types     
Male 15 22.0 68.1 (38.1-112.4)   Male 147 165.2 89.0 (75.2-104.6) 
Female 20 21.1 95.0 (58.0-146.7)   Female 170 162.4 104.7 (89.5-121.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
155 
Lancaster 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 9.3 75.2 (30.1-154.9)   Male 5 5.9 84.6 (27.3-197.3) 
Female 6 2.5 238.4 (87.1-518.9)   Female 4 3.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.8 nc (nc-nc)   Male 1 1.9 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.3 nc (nc-nc)   Male 6 5.3 113.2 (41.4-246.5) 
Female 31 30.4 102.0 (69.3-144.8)   Female 5 3.5 140.9 (45.4-328.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 4.3 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 0 1.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 9.4 74.6 (29.9-153.8)             
Female 6 7.3 81.8 (29.9-178.0)   Female 3 2.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 2.4 nc (nc-nc)   Male 2 3.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 2.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.8 nc (nc-nc)   Male 28 28.7 97.7 (64.9-141.1) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 5.3 nc (nc-nc)   Male 0 2.2 nc (nc-nc) 
Female 2 2.4 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Larynx            Testis     
Male 2 1.4 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 3.8 nc (nc-nc)   Male 3 2.4 nc (nc-nc) 
Female 1 2.1 nc (nc-nc)   Female 4 5.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 3.2 nc (nc-nc)             
Female 1 0.9 nc (nc-nc)   Female 2 6.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 6 16.5 36.3 (13.2-79.0)   Male 85 119.1 71.4 (57.0-88.3) 
Female 13 13.5 96.5 (51.3-165.1)   Female 87 99.3 87.6 (70.2-108.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
156 
Lanesborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 2.7 nc (nc-nc)   Male 4 1.9 nc (nc-nc) 
Female 2 1.3 nc (nc-nc)   Female 3 1.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.6 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 5 1.7 292.5 (94.3-682.6) 
Female 12 14.3 83.8 (43.3-146.4)   Female 1 1.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 1.7 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 3.1 nc (nc-nc)             
Female 3 3.7 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 0.8 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 3 1.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.2 nc (nc-nc)   Male 11 10.8 101.4 (50.5-181.4) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.9 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 2 1.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Larynx            Testis     
Male 1 0.5 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 1.2 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 3 1.0 nc (nc-nc)   Female 4 2.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.2 nc (nc-nc)             
Female 1 0.4 nc (nc-nc)   Female 2 3.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 8 5.3 151.2 (65.1-298.0)   Male 48 40.5 118.5 (87.4-157.2) 
Female 4 6.6 nc (nc-nc)   Female 42 47.5 88.5 (63.8-119.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
157 
Lawrence 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 51 51.0 100.1 (74.5-131.6)   Male 6 35.9 16.7 (6.1-36.4) 
Female 16 21.1 75.9 (43.4-123.3)   Female 9 34.3 26.2 (12.0-49.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 9 12.8 70.3 (32.1-133.4)   Male 13 11.2 116.2 (61.8-198.7) 
Female 7 12.0 58.5 (23.5-120.6)   Female 23 10.2 226.5 (143.5-339.9) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.9 nc (nc-nc)   Male 25 32.3 77.4 (50.1-114.3) 
Female 190 268.5 70.8 (61.1-81.6)   Female 33 31.1 106.3 (73.1-149.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 25 28.2 88.6 (57.3-130.8) 
Female 17 10.0 170.8 (99.4-273.5)   Female 9 14.0 64.1 (29.3-121.7) 
Colon / Rectum            Ovary     
Male 63 58.4 108.0 (83.0-138.1)             
Female 42 63.9 65.7 (47.3-88.8)   Female 13 22.9 56.8 (30.2-97.1) 
Esophagus            Pancreas     
Male 7 13.8 50.8 (20.4-104.8)   Male 17 19.7 86.2 (50.2-138.0) 
Female 7 4.2 166.6 (66.7-343.2)   Female 13 22.1 58.9 (31.4-100.8) 
Hodgkin Lymphoma            Prostate     
Male 4 5.9 nc (nc-nc)   Male 198 165.9 119.4 (103.3-137.2) 
Female 10 5.5 183.1 (87.7-336.8)             
Kidney & Renal Pelvis            Stomach     
Male 26 34.0 76.4 (49.9-111.9)   Male 16 12.6 126.8 (72.4-205.9) 
Female 29 20.7 139.8 (93.6-200.7)   Female 14 9.0 155.9 (85.2-261.6) 
Larynx            Testis     
Male 12 8.0 149.2 (77.0-260.6)   Male 11 11.9 92.3 (46.0-165.1) 
Female 2 2.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 21 24.2 86.7 (53.7-132.6)   Male 14 17.6 79.6 (43.5-133.6) 
Female 21 19.5 107.5 (66.5-164.3)   Female 65 58.7 110.7 (85.4-141.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 38 19.8 191.7 (135.6-263.1)             
Female 16 7.4 215.6 (123.2-350.2)   Female 48 58.9 81.5 (60.1-108.0) 
Lung and Bronchus            All Sites / Types     
Male 93 90.8 102.4 (82.7-125.5)   Male 710 712.2 99.7 (92.5-107.3) 
Female 101 110.7 91.2 (74.3-110.8)   Female 740 875.4 84.5 (78.6-90.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
158 
Lee 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 16 8.9 179.9 (102.8-292.2)   Male 4 5.3 nc (nc-nc) 
Female 1 3.0 nc (nc-nc)   Female 5 3.9 129.8 (41.8-303.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.4 nc (nc-nc)   Male 1 1.7 nc (nc-nc) 
Female 2 1.3 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 1 4.6 nc (nc-nc) 
Female 30 31.8 94.3 (63.6-134.6)   Female 4 4.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 3.6 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 8.6 104.2 (47.5-197.8)             
Female 11 8.1 135.5 (67.5-242.4)   Female 2 2.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 2.1 nc (nc-nc)   Male 3 3.1 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 1 3.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.5 nc (nc-nc)   Male 19 24.1 78.9 (47.5-123.3) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 4.5 133.4 (48.7-290.4)   Male 0 2.0 nc (nc-nc) 
Female 3 2.6 nc (nc-nc)   Female 5 1.2 429.7 (138.5-1002.7) 
Larynx            Testis     
Male 2 1.2 nc (nc-nc)   Male 2 0.8 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 3.3 nc (nc-nc)   Male 4 1.7 nc (nc-nc) 
Female 1 2.3 nc (nc-nc)   Female 4 5.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 2.8 nc (nc-nc)             
Female 1 1.0 nc (nc-nc)   Female 7 7.4 94.3 (37.8-194.2) 
Lung and Bronchus            All Sites / Types     
Male 17 15.2 111.5 (64.9-178.6)   Male 105 104.4 100.5 (82.2-121.7) 
Female 24 16.0 149.8 (95.9-222.9)   Female 110 107.7 102.1 (83.9-123.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
159 
Leicester 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 12.5 95.8 (49.4-167.3)   Male 11 8.3 133.3 (66.5-238.6) 
Female 4 5.1 nc (nc-nc)   Female 12 6.8 176.5 (91.1-308.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.5 nc (nc-nc)   Male 3 2.7 nc (nc-nc) 
Female 2 2.2 nc (nc-nc)   Female 2 2.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.5 nc (nc-nc)   Male 2 7.3 nc (nc-nc) 
Female 39 56.5 69.0 (49.1-94.3)   Female 4 6.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 6.4 156.5 (74.9-287.8) 
Female 2 1.7 nc (nc-nc)   Female 3 3.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 13.3 52.6 (21.1-108.4)             
Female 11 14.0 78.7 (39.2-140.8)   Female 6 4.9 122.4 (44.7-266.4) 
Esophagus            Pancreas     
Male 6 3.3 179.2 (65.4-390.1)   Male 1 4.8 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 6 5.1 117.4 (42.9-255.5) 
Hodgkin Lymphoma            Prostate     
Male 0 0.9 nc (nc-nc)   Male 37 40.7 90.8 (64.0-125.2) 
Female 1 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 7.6 78.8 (28.8-171.5)   Male 1 3.0 nc (nc-nc) 
Female 6 4.6 131.2 (47.9-285.5)   Female 0 1.9 nc (nc-nc) 
Larynx            Testis     
Male 3 2.0 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 12 5.1 235.3 (121.4-411.0)   Male 6 3.3 180.1 (65.8-392.1) 
Female 6 3.9 154.2 (56.3-335.6)   Female 4 9.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 4.9 nc (nc-nc)             
Female 2 1.7 nc (nc-nc)   Female 12 13.0 92.5 (47.7-161.5) 
Lung and Bronchus            All Sites / Types     
Male 10 22.6 44.3 (21.2-81.4)   Male 141 166.1 84.9 (71.5-100.1) 
Female 21 27.7 75.9 (47.0-116.1)   Female 158 187.7 84.2 (71.5-98.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
160 
Lenox 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 10.8 129.3 (70.6-217.0)   Male 7 5.9 119.4 (47.8-246.1) 
Female 2 4.3 nc (nc-nc)   Female 8 4.6 174.4 (75.1-343.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.4 nc (nc-nc)   Male 4 1.9 nc (nc-nc) 
Female 4 1.4 nc (nc-nc)   Female 1 1.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 6 5.1 116.5 (42.5-253.6) 
Female 35 36.4 96.1 (66.9-133.7)   Female 4 5.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 3.7 136.6 (44.0-318.7) 
Female 0 0.9 nc (nc-nc)   Female 2 2.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 14 10.0 140.6 (76.8-235.9)             
Female 17 11.9 143.3 (83.4-229.5)   Female 5 3.3 152.0 (49.0-354.6) 
Esophagus            Pancreas     
Male 1 2.3 nc (nc-nc)   Male 4 3.6 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 5 4.7 107.5 (34.6-250.8) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 24 25.2 95.4 (61.1-141.9) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 4.6 109.5 (35.3-255.6)   Male 0 2.3 nc (nc-nc) 
Female 5 3.1 159.1 (51.3-371.4)   Female 0 1.7 nc (nc-nc) 
Larynx            Testis     
Male 0 1.3 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 3.7 nc (nc-nc)   Male 0 1.6 nc (nc-nc) 
Female 3 3.1 nc (nc-nc)   Female 2 4.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 2.9 nc (nc-nc)             
Female 2 1.3 nc (nc-nc)   Female 5 8.2 61.2 (19.7-142.8) 
Lung and Bronchus            All Sites / Types     
Male 11 17.2 64.0 (31.9-114.4)   Male 108 114.8 94.1 (77.2-113.6) 
Female 16 21.0 76.3 (43.6-123.9)   Female 127 133.8 94.9 (79.1-112.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
161 
Leominster 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 63 47.2 133.3 (102.5-170.6)   Male 22 29.7 74.0 (46.4-112.1) 
Female 27 15.7 171.7 (113.1-249.9)   Female 19 22.7 83.9 (50.5-131.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 8.5 70.2 (25.6-152.8)   Male 10 9.5 105.7 (50.6-194.3) 
Female 9 7.3 122.7 (56.0-232.9)   Female 4 7.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.6 nc (nc-nc)   Male 21 26.3 79.8 (49.4-122.0) 
Female 169 179.3 94.3 (80.6-109.6)   Female 24 21.8 109.9 (70.4-163.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 23 21.2 108.5 (68.7-162.8) 
Female 7 6.1 114.8 (46.0-236.5)   Female 12 9.7 123.9 (64.0-216.5) 
Colon / Rectum            Ovary     
Male 44 49.0 89.8 (65.2-120.6)             
Female 37 46.0 80.4 (56.6-110.8)   Female 29 15.5 187.1 (125.3-268.7) 
Esophagus            Pancreas     
Male 14 11.4 122.4 (66.9-205.4)   Male 18 17.1 105.1 (62.3-166.2) 
Female 2 3.0 nc (nc-nc)   Female 21 16.4 127.9 (79.1-195.5) 
Hodgkin Lymphoma            Prostate     
Male 2 3.3 nc (nc-nc)   Male 127 130.9 97.0 (80.9-115.4) 
Female 3 3.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 34 25.9 131.1 (90.8-183.2)   Male 11 10.9 100.8 (50.3-180.5) 
Female 15 14.3 105.1 (58.8-173.4)   Female 1 6.4 nc (nc-nc) 
Larynx            Testis     
Male 11 6.6 167.0 (83.2-298.8)   Male 4 6.3 nc (nc-nc) 
Female 0 2.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 18 18.7 96.4 (57.1-152.4)   Male 13 11.6 112.1 (59.6-191.8) 
Female 14 13.1 107.1 (58.5-179.7)   Female 27 34.8 77.6 (51.1-112.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 10 15.7 63.6 (30.4-116.9)             
Female 5 5.3 94.9 (30.6-221.4)   Female 41 39.8 102.9 (73.9-139.6) 
Lung and Bronchus            All Sites / Types     
Male 82 80.7 101.7 (80.9-126.2)   Male 579 580.2 99.8 (91.8-108.3) 
Female 88 81.8 107.6 (86.3-132.5)   Female 602 599.3 100.5 (92.6-108.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
162 
Leverett 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 3.6 nc (nc-nc)   Male 1 2.2 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 3 1.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.6 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 2 0.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 4 1.9 nc (nc-nc) 
Female 11 11.2 97.8 (48.8-175.1)   Female 1 1.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 3.5 nc (nc-nc)             
Female 1 2.5 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.9 nc (nc-nc)   Male 3 1.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 4 11.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 1.9 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 2 0.9 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Larynx            Testis     
Male 0 0.5 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.3 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 2 0.7 nc (nc-nc)   Female 1 1.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.2 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 4 2.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 5 6.4 78.2 (25.2-182.6)   Male 30 44.3 67.8 (45.7-96.7) 
Female 4 5.4 nc (nc-nc)   Female 34 36.5 93.2 (64.6-130.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
163 
Lexington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 26 42.5 61.2 (40.0-89.7)   Male 26 26.3 98.9 (64.6-144.9) 
Female 3 15.4 nc (nc-nc)   Female 24 20.6 116.8 (74.8-173.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 7.3 nc (nc-nc)   Male 12 8.5 141.3 (72.9-246.9) 
Female 6 6.6 91.0 (33.2-198.2)   Female 8 7.1 112.6 (48.5-221.9) 
Breast            Non-Hodgkin Lymphoma     
Male 4 1.5 nc (nc-nc)   Male 19 23.2 81.8 (49.2-127.7) 
Female 183 168.0 108.9 (93.7-125.9)   Female 21 20.8 101.1 (62.6-154.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 18 18.9 95.1 (56.4-150.4) 
Female 1 5.3 nc (nc-nc)   Female 4 9.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 37 43.5 85.1 (59.9-117.2)             
Female 28 44.5 62.9 (41.8-90.9)   Female 15 14.4 104.4 (58.4-172.2) 
Esophagus            Pancreas     
Male 5 10.3 48.4 (15.6-112.8)   Male 16 15.4 103.9 (59.4-168.8) 
Female 1 3.0 nc (nc-nc)   Female 18 16.3 110.5 (65.4-174.6) 
Hodgkin Lymphoma            Prostate     
Male 2 2.4 nc (nc-nc)   Male 129 120.5 107.0 (89.3-127.2) 
Female 1 2.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 15 23.2 64.7 (36.2-106.7)   Male 1 9.8 nc (nc-nc) 
Female 5 13.4 37.3 (12.0-87.0)   Female 2 6.2 nc (nc-nc) 
Larynx            Testis     
Male 3 5.9 nc (nc-nc)   Male 6 4.3 139.3 (50.9-303.1) 
Female 0 1.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 17 16.4 104.0 (60.5-166.5)   Male 11 9.8 112.0 (55.8-200.4) 
Female 10 12.3 81.5 (39.0-149.9)   Female 34 28.9 117.7 (81.5-164.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 14.1 nc (nc-nc)             
Female 5 5.0 99.6 (32.1-232.3)   Female 32 37.4 85.6 (58.5-120.9) 
Lung and Bronchus            All Sites / Types     
Male 29 72.6 39.9 (26.7-57.4)   Male 416 518.7 80.2 (72.7-88.3) 
Female 40 79.5 50.3 (35.9-68.5)   Female 483 564.1 85.6 (78.2-93.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
164 
Leyden 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 0.9 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 2 4.1 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 1.0 nc (nc-nc)             
Female 0 0.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.1 nc (nc-nc)   Male 1 3.4 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.6 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.4 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 1.6 nc (nc-nc)   Male 9 12.5 72.2 (32.9-137.0) 
Female 2 1.6 nc (nc-nc)   Female 16 12.5 127.7 (73.0-207.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
165 
Lincoln 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 9.9 nc (nc-nc)   Male 7 6.0 117.6 (47.1-242.4) 
Female 8 3.0 262.3 (113.0-516.9)   Female 7 4.1 171.2 (68.6-352.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 1.6 372.3 (135.9-810.4)   Male 3 1.9 nc (nc-nc) 
Female 0 1.3 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 4 5.3 nc (nc-nc) 
Female 44 31.9 137.9 (100.2-185.2)   Female 2 4.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 4.0 150.9 (55.1-328.5) 
Female 0 1.0 nc (nc-nc)   Female 3 1.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 9.8 71.4 (28.6-147.1)             
Female 8 8.9 89.7 (38.6-176.7)   Female 4 2.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 2.3 nc (nc-nc)   Male 5 3.5 143.1 (46.1-334.0) 
Female 0 0.6 nc (nc-nc)   Female 4 3.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.5 nc (nc-nc)   Male 42 24.3 173.1 (124.8-234.0) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 4.9 nc (nc-nc)   Male 0 2.2 nc (nc-nc) 
Female 4 2.6 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Larynx            Testis     
Male 0 1.3 nc (nc-nc)   Male 3 1.0 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 3.8 186.2 (74.6-383.7)   Male 3 2.1 nc (nc-nc) 
Female 5 2.6 195.9 (63.1-457.3)   Female 6 5.7 105.9 (38.7-230.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.1 nc (nc-nc)             
Female 1 1.0 nc (nc-nc)   Female 13 7.2 179.5 (95.5-307.0) 
Lung and Bronchus            All Sites / Types     
Male 6 16.3 36.7 (13.4-80.0)   Male 118 114.1 103.4 (85.6-123.8) 
Female 9 15.1 59.6 (27.2-113.2)   Female 129 109.9 117.3 (98.0-139.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
166 
Littleton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 13 9.2 142.0 (75.5-242.9)   Male 6 6.4 93.6 (34.2-203.7) 
Female 1 3.9 nc (nc-nc)   Female 4 5.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 2.0 nc (nc-nc)   Male 1 2.0 nc (nc-nc) 
Female 1 1.7 nc (nc-nc)   Female 0 1.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 8 5.6 142.3 (61.3-280.3) 
Female 49 45.1 108.6 (80.4-143.6)   Female 5 5.4 93.1 (30.0-217.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 5.1 156.3 (67.3-307.9) 
Female 0 1.4 nc (nc-nc)   Female 0 2.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 10.3 58.0 (21.2-126.2)             
Female 8 11.3 70.9 (30.5-139.7)   Female 6 3.9 155.2 (56.7-337.7) 
Esophagus            Pancreas     
Male 1 2.5 nc (nc-nc)   Male 8 3.6 221.8 (95.5-437.1) 
Female 0 0.8 nc (nc-nc)   Female 4 4.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 3 0.7 nc (nc-nc)   Male 35 30.7 114.0 (79.4-158.5) 
Female 0 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 6.0 nc (nc-nc)   Male 1 2.3 nc (nc-nc) 
Female 4 3.6 nc (nc-nc)   Female 0 1.6 nc (nc-nc) 
Larynx            Testis     
Male 1 1.5 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 3.9 153.3 (56.0-333.8)   Male 3 2.8 nc (nc-nc) 
Female 3 3.1 nc (nc-nc)   Female 8 8.2 97.8 (42.1-192.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 3.8 nc (nc-nc)             
Female 1 1.3 nc (nc-nc)   Female 12 10.3 116.8 (60.3-204.1) 
Lung and Bronchus            All Sites / Types     
Male 17 16.7 101.8 (59.3-163.0)   Male 131 126.7 103.4 (86.4-122.7) 
Female 14 20.8 67.4 (36.8-113.0)   Female 132 149.0 88.6 (74.1-105.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
167 
Longmeadow 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 22.0 63.7 (34.8-106.9)   Male 16 13.3 120.4 (68.7-195.5) 
Female 6 7.9 75.7 (27.6-164.7)   Female 12 10.2 117.3 (60.6-205.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 3.5 nc (nc-nc)   Male 2 4.2 nc (nc-nc) 
Female 5 3.3 151.1 (48.7-352.7)   Female 1 3.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.7 nc (nc-nc)   Male 11 11.7 94.4 (47.1-168.9) 
Female 88 82.1 107.2 (86.0-132.1)   Female 11 10.4 105.5 (52.6-188.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 9.5 73.8 (29.5-152.0) 
Female 0 2.6 nc (nc-nc)   Female 0 4.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 14 22.3 62.7 (34.2-105.2)             
Female 13 23.2 56.0 (29.8-95.7)   Female 6 7.1 84.0 (30.7-182.8) 
Esophagus            Pancreas     
Male 2 5.2 nc (nc-nc)   Male 4 7.9 nc (nc-nc) 
Female 1 1.5 nc (nc-nc)   Female 5 8.5 58.7 (18.9-137.0) 
Hodgkin Lymphoma            Prostate     
Male 1 1.2 nc (nc-nc)   Male 50 61.0 81.9 (60.8-108.0) 
Female 2 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 11 11.5 95.3 (47.5-170.6)   Male 4 5.0 nc (nc-nc) 
Female 4 6.6 nc (nc-nc)   Female 2 3.2 nc (nc-nc) 
Larynx            Testis     
Male 1 3.0 nc (nc-nc)   Male 3 2.0 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 8.2 121.5 (58.2-223.5)   Male 6 4.7 128.1 (46.8-278.7) 
Female 2 6.3 nc (nc-nc)   Female 8 13.8 57.8 (24.9-114.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 7.1 nc (nc-nc)             
Female 7 2.5 278.8 (111.7-574.5)   Female 13 18.0 72.1 (38.4-123.4) 
Lung and Bronchus            All Sites / Types     
Male 26 37.1 70.1 (45.8-102.7)   Male 214 262.6 81.5 (70.9-93.2) 
Female 23 39.6 58.0 (36.8-87.0)   Female 236 281.4 83.9 (73.5-95.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
168 
Lowell 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 81 82.9 97.7 (77.6-121.5)   Male 25 57.6 43.4 (28.1-64.0) 
Female 35 32.1 108.9 (75.8-151.4)   Female 28 48.8 57.4 (38.1-82.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 13 19.5 66.8 (35.5-114.2)   Male 19 18.0 105.3 (63.4-164.5) 
Female 12 16.6 72.1 (37.2-126.0)   Female 19 15.1 126.1 (75.9-196.9) 
Breast            Non-Hodgkin Lymphoma     
Male 2 3.0 nc (nc-nc)   Male 34 51.6 65.9 (45.6-92.1) 
Female 329 378.4 86.9 (77.8-96.9)   Female 36 45.5 79.1 (55.4-109.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 59 45.3 130.2 (99.1-167.9) 
Female 20 13.4 149.5 (91.3-230.8)   Female 11 20.4 54.0 (26.9-96.7) 
Colon / Rectum            Ovary     
Male 92 93.9 98.0 (79.0-120.1)             
Female 107 94.3 113.5 (93.0-137.1)   Female 32 32.9 97.3 (66.5-137.3) 
Esophagus            Pancreas     
Male 20 22.3 89.8 (54.8-138.7)   Male 30 32.0 93.7 (63.2-133.7) 
Female 6 6.3 95.7 (35.0-208.4)   Female 33 33.4 98.9 (68.1-138.9) 
Hodgkin Lymphoma            Prostate     
Male 14 9.0 156.1 (85.3-262.0)   Male 206 270.1 76.3 (66.2-87.4) 
Female 5 7.7 65.0 (21.0-151.8)             
Kidney & Renal Pelvis            Stomach     
Male 67 54.1 123.9 (96.0-157.3)   Male 23 20.4 112.8 (71.5-169.2) 
Female 30 30.1 99.7 (67.3-142.4)   Female 33 13.3 249.0 (171.4-349.7) 
Larynx            Testis     
Male 15 13.1 114.8 (64.2-189.3)   Male 14 18.0 77.9 (42.5-130.7) 
Female 7 4.1 171.3 (68.6-353.0)             
Leukemia            Thyroid     
Male 36 37.6 95.8 (67.1-132.7)   Male 20 27.3 73.3 (44.7-113.1) 
Female 32 28.2 113.5 (77.6-160.2)   Female 88 79.4 110.8 (88.9-136.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 60 32.4 185.4 (141.5-238.7)             
Female 15 11.0 136.4 (76.3-225.0)   Female 69 84.4 81.8 (63.6-103.5) 
Lung and Bronchus            All Sites / Types     
Male 175 147.1 119.0 (102.0-138.0)   Male 1110 1144.8 97.0 (91.3-102.8) 
Female 188 168.9 111.3 (96.0-128.4)   Female 1234 1263.9 97.6 (92.3-103.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
169 
Ludlow 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 28 26.7 105.0 (69.8-151.8)   Male 11 17.0 64.6 (32.2-115.6) 
Female 5 10.3 48.4 (15.6-112.9)   Female 13 13.3 97.7 (52.0-167.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 4.9 nc (nc-nc)   Male 4 5.5 nc (nc-nc) 
Female 2 4.2 nc (nc-nc)   Female 7 4.7 148.5 (59.5-306.1) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.9 nc (nc-nc)   Male 15 15.0 99.7 (55.8-164.5) 
Female 99 107.7 92.0 (74.7-112.0)   Female 16 13.7 116.6 (66.6-189.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 12.8 47.0 (17.2-102.3) 
Female 6 3.3 182.8 (66.7-397.9)   Female 4 6.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 27 27.7 97.5 (64.2-141.8)             
Female 30 29.0 103.5 (69.8-147.8)   Female 8 9.4 85.5 (36.8-168.5) 
Esophagus            Pancreas     
Male 3 6.8 nc (nc-nc)   Male 10 9.9 101.1 (48.4-186.0) 
Female 2 2.0 nc (nc-nc)   Female 10 10.8 92.6 (44.3-170.2) 
Hodgkin Lymphoma            Prostate     
Male 3 1.8 nc (nc-nc)   Male 50 81.2 61.5 (45.7-81.1) 
Female 1 1.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 22 15.3 143.7 (90.0-217.6)   Male 8 6.3 127.9 (55.1-252.0) 
Female 5 8.8 57.0 (18.4-133.0)   Female 5 4.1 121.6 (39.2-283.9) 
Larynx            Testis     
Male 5 3.9 126.8 (40.9-296.0)   Male 1 3.3 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 10.5 57.0 (20.8-124.0)   Male 4 6.7 nc (nc-nc) 
Female 7 8.0 87.2 (34.9-179.6)   Female 8 18.1 44.3 (19.1-87.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 10 9.6 103.7 (49.6-190.7)             
Female 2 3.3 nc (nc-nc)   Female 27 24.6 109.8 (72.3-159.7) 
Lung and Bronchus            All Sites / Types     
Male 35 46.7 74.9 (52.2-104.2)   Male 282 339.4 83.1 (73.7-93.4) 
Female 32 53.4 59.9 (41.0-84.6)   Female 318 367.8 86.5 (77.2-96.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
170 
Lunenburg 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 12.7 86.5 (43.1-154.7)   Male 10 8.1 122.9 (58.8-226.0) 
Female 7 4.5 154.9 (62.1-319.3)   Female 2 6.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 2.3 nc (nc-nc)   Male 5 2.6 192.5 (62.0-449.1) 
Female 3 2.1 nc (nc-nc)   Female 1 2.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 6 7.2 83.1 (30.3-180.9) 
Female 64 54.9 116.6 (89.8-148.9)   Female 6 6.5 92.8 (33.9-202.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 6.1 98.1 (35.8-213.5) 
Female 2 1.8 nc (nc-nc)   Female 0 2.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 13.7 72.8 (34.8-133.8)             
Female 15 13.1 114.6 (64.1-189.0)   Female 2 4.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 3.2 nc (nc-nc)   Male 4 4.7 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 2 4.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 3 0.8 nc (nc-nc)   Male 35 37.5 93.3 (65.0-129.8) 
Female 0 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 7.4 94.8 (38.0-195.4)   Male 2 3.0 nc (nc-nc) 
Female 3 4.2 nc (nc-nc)   Female 1 1.9 nc (nc-nc) 
Larynx            Testis     
Male 4 1.8 nc (nc-nc)   Male 3 1.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 5.0 158.7 (68.3-312.7)   Male 5 3.3 150.8 (48.6-351.9) 
Female 6 3.7 163.7 (59.8-356.3)   Female 12 10.0 120.3 (62.1-210.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 4.4 nc (nc-nc)             
Female 2 1.6 nc (nc-nc)   Female 16 12.7 126.1 (72.0-204.8) 
Lung and Bronchus            All Sites / Types     
Male 23 21.6 106.5 (67.5-159.8)   Male 165 160.6 102.8 (87.7-119.7) 
Female 18 23.8 75.6 (44.8-119.4)   Female 171 177.6 96.3 (82.4-111.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
171 
Lynn 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 84 72.8 115.4 (92.0-142.8)   Male 41 49.5 82.8 (59.4-112.4) 
Female 26 27.6 94.2 (61.5-138.0)   Female 37 42.2 87.7 (61.7-120.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 19 16.3 116.5 (70.1-182.0)   Male 31 15.6 199.2 (135.3-282.8) 
Female 20 14.4 139.0 (84.9-214.7)   Female 18 13.1 137.7 (81.6-217.6) 
Breast            Non-Hodgkin Lymphoma     
Male 5 2.6 189.1 (60.9-441.3)   Male 49 44.2 110.8 (82.0-146.5) 
Female 307 329.9 93.1 (82.9-104.1)   Female 49 39.4 124.4 (92.1-164.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 44 37.8 116.5 (84.6-156.4) 
Female 16 11.6 138.0 (78.9-224.2)   Female 24 17.6 136.0 (87.1-202.4) 
Colon / Rectum            Ovary     
Male 117 80.9 144.6 (119.6-173.3)             
Female 112 81.3 137.8 (113.5-165.9)   Female 25 28.5 87.6 (56.7-129.3) 
Esophagus            Pancreas     
Male 15 19.0 79.0 (44.2-130.4)   Male 35 27.7 126.5 (88.1-175.9) 
Female 4 5.4 nc (nc-nc)   Female 25 28.7 87.0 (56.3-128.5) 
Hodgkin Lymphoma            Prostate     
Male 6 7.2 83.0 (30.3-180.7)   Male 284 225.3 126.1 (111.8-141.6) 
Female 3 6.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 40 45.6 87.7 (62.6-119.4)   Male 20 17.7 113.3 (69.2-175.0) 
Female 29 26.1 111.0 (74.3-159.4)   Female 16 11.4 140.1 (80.0-227.5) 
Larynx            Testis     
Male 12 11.1 107.8 (55.7-188.4)   Male 11 14.7 74.6 (37.2-133.5) 
Female 5 3.6 140.5 (45.3-327.8)             
Leukemia            Thyroid     
Male 44 32.1 137.2 (99.7-184.2)   Male 20 22.6 88.4 (53.9-136.5) 
Female 29 24.5 118.4 (79.3-170.0)   Female 61 68.4 89.2 (68.3-114.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 53 27.0 196.5 (147.2-257.0)             
Female 21 9.5 221.0 (136.7-337.8)   Female 80 73.7 108.5 (86.0-135.0) 
Lung and Bronchus            All Sites / Types     
Male 197 128.0 153.9 (133.2-177.0)   Male 1209 975.5 123.9 (117.0-131.1) 
Female 179 145.4 123.1 (105.7-142.5)   Female 1190 1095.0 108.7 (102.6-115.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
172 
Lynnfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 13 18.3 70.9 (37.7-121.2)   Male 26 11.1 233.8 (152.7-342.6) 
Female 6 5.4 110.4 (40.3-240.4)   Female 12 7.4 161.6 (83.4-282.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 3.0 nc (nc-nc)   Male 3 3.6 nc (nc-nc) 
Female 5 2.4 210.9 (68.0-492.3)   Female 5 2.5 196.6 (63.4-458.8) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.6 nc (nc-nc)   Male 13 9.8 132.6 (70.6-226.8) 
Female 67 61.4 109.2 (84.6-138.7)   Female 14 7.4 189.5 (103.5-318.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 7.9 63.3 (20.4-147.8) 
Female 0 1.9 nc (nc-nc)   Female 2 3.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 12 18.6 64.5 (33.3-112.6)             
Female 21 15.5 135.4 (83.8-206.9)   Female 8 5.2 153.0 (65.9-301.5) 
Esophagus            Pancreas     
Male 1 4.4 nc (nc-nc)   Male 4 6.6 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 5 5.7 87.9 (28.3-205.1) 
Hodgkin Lymphoma            Prostate     
Male 0 1.0 nc (nc-nc)   Male 40 50.4 79.3 (56.7-108.0) 
Female 2 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 9.6 83.1 (35.8-163.7)   Male 2 4.2 nc (nc-nc) 
Female 5 4.9 102.4 (33.0-239.0)   Female 3 2.2 nc (nc-nc) 
Larynx            Testis     
Male 1 2.5 nc (nc-nc)   Male 7 1.7 403.6 (161.7-831.6) 
Female 0 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 12 6.9 174.5 (90.1-304.8)   Male 7 4.0 175.5 (70.3-361.7) 
Female 3 4.3 nc (nc-nc)   Female 17 10.7 158.5 (92.3-253.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 5.9 nc (nc-nc)             
Female 0 1.8 nc (nc-nc)   Female 15 13.9 107.5 (60.1-177.4) 
Lung and Bronchus            All Sites / Types     
Male 14 31.0 45.2 (24.7-75.9)   Male 190 219.1 86.7 (74.8-99.9) 
Female 25 28.7 87.1 (56.3-128.5)   Female 226 203.5 111.0 (97.0-126.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
173 
Malden 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 30 48.4 61.9 (41.8-88.4)   Male 10 33.4 30.0 (14.4-55.1) 
Female 19 19.2 99.0 (59.6-154.7)   Female 12 29.1 41.3 (21.3-72.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 10.8 46.1 (14.9-107.6)   Male 10 10.4 95.8 (45.9-176.2) 
Female 8 9.7 82.8 (35.7-163.2)   Female 4 9.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 3 1.8 nc (nc-nc)   Male 47 29.8 157.5 (115.7-209.5) 
Female 200 222.5 89.9 (77.9-103.2)   Female 23 27.1 84.7 (53.7-127.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 29 25.2 115.1 (77.1-165.4) 
Female 15 8.0 188.5 (105.4-310.9)   Female 14 12.1 115.8 (63.3-194.3) 
Colon / Rectum            Ovary     
Male 65 53.1 122.4 (94.4-156.0)             
Female 67 56.2 119.1 (92.3-151.3)   Female 16 19.4 82.6 (47.2-134.1) 
Esophagus            Pancreas     
Male 21 12.8 164.4 (101.7-251.2)   Male 19 18.5 102.8 (61.9-160.5) 
Female 8 3.7 214.1 (92.2-422.0)   Female 20 20.0 99.8 (60.9-154.1) 
Hodgkin Lymphoma            Prostate     
Male 3 5.2 nc (nc-nc)   Male 144 152.2 94.6 (79.8-111.4) 
Female 5 4.7 107.5 (34.6-250.8)             
Kidney & Renal Pelvis            Stomach     
Male 32 30.5 104.9 (71.7-148.1)   Male 20 11.8 169.9 (103.8-262.5) 
Female 20 17.7 112.8 (68.9-174.2)   Female 12 7.9 151.7 (78.3-265.0) 
Larynx            Testis     
Male 5 7.5 66.3 (21.4-154.8)   Male 6 10.8 55.8 (20.4-121.4) 
Female 2 2.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 18 21.3 84.6 (50.1-133.8)   Male 13 15.6 83.2 (44.3-142.3) 
Female 16 16.6 96.3 (55.0-156.4)   Female 56 47.1 119.0 (89.9-154.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 29 18.4 157.7 (105.6-226.6)             
Female 16 6.5 244.8 (139.8-397.5)   Female 41 49.8 82.4 (59.1-111.8) 
Lung and Bronchus            All Sites / Types     
Male 114 86.3 132.1 (109.0-158.7)   Male 655 655.5 99.9 (92.4-107.9) 
Female 99 100.1 98.9 (80.4-120.4)   Female 728 748.3 97.3 (90.3-104.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
174 
Manchester by the Sea 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 9.3 nc (nc-nc)   Male 8 5.4 146.9 (63.2-289.5) 
Female 1 2.8 nc (nc-nc)   Female 5 3.7 136.6 (44.0-318.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.4 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.3 nc (nc-nc)   Male 6 4.8 125.4 (45.8-273.0) 
Female 32 31.1 102.9 (70.4-145.3)   Female 2 3.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 3.8 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 9.0 nc (nc-nc)             
Female 9 7.7 117.3 (53.5-222.6)   Female 2 2.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.2 nc (nc-nc)   Male 1 3.3 nc (nc-nc) 
Female 2 0.6 nc (nc-nc)   Female 5 2.9 172.7 (55.6-402.9) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 23 25.7 89.6 (56.8-134.5) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 4.7 nc (nc-nc)   Male 0 2.1 nc (nc-nc) 
Female 1 2.5 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Larynx            Testis     
Male 1 1.2 nc (nc-nc)   Male 2 0.6 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 3.4 nc (nc-nc)   Male 0 1.8 nc (nc-nc) 
Female 2 2.1 nc (nc-nc)   Female 7 5.0 138.8 (55.6-286.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 2.9 nc (nc-nc)             
Female 0 0.9 nc (nc-nc)   Female 4 7.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 7 15.9 44.2 (17.7-91.0)   Male 80 108.8 73.5 (58.3-91.5) 
Female 8 15.0 53.4 (23.0-105.1)   Female 89 102.8 86.5 (69.5-106.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Mansfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 23 17.3 132.7 (84.1-199.2)   Male 20 12.5 160.4 (97.9-247.8) 
Female 1 5.9 nc (nc-nc)   Female 20 10.7 187.1 (114.2-288.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 4.2 192.5 (82.9-379.3)   Male 5 3.9 128.4 (41.4-299.8) 
Female 6 3.5 170.7 (62.3-371.6)   Female 1 2.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.7 nc (nc-nc)   Male 14 11.2 125.5 (68.5-210.5) 
Female 99 87.5 113.1 (91.9-137.7)   Female 3 9.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 10.1 69.4 (27.8-142.9) 
Female 0 3.3 nc (nc-nc)   Female 3 4.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 24 20.6 116.6 (74.7-173.5)             
Female 27 19.1 141.6 (93.3-206.1)   Female 10 7.2 138.0 (66.1-253.8) 
Esophagus            Pancreas     
Male 1 4.8 nc (nc-nc)   Male 5 6.9 72.8 (23.5-169.9) 
Female 2 1.2 nc (nc-nc)   Female 4 6.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.8 nc (nc-nc)   Male 62 58.7 105.5 (80.9-135.3) 
Female 2 1.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 11 12.1 91.1 (45.4-163.1)   Male 2 4.4 nc (nc-nc) 
Female 4 6.4 nc (nc-nc)   Female 4 2.6 nc (nc-nc) 
Larynx            Testis     
Male 0 2.8 nc (nc-nc)   Male 8 3.7 216.9 (93.4-427.4) 
Female 1 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 7.9 101.1 (43.5-199.2)   Male 13 6.2 208.9 (111.1-357.2) 
Female 8 5.6 143.8 (61.9-283.4)   Female 15 19.5 77.1 (43.1-127.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 10 7.0 142.2 (68.1-261.6)             
Female 3 2.2 nc (nc-nc)   Female 12 18.7 64.1 (33.1-112.0) 
Lung and Bronchus            All Sites / Types     
Male 37 30.9 119.6 (84.2-164.8)   Male 276 246.5 112.0 (99.1-126.0) 
Female 28 32.3 86.6 (57.6-125.2)   Female 279 269.9 103.4 (91.6-116.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Marblehead 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 25 30.1 83.1 (53.8-122.7)   Male 41 18.3 224.0 (160.7-303.9) 
Female 7 10.4 67.4 (27.0-138.9)   Female 24 13.8 174.2 (111.5-259.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 5.0 nc (nc-nc)   Male 7 6.0 116.6 (46.7-240.3) 
Female 4 4.4 nc (nc-nc)   Female 8 4.8 166.0 (71.5-327.2) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.0 nc (nc-nc)   Male 14 16.1 87.0 (47.5-145.9) 
Female 113 115.7 97.7 (80.5-117.5)   Female 15 14.0 107.2 (59.9-176.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 12 13.0 92.0 (47.5-160.8) 
Female 4 3.5 nc (nc-nc)   Female 5 6.2 80.1 (25.8-186.9) 
Colon / Rectum            Ovary     
Male 23 29.8 77.2 (48.9-115.8)             
Female 22 29.1 75.6 (47.3-114.4)   Female 5 9.8 50.9 (16.4-118.8) 
Esophagus            Pancreas     
Male 9 7.3 122.7 (56.0-233.0)   Male 8 10.8 73.7 (31.8-145.3) 
Female 2 2.0 nc (nc-nc)   Female 15 10.8 138.9 (77.7-229.1) 
Hodgkin Lymphoma            Prostate     
Male 0 1.5 nc (nc-nc)   Male 84 85.6 98.1 (78.2-121.5) 
Female 4 1.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 12 16.0 74.9 (38.6-130.8)   Male 6 6.8 87.6 (32.0-190.7) 
Female 7 9.2 75.9 (30.4-156.3)   Female 1 4.1 nc (nc-nc) 
Larynx            Testis     
Male 1 4.2 nc (nc-nc)   Male 3 2.4 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 12 11.3 105.9 (54.7-185.1)   Male 7 6.3 110.9 (44.4-228.5) 
Female 9 8.0 112.4 (51.3-213.3)   Female 17 19.4 87.6 (51.0-140.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 10.0 nc (nc-nc)             
Female 1 3.4 nc (nc-nc)   Female 22 26.4 83.3 (52.2-126.2) 
Lung and Bronchus            All Sites / Types     
Male 28 52.4 53.4 (35.5-77.2)   Male 323 363.4 88.9 (79.5-99.1) 
Female 39 55.4 70.4 (50.1-96.3)   Female 357 383.5 93.1 (83.7-103.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
177 
Marion 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 7.9 89.0 (35.7-183.4)   Male 11 4.7 235.4 (117.4-421.3) 
Female 5 3.0 167.3 (53.9-390.3)   Female 2 3.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.3 nc (nc-nc)   Male 2 1.6 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 10 4.2 239.8 (114.8-441.0) 
Female 31 29.3 105.6 (71.8-150.0)   Female 3 3.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 3.3 nc (nc-nc) 
Female 2 0.8 nc (nc-nc)   Female 2 1.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 11 7.6 144.3 (72.0-258.3)             
Female 10 8.3 120.5 (57.7-221.7)   Female 0 2.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.9 nc (nc-nc)   Male 2 2.8 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 3 3.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 14 22.9 61.2 (33.5-102.8) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 4.1 nc (nc-nc)   Male 0 1.8 nc (nc-nc) 
Female 3 2.4 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Larynx            Testis     
Male 3 1.1 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 2.9 206.7 (75.5-449.9)   Male 3 1.6 nc (nc-nc) 
Female 4 2.3 nc (nc-nc)   Female 6 4.5 134.4 (49.1-292.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.5 nc (nc-nc)             
Female 1 0.9 nc (nc-nc)   Female 7 6.7 104.4 (41.8-215.1) 
Lung and Bronchus            All Sites / Types     
Male 10 13.6 73.4 (35.1-134.9)   Male 99 94.4 104.9 (85.2-127.7) 
Female 16 15.1 106.1 (60.6-172.3)   Female 108 101.9 106.0 (86.9-128.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
178 
Marlborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 36 39.6 90.8 (63.6-125.8)   Male 26 26.5 98.3 (64.2-144.0) 
Female 12 13.4 89.6 (46.3-156.6)   Female 13 19.8 65.6 (34.9-112.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 8.1 86.0 (34.5-177.2)   Male 9 8.4 107.7 (49.2-204.5) 
Female 10 6.5 154.3 (73.9-283.7)   Female 7 6.3 110.9 (44.4-228.4) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.4 nc (nc-nc)   Male 16 23.3 68.6 (39.2-111.3) 
Female 152 158.0 96.2 (81.5-112.8)   Female 26 18.9 137.5 (89.8-201.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 19 19.9 95.4 (57.4-149.0) 
Female 9 5.5 163.3 (74.5-310.1)   Female 20 8.4 237.6 (145.1-367.0) 
Colon / Rectum            Ovary     
Male 43 43.0 100.0 (72.3-134.7)             
Female 44 38.6 114.0 (82.8-153.0)   Female 16 13.5 118.3 (67.6-192.2) 
Esophagus            Pancreas     
Male 10 10.2 97.8 (46.8-179.9)   Male 14 14.9 94.0 (51.3-157.7) 
Female 5 2.6 190.5 (61.4-444.5)   Female 15 13.8 108.3 (60.6-178.7) 
Hodgkin Lymphoma            Prostate     
Male 7 3.4 208.2 (83.4-428.9)   Male 102 120.6 84.6 (69.0-102.7) 
Female 3 2.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 15 24.1 62.2 (34.8-102.7)   Male 4 9.5 nc (nc-nc) 
Female 13 12.5 103.9 (55.3-177.7)   Female 7 5.4 129.9 (52.0-267.6) 
Larynx            Testis     
Male 6 6.0 100.3 (36.6-218.2)   Male 3 6.8 nc (nc-nc) 
Female 1 1.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 12 16.6 72.1 (37.2-125.9)   Male 13 11.5 113.2 (60.2-193.6) 
Female 14 11.2 125.0 (68.3-209.7)   Female 38 31.4 120.9 (85.5-165.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 14 14.5 96.3 (52.6-161.6)             
Female 7 4.6 152.7 (61.2-314.6)   Female 36 35.8 100.6 (70.4-139.3) 
Lung and Bronchus            All Sites / Types     
Male 56 70.0 80.0 (60.4-103.9)   Male 445 519.6 85.6 (77.9-94.0) 
Female 76 71.3 106.6 (84.0-133.5)   Female 569 522.5 108.9 (100.1-118.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
179 
Marshfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 24 29.0 82.8 (53.0-123.2)   Male 31 19.1 162.4 (110.3-230.5) 
Female 10 9.7 103.1 (49.4-189.7)   Female 29 14.4 201.1 (134.6-288.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 11 5.6 196.6 (98.0-351.8)   Male 10 6.2 162.1 (77.6-298.1) 
Female 4 4.7 nc (nc-nc)   Female 4 4.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.0 nc (nc-nc)   Male 10 16.8 59.5 (28.5-109.5) 
Female 145 121.4 119.5 (100.8-140.6)   Female 13 13.9 93.4 (49.7-159.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 17 15.0 113.2 (65.9-181.3) 
Female 4 3.9 nc (nc-nc)   Female 5 6.3 78.9 (25.4-184.2) 
Colon / Rectum            Ovary     
Male 23 31.3 73.4 (46.5-110.2)             
Female 27 27.6 97.9 (64.5-142.4)   Female 8 10.2 78.7 (33.9-155.1) 
Esophagus            Pancreas     
Male 7 7.7 91.0 (36.5-187.6)   Male 12 11.1 108.5 (56.0-189.6) 
Female 0 2.0 nc (nc-nc)   Female 10 10.0 100.5 (48.1-184.8) 
Hodgkin Lymphoma            Prostate     
Male 0 2.0 nc (nc-nc)   Male 102 95.1 107.2 (87.4-130.2) 
Female 3 1.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 20 17.9 111.6 (68.2-172.4)   Male 5 7.0 71.8 (23.1-167.6) 
Female 6 9.4 63.9 (23.3-139.2)   Female 4 3.9 nc (nc-nc) 
Larynx            Testis     
Male 1 4.5 nc (nc-nc)   Male 5 3.6 140.6 (45.3-328.2) 
Female 1 1.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 15 11.8 127.5 (71.3-210.2)   Male 8 7.8 102.4 (44.1-201.8) 
Female 5 7.9 63.4 (20.4-147.9)   Female 17 22.4 75.9 (44.2-121.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 13 11.0 118.5 (63.0-202.7)             
Female 0 3.4 nc (nc-nc)   Female 21 28.3 74.3 (46.0-113.6) 
Lung and Bronchus            All Sites / Types     
Male 49 51.9 94.4 (69.8-124.8)   Male 392 384.5 102.0 (92.1-112.6) 
Female 71 53.3 133.3 (104.1-168.1)   Female 414 389.2 106.4 (96.4-117.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Mashpee 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 25 24.6 101.7 (65.8-150.2)   Male 17 14.4 118.4 (68.9-189.5) 
Female 6 8.8 68.5 (25.0-149.1)   Female 16 10.5 152.9 (87.4-248.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 3.8 nc (nc-nc)   Male 10 4.8 209.5 (100.3-385.3) 
Female 1 3.4 nc (nc-nc)   Female 2 4.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.8 nc (nc-nc)   Male 18 12.6 143.0 (84.7-226.0) 
Female 96 89.4 107.3 (86.9-131.1)   Female 10 11.4 88.0 (42.1-161.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 14 9.8 143.4 (78.3-240.6) 
Female 0 2.4 nc (nc-nc)   Female 5 5.0 101.0 (32.5-235.7) 
Colon / Rectum            Ovary     
Male 16 23.1 69.2 (39.5-112.4)             
Female 19 23.2 81.7 (49.2-127.7)   Female 4 7.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 5 5.8 85.5 (27.6-199.6)   Male 10 8.6 115.9 (55.5-213.1) 
Female 0 1.7 nc (nc-nc)   Female 8 9.0 89.2 (38.4-175.7) 
Hodgkin Lymphoma            Prostate     
Male 2 1.1 nc (nc-nc)   Male 60 67.7 88.7 (67.7-114.1) 
Female 1 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 12.2 57.2 (22.9-117.8)   Male 4 5.5 nc (nc-nc) 
Female 7 7.4 94.3 (37.8-194.2)   Female 1 3.3 nc (nc-nc) 
Larynx            Testis     
Male 3 3.4 nc (nc-nc)   Male 3 1.7 nc (nc-nc) 
Female 2 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 8.9 90.3 (38.9-177.9)   Male 3 4.5 nc (nc-nc) 
Female 11 6.4 171.6 (85.6-307.1)   Female 7 13.1 53.4 (21.4-109.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 7.7 65.3 (21.0-152.4)             
Female 1 2.8 nc (nc-nc)   Female 18 20.9 86.0 (50.9-135.9) 
Lung and Bronchus            All Sites / Types     
Male 40 43.0 93.1 (66.5-126.8)   Male 275 286.8 95.9 (84.9-107.9) 
Female 57 47.6 119.9 (90.8-155.3)   Female 302 304.4 99.2 (88.3-111.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Mattapoisett 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 8.4 142.4 (73.5-248.8)   Male 4 5.3 nc (nc-nc) 
Female 3 2.9 nc (nc-nc)   Female 2 3.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.5 nc (nc-nc)   Male 0 1.7 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.3 nc (nc-nc)   Male 1 4.6 nc (nc-nc) 
Female 37 33.5 110.5 (77.8-152.3)   Female 4 4.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 13 4.0 328.8 (174.9-562.4) 
Female 0 1.0 nc (nc-nc)   Female 2 1.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 13 8.6 151.7 (80.7-259.5)             
Female 3 8.0 nc (nc-nc)   Female 3 2.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.2 nc (nc-nc)   Male 4 3.1 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 2 3.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.5 nc (nc-nc)   Male 35 26.6 131.5 (91.6-182.9) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 4.9 nc (nc-nc)   Male 1 2.0 nc (nc-nc) 
Female 0 2.7 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Larynx            Testis     
Male 0 1.2 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 3.3 nc (nc-nc)   Male 2 2.0 nc (nc-nc) 
Female 4 2.2 nc (nc-nc)   Female 5 5.6 89.9 (29.0-209.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 2.9 nc (nc-nc)             
Female 3 1.0 nc (nc-nc)   Female 9 7.8 115.3 (52.6-219.0) 
Lung and Bronchus            All Sites / Types     
Male 15 15.0 99.7 (55.8-164.5)   Male 123 106.9 115.0 (95.6-137.2) 
Female 14 16.1 86.9 (47.5-145.8)   Female 99 109.8 90.2 (73.3-109.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
182 
Maynard 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 9 13.8 65.4 (29.9-124.2)   Male 10 8.8 113.9 (54.6-209.6) 
Female 4 3.6 nc (nc-nc)   Female 5 5.5 91.0 (29.3-212.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.5 nc (nc-nc)   Male 0 2.8 nc (nc-nc) 
Female 0 1.7 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 3 7.8 nc (nc-nc) 
Female 37 43.8 84.6 (59.5-116.6)   Female 3 5.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 6.4 94.1 (34.3-204.7) 
Female 1 1.4 nc (nc-nc)   Female 4 2.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 17 14.1 120.7 (70.3-193.3)             
Female 15 10.5 142.6 (79.7-235.2)   Female 3 3.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 3.5 nc (nc-nc)   Male 4 5.1 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 5 3.7 133.9 (43.2-312.5) 
Hodgkin Lymphoma            Prostate     
Male 1 0.9 nc (nc-nc)   Male 22 40.3 54.6 (34.2-82.6) 
Female 0 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 7.7 nc (nc-nc)   Male 1 3.2 nc (nc-nc) 
Female 4 3.5 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Larynx            Testis     
Male 1 2.0 nc (nc-nc)   Male 0 1.6 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 5.5 nc (nc-nc)   Male 3 3.3 nc (nc-nc) 
Female 6 3.0 199.0 (72.7-433.2)   Female 9 8.5 105.8 (48.3-200.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 4.9 nc (nc-nc)             
Female 2 1.3 nc (nc-nc)   Female 5 10.4 48.0 (15.5-112.0) 
Lung and Bronchus            All Sites / Types     
Male 12 24.2 49.6 (25.6-86.6)   Male 109 172.8 63.1 (51.8-76.1) 
Female 20 19.2 104.2 (63.6-161.0)   Female 139 143.7 96.8 (81.3-114.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
183 
Medfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 12.8 62.6 (26.9-123.3)   Male 14 8.7 161.1 (88.0-270.3) 
Female 4 3.8 nc (nc-nc)   Female 5 6.3 79.6 (25.7-185.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 2.6 232.7 (85.0-506.6)   Male 2 2.8 nc (nc-nc) 
Female 3 2.0 nc (nc-nc)   Female 4 1.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.5 nc (nc-nc)   Male 5 7.7 65.0 (20.9-151.7) 
Female 39 53.6 72.8 (51.8-99.5)   Female 4 5.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 6.7 88.9 (32.5-193.5) 
Female 0 1.9 nc (nc-nc)   Female 1 2.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 16 14.3 111.8 (63.9-181.6)             
Female 10 12.0 83.6 (40.0-153.8)   Female 4 4.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 3.4 nc (nc-nc)   Male 4 5.0 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 2 3.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.9 nc (nc-nc)   Male 53 40.0 132.5 (99.3-173.3) 
Female 1 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 8.1 86.9 (34.8-179.1)   Male 2 3.1 nc (nc-nc) 
Female 3 4.0 nc (nc-nc)   Female 2 1.6 nc (nc-nc) 
Larynx            Testis     
Male 0 2.0 nc (nc-nc)   Male 0 1.7 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 5.3 nc (nc-nc)   Male 3 3.8 nc (nc-nc) 
Female 3 3.3 nc (nc-nc)   Female 6 10.7 56.2 (20.5-122.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 4.9 nc (nc-nc)             
Female 1 1.4 nc (nc-nc)   Female 10 11.7 85.6 (41.0-157.5) 
Lung and Bronchus            All Sites / Types     
Male 11 22.7 48.5 (24.2-86.9)   Male 155 170.3 91.0 (77.3-106.5) 
Female 14 20.7 67.5 (36.9-113.3)   Female 123 165.6 74.3 (61.7-88.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
184 
Medford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 56 57.1 98.0 (74.0-127.3)   Male 17 36.0 47.3 (27.5-75.7) 
Female 22 21.9 100.4 (62.9-152.0)   Female 17 30.6 55.6 (32.4-89.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 12 10.9 109.8 (56.7-191.8)   Male 11 11.4 96.8 (48.3-173.3) 
Female 10 10.1 98.8 (47.3-181.8)   Female 9 10.1 89.1 (40.6-169.1) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.9 nc (nc-nc)   Male 30 32.0 93.7 (63.2-133.8) 
Female 233 234.0 99.6 (87.2-113.2)   Female 29 29.9 96.9 (64.9-139.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 24 25.3 94.9 (60.8-141.2) 
Female 6 7.8 77.4 (28.3-168.4)   Female 13 13.1 99.4 (52.9-170.0) 
Colon / Rectum            Ovary     
Male 62 58.6 105.8 (81.1-135.7)             
Female 70 61.7 113.4 (88.4-143.3)   Female 19 20.7 91.7 (55.2-143.2) 
Esophagus            Pancreas     
Male 14 13.8 101.6 (55.5-170.4)   Male 17 20.6 82.6 (48.1-132.3) 
Female 8 4.2 189.5 (81.6-373.4)   Female 22 22.7 96.8 (60.7-146.6) 
Hodgkin Lymphoma            Prostate     
Male 5 4.8 104.6 (33.7-244.2)   Male 148 159.3 92.9 (78.6-109.2) 
Female 5 4.7 107.3 (34.6-250.4)             
Kidney & Renal Pelvis            Stomach     
Male 28 31.1 89.9 (59.8-130.0)   Male 13 13.1 98.9 (52.6-169.1) 
Female 21 19.2 109.6 (67.8-167.5)   Female 9 8.7 103.0 (47.0-195.5) 
Larynx            Testis     
Male 7 8.0 87.6 (35.1-180.5)   Male 10 9.4 106.8 (51.1-196.5) 
Female 3 2.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 30 23.1 130.0 (87.7-185.6)   Male 13 14.3 91.0 (48.4-155.7) 
Female 23 18.0 127.9 (81.1-192.0)   Female 44 45.6 96.4 (70.0-129.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 27 18.9 142.7 (94.0-207.6)             
Female 6 7.3 82.1 (30.0-178.8)   Female 55 53.5 102.8 (77.5-133.9) 
Lung and Bronchus            All Sites / Types     
Male 105 98.4 106.8 (87.3-129.2)   Male 685 706.1 97.0 (89.9-104.6) 
Female 142 113.9 124.7 (105.0-147.0)   Female 834 805.9 103.5 (96.6-110.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
185 
Medway 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 11.2 98.2 (49.0-175.8)   Male 9 7.8 116.0 (52.9-220.2) 
Female 3 4.6 nc (nc-nc)   Female 5 7.1 70.6 (22.8-164.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 2.5 nc (nc-nc)   Male 2 2.5 nc (nc-nc) 
Female 3 2.3 nc (nc-nc)   Female 2 2.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.4 nc (nc-nc)   Male 11 6.9 158.8 (79.1-284.1) 
Female 63 56.9 110.7 (85.1-141.7)   Female 10 6.6 151.4 (72.5-278.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 6.3 nc (nc-nc) 
Female 2 2.0 nc (nc-nc)   Female 2 3.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 16 13.1 122.1 (69.7-198.3)             
Female 10 14.4 69.7 (33.4-128.1)   Female 7 4.8 145.5 (58.3-299.8) 
Esophagus            Pancreas     
Male 4 3.1 nc (nc-nc)   Male 5 4.4 114.6 (36.9-267.5) 
Female 1 0.9 nc (nc-nc)   Female 2 4.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.9 nc (nc-nc)   Male 55 37.2 148.0 (111.5-192.7) 
Female 0 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 7.5 93.6 (37.5-192.9)   Male 2 2.8 nc (nc-nc) 
Female 5 4.4 114.9 (37.0-268.2)   Female 0 2.0 nc (nc-nc) 
Larynx            Testis     
Male 1 1.8 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 4.8 nc (nc-nc)   Male 6 3.5 169.8 (62.0-369.5) 
Female 6 4.0 150.7 (55.0-327.9)   Female 10 11.3 88.7 (42.5-163.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 4.4 112.7 (36.3-263.0)             
Female 3 1.6 nc (nc-nc)   Female 15 12.3 121.7 (68.1-200.7) 
Lung and Bronchus            All Sites / Types     
Male 19 19.9 95.3 (57.3-148.8)   Male 179 154.7 115.7 (99.4-133.9) 
Female 23 23.4 98.4 (62.4-147.7)   Female 189 184.5 102.4 (88.4-118.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
186 
Melrose 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 13 29.5 44.1 (23.5-75.4)   Male 16 19.1 83.8 (47.9-136.2) 
Female 8 11.2 71.2 (30.6-140.2)   Female 20 15.7 127.3 (77.7-196.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 5.8 nc (nc-nc)   Male 7 6.1 115.1 (46.1-237.1) 
Female 7 5.0 138.8 (55.6-286.0)   Female 2 5.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.0 nc (nc-nc)   Male 21 16.9 124.1 (76.8-189.6) 
Female 134 125.5 106.7 (89.4-126.4)   Female 22 15.5 142.1 (89.0-215.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 14.2 77.4 (38.6-138.5) 
Female 2 4.2 nc (nc-nc)   Female 5 6.8 73.2 (23.6-170.8) 
Colon / Rectum            Ovary     
Male 43 31.2 137.9 (99.8-185.8)             
Female 40 32.0 125.2 (89.4-170.5)   Female 5 10.8 46.2 (14.9-107.8) 
Esophagus            Pancreas     
Male 9 7.5 120.0 (54.8-227.8)   Male 16 10.9 146.4 (83.7-237.8) 
Female 1 2.2 nc (nc-nc)   Female 13 11.7 111.2 (59.1-190.1) 
Hodgkin Lymphoma            Prostate     
Male 1 2.3 nc (nc-nc)   Male 79 90.2 87.6 (69.3-109.2) 
Female 2 1.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 14 17.4 80.4 (43.9-134.9)   Male 9 7.0 129.2 (59.0-245.3) 
Female 6 10.1 59.3 (21.7-129.1)   Female 3 4.5 nc (nc-nc) 
Larynx            Testis     
Male 7 4.3 161.8 (64.8-333.5)   Male 3 4.6 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 20 12.1 165.7 (101.2-255.9)   Male 8 8.1 99.0 (42.6-195.0) 
Female 9 9.1 98.6 (45.0-187.2)   Female 23 23.3 98.6 (62.5-147.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 10.4 67.3 (26.9-138.6)             
Female 5 3.8 132.6 (42.7-309.4)   Female 35 28.7 122.0 (85.0-169.7) 
Lung and Bronchus            All Sites / Types     
Male 41 51.4 79.8 (57.3-108.3)   Male 361 379.9 95.0 (85.5-105.4) 
Female 60 59.3 101.2 (77.3-130.3)   Female 438 421.6 103.9 (94.4-114.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
187 
Mendon 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 6.5 nc (nc-nc)   Male 3 4.4 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)   Female 4 2.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.3 nc (nc-nc)   Male 0 1.4 nc (nc-nc) 
Female 2 1.0 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.2 nc (nc-nc)   Male 5 3.9 128.1 (41.3-299.1) 
Female 18 25.6 70.4 (41.7-111.3)   Female 4 2.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 3.7 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 7.4 81.6 (29.8-177.5)             
Female 6 5.0 120.1 (43.9-261.4)   Female 2 2.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.8 nc (nc-nc)   Male 1 2.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 4 1.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 18 24.0 74.9 (44.4-118.4) 
Female 1 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 4.4 114.8 (37.0-268.0)   Male 0 1.6 nc (nc-nc) 
Female 1 1.9 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Larynx            Testis     
Male 0 1.1 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 2.7 nc (nc-nc)   Male 0 1.9 nc (nc-nc) 
Female 1 1.5 nc (nc-nc)   Female 7 5.2 134.4 (53.8-276.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.7 nc (nc-nc)             
Female 1 0.6 nc (nc-nc)   Female 8 5.9 135.2 (58.2-266.4) 
Lung and Bronchus            All Sites / Types     
Male 8 11.7 68.4 (29.4-134.7)   Male 64 91.1 70.2 (54.1-89.7) 
Female 10 9.3 107.4 (51.4-197.6)   Female 80 76.7 104.3 (82.7-129.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
188 
Merrimac 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 9 7.3 122.5 (55.9-232.5)   Male 3 4.8 nc (nc-nc) 
Female 4 2.5 nc (nc-nc)   Female 4 3.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.4 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 3 4.2 nc (nc-nc) 
Female 26 31.8 81.6 (53.3-119.6)   Female 3 3.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 3.7 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 8 7.8 102.2 (44.0-201.4)             
Female 6 7.3 82.6 (30.2-179.8)   Female 4 2.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.9 nc (nc-nc)   Male 3 2.8 nc (nc-nc) 
Female 2 0.5 nc (nc-nc)   Female 2 2.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 18 24.0 75.0 (44.4-118.5) 
Female 2 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 4.5 nc (nc-nc)   Male 3 1.8 nc (nc-nc) 
Female 2 2.4 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Larynx            Testis     
Male 2 1.1 nc (nc-nc)   Male 3 0.9 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 3.0 nc (nc-nc)   Male 1 2.0 nc (nc-nc) 
Female 1 2.0 nc (nc-nc)   Female 6 6.0 99.9 (36.5-217.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 2.7 nc (nc-nc)             
Female 3 0.9 nc (nc-nc)   Female 1 7.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 16 13.3 120.7 (69.0-196.1)   Male 90 96.7 93.1 (74.9-114.5) 
Female 24 13.6 176.9 (113.3-263.2)   Female 103 101.3 101.7 (83.0-123.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
189 
Methuen 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 53 49.5 107.1 (80.2-140.0)   Male 24 32.3 74.3 (47.6-110.5) 
Female 23 18.2 126.1 (79.9-189.2)   Female 20 26.0 76.9 (46.9-118.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 12 9.8 122.7 (63.3-214.4)   Male 7 10.3 68.0 (27.2-140.1) 
Female 10 8.4 118.4 (56.7-217.7)   Female 8 8.5 93.9 (40.4-185.1) 
Breast            Non-Hodgkin Lymphoma     
Male 4 1.8 nc (nc-nc)   Male 36 28.7 125.5 (87.9-173.8) 
Female 186 208.7 89.1 (76.8-102.9)   Female 24 25.3 94.9 (60.8-141.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 25 24.3 102.7 (66.5-151.6) 
Female 6 6.9 86.9 (31.7-189.0)   Female 9 11.2 80.0 (36.5-151.9) 
Colon / Rectum            Ovary     
Male 48 52.6 91.2 (67.2-120.9)             
Female 44 52.1 84.4 (61.3-113.3)   Female 21 18.0 116.7 (72.2-178.4) 
Esophagus            Pancreas     
Male 9 12.7 70.9 (32.3-134.6)   Male 12 18.6 64.5 (33.3-112.7) 
Female 3 3.6 nc (nc-nc)   Female 23 18.9 121.9 (77.2-182.8) 
Hodgkin Lymphoma            Prostate     
Male 6 3.9 155.4 (56.7-338.2)   Male 158 152.5 103.6 (88.1-121.1) 
Female 0 3.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 36 29.3 122.9 (86.1-170.2)   Male 12 11.7 102.1 (52.7-178.4) 
Female 20 16.6 120.1 (73.4-185.6)   Female 9 7.3 122.9 (56.1-233.4) 
Larynx            Testis     
Male 10 7.4 134.5 (64.4-247.5)   Male 12 7.2 165.8 (85.6-289.7) 
Female 6 2.3 258.0 (94.2-561.7)             
Leukemia            Thyroid     
Male 26 20.4 127.2 (83.1-186.4)   Male 18 13.4 134.3 (79.5-212.2) 
Female 15 14.8 101.0 (56.5-166.6)   Female 45 39.6 113.6 (82.9-152.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 15 18.0 83.2 (46.5-137.2)             
Female 6 6.1 98.1 (35.8-213.5)   Female 50 47.3 105.6 (78.4-139.3) 
Lung and Bronchus            All Sites / Types     
Male 101 86.7 116.6 (94.9-141.6)   Male 663 642.1 103.3 (95.5-111.4) 
Female 133 96.9 137.2 (114.9-162.6)   Female 733 695.0 105.5 (98.0-113.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
190 
Middleborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 37 25.4 145.9 (102.7-201.1)   Male 17 16.6 102.1 (59.5-163.5) 
Female 10 9.3 107.7 (51.6-198.1)   Female 15 13.2 113.8 (63.7-187.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 5.1 136.3 (54.6-280.8)   Male 5 5.4 92.5 (29.8-215.8) 
Female 6 4.2 141.5 (51.7-308.1)   Female 6 4.4 137.7 (50.3-299.7) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.9 nc (nc-nc)   Male 17 14.8 115.1 (67.0-184.2) 
Female 109 108.3 100.6 (82.6-121.4)   Female 11 12.9 85.5 (42.6-153.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 15 13.1 114.7 (64.2-189.3) 
Female 4 3.6 nc (nc-nc)   Female 4 5.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 26 27.3 95.1 (62.1-139.3)             
Female 24 26.4 91.0 (58.3-135.4)   Female 10 9.2 109.2 (52.3-200.8) 
Esophagus            Pancreas     
Male 10 6.7 148.3 (71.0-272.8)   Male 13 9.6 134.7 (71.7-230.4) 
Female 3 1.8 nc (nc-nc)   Female 12 9.7 124.3 (64.2-217.1) 
Hodgkin Lymphoma            Prostate     
Male 1 1.8 nc (nc-nc)   Male 86 84.7 101.5 (81.2-125.4) 
Female 2 1.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 23 15.8 145.8 (92.4-218.7)   Male 6 6.1 98.3 (35.9-214.0) 
Female 6 8.5 70.2 (25.6-152.8)   Female 1 3.7 nc (nc-nc) 
Larynx            Testis     
Male 3 4.0 nc (nc-nc)   Male 4 3.4 nc (nc-nc) 
Female 5 1.2 412.4 (132.9-962.5)             
Leukemia            Thyroid     
Male 11 10.5 105.1 (52.4-188.1)   Male 8 6.9 115.8 (49.9-228.2) 
Female 10 7.4 134.9 (64.6-248.2)   Female 25 20.2 123.8 (80.1-182.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 12 9.6 125.4 (64.7-219.1)             
Female 6 3.1 193.9 (70.8-422.0)   Female 33 24.7 133.6 (92.0-187.6) 
Lung and Bronchus            All Sites / Types     
Male 67 45.6 146.8 (113.8-186.4)   Male 393 338.9 116.0 (104.8-128.0) 
Female 80 50.1 159.7 (126.6-198.7)   Female 412 356.8 115.5 (104.6-127.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
191 
Middlefield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 1.0 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 3.1 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 1.0 nc (nc-nc)             
Female 1 0.6 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 1 3.6 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.6 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.4 nc (nc-nc)             
Female 1 0.1 nc (nc-nc)   Female 2 0.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 1.9 nc (nc-nc)   Male 7 13.3 52.7 (21.1-108.6) 
Female 1 1.3 nc (nc-nc)   Female 8 9.7 82.9 (35.7-163.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Middleton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 17 11.0 154.2 (89.8-246.9)   Male 8 7.4 107.5 (46.3-211.8) 
Female 3 3.0 nc (nc-nc)   Female 4 4.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 2.3 216.6 (69.8-505.6)   Male 2 2.3 nc (nc-nc) 
Female 3 1.4 nc (nc-nc)   Female 2 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 12 6.6 181.0 (93.4-316.2) 
Female 38 35.5 107.0 (75.7-146.9)   Female 8 4.2 192.3 (82.8-378.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 5.9 85.1 (27.4-198.7) 
Female 0 1.1 nc (nc-nc)   Female 2 1.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 11 12.3 89.6 (44.7-160.4)             
Female 11 8.4 130.9 (65.3-234.3)   Female 0 3.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 2.9 nc (nc-nc)   Male 3 4.2 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 2 3.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.0 nc (nc-nc)   Male 35 36.4 96.3 (67.0-133.9) 
Female 2 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 7.0 nc (nc-nc)   Male 7 2.7 261.5 (104.8-538.9) 
Female 4 2.8 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Larynx            Testis     
Male 3 1.7 nc (nc-nc)   Male 2 2.0 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 4.7 107.3 (34.6-250.5)   Male 3 3.3 nc (nc-nc) 
Female 2 2.4 nc (nc-nc)   Female 12 6.4 188.8 (97.4-329.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 4.2 nc (nc-nc)             
Female 1 1.0 nc (nc-nc)   Female 15 8.2 183.6 (102.7-302.9) 
Lung and Bronchus            All Sites / Types     
Male 17 19.4 87.7 (51.1-140.5)   Male 151 149.1 101.3 (85.8-118.8) 
Female 21 16.8 125.1 (77.4-191.2)   Female 140 116.3 120.4 (101.3-142.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
193 
Milford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 42 26.3 159.5 (114.9-215.6)   Male 15 17.8 84.2 (47.1-138.9) 
Female 17 9.8 173.0 (100.7-277.0)   Female 13 14.6 89.0 (47.3-152.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 5.5 90.1 (29.0-210.3)   Male 2 5.7 nc (nc-nc) 
Female 5 4.8 104.8 (33.8-244.6)   Female 10 4.7 213.7 (102.3-393.0) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.0 nc (nc-nc)   Male 22 15.8 138.9 (87.0-210.3) 
Female 114 116.9 97.5 (80.4-117.1)   Female 18 13.9 129.2 (76.6-204.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 18 13.6 131.9 (78.1-208.5) 
Female 5 4.0 125.4 (40.4-292.7)   Female 4 6.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 32 29.2 109.6 (75.0-154.7)             
Female 29 28.6 101.3 (67.8-145.4)   Female 9 10.0 90.0 (41.1-170.9) 
Esophagus            Pancreas     
Male 8 6.9 115.8 (49.8-228.1)   Male 10 10.0 99.8 (47.8-183.5) 
Female 2 2.0 nc (nc-nc)   Female 9 10.3 87.6 (40.0-166.2) 
Hodgkin Lymphoma            Prostate     
Male 5 2.3 220.8 (71.2-515.2)   Male 97 82.2 118.0 (95.7-144.0) 
Female 1 2.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 24 16.5 145.3 (93.1-216.2)   Male 11 6.4 172.2 (85.8-308.1) 
Female 12 9.2 130.7 (67.5-228.3)   Female 0 4.0 nc (nc-nc) 
Larynx            Testis     
Male 1 4.0 nc (nc-nc)   Male 2 4.6 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 11 11.2 98.1 (48.9-175.6)   Male 6 8.0 75.0 (27.4-163.4) 
Female 9 8.3 108.5 (49.5-205.9)   Female 21 22.9 91.8 (56.8-140.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 9 9.8 91.8 (41.9-174.3)             
Female 4 3.4 nc (nc-nc)   Female 22 26.7 82.4 (51.6-124.7) 
Lung and Bronchus            All Sites / Types     
Male 50 46.4 107.8 (80.0-142.2)   Male 402 351.0 114.5 (103.6-126.3) 
Female 71 51.7 137.4 (107.3-173.3)   Female 412 385.5 106.9 (96.8-117.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Millbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 22 16.2 135.9 (85.1-205.8)   Male 10 10.3 96.6 (46.3-177.7) 
Female 2 5.1 nc (nc-nc)   Female 8 7.3 109.8 (47.3-216.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 3.0 nc (nc-nc)   Male 5 3.3 151.2 (48.7-352.9) 
Female 2 2.4 nc (nc-nc)   Female 6 2.4 249.4 (91.1-542.9) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.6 nc (nc-nc)   Male 14 9.1 153.6 (83.9-257.7) 
Female 64 59.6 107.4 (82.7-137.1)   Female 4 7.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 7.7 129.1 (61.8-237.4) 
Female 4 2.0 nc (nc-nc)   Female 2 3.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 12 16.8 71.4 (36.8-124.7)             
Female 12 14.6 82.2 (42.4-143.6)   Female 7 5.1 136.5 (54.7-281.2) 
Esophagus            Pancreas     
Male 7 4.1 170.3 (68.2-350.9)   Male 6 6.0 99.6 (36.4-216.8) 
Female 3 1.0 nc (nc-nc)   Female 9 5.3 170.4 (77.7-323.4) 
Hodgkin Lymphoma            Prostate     
Male 2 1.1 nc (nc-nc)   Male 54 50.8 106.2 (79.8-138.6) 
Female 2 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 9.5 105.3 (50.4-193.6)   Male 2 3.8 nc (nc-nc) 
Female 7 4.8 147.3 (59.0-303.6)   Female 3 2.0 nc (nc-nc) 
Larynx            Testis     
Male 6 2.4 250.7 (91.6-545.7)   Male 1 1.9 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 6.4 155.5 (74.4-286.0)   Male 10 4.1 242.1 (115.9-445.2) 
Female 6 4.1 145.0 (52.9-315.6)   Female 13 11.1 117.0 (62.3-200.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 5.7 87.5 (28.2-204.2)             
Female 1 1.7 nc (nc-nc)   Female 12 13.7 87.6 (45.2-153.0) 
Lung and Bronchus            All Sites / Types     
Male 49 28.7 170.7 (126.3-225.7)   Male 253 207.7 121.8 (107.3-137.8) 
Female 32 27.6 116.0 (79.3-163.8)   Female 210 196.8 106.7 (92.8-122.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
195 
Millis 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 6.1 130.3 (56.1-256.7)   Male 4 4.5 nc (nc-nc) 
Female 4 2.8 nc (nc-nc)   Female 6 4.4 137.6 (50.2-299.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 1.5 nc (nc-nc)   Male 0 1.4 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 2 4.1 nc (nc-nc) 
Female 39 36.2 107.7 (76.6-147.2)   Female 6 4.1 146.2 (53.4-318.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 3.8 156.4 (57.1-340.3) 
Female 3 1.2 nc (nc-nc)   Female 0 1.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 8 7.5 106.8 (46.0-210.4)             
Female 8 8.3 96.0 (41.3-189.2)   Female 1 3.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.8 nc (nc-nc)   Male 2 2.5 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 2 2.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.6 nc (nc-nc)   Male 30 22.9 131.0 (88.4-187.0) 
Female 3 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 4.5 131.9 (48.2-287.1)   Male 0 1.6 nc (nc-nc) 
Female 4 2.8 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Larynx            Testis     
Male 0 1.1 nc (nc-nc)   Male 2 1.2 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 2.8 nc (nc-nc)   Male 2 2.3 nc (nc-nc) 
Female 4 2.4 nc (nc-nc)   Female 10 7.0 142.7 (68.3-262.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 2.7 nc (nc-nc)             
Female 1 1.0 nc (nc-nc)   Female 8 8.3 95.8 (41.3-188.9) 
Lung and Bronchus            All Sites / Types     
Male 9 11.4 78.7 (35.9-149.4)   Male 98 91.4 107.2 (87.1-130.7) 
Female 23 15.7 146.5 (92.8-219.8)   Female 133 116.4 114.3 (95.7-135.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Millville 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 2.1 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 2 1.2 nc (nc-nc)   Female 0 1.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.5 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 15 14.6 103.0 (57.6-170.0)   Female 1 1.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 1.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 2.7 nc (nc-nc)             
Female 1 3.5 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.6 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 11 7.9 138.4 (69.0-247.7) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.6 nc (nc-nc)   Male 3 0.6 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Larynx            Testis     
Male 0 0.4 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.0 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 0 2.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 1.0 nc (nc-nc)             
Female 1 0.4 nc (nc-nc)   Female 2 3.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 7 3.9 180.3 (72.2-371.5)   Male 40 32.1 124.8 (89.1-169.9) 
Female 9 6.4 140.6 (64.2-267.0)   Female 38 47.2 80.4 (56.9-110.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
197 
Milton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 17 29.1 58.5 (34.0-93.6)   Male 35 18.3 191.7 (133.5-266.6) 
Female 7 10.9 64.2 (25.7-132.3)   Female 24 15.0 160.4 (102.7-238.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 5.4 nc (nc-nc)   Male 7 5.8 120.7 (48.4-248.7) 
Female 6 4.9 121.4 (44.3-264.2)   Female 10 5.0 200.0 (95.7-367.8) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.0 nc (nc-nc)   Male 21 16.1 130.1 (80.5-198.9) 
Female 153 118.3 129.4 (109.7-151.6)   Female 10 14.8 67.6 (32.4-124.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 13.2 53.2 (21.3-109.6) 
Female 4 4.0 nc (nc-nc)   Female 7 6.5 107.9 (43.2-222.3) 
Colon / Rectum            Ovary     
Male 25 30.1 83.2 (53.8-122.8)             
Female 29 31.3 92.5 (62.0-132.9)   Female 18 10.2 176.3 (104.4-278.7) 
Esophagus            Pancreas     
Male 8 7.1 113.0 (48.7-222.7)   Male 12 10.5 113.9 (58.8-198.9) 
Female 4 2.1 nc (nc-nc)   Female 11 11.5 96.0 (47.8-171.7) 
Hodgkin Lymphoma            Prostate     
Male 2 2.0 nc (nc-nc)   Male 93 82.0 113.5 (91.6-139.0) 
Female 4 1.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 16 16.1 99.2 (56.7-161.2)   Male 6 6.7 89.3 (32.6-194.4) 
Female 11 9.5 115.8 (57.7-207.1)   Female 4 4.4 nc (nc-nc) 
Larynx            Testis     
Male 2 4.0 nc (nc-nc)   Male 0 3.6 nc (nc-nc) 
Female 0 1.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 14 11.8 119.1 (65.1-199.9)   Male 6 7.1 84.2 (30.8-183.4) 
Female 8 8.8 90.6 (39.0-178.5)   Female 34 21.9 155.0 (107.4-216.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 8 9.7 82.7 (35.6-162.9)             
Female 1 3.5 nc (nc-nc)   Female 27 26.2 103.0 (67.9-149.9) 
Lung and Bronchus            All Sites / Types     
Male 38 49.9 76.1 (53.9-104.5)   Male 351 359.0 97.8 (87.8-108.6) 
Female 48 56.2 85.5 (63.0-113.3)   Female 451 401.1 112.5 (102.3-123.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
198 
Monroe 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.0 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 0.1 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.0 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.1 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Larynx            Testis     
Male 0 0.0 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.0 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.0 nc (nc-nc)             
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 0.2 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 2.2 nc (nc-nc) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
199 
Monson 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 9 11.0 82.1 (37.5-155.9)   Male 4 7.1 nc (nc-nc) 
Female 1 3.4 nc (nc-nc)   Female 1 5.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.0 nc (nc-nc)   Male 1 2.3 nc (nc-nc) 
Female 2 1.7 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 5 6.2 80.2 (25.8-187.1) 
Female 50 44.5 112.3 (83.3-148.0)   Female 7 4.9 142.0 (56.9-292.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 5.5 nc (nc-nc) 
Female 2 1.4 nc (nc-nc)   Female 3 2.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 11 11.6 94.8 (47.2-169.6)             
Female 5 9.7 51.8 (16.7-120.9)   Female 0 3.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.9 nc (nc-nc)   Male 3 4.1 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 3 3.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.7 nc (nc-nc)   Male 33 35.3 93.5 (64.3-131.3) 
Female 0 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 6.6 75.8 (24.4-176.8)   Male 0 2.6 nc (nc-nc) 
Female 0 3.4 nc (nc-nc)   Female 2 1.4 nc (nc-nc) 
Larynx            Testis     
Male 2 1.7 nc (nc-nc)   Male 0 1.3 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 4.3 nc (nc-nc)   Male 2 2.8 nc (nc-nc) 
Female 1 2.7 nc (nc-nc)   Female 4 8.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 4.0 nc (nc-nc)             
Female 1 1.2 nc (nc-nc)   Female 6 10.5 57.1 (20.8-124.3) 
Lung and Bronchus            All Sites / Types     
Male 16 19.7 81.2 (46.4-131.8)   Male 112 142.9 78.4 (64.5-94.3) 
Female 14 18.6 75.3 (41.1-126.3)   Female 114 139.6 81.7 (67.4-98.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
200 
Montague 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 10 10.3 97.4 (46.6-179.1)   Male 8 6.4 125.0 (53.8-246.2) 
Female 3 4.1 nc (nc-nc)   Female 1 5.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 1.8 275.6 (88.8-643.2)   Male 4 2.1 nc (nc-nc) 
Female 1 1.7 nc (nc-nc)   Female 0 1.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 6 5.7 106.1 (38.8-231.0) 
Female 38 44.5 85.4 (60.4-117.3)   Female 3 5.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 4.7 nc (nc-nc) 
Female 3 1.4 nc (nc-nc)   Female 2 2.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 10.4 67.2 (26.9-138.5)             
Female 12 11.8 101.6 (52.4-177.5)   Female 6 3.9 154.8 (56.5-337.0) 
Esophagus            Pancreas     
Male 8 2.6 311.6 (134.2-614.0)   Male 2 3.8 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 2 4.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.7 nc (nc-nc)   Male 17 31.1 54.7 (31.8-87.6) 
Female 0 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 5.7 87.5 (28.2-204.2)   Male 2 2.4 nc (nc-nc) 
Female 4 3.6 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Larynx            Testis     
Male 2 1.5 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 4.0 125.7 (40.5-293.3)   Male 1 2.4 nc (nc-nc) 
Female 6 3.2 184.9 (67.5-402.6)   Female 3 7.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 3.5 141.4 (45.6-330.0)             
Female 0 1.4 nc (nc-nc)   Female 9 10.4 86.4 (39.4-164.1) 
Lung and Bronchus            All Sites / Types     
Male 19 17.9 106.2 (63.9-165.9)   Male 121 128.5 94.2 (78.1-112.5) 
Female 20 21.3 93.7 (57.2-144.7)   Female 124 150.8 82.2 (68.4-98.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
201 
Monterey 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.8 nc (nc-nc)   Male 3 1.1 nc (nc-nc) 
Female 2 0.5 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 6 5.0 120.4 (44.0-262.1)   Female 0 0.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.8 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 1.7 nc (nc-nc)             
Female 0 1.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.4 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 3 5.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.9 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 1 0.3 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.6 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.6 nc (nc-nc)             
Female 1 0.2 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 3.0 nc (nc-nc)   Male 13 21.3 61.0 (32.4-104.3) 
Female 0 2.6 nc (nc-nc)   Female 11 17.1 64.2 (32.0-114.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
202 
Montgomery 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.1 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 4.4 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 1.2 nc (nc-nc)             
Female 0 1.0 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.3 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 8 3.6 222.3 (95.7-438.0) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.7 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 1 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 0.4 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.4 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 2.0 nc (nc-nc)   Male 16 14.4 110.8 (63.3-179.9) 
Female 0 1.9 nc (nc-nc)   Female 6 14.2 42.2 (15.4-91.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
203 
Mount Washington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 0.3 nc (nc-nc)             
Female 2 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.0 nc (nc-nc) 
Larynx            Testis     
Male 0 0.0 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.1 nc (nc-nc)             
Female 0 0.0 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 0.6 nc (nc-nc)   Male 2 4.0 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 3 4.4 nc (nc-nc) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
204 
Nahant 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 5.4 111.5 (40.7-242.6)   Male 6 3.2 189.4 (69.1-412.2) 
Female 0 2.1 nc (nc-nc)   Female 7 2.7 257.9 (103.3-531.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.8 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 2 0.9 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 2 2.8 nc (nc-nc) 
Female 19 21.5 88.4 (53.2-138.1)   Female 3 2.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 2.3 nc (nc-nc) 
Female 2 0.6 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 5.1 116.8 (42.7-254.3)             
Female 7 6.1 114.7 (45.9-236.3)   Female 0 1.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.3 nc (nc-nc)   Male 3 1.9 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 2 2.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.3 nc (nc-nc)   Male 24 16.0 149.7 (95.9-222.8) 
Female 1 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 2.8 nc (nc-nc)   Male 3 1.2 nc (nc-nc) 
Female 0 1.7 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Larynx            Testis     
Male 1 0.7 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 2.0 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 1 1.7 nc (nc-nc)   Female 3 3.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.8 nc (nc-nc)             
Female 0 0.7 nc (nc-nc)   Female 4 4.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 13 9.3 140.0 (74.5-239.4)   Male 80 64.6 123.9 (98.3-154.2) 
Female 7 10.5 66.8 (26.7-137.6)   Female 67 74.3 90.2 (69.9-114.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
205 
Nantucket 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 11.5 69.4 (29.9-136.7)   Male 15 7.7 194.8 (109.0-321.4) 
Female 4 3.4 nc (nc-nc)   Female 16 5.1 314.3 (179.6-510.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.4 nc (nc-nc)   Male 7 2.5 281.2 (112.6-579.3) 
Female 2 1.7 nc (nc-nc)   Female 0 1.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 4 6.8 nc (nc-nc) 
Female 54 41.2 131.2 (98.5-171.1)   Female 5 4.8 103.8 (33.4-242.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 5.8 155.0 (70.7-294.2) 
Female 2 1.4 nc (nc-nc)   Female 4 2.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 12.3 81.3 (38.9-149.6)             
Female 16 9.8 163.5 (93.4-265.6)   Female 4 3.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 3.1 nc (nc-nc)   Male 3 4.4 nc (nc-nc) 
Female 4 0.7 nc (nc-nc)   Female 4 3.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 3 1.0 nc (nc-nc)   Male 31 36.5 85.0 (57.7-120.6) 
Female 1 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 7.1 nc (nc-nc)   Male 1 2.8 nc (nc-nc) 
Female 0 3.3 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Larynx            Testis     
Male 1 1.8 nc (nc-nc)   Male 1 2.0 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 4.8 147.2 (59.0-303.3)   Male 4 3.3 nc (nc-nc) 
Female 5 2.9 174.5 (56.2-407.2)   Female 14 8.0 175.5 (95.9-294.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 4.2 nc (nc-nc)             
Female 0 1.2 nc (nc-nc)   Female 9 9.5 94.6 (43.2-179.6) 
Lung and Bronchus            All Sites / Types     
Male 16 20.8 76.8 (43.9-124.7)   Male 140 152.9 91.6 (77.0-108.1) 
Female 20 18.5 108.3 (66.1-167.3)   Female 176 135.0 130.4 (111.9-151.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
206 
Natick 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 28 34.3 81.7 (54.3-118.1)   Male 21 22.4 93.6 (57.9-143.0) 
Female 15 13.2 113.5 (63.5-187.2)   Female 19 19.5 97.7 (58.8-152.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 6.9 72.7 (23.4-169.7)   Male 5 7.1 70.1 (22.6-163.6) 
Female 7 6.3 111.3 (44.6-229.4)   Female 5 6.2 80.3 (25.9-187.3) 
Breast            Non-Hodgkin Lymphoma     
Male 4 1.2 nc (nc-nc)   Male 18 19.9 90.3 (53.5-142.7) 
Female 127 160.0 79.4 (66.2-94.4)   Female 15 18.6 80.7 (45.2-133.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 19 16.7 113.6 (68.4-177.4) 
Female 3 5.4 nc (nc-nc)   Female 13 8.4 155.3 (82.6-265.6) 
Colon / Rectum            Ovary     
Male 37 36.4 101.6 (71.5-140.1)             
Female 48 37.9 126.5 (93.3-167.8)   Female 19 13.5 140.9 (84.8-220.1) 
Esophagus            Pancreas     
Male 9 8.7 102.9 (47.0-195.4)   Male 14 12.8 109.4 (59.8-183.6) 
Female 4 2.6 nc (nc-nc)   Female 12 13.6 88.3 (45.6-154.3) 
Hodgkin Lymphoma            Prostate     
Male 2 2.8 nc (nc-nc)   Male 102 104.6 97.5 (79.5-118.3) 
Female 0 2.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 23 20.5 112.2 (71.1-168.3)   Male 9 8.1 110.7 (50.5-210.2) 
Female 10 12.6 79.5 (38.1-146.2)   Female 2 5.3 nc (nc-nc) 
Larynx            Testis     
Male 6 5.1 117.9 (43.1-256.6)   Male 8 5.4 147.7 (63.6-291.1) 
Female 4 1.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 15 14.3 105.1 (58.8-173.3)   Male 12 9.5 125.7 (64.9-219.5) 
Female 5 10.9 45.9 (14.8-107.0)   Female 30 30.7 97.7 (65.9-139.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 9 12.2 73.8 (33.7-140.2)             
Female 3 4.5 nc (nc-nc)   Female 39 36.0 108.4 (77.0-148.1) 
Lung and Bronchus            All Sites / Types     
Male 47 60.4 77.8 (57.2-103.5)   Male 423 444.6 95.1 (86.3-104.6) 
Female 62 72.0 86.1 (66.0-110.4)   Female 474 520.9 91.0 (83.0-99.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
207 
Needham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 43 37.7 114.2 (82.6-153.8)   Male 36 23.2 155.4 (108.8-215.2) 
Female 16 13.4 119.6 (68.3-194.3)   Female 22 17.9 123.1 (77.1-186.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 6.6 106.5 (42.6-219.4)   Male 10 7.4 134.5 (64.4-247.4) 
Female 11 5.7 191.6 (95.5-342.8)   Female 6 6.1 97.7 (35.7-212.7) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.3 nc (nc-nc)   Male 25 20.5 122.2 (79.1-180.4) 
Female 177 143.5 123.4 (105.9-142.9)   Female 24 17.9 134.1 (85.9-199.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 16.5 42.4 (17.0-87.4) 
Female 2 4.6 nc (nc-nc)   Female 6 7.9 75.6 (27.6-164.5) 
Colon / Rectum            Ovary     
Male 26 38.2 68.1 (44.5-99.8)             
Female 44 38.8 113.3 (82.3-152.1)   Female 11 12.4 88.9 (44.3-159.1) 
Esophagus            Pancreas     
Male 9 9.1 99.1 (45.2-188.2)   Male 7 13.6 51.6 (20.7-106.2) 
Female 2 2.6 nc (nc-nc)   Female 16 14.2 112.3 (64.2-182.4) 
Hodgkin Lymphoma            Prostate     
Male 2 2.2 nc (nc-nc)   Male 120 105.6 113.7 (94.2-135.9) 
Female 2 1.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 20 20.3 98.6 (60.2-152.4)   Male 3 8.6 nc (nc-nc) 
Female 14 11.5 121.7 (66.5-204.2)   Female 2 5.5 nc (nc-nc) 
Larynx            Testis     
Male 3 5.2 nc (nc-nc)   Male 4 4.0 nc (nc-nc) 
Female 0 1.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 13 14.7 88.3 (47.0-151.1)   Male 12 8.6 139.7 (72.1-244.0) 
Female 15 10.8 139.5 (78.0-230.0)   Female 32 25.3 126.5 (86.5-178.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 12.4 56.5 (22.6-116.3)             
Female 4 4.3 nc (nc-nc)   Female 33 31.9 103.4 (71.1-145.2) 
Lung and Bronchus            All Sites / Types     
Male 40 64.1 62.4 (44.6-84.9)   Male 426 457.2 93.2 (84.5-102.5) 
Female 38 67.9 56.0 (39.6-76.9)   Female 513 486.4 105.5 (96.5-115.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
208 
New Ashford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 0.5 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 3 1.5 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.2 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 0.5 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.1 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.3 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.1 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.2 nc (nc-nc)             
Female 0 0.0 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 0.8 nc (nc-nc)   Male 4 5.9 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 5 5.1 97.6 (31.4-227.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
209 
New Bedford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 96 97.6 98.3 (79.6-120.1)   Male 25 62.2 40.2 (26.0-59.3) 
Female 25 39.4 63.5 (41.1-93.8)   Female 17 52.6 32.3 (18.8-51.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 10 18.6 53.7 (25.7-98.8)   Male 20 19.8 101.0 (61.6-155.9) 
Female 11 17.3 63.5 (31.7-113.7)   Female 15 18.0 83.5 (46.7-137.8) 
Breast            Non-Hodgkin Lymphoma     
Male 2 3.4 nc (nc-nc)   Male 46 55.3 83.2 (60.9-110.9) 
Female 340 406.9 83.6 (74.9-92.9)   Female 48 52.6 91.3 (67.3-121.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 46 45.0 102.1 (74.8-136.2) 
Female 17 13.2 128.9 (75.0-206.3)   Female 26 23.0 113.1 (73.8-165.7) 
Colon / Rectum            Ovary     
Male 120 101.4 118.3 (98.1-141.5)             
Female 104 113.1 92.0 (75.1-111.4)   Female 30 36.0 83.4 (56.3-119.1) 
Esophagus            Pancreas     
Male 24 24.1 99.5 (63.7-148.1)   Male 37 35.8 103.4 (72.8-142.6) 
Female 9 7.6 118.9 (54.3-225.8)   Female 50 41.7 119.9 (89.0-158.1) 
Hodgkin Lymphoma            Prostate     
Male 8 7.6 105.4 (45.4-207.8)   Male 315 281.4 111.9 (99.9-125.0) 
Female 5 6.9 72.2 (23.3-168.5)             
Kidney & Renal Pelvis            Stomach     
Male 57 54.9 103.8 (78.6-134.5)   Male 38 22.7 167.4 (118.5-229.8) 
Female 40 33.3 120.1 (85.8-163.6)   Female 19 15.9 119.2 (71.7-186.1) 
Larynx            Testis     
Male 32 13.9 229.5 (157.0-324.0)   Male 9 14.6 61.6 (28.1-116.9) 
Female 6 4.6 130.3 (47.6-283.7)             
Leukemia            Thyroid     
Male 35 39.6 88.4 (61.6-123.0)   Male 20 25.0 79.9 (48.8-123.4) 
Female 21 32.2 65.2 (40.3-99.6)   Female 84 74.8 112.3 (89.5-139.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 59 33.5 176.3 (134.2-227.5)             
Female 15 12.8 117.2 (65.5-193.3)   Female 73 91.2 80.1 (62.8-100.7) 
Lung and Bronchus            All Sites / Types     
Male 257 168.1 152.9 (134.8-172.8)   Male 1349 1224.5 110.2 (104.4-116.2) 
Female 204 198.5 102.8 (89.2-117.9)   Female 1274 1410.9 90.3 (85.4-95.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
210 
New Braintree 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 1.1 nc (nc-nc)   Male 3 0.8 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 4 4.9 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 0.7 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 1.3 nc (nc-nc)             
Female 3 1.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 6 4.2 143.1 (52.3-311.5) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.8 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 1 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.5 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 2 0.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.5 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 2.0 nc (nc-nc)   Male 20 16.0 124.7 (76.1-192.5) 
Female 2 2.2 nc (nc-nc)   Female 14 16.1 87.0 (47.5-145.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
211 
New Marlborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 2.7 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 2 1.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.4 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 9 9.0 99.5 (45.4-188.9)   Female 1 1.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 2 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 2.7 nc (nc-nc)             
Female 3 2.1 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.7 nc (nc-nc)   Male 2 1.0 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 2 8.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.5 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 1 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.0 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.0 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 1 2.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 4.8 nc (nc-nc)   Male 18 34.2 52.6 (31.2-83.2) 
Female 3 4.3 nc (nc-nc)   Female 22 29.3 75.0 (47.0-113.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
212 
New Salem 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 1.4 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 2 0.8 nc (nc-nc) 
Female 3 5.4 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 0.7 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 1.5 nc (nc-nc)             
Female 4 1.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.4 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 4 5.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.9 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.6 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.6 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 2 1.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 2.5 nc (nc-nc)   Male 14 19.0 73.6 (40.2-123.5) 
Female 1 2.6 nc (nc-nc)   Female 15 17.8 84.1 (47.0-138.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
213 
Newbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 10 8.2 122.3 (58.5-224.9)   Male 17 5.3 318.8 (185.6-510.4) 
Female 3 3.1 nc (nc-nc)   Female 4 4.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 1.5 nc (nc-nc)   Male 3 1.8 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 2 1.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 4 4.7 nc (nc-nc) 
Female 37 37.9 97.5 (68.7-134.4)   Female 6 4.4 137.9 (50.3-300.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 4.2 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 3 2.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 11 8.6 127.4 (63.5-228.0)             
Female 2 8.3 nc (nc-nc)   Female 4 3.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 2.2 nc (nc-nc)   Male 3 3.2 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 1 3.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.5 nc (nc-nc)   Male 41 27.7 148.2 (106.3-201.1) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 5.0 nc (nc-nc)   Male 0 2.0 nc (nc-nc) 
Female 5 3.0 169.0 (54.5-394.3)   Female 1 1.2 nc (nc-nc) 
Larynx            Testis     
Male 0 1.3 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 3.2 nc (nc-nc)   Male 2 2.1 nc (nc-nc) 
Female 3 2.4 nc (nc-nc)   Female 7 6.7 105.1 (42.1-216.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 3.2 nc (nc-nc)             
Female 1 1.1 nc (nc-nc)   Female 12 9.2 131.0 (67.6-228.9) 
Lung and Bronchus            All Sites / Types     
Male 11 15.0 73.6 (36.7-131.6)   Male 123 108.7 113.1 (94.0-135.0) 
Female 10 17.2 58.1 (27.8-106.8)   Female 104 121.4 85.7 (70.0-103.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
214 
Newburyport 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 21 21.3 98.8 (61.1-151.0)   Male 20 14.0 143.4 (87.5-221.4) 
Female 5 8.9 56.0 (18.0-130.7)   Female 15 11.9 125.7 (70.3-207.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 4.1 nc (nc-nc)   Male 1 4.6 nc (nc-nc) 
Female 3 3.8 nc (nc-nc)   Female 5 4.2 119.3 (38.4-278.3) 
Breast            Non-Hodgkin Lymphoma     
Male 3 0.8 nc (nc-nc)   Male 14 12.4 113.3 (61.9-190.1) 
Female 96 99.6 96.4 (78.1-117.7)   Female 9 12.1 74.2 (33.8-140.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 11.1 81.1 (37.0-154.0) 
Female 0 3.0 nc (nc-nc)   Female 6 5.5 110.1 (40.2-239.6) 
Colon / Rectum            Ovary     
Male 25 22.9 109.1 (70.6-161.1)             
Female 21 24.9 84.4 (52.2-129.0)   Female 3 8.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 5.7 nc (nc-nc)   Male 9 8.2 110.0 (50.2-208.9) 
Female 0 1.8 nc (nc-nc)   Female 8 9.3 86.2 (37.1-169.8) 
Hodgkin Lymphoma            Prostate     
Male 1 1.4 nc (nc-nc)   Male 90 72.0 125.0 (100.5-153.6) 
Female 2 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 13.2 45.4 (16.6-98.9)   Male 4 5.1 nc (nc-nc) 
Female 3 8.0 nc (nc-nc)   Female 3 3.5 nc (nc-nc) 
Larynx            Testis     
Male 1 3.4 nc (nc-nc)   Male 1 2.5 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 11 8.5 129.2 (64.4-231.2)   Male 12 5.7 212.2 (109.5-370.7) 
Female 1 6.9 nc (nc-nc)   Female 21 16.7 126.0 (78.0-192.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 8.2 60.7 (19.6-141.6)             
Female 3 3.0 nc (nc-nc)   Female 26 23.6 110.3 (72.1-161.7) 
Lung and Bronchus            All Sites / Types     
Male 25 38.2 65.4 (42.3-96.5)   Male 282 284.3 99.2 (87.9-111.5) 
Female 36 47.5 75.8 (53.1-104.9)   Female 295 331.1 89.1 (79.2-99.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
215 
Newton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 111 102.0 108.8 (89.5-131.0)   Male 68 63.4 107.2 (83.3-135.9) 
Female 46 35.6 129.1 (94.5-172.2)   Female 68 49.4 137.8 (107.0-174.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 22 18.3 120.3 (75.4-182.2)   Male 28 20.5 136.3 (90.5-197.0) 
Female 18 16.3 110.2 (65.3-174.2)   Female 16 16.7 96.1 (54.9-156.0) 
Breast            Non-Hodgkin Lymphoma     
Male 3 3.5 nc (nc-nc)   Male 64 56.3 113.6 (87.5-145.1) 
Female 447 399.4 111.9 (101.8-122.8)   Female 54 48.9 110.4 (82.9-144.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 28 45.7 61.3 (40.7-88.6) 
Female 8 13.0 61.7 (26.6-121.5)   Female 29 21.8 133.1 (89.1-191.1) 
Colon / Rectum            Ovary     
Male 100 103.9 96.2 (78.3-117.0)             
Female 82 102.1 80.3 (63.9-99.7)   Female 47 34.3 136.9 (100.6-182.1) 
Esophagus            Pancreas     
Male 9 25.1 35.9 (16.4-68.1)   Male 30 37.1 80.8 (54.5-115.3) 
Female 6 7.0 85.5 (31.2-186.0)   Female 51 37.4 136.3 (101.5-179.2) 
Hodgkin Lymphoma            Prostate     
Male 10 6.6 151.3 (72.4-278.2)   Male 332 294.3 112.8 (101.0-125.6) 
Female 8 5.9 135.1 (58.2-266.2)             
Kidney & Renal Pelvis            Stomach     
Male 51 56.0 91.1 (67.8-119.8)   Male 25 23.5 106.3 (68.8-156.9) 
Female 27 31.8 84.8 (55.9-123.4)   Female 11 14.4 76.5 (38.1-136.9) 
Larynx            Testis     
Male 9 14.5 62.1 (28.3-117.9)   Male 13 11.8 110.4 (58.7-188.9) 
Female 0 4.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 34 40.0 85.0 (58.9-118.8)   Male 32 24.0 133.5 (91.3-188.5) 
Female 27 29.0 93.0 (61.3-135.3)   Female 84 72.4 116.0 (92.5-143.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 22 34.2 64.3 (40.3-97.3)             
Female 9 11.9 75.5 (34.4-143.2)   Female 87 91.1 95.5 (76.5-117.8) 
Lung and Bronchus            All Sites / Types     
Male 113 176.1 64.2 (52.9-77.1)   Male 1175 1258.9 93.3 (88.1-98.8) 
Female 148 185.6 79.7 (67.4-93.7)   Female 1380 1336.2 103.3 (97.9-108.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
216 
Norfolk 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 13.2 60.8 (26.2-119.8)   Male 24 9.4 255.4 (163.6-380.0) 
Female 1 2.8 nc (nc-nc)   Female 4 4.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 2.9 nc (nc-nc)   Male 3 3.0 nc (nc-nc) 
Female 2 1.5 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 6 8.3 72.4 (26.5-157.7) 
Female 41 39.1 105.0 (75.3-142.4)   Female 2 4.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 7.7 77.4 (28.3-168.6) 
Female 0 1.4 nc (nc-nc)   Female 1 2.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 15.1 59.6 (27.2-113.1)             
Female 6 8.4 71.8 (26.2-156.3)   Female 1 3.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 5 3.8 131.6 (42.4-307.2)   Male 2 5.3 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 3 2.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 1.2 nc (nc-nc)   Male 38 47.6 79.8 (56.5-109.5) 
Female 0 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 12 9.1 131.3 (67.8-229.4)   Male 5 3.3 150.2 (48.4-350.5) 
Female 4 2.9 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Larynx            Testis     
Male 3 2.3 nc (nc-nc)   Male 0 2.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 5.7 87.8 (28.3-204.9)   Male 2 4.4 nc (nc-nc) 
Female 2 2.5 nc (nc-nc)   Female 10 7.7 129.9 (62.2-239.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 5.6 nc (nc-nc)             
Female 1 1.0 nc (nc-nc)   Female 7 9.1 76.9 (30.8-158.4) 
Lung and Bronchus            All Sites / Types     
Male 16 24.4 65.7 (37.5-106.6)   Male 155 189.1 82.0 (69.6-95.9) 
Female 13 15.2 85.4 (45.4-146.1)   Female 105 121.3 86.6 (70.8-104.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
217 
North Adams 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 19 16.6 114.5 (68.9-178.8)   Male 4 10.3 nc (nc-nc) 
Female 10 6.3 159.8 (76.5-293.9)   Female 6 8.0 74.9 (27.4-163.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 2.9 nc (nc-nc)   Male 4 3.3 nc (nc-nc) 
Female 1 2.7 nc (nc-nc)   Female 1 2.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.6 nc (nc-nc)   Male 10 9.1 110.5 (52.9-203.2) 
Female 50 63.9 78.2 (58.0-103.1)   Female 7 8.2 85.3 (34.2-175.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 7.3 137.0 (65.6-251.9) 
Female 1 2.0 nc (nc-nc)   Female 6 3.6 166.5 (60.8-362.3) 
Colon / Rectum            Ovary     
Male 24 16.6 144.4 (92.5-214.9)             
Female 17 17.6 96.4 (56.1-154.4)   Female 7 5.6 125.1 (50.1-257.9) 
Esophagus            Pancreas     
Male 7 4.0 172.9 (69.3-356.2)   Male 0 6.0 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 7 6.6 106.0 (42.5-218.4) 
Hodgkin Lymphoma            Prostate     
Male 0 1.1 nc (nc-nc)   Male 38 47.2 80.4 (56.9-110.4) 
Female 1 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 9.0 78.1 (31.3-160.9)   Male 5 3.8 131.6 (42.4-307.2) 
Female 3 5.2 nc (nc-nc)   Female 2 2.5 nc (nc-nc) 
Larynx            Testis     
Male 2 2.3 nc (nc-nc)   Male 1 1.9 nc (nc-nc) 
Female 3 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 6.4 77.6 (25.0-181.1)   Male 6 3.8 157.6 (57.5-343.0) 
Female 3 4.9 nc (nc-nc)   Female 11 10.9 100.7 (50.2-180.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 10 5.6 179.6 (86.0-330.3)             
Female 3 2.0 nc (nc-nc)   Female 12 14.5 83.0 (42.8-145.0) 
Lung and Bronchus            All Sites / Types     
Male 28 29.0 96.7 (64.2-139.8)   Male 203 203.2 99.9 (86.6-114.6) 
Female 41 32.1 127.8 (91.7-173.4)   Female 209 220.9 94.6 (82.2-108.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
218 
North Andover 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 32 28.8 111.2 (76.1-157.0)   Male 20 18.9 105.8 (64.6-163.4) 
Female 6 11.4 52.6 (19.2-114.5)   Female 15 16.2 92.4 (51.7-152.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 5.8 103.8 (37.9-225.9)   Male 6 6.0 100.3 (36.6-218.2) 
Female 6 5.2 115.5 (42.2-251.3)   Female 8 5.4 149.1 (64.2-293.9) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.0 nc (nc-nc)   Male 20 16.8 118.8 (72.5-183.4) 
Female 128 131.1 97.6 (81.5-116.1)   Female 14 15.8 88.5 (48.4-148.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 14.5 76.0 (37.9-136.0) 
Female 3 4.4 nc (nc-nc)   Female 1 7.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 24 31.6 76.0 (48.7-113.0)             
Female 37 33.7 109.7 (77.2-151.2)   Female 11 11.2 98.2 (49.0-175.7) 
Esophagus            Pancreas     
Male 8 7.3 108.9 (46.9-214.7)   Male 6 10.8 55.5 (20.3-120.8) 
Female 0 2.2 nc (nc-nc)   Female 12 12.0 99.7 (51.5-174.2) 
Hodgkin Lymphoma            Prostate     
Male 2 2.2 nc (nc-nc)   Male 90 87.7 102.6 (82.5-126.1) 
Female 5 1.9 266.4 (85.8-621.6)             
Kidney & Renal Pelvis            Stomach     
Male 12 17.3 69.5 (35.9-121.5)   Male 5 6.9 72.7 (23.4-169.7) 
Female 7 10.3 67.8 (27.2-139.8)   Female 7 4.7 148.9 (59.6-306.8) 
Larynx            Testis     
Male 0 4.3 nc (nc-nc)   Male 5 4.3 116.5 (37.5-271.9) 
Female 0 1.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 14 12.0 116.8 (63.8-195.9)   Male 12 8.1 148.8 (76.8-259.9) 
Female 11 9.3 117.9 (58.8-210.9)   Female 22 24.5 89.6 (56.2-135.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 10.5 56.9 (20.8-123.8)             
Female 3 3.8 nc (nc-nc)   Female 25 29.0 86.2 (55.8-127.2) 
Lung and Bronchus            All Sites / Types     
Male 37 49.2 75.1 (52.9-103.6)   Male 351 374.1 93.8 (84.3-104.2) 
Female 49 59.1 82.9 (61.3-109.6)   Female 397 434.7 91.3 (82.6-100.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
219 
North Attleborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 28 22.6 124.0 (82.4-179.2)   Male 15 16.3 91.8 (51.3-151.4) 
Female 8 9.1 87.9 (37.8-173.2)   Female 20 14.3 139.4 (85.1-215.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 5.3 112.5 (41.1-245.0)   Male 8 5.2 154.7 (66.6-304.7) 
Female 6 4.7 127.6 (46.6-277.8)   Female 6 4.4 136.8 (50.0-297.8) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.9 nc (nc-nc)   Male 16 14.5 110.4 (63.1-179.3) 
Female 117 116.3 100.6 (83.2-120.5)   Female 16 13.2 121.1 (69.1-196.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 14 13.3 105.5 (57.6-177.0) 
Female 0 4.2 nc (nc-nc)   Female 3 6.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 31 26.4 117.2 (79.6-166.4)             
Female 22 27.4 80.3 (50.3-121.6)   Female 4 9.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 9 6.4 140.7 (64.2-267.0)   Male 11 9.0 122.0 (60.8-218.4) 
Female 1 1.8 nc (nc-nc)   Female 11 9.5 115.5 (57.6-206.7) 
Hodgkin Lymphoma            Prostate     
Male 1 2.2 nc (nc-nc)   Male 79 78.8 100.2 (79.3-124.9) 
Female 1 1.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 12 15.9 75.6 (39.0-132.0)   Male 3 5.7 nc (nc-nc) 
Female 9 8.9 100.8 (46.0-191.3)   Female 4 3.8 nc (nc-nc) 
Larynx            Testis     
Male 3 3.8 nc (nc-nc)   Male 5 4.5 110.1 (35.5-257.0) 
Female 1 1.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 10.1 49.3 (15.9-115.0)   Male 6 8.0 74.6 (27.2-162.4) 
Female 4 7.9 nc (nc-nc)   Female 25 23.8 105.2 (68.0-155.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 9 9.3 96.4 (44.0-183.0)             
Female 3 3.2 nc (nc-nc)   Female 21 25.8 81.4 (50.3-124.4) 
Lung and Bronchus            All Sites / Types     
Male 39 41.7 93.6 (66.6-128.0)   Male 334 324.4 103.0 (92.2-114.6) 
Female 41 48.6 84.3 (60.5-114.4)   Female 350 374.5 93.5 (83.9-103.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
220 
North Brookfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 5.3 nc (nc-nc)   Male 4 3.5 nc (nc-nc) 
Female 1 1.9 nc (nc-nc)   Female 0 2.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.0 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 2 0.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 1 3.1 nc (nc-nc) 
Female 16 20.7 77.2 (44.1-125.5)   Female 4 2.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 2.7 nc (nc-nc) 
Female 2 0.7 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 5.6 106.2 (38.8-231.2)             
Female 5 5.3 94.2 (30.4-219.8)   Female 2 1.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.4 nc (nc-nc)   Male 4 2.0 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 2 1.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 18 16.1 111.9 (66.3-176.8) 
Female 1 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 3.2 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 1 1.7 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Larynx            Testis     
Male 1 0.8 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 2.2 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 1 1.5 nc (nc-nc)   Female 2 3.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 2.0 nc (nc-nc)             
Female 2 0.6 nc (nc-nc)   Female 6 4.6 130.4 (47.6-283.9) 
Lung and Bronchus            All Sites / Types     
Male 10 9.6 104.1 (49.9-191.5)   Male 71 69.0 102.9 (80.4-129.8) 
Female 6 9.7 61.6 (22.5-134.2)   Female 63 69.2 91.0 (69.9-116.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
221 
North Reading 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 16.2 86.7 (47.3-145.4)   Male 11 10.8 101.5 (50.6-181.7) 
Female 7 5.6 125.4 (50.2-258.3)   Female 9 8.5 105.8 (48.3-200.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 3.3 nc (nc-nc)   Male 2 3.5 nc (nc-nc) 
Female 5 2.7 186.0 (59.9-434.1)   Female 1 2.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.6 nc (nc-nc)   Male 10 9.6 104.2 (49.9-191.6) 
Female 82 71.7 114.4 (91.0-142.0)   Female 4 8.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 8.4 nc (nc-nc) 
Female 3 2.4 nc (nc-nc)   Female 1 3.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 14 17.5 79.9 (43.6-134.0)             
Female 14 16.4 85.3 (46.6-143.2)   Female 4 6.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 8 4.3 185.6 (79.9-365.7)   Male 6 6.2 97.1 (35.4-211.3) 
Female 0 1.1 nc (nc-nc)   Female 7 5.7 122.3 (49.0-252.1) 
Hodgkin Lymphoma            Prostate     
Male 1 1.2 nc (nc-nc)   Male 50 52.1 95.9 (71.2-126.4) 
Female 1 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 10.1 98.9 (47.4-182.0)   Male 3 3.9 nc (nc-nc) 
Female 3 5.5 nc (nc-nc)   Female 0 2.3 nc (nc-nc) 
Larynx            Testis     
Male 2 2.6 nc (nc-nc)   Male 1 2.3 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 6.7 119.5 (51.5-235.5)   Male 6 4.6 129.7 (47.4-282.3) 
Female 4 4.6 nc (nc-nc)   Female 18 13.7 131.6 (78.0-208.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 6.2 80.8 (26.0-188.5)             
Female 2 1.9 nc (nc-nc)   Female 18 16.2 111.0 (65.7-175.4) 
Lung and Bronchus            All Sites / Types     
Male 15 29.2 51.4 (28.8-84.8)   Male 189 215.9 87.6 (75.5-101.0) 
Female 24 30.8 78.0 (50.0-116.1)   Female 219 227.9 96.1 (83.8-109.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
222 
Northampton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 41 29.7 138.3 (99.2-187.6)   Male 13 18.8 69.3 (36.9-118.5) 
Female 11 11.4 96.9 (48.3-173.4)   Female 9 15.9 56.7 (25.9-107.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 5.5 108.5 (39.6-236.1)   Male 1 6.1 nc (nc-nc) 
Female 4 5.4 nc (nc-nc)   Female 7 5.4 130.0 (52.1-267.8) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.1 nc (nc-nc)   Male 18 16.8 107.3 (63.6-169.6) 
Female 166 127.3 130.4 (111.3-151.8)   Female 16 15.8 101.5 (58.0-164.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 15 13.9 107.9 (60.4-178.0) 
Female 5 4.0 123.9 (39.9-289.2)   Female 4 7.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 29 30.5 95.2 (63.7-136.7)             
Female 37 32.5 113.7 (80.0-156.7)   Female 17 11.1 152.6 (88.8-244.3) 
Esophagus            Pancreas     
Male 8 7.5 106.2 (45.7-209.3)   Male 10 11.0 91.1 (43.6-167.5) 
Female 4 2.2 nc (nc-nc)   Female 11 11.9 92.4 (46.1-165.4) 
Hodgkin Lymphoma            Prostate     
Male 1 2.2 nc (nc-nc)   Male 54 91.4 59.1 (44.4-77.1) 
Female 1 2.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 12 16.9 71.1 (36.7-124.1)   Male 6 6.9 86.7 (31.7-188.8) 
Female 9 10.2 88.4 (40.4-167.9)   Female 4 4.6 nc (nc-nc) 
Larynx            Testis     
Male 2 4.4 nc (nc-nc)   Male 7 4.0 175.4 (70.3-361.5) 
Female 3 1.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 13 11.8 110.5 (58.8-188.9)   Male 4 7.4 nc (nc-nc) 
Female 7 9.3 75.2 (30.1-154.9)   Female 10 23.3 42.9 (20.6-79.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 10.5 47.7 (15.4-111.3)             
Female 3 3.9 nc (nc-nc)   Female 44 29.7 148.2 (107.7-198.9) 
Lung and Bronchus            All Sites / Types     
Male 44 51.8 84.9 (61.7-114.0)   Male 314 377.7 83.1 (74.2-92.9) 
Female 44 59.0 74.6 (54.2-100.2)   Female 454 428.0 106.1 (96.5-116.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
223 
Northborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 21 16.2 129.5 (80.2-198.0)   Male 12 10.7 111.6 (57.6-195.0) 
Female 7 5.8 121.1 (48.5-249.4)   Female 8 8.1 98.2 (42.3-193.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 3.2 nc (nc-nc)   Male 4 3.5 nc (nc-nc) 
Female 1 2.6 nc (nc-nc)   Female 5 2.7 185.0 (59.6-431.8) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.6 nc (nc-nc)   Male 10 9.5 104.7 (50.1-192.6) 
Female 73 66.0 110.6 (86.7-139.0)   Female 5 8.0 62.5 (20.2-145.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 8.3 96.4 (41.5-190.0) 
Female 1 2.2 nc (nc-nc)   Female 2 3.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 11 17.9 61.6 (30.7-110.2)             
Female 15 16.8 89.3 (49.9-147.2)   Female 3 5.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 8 4.2 190.9 (82.2-376.3)   Male 6 6.2 97.4 (35.6-212.1) 
Female 0 1.1 nc (nc-nc)   Female 6 6.0 99.5 (36.3-216.6) 
Hodgkin Lymphoma            Prostate     
Male 1 1.2 nc (nc-nc)   Male 50 50.3 99.5 (73.8-131.1) 
Female 0 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 10.0 100.4 (48.0-184.6)   Male 2 3.9 nc (nc-nc) 
Female 4 5.2 nc (nc-nc)   Female 2 2.3 nc (nc-nc) 
Larynx            Testis     
Male 0 2.5 nc (nc-nc)   Male 3 2.3 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 6.6 151.8 (72.7-279.1)   Male 3 4.5 nc (nc-nc) 
Female 7 4.7 149.7 (60.0-308.5)   Female 8 12.2 65.8 (28.3-129.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 5.9 nc (nc-nc)             
Female 2 1.9 nc (nc-nc)   Female 15 14.9 100.7 (56.3-166.1) 
Lung and Bronchus            All Sites / Types     
Male 13 28.6 45.4 (24.1-77.6)   Male 196 212.6 92.2 (79.7-106.1) 
Female 30 30.3 98.9 (66.7-141.2)   Female 209 219.2 95.3 (82.8-109.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
224 
Northbridge 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 18 15.9 113.5 (67.2-179.4)   Male 9 10.7 84.1 (38.4-159.7) 
Female 5 6.3 79.7 (25.7-186.1)   Female 8 8.9 89.7 (38.6-176.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 3.2 nc (nc-nc)   Male 8 3.4 232.6 (100.2-458.4) 
Female 2 3.0 nc (nc-nc)   Female 3 2.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.6 nc (nc-nc)   Male 9 9.4 95.6 (43.6-181.5) 
Female 58 70.6 82.1 (62.4-106.2)   Female 12 8.7 137.9 (71.2-240.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 8.4 94.9 (40.9-187.1) 
Female 3 2.4 nc (nc-nc)   Female 2 3.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 17.6 51.1 (23.3-97.0)             
Female 26 18.3 142.1 (92.8-208.3)   Female 4 6.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 4.3 nc (nc-nc)   Male 5 6.1 81.9 (26.4-191.2) 
Female 1 1.2 nc (nc-nc)   Female 7 6.5 106.9 (42.8-220.3) 
Hodgkin Lymphoma            Prostate     
Male 3 1.2 nc (nc-nc)   Male 50 51.9 96.4 (71.5-127.1) 
Female 2 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 14 10.1 138.9 (75.9-233.0)   Male 5 3.9 129.1 (41.6-301.2) 
Female 6 5.6 107.1 (39.1-233.1)   Female 3 2.6 nc (nc-nc) 
Larynx            Testis     
Male 3 2.5 nc (nc-nc)   Male 1 2.3 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 6.6 nc (nc-nc)   Male 4 4.6 nc (nc-nc) 
Female 5 5.2 95.6 (30.8-223.1)   Female 12 13.6 88.2 (45.5-154.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 6.1 nc (nc-nc)             
Female 2 2.1 nc (nc-nc)   Female 18 15.4 116.7 (69.1-184.5) 
Lung and Bronchus            All Sites / Types     
Male 27 28.6 94.5 (62.3-137.6)   Male 194 213.6 90.8 (78.5-104.5) 
Female 30 32.3 93.0 (62.7-132.7)   Female 224 236.5 94.7 (82.7-108.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
225 
Northfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 3.9 nc (nc-nc)   Male 4 2.5 nc (nc-nc) 
Female 2 1.2 nc (nc-nc)   Female 4 1.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.7 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 2.2 nc (nc-nc) 
Female 12 13.9 86.6 (44.7-151.3)   Female 1 1.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 1.9 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 4.1 nc (nc-nc)             
Female 2 3.4 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.0 nc (nc-nc)   Male 0 1.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 5 12.6 39.8 (12.8-92.8) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 2.3 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 3 1.1 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Larynx            Testis     
Male 1 0.6 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.6 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 2 1.0 nc (nc-nc)   Female 0 2.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.4 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 4 3.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 4 6.8 nc (nc-nc)   Male 35 50.7 69.1 (48.1-96.1) 
Female 4 6.1 nc (nc-nc)   Female 41 45.5 90.1 (64.7-122.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
226 
Norton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 13 18.7 69.6 (37.0-119.0)   Male 14 12.6 111.3 (60.8-186.7) 
Female 9 6.0 149.6 (68.3-284.0)   Female 16 9.0 176.8 (101.0-287.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 3.9 128.6 (41.5-300.2)   Male 4 4.0 nc (nc-nc) 
Female 2 3.1 nc (nc-nc)   Female 3 2.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.7 nc (nc-nc)   Male 7 11.1 62.9 (25.2-129.5) 
Female 77 74.2 103.7 (81.8-129.6)   Female 12 8.6 138.8 (71.6-242.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 10.0 80.2 (34.5-158.1) 
Female 1 2.5 nc (nc-nc)   Female 2 3.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 24 20.6 116.6 (74.7-173.4)             
Female 22 17.7 124.6 (78.1-188.7)   Female 8 6.4 126.0 (54.2-248.2) 
Esophagus            Pancreas     
Male 5 5.0 99.4 (32.0-231.9)   Male 9 7.2 125.6 (57.3-238.5) 
Female 1 1.2 nc (nc-nc)   Female 10 6.2 161.2 (77.2-296.5) 
Hodgkin Lymphoma            Prostate     
Male 2 1.5 nc (nc-nc)   Male 54 62.3 86.7 (65.1-113.1) 
Female 0 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 15 11.9 126.0 (70.5-207.8)   Male 5 4.6 109.9 (35.4-256.4) 
Female 7 5.8 121.3 (48.6-249.9)   Female 4 2.5 nc (nc-nc) 
Larynx            Testis     
Male 2 2.9 nc (nc-nc)   Male 2 2.8 nc (nc-nc) 
Female 2 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 11 7.9 139.4 (69.5-249.5)   Male 6 5.5 109.1 (39.8-237.4) 
Female 6 5.1 118.2 (43.1-257.2)   Female 15 14.3 104.6 (58.5-172.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 7.2 83.3 (30.4-181.3)             
Female 1 2.1 nc (nc-nc)   Female 24 16.9 141.9 (90.9-211.1) 
Lung and Bronchus            All Sites / Types     
Male 34 33.6 101.1 (70.0-141.3)   Male 248 253.3 97.9 (86.1-110.9) 
Female 30 32.1 93.4 (63.0-133.4)   Female 272 241.1 112.8 (99.8-127.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
227 
Norwell 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 13.4 104.7 (57.2-175.6)   Male 9 8.5 105.8 (48.3-200.9) 
Female 4 4.5 nc (nc-nc)   Female 16 6.2 258.2 (147.5-419.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 2.4 287.0 (115.0-591.3)   Male 1 2.7 nc (nc-nc) 
Female 4 2.0 nc (nc-nc)   Female 6 2.1 289.9 (105.9-631.1) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.5 nc (nc-nc)   Male 5 7.5 66.7 (21.5-155.7) 
Female 54 51.8 104.2 (78.3-136.0)   Female 9 6.1 146.9 (67.0-278.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 6.3 80.0 (25.8-186.7) 
Female 1 1.7 nc (nc-nc)   Female 5 2.7 182.7 (58.9-426.3) 
Colon / Rectum            Ovary     
Male 11 14.1 78.0 (38.9-139.7)             
Female 11 13.0 84.5 (42.1-151.2)   Female 6 4.4 137.9 (50.4-300.2) 
Esophagus            Pancreas     
Male 4 3.3 nc (nc-nc)   Male 7 4.9 142.2 (57.0-292.9) 
Female 0 0.9 nc (nc-nc)   Female 4 4.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.8 nc (nc-nc)   Male 37 38.4 96.3 (67.8-132.7) 
Female 1 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 7.6 nc (nc-nc)   Male 2 3.1 nc (nc-nc) 
Female 4 4.1 nc (nc-nc)   Female 2 1.8 nc (nc-nc) 
Larynx            Testis     
Male 1 1.9 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 5.3 94.1 (30.3-219.7)   Male 3 3.3 nc (nc-nc) 
Female 4 3.6 nc (nc-nc)   Female 4 9.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 4.6 152.0 (60.9-313.1)             
Female 1 1.5 nc (nc-nc)   Female 16 11.4 139.8 (79.8-227.0) 
Lung and Bronchus            All Sites / Types     
Male 13 23.2 56.1 (29.8-95.9)   Male 153 166.9 91.7 (77.7-107.4) 
Female 14 23.8 58.9 (32.1-98.8)   Female 182 169.8 107.2 (92.2-123.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
228 
Norwood 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 32.4 34.0 (16.9-60.8)   Male 36 20.4 176.8 (123.8-244.7) 
Female 7 13.2 53.0 (21.3-109.3)   Female 20 17.3 115.8 (70.7-178.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 6.0 99.9 (36.5-217.5)   Male 8 6.5 123.6 (53.2-243.5) 
Female 8 5.5 144.4 (62.2-284.5)   Female 7 6.0 116.7 (46.8-240.6) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.1 nc (nc-nc)   Male 18 18.0 100.2 (59.3-158.3) 
Female 143 136.3 104.9 (88.4-123.6)   Female 19 17.6 108.2 (65.1-169.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 16 14.3 112.2 (64.1-182.3) 
Female 5 4.4 114.9 (37.0-268.0)   Female 7 7.6 92.5 (37.1-190.6) 
Colon / Rectum            Ovary     
Male 49 33.3 147.2 (108.9-194.6)             
Female 51 37.4 136.4 (101.6-179.4)   Female 11 11.9 92.4 (46.1-165.4) 
Esophagus            Pancreas     
Male 8 7.8 102.6 (44.2-202.1)   Male 20 11.6 172.3 (105.2-266.1) 
Female 3 2.5 nc (nc-nc)   Female 20 13.8 145.1 (88.6-224.2) 
Hodgkin Lymphoma            Prostate     
Male 2 2.4 nc (nc-nc)   Male 78 87.7 88.9 (70.3-110.9) 
Female 3 2.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 12 17.7 68.0 (35.1-118.7)   Male 9 7.5 120.8 (55.1-229.3) 
Female 15 11.2 134.2 (75.1-221.4)   Female 4 5.2 nc (nc-nc) 
Larynx            Testis     
Male 6 4.5 134.1 (49.0-292.0)   Male 9 4.7 191.1 (87.2-362.7) 
Female 3 1.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 14 12.9 108.5 (59.2-182.0)   Male 13 8.0 162.6 (86.5-278.1) 
Female 11 10.4 105.7 (52.7-189.2)   Female 25 24.3 103.0 (66.6-152.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 12 10.5 114.1 (58.9-199.4)             
Female 3 4.2 nc (nc-nc)   Female 32 30.2 106.0 (72.5-149.6) 
Lung and Bronchus            All Sites / Types     
Male 58 55.7 104.0 (79.0-134.5)   Male 430 395.7 108.7 (98.6-119.5) 
Female 93 68.1 136.5 (110.2-167.3)   Female 522 469.5 111.2 (101.8-121.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
229 
Oak Bluffs 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 10 8.0 124.5 (59.6-229.0)   Male 8 4.9 162.6 (70.0-320.4) 
Female 1 2.3 nc (nc-nc)   Female 7 3.0 236.6 (94.8-487.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.3 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 4 4.3 nc (nc-nc) 
Female 24 24.2 99.3 (63.6-147.7)   Female 1 3.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 3.4 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 3 1.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 8 7.7 104.0 (44.8-204.9)             
Female 5 6.6 76.1 (24.5-177.5)   Female 2 2.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 2.0 nc (nc-nc)   Male 4 2.9 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 2.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.4 nc (nc-nc)   Male 16 23.0 69.5 (39.7-112.8) 
Female 1 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 4.3 nc (nc-nc)   Male 1 1.8 nc (nc-nc) 
Female 1 1.9 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Larynx            Testis     
Male 1 1.2 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 3.0 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 1 1.8 nc (nc-nc)   Female 4 4.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 2.7 nc (nc-nc)             
Female 0 0.7 nc (nc-nc)   Female 5 5.5 91.5 (29.5-213.6) 
Lung and Bronchus            All Sites / Types     
Male 12 14.6 82.1 (42.3-143.3)   Male 84 97.3 86.3 (68.9-106.9) 
Female 13 12.0 108.6 (57.8-185.7)   Female 79 82.6 95.6 (75.7-119.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
230 
Oakham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 2.1 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 2 1.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 2 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 8 8.0 100.0 (43.1-197.1)   Female 2 0.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.1 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 2.3 nc (nc-nc)             
Female 1 1.8 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.6 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 2 0.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.1 nc (nc-nc)   Male 8 7.3 109.6 (47.2-215.9) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.3 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.8 nc (nc-nc)   Male 2 0.6 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 4 1.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 0.9 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 1 1.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 7 3.8 185.5 (74.3-382.1)   Male 26 28.6 90.9 (59.4-133.2) 
Female 1 3.3 nc (nc-nc)   Female 27 25.3 106.7 (70.3-155.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
231 
Orange 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 9.1 88.1 (37.9-173.6)   Male 1 5.9 nc (nc-nc) 
Female 3 3.0 nc (nc-nc)   Female 3 4.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.7 nc (nc-nc)   Male 0 1.9 nc (nc-nc) 
Female 5 1.4 348.9 (112.4-814.3)   Female 2 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 5 5.3 95.1 (30.6-221.9) 
Female 32 37.9 84.4 (57.7-119.1)   Female 6 4.3 141.0 (51.5-307.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 4.5 155.0 (62.1-319.3) 
Female 0 1.2 nc (nc-nc)   Female 3 2.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 9.6 52.1 (16.8-121.6)             
Female 8 8.7 92.5 (39.8-182.2)   Female 2 3.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 2.4 nc (nc-nc)   Male 4 3.4 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 3 3.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.6 nc (nc-nc)   Male 25 28.8 86.7 (56.1-127.9) 
Female 1 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 5.4 110.1 (40.2-239.7)   Male 0 2.2 nc (nc-nc) 
Female 1 2.9 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Larynx            Testis     
Male 1 1.4 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 2 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 3.6 nc (nc-nc)   Male 2 2.3 nc (nc-nc) 
Female 1 2.5 nc (nc-nc)   Female 5 6.9 72.3 (23.3-168.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 3.4 nc (nc-nc)             
Female 1 1.0 nc (nc-nc)   Female 10 8.8 113.7 (54.4-209.0) 
Lung and Bronchus            All Sites / Types     
Male 21 16.4 128.0 (79.2-195.7)   Male 110 118.7 92.7 (76.2-111.7) 
Female 17 16.2 105.1 (61.2-168.3)   Female 117 120.5 97.1 (80.3-116.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
232 
Orleans 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 15.5 77.2 (39.8-134.9)   Male 21 8.6 242.8 (150.3-371.2) 
Female 6 5.0 118.9 (43.4-258.9)   Female 9 5.5 163.8 (74.7-310.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.1 nc (nc-nc)   Male 3 2.9 nc (nc-nc) 
Female 2 1.7 nc (nc-nc)   Female 2 2.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 13 7.5 172.5 (91.8-295.1) 
Female 66 46.5 142.1 (109.9-180.7)   Female 7 6.3 111.3 (44.6-229.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 5.5 90.8 (29.3-212.0) 
Female 0 1.1 nc (nc-nc)   Female 5 2.7 184.6 (59.5-430.8) 
Colon / Rectum            Ovary     
Male 14 13.7 102.1 (55.7-171.2)             
Female 12 13.1 91.3 (47.1-159.5)   Female 6 4.1 146.9 (53.7-319.8) 
Esophagus            Pancreas     
Male 1 3.6 nc (nc-nc)   Male 5 5.3 94.2 (30.4-219.8) 
Female 0 1.0 nc (nc-nc)   Female 8 5.3 151.9 (65.4-299.4) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 36 40.8 88.3 (61.9-122.3) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 7.1 nc (nc-nc)   Male 1 3.4 nc (nc-nc) 
Female 1 4.0 nc (nc-nc)   Female 2 1.8 nc (nc-nc) 
Larynx            Testis     
Male 1 2.0 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 5.2 133.4 (53.4-274.9)   Male 2 2.3 nc (nc-nc) 
Female 2 3.5 nc (nc-nc)   Female 3 5.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 4.4 113.7 (36.7-265.4)             
Female 0 1.6 nc (nc-nc)   Female 7 11.2 62.7 (25.1-129.2) 
Lung and Bronchus            All Sites / Types     
Male 10 27.3 36.6 (17.5-67.3)   Male 160 172.9 92.5 (78.7-108.0) 
Female 18 26.6 67.7 (40.1-107.0)   Female 180 164.0 109.7 (94.3-127.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
233 
Otis 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 2.8 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.5 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 13 8.5 153.2 (81.5-262.1)   Female 3 1.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 2.8 nc (nc-nc)             
Female 2 2.1 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.7 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 5 8.8 56.8 (18.3-132.6) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.6 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.1 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 2 1.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.0 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 2 1.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 5 5.2 96.1 (31.0-224.3)   Male 18 35.6 50.5 (29.9-79.8) 
Female 5 4.3 117.0 (37.7-273.1)   Female 29 28.3 102.4 (68.5-147.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Oxford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 19 11.1 171.4 (103.1-267.7)   Male 11 7.9 139.8 (69.7-250.2) 
Female 6 4.8 124.6 (45.5-271.2)   Female 10 7.4 136.0 (65.1-250.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.6 nc (nc-nc)   Male 8 2.5 314.9 (135.6-620.6) 
Female 1 2.4 nc (nc-nc)   Female 5 2.3 217.5 (70.1-507.7) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 11 7.0 157.3 (78.4-281.5) 
Female 57 58.5 97.4 (73.7-126.1)   Female 9 6.9 130.2 (59.4-247.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 6.5 153.1 (73.3-281.6) 
Female 1 2.0 nc (nc-nc)   Female 4 3.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 12.8 78.4 (37.5-144.2)             
Female 18 14.2 126.7 (75.1-200.3)   Female 9 5.0 179.8 (82.0-341.3) 
Esophagus            Pancreas     
Male 4 3.2 nc (nc-nc)   Male 5 4.4 112.9 (36.4-263.5) 
Female 2 0.9 nc (nc-nc)   Female 6 5.0 120.1 (43.9-261.4) 
Hodgkin Lymphoma            Prostate     
Male 0 1.0 nc (nc-nc)   Male 43 41.3 104.1 (75.3-140.2) 
Female 1 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 7.9 76.4 (27.9-166.2)   Male 1 2.8 nc (nc-nc) 
Female 9 4.6 196.9 (89.8-373.7)   Female 3 2.0 nc (nc-nc) 
Larynx            Testis     
Male 5 1.9 262.1 (84.5-611.7)   Male 4 2.1 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 4.9 202.9 (97.1-373.1)   Male 8 3.8 212.3 (91.4-418.3) 
Female 6 4.1 145.0 (53.0-315.6)   Female 14 11.7 119.6 (65.3-200.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 4.7 148.8 (59.6-306.7)             
Female 2 1.7 nc (nc-nc)   Female 22 13.2 166.5 (104.3-252.2) 
Lung and Bronchus            All Sites / Types     
Male 29 20.7 140.4 (94.0-201.6)   Male 203 161.0 126.1 (109.3-144.7) 
Female 25 25.3 98.7 (63.9-145.8)   Female 230 191.7 120.0 (105.0-136.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
235 
Palmer 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 17 13.3 128.0 (74.5-205.0)   Male 13 8.8 148.5 (79.0-254.0) 
Female 8 5.4 149.1 (64.2-293.9)   Female 7 7.2 96.8 (38.8-199.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 2.6 269.5 (108.0-555.3)   Male 2 2.8 nc (nc-nc) 
Female 1 2.4 nc (nc-nc)   Female 1 2.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 6 7.7 77.9 (28.4-169.6) 
Female 63 59.5 105.8 (81.3-135.4)   Female 8 7.3 110.0 (47.4-216.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 6.7 89.0 (32.5-193.7) 
Female 1 1.8 nc (nc-nc)   Female 2 3.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 12 14.3 83.9 (43.3-146.5)             
Female 13 14.9 87.0 (46.3-148.8)   Female 8 5.1 157.4 (67.8-310.2) 
Esophagus            Pancreas     
Male 3 3.5 nc (nc-nc)   Male 4 5.0 nc (nc-nc) 
Female 2 1.1 nc (nc-nc)   Female 7 5.7 123.8 (49.6-255.1) 
Hodgkin Lymphoma            Prostate     
Male 1 1.0 nc (nc-nc)   Male 32 42.1 76.1 (52.0-107.4) 
Female 1 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 14 8.1 173.3 (94.7-290.8)   Male 6 3.2 188.7 (68.9-410.7) 
Female 6 4.8 125.9 (46.0-274.0)   Female 3 2.1 nc (nc-nc) 
Larynx            Testis     
Male 4 2.0 nc (nc-nc)   Male 2 1.9 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 5.4 92.7 (29.9-216.4)   Male 1 3.6 nc (nc-nc) 
Female 4 4.2 nc (nc-nc)   Female 7 10.3 67.7 (27.1-139.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 4.9 101.2 (32.6-236.1)             
Female 2 1.8 nc (nc-nc)   Female 8 14.0 57.3 (24.7-113.0) 
Lung and Bronchus            All Sites / Types     
Male 29 23.8 121.7 (81.5-174.8)   Male 183 174.6 104.8 (90.2-121.1) 
Female 20 28.5 70.1 (42.8-108.3)   Female 186 199.4 93.3 (80.4-107.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Paxton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 5.8 137.2 (59.1-270.4)   Male 5 3.7 135.3 (43.6-315.6) 
Female 2 1.7 nc (nc-nc)   Female 2 2.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.1 nc (nc-nc)   Male 3 1.2 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.2 nc (nc-nc)   Male 1 3.3 nc (nc-nc) 
Female 19 21.0 90.5 (54.5-141.4)   Female 2 2.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 2.9 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 6.1 nc (nc-nc)             
Female 3 4.9 nc (nc-nc)   Female 0 1.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 1.5 nc (nc-nc)   Male 4 2.2 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.4 nc (nc-nc)   Male 22 18.4 119.3 (74.8-180.7) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 3.4 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Larynx            Testis     
Male 2 0.9 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 2.3 213.7 (68.9-498.6)   Male 1 1.4 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 1 3.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 2.1 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 7 5.0 141.2 (56.6-290.9) 
Lung and Bronchus            All Sites / Types     
Male 5 10.3 48.8 (15.7-113.8)   Male 79 75.0 105.3 (83.4-131.2) 
Female 4 9.4 nc (nc-nc)   Female 52 68.1 76.4 (57.0-100.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Peabody 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 100 73.3 136.4 (110.9-165.8)   Male 41 43.9 93.3 (66.9-126.6) 
Female 38 28.0 135.6 (96.0-186.2)   Female 33 34.3 96.1 (66.1-134.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 12.0 58.1 (23.3-119.8)   Male 21 14.3 147.4 (91.2-225.3) 
Female 15 10.9 137.1 (76.7-226.1)   Female 14 12.5 111.7 (61.0-187.4) 
Breast            Non-Hodgkin Lymphoma     
Male 2 2.4 nc (nc-nc)   Male 41 38.9 105.5 (75.7-143.1) 
Female 294 269.0 109.3 (97.2-122.5)   Female 60 36.2 165.8 (126.5-213.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 28 30.0 93.2 (61.9-134.7) 
Female 11 8.2 134.3 (67.0-240.4)   Female 17 15.5 109.5 (63.8-175.3) 
Colon / Rectum            Ovary     
Male 63 72.0 87.5 (67.2-112.0)             
Female 79 78.9 100.2 (79.3-124.8)   Female 20 23.9 83.8 (51.2-129.5) 
Esophagus            Pancreas     
Male 14 17.2 81.3 (44.4-136.4)   Male 26 25.9 100.4 (65.6-147.1) 
Female 3 5.3 nc (nc-nc)   Female 27 29.7 91.0 (60.0-132.5) 
Hodgkin Lymphoma            Prostate     
Male 4 4.2 nc (nc-nc)   Male 200 194.0 103.1 (89.3-118.4) 
Female 4 3.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 36 37.1 97.0 (68.0-134.4)   Male 17 16.4 103.5 (60.2-165.7) 
Female 14 22.4 62.5 (34.1-104.9)   Female 8 11.1 71.8 (30.9-141.6) 
Larynx            Testis     
Male 18 9.8 183.3 (108.5-289.6)   Male 7 7.3 95.9 (38.4-197.6) 
Female 1 3.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 30 27.7 108.4 (73.1-154.7)   Male 12 15.2 79.2 (40.9-138.3) 
Female 29 21.5 134.9 (90.3-193.7)   Female 50 44.4 112.6 (83.6-148.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 16 23.2 69.1 (39.5-112.2)             
Female 12 8.8 135.9 (70.1-237.3)   Female 45 60.3 74.6 (54.4-99.9) 
Lung and Bronchus            All Sites / Types     
Male 124 124.1 99.9 (83.1-119.1)   Male 898 861.4 104.3 (97.5-111.3) 
Female 153 139.7 109.5 (92.8-128.3)   Female 1022 950.2 107.6 (101.1-114.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Pelham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 2.0 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 3 0.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 4 7.8 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.9 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 2.0 nc (nc-nc)             
Female 0 2.0 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.5 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 3 6.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.1 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.8 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 0.7 nc (nc-nc)             
Female 1 0.2 nc (nc-nc)   Female 2 1.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 3.5 nc (nc-nc)   Male 18 25.1 71.7 (42.5-113.3) 
Female 3 3.8 nc (nc-nc)   Female 16 26.1 61.3 (35.0-99.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Pembroke 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 19 17.8 107.0 (64.4-167.1)   Male 11 12.1 90.7 (45.2-162.2) 
Female 6 6.1 98.1 (35.8-213.5)   Female 15 9.6 156.3 (87.4-257.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 3.7 134.1 (43.2-312.9)   Male 2 3.9 nc (nc-nc) 
Female 2 3.1 nc (nc-nc)   Female 2 3.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.7 nc (nc-nc)   Male 13 10.7 121.6 (64.7-207.9) 
Female 76 79.4 95.8 (75.4-119.9)   Female 7 9.1 77.2 (30.9-159.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 9.8 111.8 (55.7-200.1) 
Female 2 2.7 nc (nc-nc)   Female 3 4.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 28 19.7 141.9 (94.3-205.1)             
Female 18 18.2 99.1 (58.7-156.7)   Female 5 6.7 74.9 (24.1-174.9) 
Esophagus            Pancreas     
Male 7 4.9 141.6 (56.7-291.8)   Male 7 6.9 101.2 (40.6-208.6) 
Female 0 1.2 nc (nc-nc)   Female 4 6.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.5 nc (nc-nc)   Male 59 61.5 95.9 (73.0-123.7) 
Female 2 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 17 11.6 146.1 (85.0-233.9)   Male 7 4.4 160.0 (64.1-329.6) 
Female 7 6.1 115.6 (46.3-238.2)   Female 1 2.6 nc (nc-nc) 
Larynx            Testis     
Male 3 2.9 nc (nc-nc)   Male 5 2.8 178.3 (57.5-416.2) 
Female 0 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 7.5 93.9 (37.6-193.5)   Male 7 5.4 129.1 (51.7-266.0) 
Female 6 5.1 116.8 (42.6-254.2)   Female 26 15.4 168.4 (110.0-246.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 7.1 nc (nc-nc)             
Female 1 2.2 nc (nc-nc)   Female 19 18.3 103.6 (62.3-161.8) 
Lung and Bronchus            All Sites / Types     
Male 39 32.2 121.3 (86.2-165.8)   Male 273 245.3 111.3 (98.5-125.3) 
Female 42 32.9 127.8 (92.1-172.7)   Female 261 252.9 103.2 (91.1-116.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Pepperell 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 12.0 91.7 (45.7-164.1)   Male 4 8.1 nc (nc-nc) 
Female 3 4.0 nc (nc-nc)   Female 5 6.3 78.9 (25.4-184.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.5 nc (nc-nc)   Male 1 2.7 nc (nc-nc) 
Female 2 2.1 nc (nc-nc)   Female 1 2.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 5 7.2 69.6 (22.4-162.3) 
Female 49 53.1 92.2 (68.2-121.9)   Female 3 5.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 6.6 91.2 (33.3-198.4) 
Female 0 1.8 nc (nc-nc)   Female 1 2.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 15 13.4 111.7 (62.5-184.2)             
Female 16 11.9 134.4 (76.8-218.3)   Female 5 4.4 113.0 (36.4-263.8) 
Esophagus            Pancreas     
Male 5 3.3 151.5 (48.8-353.5)   Male 6 4.7 128.9 (47.1-280.7) 
Female 0 0.8 nc (nc-nc)   Female 2 4.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.9 nc (nc-nc)   Male 23 40.6 56.6 (35.9-84.9) 
Female 1 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 7.8 89.6 (35.9-184.7)   Male 3 2.9 nc (nc-nc) 
Female 6 4.0 148.5 (54.2-323.1)   Female 0 1.7 nc (nc-nc) 
Larynx            Testis     
Male 3 1.9 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 5.0 nc (nc-nc)   Male 6 3.5 169.6 (61.9-369.3) 
Female 4 3.4 nc (nc-nc)   Female 9 10.5 86.1 (39.3-163.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 4.7 nc (nc-nc)             
Female 0 1.4 nc (nc-nc)   Female 16 12.0 133.5 (76.3-216.8) 
Lung and Bronchus            All Sites / Types     
Male 24 21.7 110.6 (70.8-164.6)   Male 142 164.0 86.6 (72.9-102.0) 
Female 16 21.9 73.1 (41.8-118.8)   Female 151 167.7 90.1 (76.3-105.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
241 
Peru 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 1.0 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.0 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 1 3.8 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 1.1 nc (nc-nc)             
Female 0 0.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 3 3.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.6 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.4 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.4 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 1.8 nc (nc-nc)   Male 10 13.4 74.8 (35.8-137.6) 
Female 0 1.4 nc (nc-nc)   Female 2 11.8 nc (nc-nc) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Petersham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 1.8 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 2 0.9 nc (nc-nc) 
Female 5 6.6 76.0 (24.5-177.3)   Female 0 0.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.8 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 1.9 nc (nc-nc)             
Female 1 1.7 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.4 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 5 5.1 98.8 (31.8-230.6) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.9 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 1 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.6 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.6 nc (nc-nc)             
Female 1 0.2 nc (nc-nc)   Female 2 1.5 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 2.9 nc (nc-nc)   Male 21 21.2 99.0 (61.2-151.3) 
Female 1 3.1 nc (nc-nc)   Female 13 21.9 59.4 (31.6-101.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Phillipston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 1.5 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 2 1.0 nc (nc-nc) 
Female 3 8.2 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.9 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 1.8 nc (nc-nc)             
Female 0 1.7 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.5 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 2 0.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 9 5.9 153.0 (69.8-290.4) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.1 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.7 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 2 1.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.7 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 1 1.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 4 2.8 nc (nc-nc)   Male 26 22.5 115.7 (75.5-169.5) 
Female 3 3.1 nc (nc-nc)   Female 15 25.3 59.3 (33.1-97.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Pittsfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 72 55.8 129.1 (101.0-162.5)   Male 29 34.4 84.3 (56.4-121.1) 
Female 24 20.4 117.5 (75.2-174.8)   Female 21 26.7 78.6 (48.6-120.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 13 9.8 132.5 (70.5-226.6)   Male 8 11.1 72.1 (31.0-142.0) 
Female 6 8.6 69.5 (25.4-151.4)   Female 2 9.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.9 nc (nc-nc)   Male 30 30.4 98.7 (66.6-140.9) 
Female 206 214.1 96.2 (83.5-110.3)   Female 27 27.2 99.2 (65.3-144.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 33 24.9 132.8 (91.4-186.5) 
Female 5 6.6 75.9 (24.5-177.2)   Female 12 11.9 100.5 (51.8-175.5) 
Colon / Rectum            Ovary     
Male 61 56.5 108.0 (82.6-138.8)             
Female 85 57.2 148.7 (118.8-183.8)   Female 16 18.7 85.5 (48.8-138.8) 
Esophagus            Pancreas     
Male 24 13.7 175.6 (112.5-261.3)   Male 20 20.2 99.0 (60.4-152.9) 
Female 5 3.9 126.6 (40.8-295.5)   Female 25 21.3 117.3 (75.9-173.1) 
Hodgkin Lymphoma            Prostate     
Male 5 3.6 139.5 (45.0-325.6)   Male 157 162.5 96.6 (82.1-113.0) 
Female 1 3.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 33 30.4 108.7 (74.8-152.7)   Male 14 12.8 109.4 (59.8-183.6) 
Female 25 17.5 142.9 (92.4-210.9)   Female 8 8.1 99.1 (42.7-195.2) 
Larynx            Testis     
Male 9 7.9 114.4 (52.2-217.3)   Male 8 6.4 124.5 (53.6-245.3) 
Female 1 2.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 23 21.7 106.1 (67.3-159.3)   Male 10 12.7 78.5 (37.6-144.3) 
Female 10 16.1 62.3 (29.8-114.6)   Female 33 37.1 89.0 (61.3-125.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 20 18.7 107.0 (65.3-165.3)             
Female 6 6.7 90.0 (32.9-195.9)   Female 67 49.1 136.4 (105.7-173.3) 
Lung and Bronchus            All Sites / Types     
Male 117 96.3 121.5 (100.4-145.6)   Male 746 686.6 108.7 (101.0-116.7) 
Female 131 106.3 123.3 (103.1-146.3)   Female 771 732.7 105.2 (97.9-112.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
245 
Plainfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 1.0 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 4 3.4 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 1.0 nc (nc-nc)             
Female 1 0.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.3 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 1 3.3 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.6 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.4 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 1.8 nc (nc-nc)   Male 7 12.8 54.7 (21.9-112.7) 
Female 5 1.6 320.4 (103.3-747.8)   Female 13 11.0 118.2 (62.9-202.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
246 
Plainville 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 9 7.7 116.3 (53.1-220.7)   Male 7 5.5 127.1 (50.9-262.0) 
Female 2 3.2 nc (nc-nc)   Female 3 4.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.7 nc (nc-nc)   Male 4 1.8 nc (nc-nc) 
Female 0 1.5 nc (nc-nc)   Female 2 1.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.3 nc (nc-nc)   Male 7 4.9 143.3 (57.4-295.3) 
Female 39 37.3 104.5 (74.3-142.8)   Female 1 4.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 4.5 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 3 2.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 9.2 108.9 (52.1-200.3)             
Female 8 9.3 86.2 (37.1-169.9)   Female 4 3.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 2.2 nc (nc-nc)   Male 6 3.1 195.0 (71.2-424.4) 
Female 0 0.6 nc (nc-nc)   Female 2 3.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.7 nc (nc-nc)   Male 32 27.3 117.3 (80.2-165.6) 
Female 0 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 12 5.4 222.8 (115.0-389.2)   Male 0 2.0 nc (nc-nc) 
Female 3 3.0 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Larynx            Testis     
Male 2 1.3 nc (nc-nc)   Male 1 1.5 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 3.4 148.8 (47.9-347.2)   Male 1 2.7 nc (nc-nc) 
Female 6 2.6 226.9 (82.8-493.9)   Female 7 7.4 94.9 (38.0-195.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.1 nc (nc-nc)             
Female 0 1.1 nc (nc-nc)   Female 9 8.3 107.9 (49.2-204.9) 
Lung and Bronchus            All Sites / Types     
Male 23 14.0 164.7 (104.4-247.2)   Male 139 110.4 125.9 (105.9-148.7) 
Female 17 16.5 102.7 (59.8-164.5)   Female 119 123.1 96.7 (80.1-115.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
247 
Plymouth 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 67 68.6 97.6 (75.6-124.0)   Male 76 44.6 170.2 (134.1-213.1) 
Female 27 24.9 108.3 (71.4-157.6)   Female 50 34.4 145.3 (107.9-191.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 12 13.1 91.6 (47.3-160.0)   Male 10 14.5 68.9 (33.0-126.8) 
Female 11 11.1 99.3 (49.5-177.7)   Female 11 11.8 93.4 (46.5-167.0) 
Breast            Non-Hodgkin Lymphoma     
Male 2 2.5 nc (nc-nc)   Male 50 39.4 126.8 (94.1-167.2) 
Female 305 288.0 105.9 (94.4-118.5)   Female 27 34.3 78.7 (51.8-114.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 34 34.2 99.3 (68.8-138.8) 
Female 6 9.0 66.7 (24.4-145.2)   Female 20 15.5 129.0 (78.7-199.2) 
Colon / Rectum            Ovary     
Male 60 71.8 83.6 (63.8-107.6)             
Female 56 70.0 80.0 (60.4-103.9)   Female 33 24.4 135.0 (92.9-189.6) 
Esophagus            Pancreas     
Male 18 18.1 99.5 (58.9-157.3)   Male 27 26.0 104.0 (68.5-151.3) 
Female 1 5.0 nc (nc-nc)   Female 21 26.0 80.8 (50.0-123.6) 
Hodgkin Lymphoma            Prostate     
Male 3 4.9 nc (nc-nc)   Male 229 225.1 101.8 (89.0-115.8) 
Female 2 3.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 43 41.6 103.4 (74.8-139.3)   Male 14 16.3 85.7 (46.8-143.8) 
Female 22 22.8 96.4 (60.4-145.9)   Female 12 9.8 122.2 (63.1-213.5) 
Larynx            Testis     
Male 9 10.6 84.6 (38.6-160.5)   Male 9 8.8 102.3 (46.7-194.1) 
Female 1 3.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 28 27.5 101.7 (67.6-147.0)   Male 22 18.1 121.7 (76.2-184.2) 
Female 16 19.6 81.6 (46.6-132.5)   Female 72 50.2 143.4 (112.2-180.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 30 25.2 118.9 (80.2-169.7)             
Female 7 8.4 83.6 (33.5-172.3)   Female 79 67.3 117.3 (92.9-146.3) 
Lung and Bronchus            All Sites / Types     
Male 127 124.5 102.0 (85.0-121.4)   Male 961 903.4 106.4 (99.8-113.3) 
Female 148 134.8 109.8 (92.8-129.0)   Female 1006 947.9 106.1 (99.7-112.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
248 
Plympton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 3.8 132.4 (42.7-308.9)   Male 1 2.4 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 0.7 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 2.2 nc (nc-nc) 
Female 14 12.7 110.0 (60.1-184.7)   Female 1 1.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 1.9 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 3 0.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 3.9 nc (nc-nc)             
Female 4 2.7 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.0 nc (nc-nc)   Male 3 1.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 2 1.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 15 12.8 117.5 (65.7-193.8) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 2.3 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 3 1.0 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Larynx            Testis     
Male 0 0.6 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 1 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 1.5 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 1 2.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 1.4 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 2 3.1 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 6.9 nc (nc-nc)   Male 46 50.1 91.9 (67.3-122.6) 
Female 7 5.4 129.6 (51.9-267.0)   Female 49 40.1 122.1 (90.3-161.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
249 
Princeton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 3.5 141.2 (45.5-329.5)   Male 6 2.5 240.4 (87.8-523.2) 
Female 0 1.2 nc (nc-nc)   Female 3 1.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 0.8 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 3 2.2 nc (nc-nc) 
Female 21 17.0 123.5 (76.4-188.7)   Female 1 1.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 2.2 508.0 (253.2-908.9) 
Female 0 0.5 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 4.1 122.8 (39.6-286.5)             
Female 2 3.4 nc (nc-nc)   Female 5 1.4 359.5 (115.9-838.9) 
Esophagus            Pancreas     
Male 3 1.1 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 11 13.8 79.8 (39.8-142.8) 
Female 1 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 2.5 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 2 1.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Larynx            Testis     
Male 2 0.6 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.5 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 3 3.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.6 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 4 4.1 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 6.7 nc (nc-nc)   Male 63 51.9 121.5 (93.3-155.4) 
Female 3 7.0 nc (nc-nc)   Female 50 52.3 95.6 (70.9-126.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
250 
Provincetown 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 6.2 nc (nc-nc)   Male 3 3.7 nc (nc-nc) 
Female 7 2.1 329.5 (132.0-679.0)   Female 5 2.4 205.2 (66.1-478.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.0 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 2 3.3 nc (nc-nc) 
Female 23 21.0 109.8 (69.6-164.7)   Female 1 2.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 2.8 246.5 (98.7-507.8) 
Female 0 0.5 nc (nc-nc)   Female 4 1.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 6.3 nc (nc-nc)             
Female 11 5.5 199.6 (99.5-357.1)   Female 4 1.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.6 nc (nc-nc)   Male 2 2.2 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 4 2.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.3 nc (nc-nc)   Male 10 19.4 51.6 (24.7-94.9) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 3.4 146.0 (47.1-340.8)   Male 1 1.4 nc (nc-nc) 
Female 1 1.8 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Larynx            Testis     
Male 0 0.9 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 2.2 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 2 1.5 nc (nc-nc)   Female 2 2.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 2.1 nc (nc-nc)             
Female 0 0.7 nc (nc-nc)   Female 4 5.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 11 10.9 101.3 (50.5-181.2)   Male 66 76.7 86.1 (66.6-109.5) 
Female 11 11.4 96.3 (48.0-172.2)   Female 88 72.0 122.3 (98.1-150.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
251 
Quincy 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 100 95.9 104.3 (84.9-126.9)   Male 57 62.1 91.8 (69.6-119.0) 
Female 35 36.0 97.2 (67.7-135.2)   Female 55 50.0 110.0 (82.9-143.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 19 18.8 100.8 (60.7-157.4)   Male 14 19.7 71.1 (38.9-119.4) 
Female 17 16.2 105.0 (61.1-168.1)   Female 14 16.6 84.5 (46.1-141.7) 
Breast            Non-Hodgkin Lymphoma     
Male 5 3.4 149.1 (48.1-348.0)   Male 50 55.1 90.7 (67.3-119.5) 
Female 400 389.7 102.6 (92.8-113.2)   Female 57 49.0 116.4 (88.2-150.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 61 45.2 135.0 (103.3-173.4) 
Female 21 12.8 164.7 (101.9-251.8)   Female 29 21.6 134.2 (89.9-192.7) 
Colon / Rectum            Ovary     
Male 125 100.6 124.3 (103.5-148.1)             
Female 103 102.4 100.6 (82.1-122.0)   Female 34 34.3 99.0 (68.6-138.4) 
Esophagus            Pancreas     
Male 23 24.0 95.9 (60.8-143.9)   Male 30 35.4 84.9 (57.2-121.1) 
Female 8 6.9 115.7 (49.8-227.9)   Female 29 37.4 77.5 (51.9-111.3) 
Hodgkin Lymphoma            Prostate     
Male 10 8.2 122.5 (58.7-225.4)   Male 257 281.8 91.2 (80.4-103.1) 
Female 10 7.1 140.5 (67.3-258.4)             
Kidney & Renal Pelvis            Stomach     
Male 53 55.1 96.2 (72.1-125.9)   Male 30 22.5 133.5 (90.0-190.5) 
Female 34 31.7 107.1 (74.2-149.7)   Female 17 14.3 118.6 (69.0-189.9) 
Larynx            Testis     
Male 18 14.0 128.4 (76.1-202.9)   Male 17 16.2 105.2 (61.3-168.5) 
Female 4 4.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 23 39.2 58.6 (37.1-88.0)   Male 36 25.7 140.2 (98.2-194.2) 
Female 30 29.2 102.6 (69.2-146.5)   Female 65 74.2 87.5 (67.6-111.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 57 33.6 169.6 (128.4-219.7)             
Female 17 11.9 142.5 (83.0-228.2)   Female 87 89.0 97.8 (78.3-120.6) 
Lung and Bronchus            All Sites / Types     
Male 237 167.4 141.6 (124.1-160.8)   Male 1316 1222.0 107.7 (102.0-113.7) 
Female 241 188.2 128.0 (112.4-145.3)   Female 1406 1330.3 105.7 (100.2-111.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
252 
Randolph 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 33 34.7 95.0 (65.4-133.4)   Male 12 22.4 53.5 (27.6-93.5) 
Female 11 14.1 78.0 (38.9-139.6)   Female 13 19.6 66.4 (35.3-113.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 6.7 119.3 (51.4-235.0)   Male 8 7.2 111.4 (48.0-219.5) 
Female 5 6.3 79.0 (25.4-184.3)   Female 7 6.6 105.7 (42.3-217.7) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.2 nc (nc-nc)   Male 12 19.9 60.2 (31.1-105.2) 
Female 145 157.0 92.4 (78.0-108.7)   Female 22 19.5 113.1 (70.8-171.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 17.1 52.7 (24.0-100.0) 
Female 3 5.1 nc (nc-nc)   Female 6 8.6 69.7 (25.4-151.6) 
Colon / Rectum            Ovary     
Male 35 37.1 94.2 (65.6-131.1)             
Female 46 40.1 114.8 (84.0-153.1)   Female 11 13.6 81.0 (40.4-145.0) 
Esophagus            Pancreas     
Male 8 8.9 90.2 (38.8-177.7)   Male 10 12.9 77.2 (37.0-142.1) 
Female 2 2.8 nc (nc-nc)   Female 10 14.7 67.9 (32.5-124.9) 
Hodgkin Lymphoma            Prostate     
Male 2 2.7 nc (nc-nc)   Male 101 107.4 94.1 (76.6-114.3) 
Female 2 2.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 29 20.5 141.6 (94.8-203.3)   Male 10 8.2 122.0 (58.4-224.3) 
Female 8 12.6 63.7 (27.4-125.5)   Female 6 5.7 106.1 (38.7-230.9) 
Larynx            Testis     
Male 7 5.1 136.8 (54.8-282.0)   Male 0 5.0 nc (nc-nc) 
Female 1 1.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 11 14.1 77.9 (38.8-139.3)   Male 13 9.2 141.4 (75.2-241.7) 
Female 2 11.3 nc (nc-nc)   Female 35 28.9 121.1 (84.3-168.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 15 12.5 119.9 (67.1-197.8)             
Female 1 4.7 nc (nc-nc)   Female 41 36.3 113.0 (81.1-153.3) 
Lung and Bronchus            All Sites / Types     
Male 44 60.2 73.1 (53.1-98.1)   Male 391 448.5 87.2 (78.8-96.3) 
Female 52 73.7 70.6 (52.7-92.6)   Female 461 527.4 87.4 (79.6-95.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
253 
Raynham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 13 14.5 89.5 (47.6-153.1)   Male 11 9.6 114.6 (57.2-205.1) 
Female 6 5.7 105.7 (38.6-230.0)   Female 11 7.8 141.1 (70.4-252.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 2.9 nc (nc-nc)   Male 4 3.1 nc (nc-nc) 
Female 2 2.5 nc (nc-nc)   Female 2 2.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 12 8.4 143.0 (73.8-249.8) 
Female 69 63.2 109.3 (85.0-138.3)   Female 7 7.8 89.9 (36.0-185.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 7.5 67.0 (21.6-156.4) 
Female 1 2.0 nc (nc-nc)   Female 4 3.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 26 15.7 165.9 (108.4-243.1)             
Female 17 15.9 107.1 (62.3-171.5)   Female 9 5.4 166.5 (76.0-316.1) 
Esophagus            Pancreas     
Male 6 3.8 157.8 (57.6-343.4)   Male 5 5.5 90.8 (29.3-211.8) 
Female 1 1.1 nc (nc-nc)   Female 5 5.8 85.6 (27.6-199.7) 
Hodgkin Lymphoma            Prostate     
Male 1 1.1 nc (nc-nc)   Male 48 46.6 102.9 (75.9-136.5) 
Female 1 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 12 8.9 135.5 (69.9-236.7)   Male 3 3.5 nc (nc-nc) 
Female 6 5.1 118.2 (43.2-257.3)   Female 1 2.2 nc (nc-nc) 
Larynx            Testis     
Male 3 2.2 nc (nc-nc)   Male 4 2.0 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 6.0 nc (nc-nc)   Male 6 3.9 153.2 (55.9-333.5) 
Female 4 4.5 nc (nc-nc)   Female 24 11.5 208.2 (133.4-309.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 5.5 108.4 (39.6-236.0)             
Female 2 1.9 nc (nc-nc)   Female 16 14.3 112.1 (64.1-182.1) 
Lung and Bronchus            All Sites / Types     
Male 23 26.0 88.5 (56.1-132.7)   Male 213 191.8 111.1 (96.6-127.0) 
Female 26 30.4 85.4 (55.8-125.2)   Female 238 211.5 112.5 (98.7-127.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
254 
Reading 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 26 25.7 101.2 (66.1-148.2)   Male 14 16.7 83.8 (45.8-140.6) 
Female 11 10.3 106.8 (53.2-191.1)   Female 15 14.3 104.9 (58.7-173.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 5.0 nc (nc-nc)   Male 4 5.3 nc (nc-nc) 
Female 6 4.6 130.2 (47.5-283.4)   Female 2 4.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.9 nc (nc-nc)   Male 17 14.8 114.6 (66.7-183.5) 
Female 129 112.7 114.5 (95.6-136.0)   Female 8 14.0 57.0 (24.6-112.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 14 12.7 110.1 (60.2-184.8) 
Female 2 3.8 nc (nc-nc)   Female 6 6.2 97.1 (35.4-211.3) 
Colon / Rectum            Ovary     
Male 32 27.6 116.0 (79.3-163.8)             
Female 27 29.9 90.4 (59.6-131.5)   Female 14 9.7 143.8 (78.6-241.3) 
Esophagus            Pancreas     
Male 5 6.6 75.9 (24.5-177.1)   Male 9 9.6 94.0 (42.9-178.5) 
Female 2 2.0 nc (nc-nc)   Female 9 10.8 83.0 (37.9-157.6) 
Hodgkin Lymphoma            Prostate     
Male 1 1.9 nc (nc-nc)   Male 66 79.4 83.2 (64.3-105.8) 
Female 2 1.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 16 15.3 104.5 (59.7-169.7)   Male 2 6.1 nc (nc-nc) 
Female 8 9.0 88.7 (38.2-174.7)   Female 1 4.2 nc (nc-nc) 
Larynx            Testis     
Male 1 3.8 nc (nc-nc)   Male 6 3.7 161.0 (58.8-350.5) 
Female 0 1.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 13 10.6 123.1 (65.5-210.4)   Male 8 7.0 114.0 (49.1-224.6) 
Female 9 8.4 106.8 (48.7-202.7)   Female 25 21.0 119.2 (77.1-175.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 11 9.3 117.9 (58.8-211.0)             
Female 4 3.4 nc (nc-nc)   Female 24 25.1 95.7 (61.3-142.4) 
Lung and Bronchus            All Sites / Types     
Male 32 44.5 72.0 (49.2-101.6)   Male 307 332.9 92.2 (82.2-103.1) 
Female 37 52.5 70.4 (49.6-97.1)   Female 378 381.0 99.2 (89.5-109.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
255 
Rehoboth 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 14.9 nc (nc-nc)   Male 8 9.5 84.2 (36.3-166.0) 
Female 5 3.7 134.3 (43.3-313.4)   Female 6 5.9 102.0 (37.2-222.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 2.7 nc (nc-nc)   Male 3 3.1 nc (nc-nc) 
Female 2 2.0 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.5 nc (nc-nc)   Male 9 8.4 107.0 (48.8-203.2) 
Female 51 49.1 103.8 (77.3-136.5)   Female 7 5.5 127.8 (51.2-263.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 7.2 nc (nc-nc) 
Female 0 1.7 nc (nc-nc)   Female 3 2.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 15.7 57.2 (26.1-108.7)             
Female 9 10.8 83.7 (38.2-158.8)   Female 4 4.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 3.8 nc (nc-nc)   Male 1 5.5 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 2 3.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.0 nc (nc-nc)   Male 35 45.9 76.2 (53.1-106.0) 
Female 2 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 8.6 81.0 (32.5-166.9)   Male 1 3.5 nc (nc-nc) 
Female 5 3.8 132.9 (42.8-310.2)   Female 0 1.5 nc (nc-nc) 
Larynx            Testis     
Male 1 2.2 nc (nc-nc)   Male 2 1.8 nc (nc-nc) 
Female 2 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 5.9 84.8 (27.3-197.9)   Male 0 3.7 nc (nc-nc) 
Female 2 3.2 nc (nc-nc)   Female 10 9.6 104.3 (49.9-191.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 5.4 nc (nc-nc)             
Female 1 1.4 nc (nc-nc)   Female 16 11.7 137.3 (78.4-223.0) 
Lung and Bronchus            All Sites / Types     
Male 24 25.8 92.9 (59.5-138.2)   Male 124 190.2 65.2 (54.2-77.7) 
Female 17 20.4 83.3 (48.5-133.4)   Female 154 156.0 98.7 (83.8-115.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
256 
Revere 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 52 52.2 99.5 (74.3-130.5)   Male 18 34.9 51.6 (30.5-81.5) 
Female 18 19.8 90.9 (53.8-143.7)   Female 20 27.4 73.1 (44.6-112.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 10.9 64.2 (25.7-132.4)   Male 7 10.9 64.1 (25.7-132.1) 
Female 12 8.9 135.2 (69.8-236.1)   Female 10 9.1 109.4 (52.4-201.2) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.8 nc (nc-nc)   Male 30 30.9 97.0 (65.4-138.5) 
Female 190 216.0 87.9 (75.9-101.4)   Female 25 27.0 92.7 (60.0-136.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 21 25.8 81.4 (50.4-124.5) 
Female 5 7.0 71.2 (22.9-166.0)   Female 20 11.9 167.8 (102.5-259.2) 
Colon / Rectum            Ovary     
Male 60 56.4 106.4 (81.2-137.0)             
Female 45 55.5 81.0 (59.1-108.4)   Female 13 18.8 69.2 (36.8-118.3) 
Esophagus            Pancreas     
Male 9 13.3 67.7 (30.9-128.5)   Male 23 19.5 117.9 (74.7-176.9) 
Female 2 3.9 nc (nc-nc)   Female 16 20.5 77.9 (44.5-126.5) 
Hodgkin Lymphoma            Prostate     
Male 6 4.9 123.3 (45.0-268.3)   Male 111 156.5 70.9 (58.4-85.4) 
Female 10 3.7 267.7 (128.2-492.3)             
Kidney & Renal Pelvis            Stomach     
Male 35 31.4 111.4 (77.6-154.9)   Male 20 12.5 160.3 (97.9-247.5) 
Female 24 17.5 136.9 (87.7-203.7)   Female 11 7.9 139.5 (69.6-249.7) 
Larynx            Testis     
Male 6 7.8 77.1 (28.2-167.8)   Male 7 10.2 68.4 (27.4-141.0) 
Female 5 2.5 203.5 (65.6-474.9)             
Leukemia            Thyroid     
Male 26 22.0 118.1 (77.1-173.0)   Male 10 15.5 64.5 (30.9-118.6) 
Female 17 16.0 106.3 (61.9-170.1)   Female 53 40.5 130.8 (98.0-171.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 24 18.8 127.8 (81.8-190.1)             
Female 7 6.6 106.5 (42.7-219.5)   Female 37 49.7 74.4 (52.4-102.5) 
Lung and Bronchus            All Sites / Types     
Male 136 91.8 148.2 (124.3-175.3)   Male 659 682.7 96.5 (89.3-104.2) 
Female 141 104.3 135.1 (113.7-159.4)   Female 734 733.4 100.1 (93.0-107.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
257 
Richmond 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 3.3 nc (nc-nc)   Male 0 1.9 nc (nc-nc) 
Female 2 1.0 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.5 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.7 nc (nc-nc) 
Female 7 10.1 69.6 (27.9-143.5)   Female 1 1.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 3.1 nc (nc-nc)             
Female 2 2.6 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.8 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 12 9.9 121.2 (62.6-211.7) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.7 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Larynx            Testis     
Male 0 0.5 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 1.2 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.1 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 0 2.4 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 5.8 nc (nc-nc)   Male 19 39.6 48.0 (28.9-75.0) 
Female 0 5.2 nc (nc-nc)   Female 17 34.1 49.9 (29.0-79.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
258 
Rochester 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 6.0 83.3 (26.9-194.4)   Male 3 4.0 nc (nc-nc) 
Female 3 1.8 nc (nc-nc)   Female 0 2.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.2 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 2 0.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 3 3.5 nc (nc-nc) 
Female 26 23.3 111.5 (72.8-163.4)   Female 2 2.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 3.2 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 6.5 nc (nc-nc)             
Female 10 5.5 182.7 (87.4-335.9)   Female 1 2.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.7 nc (nc-nc)   Male 3 2.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 2 1.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 26 20.7 125.4 (81.9-183.8) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 3.8 156.4 (57.1-340.4)   Male 1 1.5 nc (nc-nc) 
Female 2 1.8 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Larynx            Testis     
Male 0 1.0 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 2.5 nc (nc-nc)   Male 1 1.7 nc (nc-nc) 
Female 2 1.6 nc (nc-nc)   Female 3 4.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 2.4 nc (nc-nc)             
Female 0 0.7 nc (nc-nc)   Female 4 5.4 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 9 11.0 81.8 (37.3-155.4)   Male 81 81.8 99.1 (78.7-123.1) 
Female 6 9.3 64.2 (23.4-139.8)   Female 73 74.6 97.9 (76.7-123.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
259 
Rockland 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 26 18.5 140.3 (91.6-205.6)   Male 16 12.0 132.8 (75.9-215.7) 
Female 9 7.2 124.8 (57.0-236.9)   Female 14 9.8 142.2 (77.7-238.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 3.7 162.5 (59.3-353.7)   Male 4 3.9 nc (nc-nc) 
Female 4 3.2 nc (nc-nc)   Female 1 3.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.7 nc (nc-nc)   Male 10 10.8 93.0 (44.5-171.0) 
Female 82 80.8 101.5 (80.8-126.0)   Female 18 9.8 183.2 (108.5-289.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 9.0 122.1 (60.9-218.5) 
Female 1 2.5 nc (nc-nc)   Female 5 4.4 113.8 (36.7-265.5) 
Colon / Rectum            Ovary     
Male 26 19.6 132.6 (86.6-194.3)             
Female 25 20.1 124.4 (80.5-183.7)   Female 7 6.9 101.0 (40.4-208.0) 
Esophagus            Pancreas     
Male 10 4.8 208.7 (99.9-383.9)   Male 6 6.9 86.7 (31.6-188.7) 
Female 1 1.4 nc (nc-nc)   Female 11 7.5 146.6 (73.1-262.4) 
Hodgkin Lymphoma            Prostate     
Male 1 1.5 nc (nc-nc)   Male 60 57.8 103.8 (79.2-133.6) 
Female 2 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 17 11.0 155.2 (90.3-248.5)   Male 4 4.4 nc (nc-nc) 
Female 15 6.5 231.0 (129.2-381.0)   Female 7 2.8 248.6 (99.6-512.1) 
Larynx            Testis     
Male 4 2.8 nc (nc-nc)   Male 2 3.0 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 7.5 119.4 (54.5-226.7)   Male 3 5.0 nc (nc-nc) 
Female 8 5.7 139.6 (60.1-275.2)   Female 17 14.2 119.7 (69.7-191.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 6.7 74.5 (24.0-173.9)             
Female 4 2.4 nc (nc-nc)   Female 23 18.8 122.2 (77.4-183.3) 
Lung and Bronchus            All Sites / Types     
Male 32 32.8 97.5 (66.6-137.6)   Male 276 241.3 114.4 (101.3-128.7) 
Female 50 38.7 129.3 (96.0-170.5)   Female 330 269.5 122.4 (109.6-136.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
260 
Rockport 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 12.3 113.4 (62.0-190.4)   Male 5 7.4 68.0 (21.9-158.7) 
Female 2 5.0 nc (nc-nc)   Female 7 5.8 120.5 (48.3-248.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.9 nc (nc-nc)   Male 2 2.5 nc (nc-nc) 
Female 3 1.8 nc (nc-nc)   Female 3 2.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.4 nc (nc-nc)   Male 3 6.4 nc (nc-nc) 
Female 50 47.9 104.3 (77.4-137.5)   Female 4 6.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 5.3 93.8 (30.2-218.8) 
Female 0 1.3 nc (nc-nc)   Female 5 2.8 181.0 (58.3-422.3) 
Colon / Rectum            Ovary     
Male 9 11.9 75.6 (34.5-143.5)             
Female 6 13.6 44.2 (16.1-96.2)   Female 5 4.2 119.5 (38.5-278.9) 
Esophagus            Pancreas     
Male 1 3.1 nc (nc-nc)   Male 2 4.4 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 3 5.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.6 nc (nc-nc)   Male 39 37.1 105.2 (74.8-143.8) 
Female 2 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 6.5 154.0 (73.7-283.3)   Male 0 2.8 nc (nc-nc) 
Female 5 4.0 124.7 (40.2-291.0)   Female 0 1.9 nc (nc-nc) 
Larynx            Testis     
Male 0 1.8 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 4.5 134.0 (48.9-291.7)   Male 0 2.4 nc (nc-nc) 
Female 4 3.7 nc (nc-nc)   Female 5 6.8 73.9 (23.8-172.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 4.1 nc (nc-nc)             
Female 1 1.6 nc (nc-nc)   Female 8 11.2 71.3 (30.7-140.4) 
Lung and Bronchus            All Sites / Types     
Male 20 21.7 92.0 (56.2-142.2)   Male 137 149.4 91.7 (77.0-108.4) 
Female 14 26.0 53.8 (29.4-90.3)   Female 143 167.9 85.2 (71.8-100.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Rowe 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 0.7 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.1 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 2.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 0.7 nc (nc-nc)             
Female 1 0.6 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.2 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 1 2.4 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.3 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 1.3 nc (nc-nc)   Male 5 9.4 53.4 (17.2-124.6) 
Female 0 1.3 nc (nc-nc)   Female 2 8.9 nc (nc-nc) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Rowley 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 6.7 89.2 (32.6-194.1)   Male 6 4.6 131.1 (47.9-285.3) 
Female 6 2.4 252.4 (92.2-549.4)   Female 7 3.6 196.3 (78.7-404.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.3 nc (nc-nc)   Male 2 1.5 nc (nc-nc) 
Female 2 1.1 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 5 4.0 126.1 (40.6-294.2) 
Female 31 28.5 108.8 (73.9-154.4)   Female 4 3.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 3.6 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 3 1.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 8 7.4 108.6 (46.7-213.9)             
Female 7 7.1 97.9 (39.2-201.8)   Female 4 2.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.8 nc (nc-nc)   Male 4 2.6 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 3 2.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 20 22.8 87.7 (53.6-135.5) 
Female 1 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 4.3 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 1 2.2 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Larynx            Testis     
Male 1 1.1 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 2.8 nc (nc-nc)   Male 1 1.9 nc (nc-nc) 
Female 0 2.0 nc (nc-nc)   Female 6 5.6 107.9 (39.4-234.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 2.7 nc (nc-nc)             
Female 1 0.8 nc (nc-nc)   Female 4 6.3 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 10 12.4 80.8 (38.7-148.7)   Male 81 91.6 88.4 (70.2-109.9) 
Female 7 12.4 56.5 (22.6-116.3)   Female 94 93.4 100.7 (81.3-123.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Royalston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 1.5 nc (nc-nc)   Male 2 1.0 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.3 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 0.9 nc (nc-nc) 
Female 7 6.2 112.0 (44.9-230.8)   Female 2 0.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 0.8 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 1.7 295.1 (95.1-688.6)             
Female 0 1.4 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.4 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 10 5.3 189.2 (90.6-347.9) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.0 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.6 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.6 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 2.7 nc (nc-nc)   Male 27 20.8 129.9 (85.6-189.0) 
Female 1 2.7 nc (nc-nc)   Female 17 19.8 85.9 (50.0-137.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Russell 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.6 nc (nc-nc)   Male 3 1.1 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 2 0.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 10 7.2 139.5 (66.8-256.5)   Female 0 0.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.9 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 1.8 332.1 (121.3-722.9)             
Female 3 1.6 nc (nc-nc)   Female 2 0.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.4 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 5 5.4 92.3 (29.8-215.5) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 1.1 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.7 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.6 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 0 1.6 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 3.0 nc (nc-nc)   Male 23 22.1 104.1 (66.0-156.3) 
Female 3 3.0 nc (nc-nc)   Female 25 22.7 110.0 (71.2-162.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Rutland 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 6.9 nc (nc-nc)   Male 6 5.0 120.6 (44.1-262.6) 
Female 2 2.3 nc (nc-nc)   Female 1 3.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.7 nc (nc-nc)   Male 3 1.6 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 6 4.5 134.1 (49.0-291.9) 
Female 38 32.7 116.2 (82.2-159.5)   Female 2 3.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 4.2 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 0 1.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 11 8.2 134.7 (67.1-241.0)             
Female 9 7.0 128.8 (58.8-244.4)   Female 2 2.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 2.0 nc (nc-nc)   Male 3 2.8 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 5 2.4 207.0 (66.7-483.1) 
Hodgkin Lymphoma            Prostate     
Male 1 0.7 nc (nc-nc)   Male 24 26.2 91.6 (58.7-136.3) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 5.0 nc (nc-nc)   Male 1 1.8 nc (nc-nc) 
Female 2 2.5 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Larynx            Testis     
Male 2 1.2 nc (nc-nc)   Male 3 1.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 3.2 220.5 (88.3-454.3)   Male 0 2.5 nc (nc-nc) 
Female 2 2.0 nc (nc-nc)   Female 6 6.6 90.5 (33.1-197.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 2.9 nc (nc-nc)             
Female 1 0.9 nc (nc-nc)   Female 6 7.6 79.4 (29.0-172.7) 
Lung and Bronchus            All Sites / Types     
Male 18 12.5 143.6 (85.1-227.0)   Male 103 101.9 101.1 (82.5-122.6) 
Female 7 13.0 53.7 (21.5-110.6)   Female 92 102.0 90.2 (72.7-110.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Salem 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 39 35.0 111.4 (79.2-152.3)   Male 33 23.4 141.1 (97.1-198.2) 
Female 13 16.1 80.6 (42.9-137.9)   Female 26 23.0 113.2 (73.9-165.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 10 7.4 134.3 (64.3-247.0)   Male 4 7.3 nc (nc-nc) 
Female 3 7.6 nc (nc-nc)   Female 14 7.5 185.8 (101.5-311.8) 
Breast            Non-Hodgkin Lymphoma     
Male 3 1.3 nc (nc-nc)   Male 21 20.9 100.5 (62.2-153.6) 
Female 164 179.7 91.3 (77.8-106.4)   Female 23 22.3 103.1 (65.4-154.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 24 17.6 136.2 (87.2-202.6) 
Female 6 6.0 100.4 (36.7-218.6)   Female 17 9.9 171.9 (100.1-275.2) 
Colon / Rectum            Ovary     
Male 35 38.2 91.7 (63.9-127.5)             
Female 35 46.1 75.9 (52.8-105.5)   Female 12 15.7 76.3 (39.4-133.3) 
Esophagus            Pancreas     
Male 12 9.0 133.7 (69.0-233.6)   Male 11 13.2 83.4 (41.6-149.2) 
Female 5 3.1 159.8 (51.5-373.0)   Female 15 16.7 89.6 (50.1-147.7) 
Hodgkin Lymphoma            Prostate     
Male 2 3.3 nc (nc-nc)   Male 145 108.0 134.3 (113.3-158.0) 
Female 8 3.3 240.5 (103.6-473.9)             
Kidney & Renal Pelvis            Stomach     
Male 24 21.3 112.6 (72.1-167.6)   Male 13 8.4 154.9 (82.4-265.0) 
Female 13 14.5 89.9 (47.8-153.7)   Female 3 6.5 nc (nc-nc) 
Larynx            Testis     
Male 6 5.3 113.2 (41.3-246.4)   Male 7 6.4 109.8 (44.0-226.2) 
Female 5 2.0 250.7 (80.8-585.0)             
Leukemia            Thyroid     
Male 13 15.0 86.8 (46.2-148.4)   Male 10 10.2 97.7 (46.8-179.6) 
Female 13 13.4 97.4 (51.8-166.5)   Female 43 34.8 123.4 (89.3-166.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 17 12.8 132.3 (77.0-211.8)             
Female 2 5.5 nc (nc-nc)   Female 44 41.0 107.4 (78.0-144.1) 
Lung and Bronchus            All Sites / Types     
Male 77 61.7 124.7 (98.4-155.9)   Male 549 462.5 118.7 (109.0-129.1) 
Female 89 84.0 106.0 (85.1-130.4)   Female 614 607.6 101.1 (93.2-109.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Salisbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 10.6 113.6 (58.6-198.4)   Male 11 6.8 162.8 (81.2-291.3) 
Female 4 3.6 nc (nc-nc)   Female 4 5.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 2.0 nc (nc-nc)   Male 2 2.2 nc (nc-nc) 
Female 1 1.7 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 6 6.0 99.9 (36.5-217.4) 
Female 41 43.5 94.2 (67.6-127.8)   Female 6 5.0 119.8 (43.7-260.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 13 5.2 249.4 (132.7-426.5) 
Female 1 1.4 nc (nc-nc)   Female 4 2.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 13 11.0 118.5 (63.0-202.6)             
Female 14 10.1 138.0 (75.4-231.6)   Female 7 3.6 192.9 (77.3-397.6) 
Esophagus            Pancreas     
Male 1 2.8 nc (nc-nc)   Male 5 4.0 125.7 (40.5-293.3) 
Female 1 0.7 nc (nc-nc)   Female 6 3.7 161.1 (58.8-350.6) 
Hodgkin Lymphoma            Prostate     
Male 0 0.7 nc (nc-nc)   Male 30 35.2 85.3 (57.5-121.8) 
Female 2 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 6.3 78.8 (25.4-184.0)   Male 4 2.5 nc (nc-nc) 
Female 4 3.4 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Larynx            Testis     
Male 0 1.6 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 4.2 nc (nc-nc)   Male 1 2.7 nc (nc-nc) 
Female 2 2.9 nc (nc-nc)   Female 9 7.8 116.1 (53.0-220.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 3.9 nc (nc-nc)             
Female 2 1.2 nc (nc-nc)   Female 12 10.2 117.3 (60.6-205.0) 
Lung and Bronchus            All Sites / Types     
Male 25 19.1 131.2 (84.9-193.7)   Male 141 138.5 101.8 (85.7-120.1) 
Female 28 19.4 144.0 (95.6-208.1)   Female 163 140.6 115.9 (98.8-135.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Sandisfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 2.2 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.0 nc (nc-nc) 
Female 1 4.5 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.8 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 2.0 nc (nc-nc)             
Female 1 1.0 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.5 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 2 5.0 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.9 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.7 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 2 0.3 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.6 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 3.5 nc (nc-nc)   Male 7 23.0 30.4 (12.2-62.6) 
Female 3 2.0 nc (nc-nc)   Female 8 14.3 55.8 (24.0-110.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
269 
Sandwich 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 34 25.8 131.5 (91.1-183.8)   Male 19 16.3 116.2 (69.9-181.5) 
Female 9 9.4 95.4 (43.5-181.1)   Female 16 12.8 125.3 (71.6-203.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 9 4.6 195.3 (89.1-370.7)   Male 8 5.3 149.6 (64.4-294.7) 
Female 7 4.2 168.2 (67.4-346.5)   Female 2 4.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.9 nc (nc-nc)   Male 21 14.5 145.2 (89.9-222.0) 
Female 122 106.0 115.0 (95.5-137.4)   Female 15 12.9 116.3 (65.0-191.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 12.3 89.4 (44.6-160.0) 
Female 2 3.2 nc (nc-nc)   Female 7 5.7 122.0 (48.9-251.4) 
Colon / Rectum            Ovary     
Male 22 26.6 82.7 (51.8-125.3)             
Female 22 26.2 83.8 (52.5-126.9)   Female 10 9.1 110.5 (52.9-203.2) 
Esophagus            Pancreas     
Male 5 6.6 75.5 (24.3-176.2)   Male 15 9.6 155.9 (87.2-257.2) 
Female 5 1.9 267.0 (86.0-623.0)   Female 9 9.7 92.6 (42.2-175.7) 
Hodgkin Lymphoma            Prostate     
Male 0 1.6 nc (nc-nc)   Male 83 80.5 103.1 (82.1-127.8) 
Female 2 1.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 14.8 67.4 (32.3-124.0)   Male 6 6.0 99.3 (36.3-216.1) 
Female 7 8.5 82.6 (33.1-170.2)   Female 4 3.7 nc (nc-nc) 
Larynx            Testis     
Male 4 3.9 nc (nc-nc)   Male 4 2.6 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 10.1 89.3 (40.8-169.6)   Male 1 6.2 nc (nc-nc) 
Female 6 7.4 80.6 (29.4-175.5)   Female 10 18.0 55.4 (26.5-102.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 9.3 75.0 (30.1-154.6)             
Female 1 3.2 nc (nc-nc)   Female 28 24.7 113.2 (75.2-163.6) 
Lung and Bronchus            All Sites / Types     
Male 33 45.7 72.2 (49.7-101.4)   Male 332 328.9 100.9 (90.4-112.4) 
Female 47 50.3 93.4 (68.7-124.3)   Female 356 351.7 101.2 (91.0-112.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
270 
Saugus 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 53 33.5 158.1 (118.4-206.8)   Male 15 21.2 70.6 (39.5-116.5) 
Female 18 13.9 129.4 (76.6-204.5)   Female 20 18.1 110.4 (67.4-170.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 5.9 117.9 (47.2-242.9)   Male 5 6.9 73.0 (23.5-170.3) 
Female 7 5.8 121.0 (48.5-249.4)   Female 5 6.4 78.0 (25.1-182.0) 
Breast            Non-Hodgkin Lymphoma     
Male 3 1.2 nc (nc-nc)   Male 36 18.8 191.6 (134.1-265.2) 
Female 145 147.6 98.2 (82.9-115.6)   Female 24 18.7 128.6 (82.4-191.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 20 15.4 130.0 (79.3-200.7) 
Female 2 4.5 nc (nc-nc)   Female 8 8.2 98.1 (42.3-193.4) 
Colon / Rectum            Ovary     
Male 48 34.6 138.7 (102.3-183.9)             
Female 27 38.9 69.5 (45.8-101.1)   Female 5 12.8 39.1 (12.6-91.3) 
Esophagus            Pancreas     
Male 16 8.3 192.8 (110.1-313.1)   Male 18 12.3 145.8 (86.3-230.4) 
Female 6 2.7 222.1 (81.1-483.3)   Female 13 14.5 89.5 (47.6-153.1) 
Hodgkin Lymphoma            Prostate     
Male 1 2.2 nc (nc-nc)   Male 79 97.2 81.3 (64.3-101.3) 
Female 4 2.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 24 18.8 127.9 (81.9-190.3)   Male 3 7.8 nc (nc-nc) 
Female 8 12.0 66.8 (28.8-131.7)   Female 2 5.4 nc (nc-nc) 
Larynx            Testis     
Male 6 4.9 122.8 (44.8-267.3)   Male 10 4.0 253.0 (121.1-465.4) 
Female 0 1.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 17 13.0 130.5 (76.0-209.0)   Male 8 8.1 98.7 (42.5-194.5) 
Female 3 10.7 nc (nc-nc)   Female 22 24.7 88.9 (55.7-134.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 21 11.6 181.5 (112.3-277.4)             
Female 5 4.6 109.9 (35.4-256.4)   Female 37 34.1 108.6 (76.4-149.6) 
Lung and Bronchus            All Sites / Types     
Male 67 58.7 114.2 (88.5-145.0)   Male 506 417.9 121.1 (110.8-132.1) 
Female 89 72.9 122.1 (98.1-150.3)   Female 489 500.6 97.7 (89.2-106.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Savoy 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.2 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 2 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 3 3.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 1.2 nc (nc-nc)             
Female 1 0.7 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 1 0.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 1 3.6 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 0.7 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 1 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 1 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.5 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 2 0.6 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.4 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 2.1 nc (nc-nc)   Male 7 15.0 46.8 (18.7-96.4) 
Female 1 1.3 nc (nc-nc)   Female 11 10.0 110.3 (55.0-197.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Scituate 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 23 23.2 99.0 (62.8-148.6)   Male 46 14.6 315.9 (231.3-421.4) 
Female 12 8.9 134.9 (69.6-235.7)   Female 27 12.0 225.1 (148.3-327.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 4.1 196.1 (84.4-386.5)   Male 7 4.7 149.0 (59.7-307.1) 
Female 2 3.8 nc (nc-nc)   Female 2 4.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.8 nc (nc-nc)   Male 7 12.8 54.7 (21.9-112.7) 
Female 95 98.7 96.3 (77.9-117.7)   Female 9 12.0 74.8 (34.1-141.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 10.6 84.8 (38.7-161.0) 
Female 0 3.1 nc (nc-nc)   Female 5 5.4 93.4 (30.1-218.0) 
Colon / Rectum            Ovary     
Male 20 23.7 84.2 (51.4-130.1)             
Female 20 25.8 77.5 (47.3-119.7)   Female 9 8.4 106.8 (48.7-202.7) 
Esophagus            Pancreas     
Male 11 5.7 191.4 (95.4-342.4)   Male 7 8.5 82.5 (33.1-170.0) 
Female 4 1.7 nc (nc-nc)   Female 1 9.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 4 1.4 nc (nc-nc)   Male 59 67.3 87.7 (66.7-113.1) 
Female 0 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 11 12.9 85.1 (42.4-152.2)   Male 5 5.4 93.2 (30.0-217.6) 
Female 7 7.8 89.3 (35.8-183.9)   Female 6 3.6 165.6 (60.5-360.5) 
Larynx            Testis     
Male 3 3.3 nc (nc-nc)   Male 2 2.4 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 9.1 99.3 (45.3-188.4)   Male 2 5.5 nc (nc-nc) 
Female 5 7.1 70.0 (22.5-163.3)   Female 16 17.2 93.3 (53.3-151.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 9 8.0 112.7 (51.4-214.0)             
Female 4 3.0 nc (nc-nc)   Female 23 21.9 104.9 (66.5-157.3) 
Lung and Bronchus            All Sites / Types     
Male 33 40.3 81.8 (56.3-114.9)   Male 301 287.4 104.7 (93.2-117.3) 
Female 48 45.8 104.8 (77.3-138.9)   Female 316 329.1 96.0 (85.7-107.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Seekonk 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 18.0 61.0 (30.4-109.2)   Male 7 11.6 60.2 (24.1-124.1) 
Female 1 6.1 nc (nc-nc)   Female 9 8.8 101.8 (46.5-193.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 3.3 nc (nc-nc)   Male 2 3.8 nc (nc-nc) 
Female 1 2.9 nc (nc-nc)   Female 1 2.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.6 nc (nc-nc)   Male 14 10.1 138.3 (75.6-232.1) 
Female 40 74.0 54.0 (38.6-73.6)   Female 4 8.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 8.8 nc (nc-nc) 
Female 1 2.4 nc (nc-nc)   Female 4 3.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 14 18.5 75.6 (41.3-126.9)             
Female 9 17.2 52.3 (23.9-99.4)   Female 6 6.3 95.9 (35.0-208.8) 
Esophagus            Pancreas     
Male 0 4.7 nc (nc-nc)   Male 5 6.7 74.2 (23.9-173.1) 
Female 0 1.2 nc (nc-nc)   Female 8 6.2 128.0 (55.1-252.3) 
Hodgkin Lymphoma            Prostate     
Male 0 1.2 nc (nc-nc)   Male 35 58.4 59.9 (41.7-83.3) 
Female 0 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 10.7 nc (nc-nc)   Male 3 4.3 nc (nc-nc) 
Female 0 5.8 nc (nc-nc)   Female 1 2.4 nc (nc-nc) 
Larynx            Testis     
Male 1 2.8 nc (nc-nc)   Male 0 2.1 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 7.0 99.8 (40.0-205.7)   Male 0 4.5 nc (nc-nc) 
Female 2 4.9 nc (nc-nc)   Female 10 13.5 74.2 (35.5-136.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 6.5 nc (nc-nc)             
Female 0 2.1 nc (nc-nc)   Female 9 17.4 51.7 (23.6-98.2) 
Lung and Bronchus            All Sites / Types     
Male 23 33.1 69.5 (44.0-104.3)   Male 153 234.3 65.3 (55.4-76.5) 
Female 26 33.1 78.5 (51.2-115.0)   Female 144 239.6 60.1 (50.7-70.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Sharon 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 20.5 53.7 (26.8-96.2)   Male 13 13.5 96.1 (51.1-164.4) 
Female 7 6.0 116.4 (46.6-239.8)   Female 17 9.6 176.2 (102.6-282.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 4.0 125.9 (40.6-293.9)   Male 3 4.4 nc (nc-nc) 
Female 0 3.1 nc (nc-nc)   Female 1 3.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.8 nc (nc-nc)   Male 12 11.9 100.7 (52.0-176.0) 
Female 88 81.0 108.6 (87.1-133.8)   Female 7 9.0 78.2 (31.3-161.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 10.7 74.6 (32.1-147.0) 
Female 0 2.8 nc (nc-nc)   Female 1 4.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 11 22.4 49.2 (24.5-88.1)             
Female 12 18.3 65.5 (33.8-114.5)   Female 5 6.7 74.3 (23.9-173.3) 
Esophagus            Pancreas     
Male 3 5.5 nc (nc-nc)   Male 10 7.9 127.4 (61.0-234.2) 
Female 2 1.2 nc (nc-nc)   Female 9 6.3 143.1 (65.3-271.7) 
Hodgkin Lymphoma            Prostate     
Male 1 1.3 nc (nc-nc)   Male 57 68.1 83.7 (63.4-108.4) 
Female 1 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 12.9 54.4 (21.8-112.1)   Male 6 5.0 121.0 (44.2-263.4) 
Female 7 6.1 115.3 (46.2-237.5)   Female 4 2.5 nc (nc-nc) 
Larynx            Testis     
Male 1 3.2 nc (nc-nc)   Male 4 2.4 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 8 8.3 96.4 (41.5-189.9)   Male 8 5.6 142.5 (61.3-280.7) 
Female 4 5.2 nc (nc-nc)   Female 24 15.9 150.9 (96.7-224.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 7.7 64.6 (20.8-150.7)             
Female 3 2.1 nc (nc-nc)   Female 22 18.3 119.9 (75.1-181.6) 
Lung and Bronchus            All Sites / Types     
Male 20 36.7 54.5 (33.3-84.1)   Male 213 273.3 77.9 (67.8-89.1) 
Female 44 32.5 135.5 (98.4-181.9)   Female 275 254.6 108.0 (95.6-121.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Sheffield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 5.8 86.0 (27.7-200.8)   Male 2 3.4 nc (nc-nc) 
Female 0 1.6 nc (nc-nc)   Female 0 2.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.9 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 4 3.0 nc (nc-nc) 
Female 15 17.7 84.8 (47.4-139.9)   Female 1 2.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 2.4 246.0 (89.8-535.5) 
Female 0 0.5 nc (nc-nc)   Female 3 1.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 5.7 87.7 (28.3-204.7)             
Female 5 4.4 113.3 (36.5-264.3)   Female 0 1.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.4 nc (nc-nc)   Male 0 2.1 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 16 16.7 95.9 (54.8-155.8) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 3.0 nc (nc-nc)   Male 2 1.3 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Larynx            Testis     
Male 0 0.8 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 2.1 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 1 2.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 1.8 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 5 4.3 117.4 (37.8-274.0) 
Lung and Bronchus            All Sites / Types     
Male 6 10.2 59.1 (21.6-128.6)   Male 54 69.4 77.9 (58.5-101.6) 
Female 13 8.6 150.7 (80.2-257.7)   Female 56 59.1 94.7 (71.5-123.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Shelburne 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 3.0 nc (nc-nc)   Male 2 1.9 nc (nc-nc) 
Female 2 1.1 nc (nc-nc)   Female 2 1.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 0.5 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 2 0.4 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.7 nc (nc-nc) 
Female 11 11.6 95.0 (47.3-169.9)   Female 2 1.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 1.5 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 3.1 nc (nc-nc)             
Female 2 2.9 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.8 nc (nc-nc)   Male 2 1.1 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 10 9.9 100.8 (48.2-185.3) 
Female 1 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.8 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Larynx            Testis     
Male 0 0.5 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.1 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 1 1.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.1 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 5 2.8 176.3 (56.8-411.3) 
Lung and Bronchus            All Sites / Types     
Male 2 5.5 nc (nc-nc)   Male 35 38.9 90.0 (62.7-125.2) 
Female 4 5.8 nc (nc-nc)   Female 38 38.9 97.6 (69.1-134.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Sherborn 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 6.0 201.0 (103.7-351.1)   Male 6 3.7 163.4 (59.7-355.7) 
Female 3 1.7 nc (nc-nc)   Female 1 2.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.0 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 2 3.2 nc (nc-nc) 
Female 19 20.6 92.2 (55.5-144.1)   Female 5 2.4 210.9 (68.0-492.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 2.7 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 6.1 147.0 (67.1-279.1)             
Female 3 5.0 nc (nc-nc)   Female 5 1.8 283.5 (91.4-661.6) 
Esophagus            Pancreas     
Male 0 1.5 nc (nc-nc)   Male 5 2.2 230.3 (74.2-537.5) 
Female 1 0.3 nc (nc-nc)   Female 4 1.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 9 17.3 51.9 (23.7-98.5) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 3.3 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 0 1.6 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Larynx            Testis     
Male 0 0.8 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 2.3 nc (nc-nc)   Male 2 1.3 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 2 3.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.0 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 3 4.6 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 6 10.3 58.3 (21.3-126.9)   Male 62 73.1 84.8 (65.0-108.7) 
Female 4 9.0 nc (nc-nc)   Female 55 66.6 82.6 (62.2-107.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Shirley 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 7.1 196.9 (107.5-330.3)   Male 4 5.3 nc (nc-nc) 
Female 7 2.3 303.2 (121.5-624.7)   Female 1 3.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.7 nc (nc-nc)   Male 3 1.6 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 9 4.7 192.0 (87.6-364.5) 
Female 27 28.2 95.7 (63.0-139.2)   Female 3 3.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 4.3 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 3 1.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 11 8.6 127.7 (63.7-228.5)             
Female 8 6.6 121.8 (52.5-240.1)   Female 3 2.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 5 2.0 249.7 (80.5-582.8)   Male 1 2.9 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 2 2.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.8 nc (nc-nc)   Male 26 24.7 105.2 (68.7-154.1) 
Female 1 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 5.1 117.5 (42.9-255.7)   Male 0 1.8 nc (nc-nc) 
Female 3 2.2 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Larynx            Testis     
Male 0 1.2 nc (nc-nc)   Male 1 1.9 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 3.2 nc (nc-nc)   Male 2 2.7 nc (nc-nc) 
Female 1 1.8 nc (nc-nc)   Female 5 5.2 95.5 (30.8-222.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 3.0 197.2 (72.0-429.2)             
Female 0 0.8 nc (nc-nc)   Female 12 6.5 183.8 (94.9-321.0) 
Lung and Bronchus            All Sites / Types     
Male 13 13.1 99.2 (52.8-169.7)   Male 115 104.0 110.6 (91.3-132.7) 
Female 10 12.7 78.9 (37.8-145.2)   Female 98 91.2 107.5 (87.2-131.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Shrewsbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 44 36.9 119.2 (86.6-160.0)   Male 19 23.9 79.5 (47.8-124.2) 
Female 12 13.0 92.4 (47.7-161.4)   Female 21 19.0 110.8 (68.6-169.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 7.2 nc (nc-nc)   Male 9 7.6 118.0 (53.9-224.1) 
Female 2 6.3 nc (nc-nc)   Female 7 6.0 116.1 (46.5-239.3) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.3 nc (nc-nc)   Male 19 21.3 89.3 (53.7-139.4) 
Female 175 152.8 114.5 (98.2-132.8)   Female 13 18.2 71.4 (38.0-122.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 16 17.6 90.7 (51.8-147.4) 
Female 7 5.4 130.2 (52.2-268.4)   Female 5 8.0 62.3 (20.1-145.5) 
Colon / Rectum            Ovary     
Male 42 39.5 106.4 (76.7-143.9)             
Female 30 38.0 78.9 (53.2-112.6)   Female 13 12.9 101.1 (53.8-172.9) 
Esophagus            Pancreas     
Male 6 9.3 64.8 (23.7-141.0)   Male 11 13.6 80.6 (40.2-144.3) 
Female 5 2.5 197.5 (63.6-460.9)   Female 11 13.5 81.7 (40.7-146.2) 
Hodgkin Lymphoma            Prostate     
Male 2 2.8 nc (nc-nc)   Male 113 108.2 104.5 (86.1-125.6) 
Female 2 2.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 29 21.5 134.7 (90.2-193.5)   Male 5 8.7 57.3 (18.5-133.8) 
Female 8 12.0 66.7 (28.7-131.5)   Female 5 5.3 93.6 (30.2-218.4) 
Larynx            Testis     
Male 5 5.4 93.3 (30.1-217.8)   Male 4 5.4 nc (nc-nc) 
Female 0 1.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 19 15.1 125.9 (75.8-196.6)   Male 15 10.0 149.7 (83.7-247.0) 
Female 13 10.8 120.2 (64.0-205.6)   Female 27 30.0 90.0 (59.3-130.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 17 12.9 132.3 (77.0-211.8)             
Female 4 4.3 nc (nc-nc)   Female 29 33.1 87.7 (58.7-126.0) 
Lung and Bronchus            All Sites / Types     
Male 55 63.7 86.4 (65.0-112.4)   Male 479 469.9 101.9 (93.0-111.5) 
Female 65 68.6 94.8 (73.2-120.8)   Female 501 503.0 99.6 (91.1-108.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
280 
Shutesbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.8 nc (nc-nc)   Male 2 1.3 nc (nc-nc) 
Female 2 0.6 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 7 9.0 77.8 (31.2-160.4)   Female 1 1.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.1 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 2.1 nc (nc-nc)             
Female 2 1.9 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.5 nc (nc-nc)   Male 3 0.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 1 7.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.3 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.8 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 2 1.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.8 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 3 2.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 0 3.4 nc (nc-nc)   Male 11 26.7 41.2 (20.6-73.8) 
Female 2 3.6 nc (nc-nc)   Female 22 27.8 79.2 (49.6-119.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
281 
Somerset 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 36 28.3 127.2 (89.1-176.1)   Male 12 16.9 71.1 (36.7-124.2) 
Female 11 9.5 116.0 (57.8-207.5)   Female 8 11.7 68.3 (29.4-134.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 4.6 130.7 (47.7-284.5)   Male 1 5.5 nc (nc-nc) 
Female 4 3.7 nc (nc-nc)   Female 6 4.3 141.2 (51.5-307.3) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.9 nc (nc-nc)   Male 15 14.9 100.7 (56.3-166.0) 
Female 79 94.3 83.7 (66.3-104.4)   Female 18 12.3 146.0 (86.5-230.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 11.6 85.9 (41.1-157.9) 
Female 0 2.9 nc (nc-nc)   Female 4 5.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 27 27.5 98.1 (64.7-142.8)             
Female 30 26.2 114.7 (77.4-163.8)   Female 9 8.2 109.7 (50.1-208.3) 
Esophagus            Pancreas     
Male 8 6.7 120.1 (51.7-236.7)   Male 12 10.0 120.0 (61.9-209.6) 
Female 1 1.8 nc (nc-nc)   Female 12 9.9 121.3 (62.6-211.9) 
Hodgkin Lymphoma            Prostate     
Male 3 1.6 nc (nc-nc)   Male 72 77.5 93.0 (72.7-117.1) 
Female 0 1.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 12 14.4 83.1 (42.9-145.2)   Male 11 6.3 173.9 (86.7-311.1) 
Female 5 7.8 64.0 (20.6-149.5)   Female 6 3.7 163.1 (59.6-355.1) 
Larynx            Testis     
Male 5 3.8 131.9 (42.5-307.8)   Male 5 2.7 186.1 (60.0-434.4) 
Female 1 1.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 11 10.6 103.9 (51.8-185.9)   Male 6 5.8 104.1 (38.0-226.6) 
Female 9 7.1 126.3 (57.6-239.8)   Female 22 15.5 141.8 (88.9-214.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 8.9 67.3 (24.6-146.5)             
Female 1 3.0 nc (nc-nc)   Female 22 21.2 103.7 (65.0-157.0) 
Lung and Bronchus            All Sites / Types     
Male 48 48.4 99.2 (73.1-131.5)   Male 334 334.3 99.9 (89.5-111.2) 
Female 46 49.1 93.6 (68.5-124.9)   Female 321 327.2 98.1 (87.7-109.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
282 
Somerville 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 33 50.5 65.4 (45.0-91.8)   Male 29 34.5 84.1 (56.3-120.7) 
Female 17 19.8 85.8 (49.9-137.4)   Female 26 31.2 83.4 (54.5-122.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 9 12.5 72.1 (32.9-137.0)   Male 8 10.5 76.5 (32.9-150.8) 
Female 14 10.8 129.3 (70.6-216.9)   Female 10 9.2 108.8 (52.1-200.1) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.8 nc (nc-nc)   Male 36 31.7 113.6 (79.5-157.2) 
Female 195 222.1 87.8 (75.9-101.0)   Female 26 28.3 91.8 (59.9-134.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 21 24.7 85.0 (52.6-130.0) 
Female 12 8.3 144.7 (74.7-252.7)   Female 14 12.4 113.2 (61.8-189.9) 
Colon / Rectum            Ovary     
Male 52 54.7 95.1 (71.0-124.7)             
Female 45 57.1 78.9 (57.5-105.5)   Female 23 20.0 115.0 (72.9-172.6) 
Esophagus            Pancreas     
Male 11 12.7 86.7 (43.2-155.1)   Male 16 18.7 85.6 (48.9-139.0) 
Female 2 3.8 nc (nc-nc)   Female 24 20.5 116.9 (74.9-173.9) 
Hodgkin Lymphoma            Prostate     
Male 8 7.7 104.4 (45.0-205.8)   Male 137 148.6 92.2 (77.4-109.0) 
Female 5 6.7 74.3 (23.9-173.4)             
Kidney & Renal Pelvis            Stomach     
Male 30 30.3 99.2 (66.9-141.6)   Male 15 12.0 124.8 (69.8-205.9) 
Female 21 18.1 116.3 (71.9-177.7)   Female 13 8.1 160.6 (85.4-274.6) 
Larynx            Testis     
Male 6 7.4 80.8 (29.5-175.9)   Male 14 16.4 85.2 (46.5-142.9) 
Female 4 2.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 20 23.4 85.6 (52.3-132.2)   Male 20 17.2 116.2 (70.9-179.4) 
Female 17 17.8 95.4 (55.6-152.8)   Female 43 53.1 81.0 (58.6-109.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 22 17.9 122.7 (76.8-185.7)             
Female 12 6.7 179.2 (92.5-313.1)   Female 56 50.1 111.8 (84.5-145.2) 
Lung and Bronchus            All Sites / Types     
Male 117 87.2 134.1 (110.9-160.7)   Male 648 676.0 95.9 (88.6-103.5) 
Female 105 103.6 101.4 (82.9-122.7)   Female 751 771.6 97.3 (90.5-104.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
283 
South Hadley 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 13 20.5 63.5 (33.8-108.7)   Male 10 12.7 78.8 (37.7-144.9) 
Female 11 8.3 132.1 (65.8-236.3)   Female 11 10.6 104.0 (51.8-186.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 3.5 nc (nc-nc)   Male 2 4.1 nc (nc-nc) 
Female 3 3.7 nc (nc-nc)   Female 3 3.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.7 nc (nc-nc)   Male 7 11.2 62.4 (25.0-128.6) 
Female 91 85.0 107.1 (86.2-131.5)   Female 13 11.0 118.6 (63.1-202.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 9.1 54.9 (17.7-128.2) 
Female 4 2.6 nc (nc-nc)   Female 1 4.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 17 20.6 82.6 (48.1-132.3)             
Female 32 23.1 138.5 (94.8-195.6)   Female 8 7.5 106.6 (45.9-210.1) 
Esophagus            Pancreas     
Male 4 5.0 nc (nc-nc)   Male 2 7.5 nc (nc-nc) 
Female 2 1.6 nc (nc-nc)   Female 11 8.7 126.9 (63.2-227.0) 
Hodgkin Lymphoma            Prostate     
Male 2 1.3 nc (nc-nc)   Male 50 59.2 84.5 (62.7-111.4) 
Female 0 1.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 11.1 72.3 (31.1-142.4)   Male 4 4.7 nc (nc-nc) 
Female 6 7.0 85.3 (31.2-185.7)   Female 0 3.2 nc (nc-nc) 
Larynx            Testis     
Male 4 2.9 nc (nc-nc)   Male 3 2.3 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 7.8 89.6 (35.9-184.6)   Male 3 4.7 nc (nc-nc) 
Female 8 6.6 122.1 (52.6-240.6)   Female 16 14.5 110.3 (63.0-179.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 7.0 nc (nc-nc)             
Female 0 2.7 nc (nc-nc)   Female 27 19.4 139.0 (91.6-202.2) 
Lung and Bronchus            All Sites / Types     
Male 25 35.3 70.8 (45.8-104.5)   Male 194 251.3 77.2 (66.7-88.9) 
Female 36 43.1 83.5 (58.5-115.6)   Female 304 294.1 103.4 (92.1-115.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
284 
Southampton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 8.7 80.8 (32.4-166.6)   Male 1 5.2 nc (nc-nc) 
Female 2 2.4 nc (nc-nc)   Female 1 3.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.4 nc (nc-nc)   Male 0 1.7 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 2 4.7 nc (nc-nc) 
Female 30 30.3 99.0 (66.8-141.3)   Female 3 3.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 3.8 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 0 1.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 8.7 103.4 (47.2-196.3)             
Female 7 6.6 105.4 (42.2-217.2)   Female 1 2.5 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 2.2 nc (nc-nc)   Male 1 3.1 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 3 2.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 2 0.5 nc (nc-nc)   Male 21 25.8 81.5 (50.4-124.6) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 4.6 nc (nc-nc)   Male 4 2.0 nc (nc-nc) 
Female 4 2.3 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Larynx            Testis     
Male 3 1.2 nc (nc-nc)   Male 2 0.8 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 3.3 nc (nc-nc)   Male 2 1.9 nc (nc-nc) 
Female 2 1.9 nc (nc-nc)   Female 1 5.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 2.9 171.7 (55.3-400.7)             
Female 1 0.8 nc (nc-nc)   Female 9 7.2 124.4 (56.8-236.2) 
Lung and Bronchus            All Sites / Types     
Male 10 14.7 68.1 (32.6-125.3)   Male 83 106.0 78.3 (62.3-97.0) 
Female 13 13.4 97.2 (51.7-166.2)   Female 86 96.7 88.9 (71.1-109.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
285 
Southborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 9.9 70.4 (28.2-145.0)   Male 8 6.9 116.6 (50.2-229.7) 
Female 6 3.5 172.7 (63.1-376.0)   Female 4 5.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.1 nc (nc-nc)   Male 4 2.2 nc (nc-nc) 
Female 2 1.7 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 2 6.0 nc (nc-nc) 
Female 50 43.4 115.3 (85.5-152.0)   Female 4 4.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 5.5 nc (nc-nc) 
Female 1 1.5 nc (nc-nc)   Female 1 2.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 11.3 62.1 (24.9-128.0)             
Female 7 10.4 67.6 (27.1-139.2)   Female 1 3.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.7 nc (nc-nc)   Male 1 3.9 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 3 3.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 3 0.8 nc (nc-nc)   Male 27 33.1 81.7 (53.8-118.8) 
Female 1 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 6.5 107.6 (43.1-221.7)   Male 0 2.5 nc (nc-nc) 
Female 2 3.4 nc (nc-nc)   Female 1 1.4 nc (nc-nc) 
Larynx            Testis     
Male 3 1.6 nc (nc-nc)   Male 3 1.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 4.2 nc (nc-nc)   Male 4 3.1 nc (nc-nc) 
Female 4 2.9 nc (nc-nc)   Female 9 8.4 106.9 (48.8-202.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 3.9 nc (nc-nc)             
Female 1 1.2 nc (nc-nc)   Female 7 9.5 73.8 (29.6-152.2) 
Lung and Bronchus            All Sites / Types     
Male 12 17.9 67.2 (34.7-117.3)   Male 118 136.1 86.7 (71.8-103.8) 
Female 13 18.8 69.2 (36.8-118.4)   Female 126 139.7 90.2 (75.1-107.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
286 
Southbridge 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 13 17.5 74.2 (39.5-126.9)   Male 11 11.0 99.7 (49.7-178.5) 
Female 7 7.2 96.9 (38.8-199.7)   Female 3 9.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 3.3 nc (nc-nc)   Male 4 3.5 nc (nc-nc) 
Female 2 3.2 nc (nc-nc)   Female 6 3.3 180.8 (66.0-393.4) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.6 nc (nc-nc)   Male 13 9.9 131.9 (70.2-225.5) 
Female 57 76.8 74.2 (56.2-96.1)   Female 12 9.7 123.7 (63.8-216.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 8 7.9 101.9 (43.9-200.8) 
Female 3 2.5 nc (nc-nc)   Female 0 4.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 18 18.1 99.5 (58.9-157.3)             
Female 21 20.5 102.2 (63.2-156.2)   Female 14 6.7 209.8 (114.6-352.0) 
Esophagus            Pancreas     
Male 2 4.2 nc (nc-nc)   Male 6 6.3 94.5 (34.5-205.7) 
Female 0 1.4 nc (nc-nc)   Female 1 7.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 1.3 nc (nc-nc)   Male 50 48.5 103.0 (76.5-135.9) 
Female 4 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 9.6 104.0 (49.8-191.2)   Male 8 4.0 198.2 (85.3-390.5) 
Female 8 6.2 128.8 (55.4-253.7)   Female 3 2.9 nc (nc-nc) 
Larynx            Testis     
Male 7 2.4 288.2 (115.4-593.8)   Male 1 2.5 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 7.1 126.5 (57.7-240.2)   Male 2 4.4 nc (nc-nc) 
Female 10 5.8 171.9 (82.3-316.2)   Female 13 13.8 94.3 (50.1-161.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 8 5.9 136.2 (58.6-268.4)             
Female 2 2.4 nc (nc-nc)   Female 22 17.5 125.8 (78.8-190.4) 
Lung and Bronchus            All Sites / Types     
Male 45 29.7 151.7 (110.6-202.9)   Male 240 215.9 111.2 (97.6-126.2) 
Female 31 36.9 84.0 (57.1-119.2)   Female 241 262.3 91.9 (80.6-104.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
287 
Southwick 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 9 12.7 70.6 (32.2-134.0)   Male 5 7.8 64.1 (20.7-149.7) 
Female 4 4.3 nc (nc-nc)   Female 3 5.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.2 nc (nc-nc)   Male 1 2.5 nc (nc-nc) 
Female 1 1.9 nc (nc-nc)   Female 0 2.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 3 6.9 nc (nc-nc) 
Female 44 45.6 96.5 (70.1-129.6)   Female 4 5.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 5.5 109.4 (39.9-238.1) 
Female 0 1.5 nc (nc-nc)   Female 1 2.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 11 13.1 83.9 (41.8-150.1)             
Female 14 12.5 112.1 (61.3-188.2)   Female 4 3.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 3.0 nc (nc-nc)   Male 2 4.5 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 2 4.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.8 nc (nc-nc)   Male 29 34.4 84.3 (56.4-121.0) 
Female 1 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 6.7 119.1 (51.3-234.7)   Male 1 2.9 nc (nc-nc) 
Female 7 3.7 191.2 (76.6-393.9)   Female 2 1.8 nc (nc-nc) 
Larynx            Testis     
Male 2 1.7 nc (nc-nc)   Male 2 1.5 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 4.9 nc (nc-nc)   Male 3 3.0 nc (nc-nc) 
Female 6 3.5 173.6 (63.4-377.9)   Female 5 8.1 61.7 (19.9-144.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 4.1 nc (nc-nc)             
Female 3 1.4 nc (nc-nc)   Female 9 9.8 91.6 (41.8-173.9) 
Lung and Bronchus            All Sites / Types     
Male 18 21.1 85.3 (50.5-134.8)   Male 120 152.6 78.7 (65.2-94.0) 
Female 16 21.8 73.4 (41.9-119.2)   Female 133 155.1 85.8 (71.8-101.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
288 
Spencer 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 19 13.1 145.1 (87.3-226.6)   Male 14 8.6 162.3 (88.6-272.3) 
Female 10 4.4 226.3 (108.4-416.3)   Female 8 6.4 124.5 (53.6-245.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 2.6 nc (nc-nc)   Male 1 2.8 nc (nc-nc) 
Female 2 2.1 nc (nc-nc)   Female 6 2.1 282.6 (103.2-615.2) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.5 nc (nc-nc)   Male 7 7.6 91.9 (36.8-189.4) 
Female 42 52.9 79.4 (57.2-107.4)   Female 7 6.3 111.9 (44.8-230.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 6.7 135.1 (61.7-256.6) 
Female 2 1.7 nc (nc-nc)   Female 2 2.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 13.7 65.8 (30.0-124.9)             
Female 12 12.4 96.6 (49.9-168.7)   Female 2 4.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 3.5 nc (nc-nc)   Male 4 5.0 nc (nc-nc) 
Female 2 0.9 nc (nc-nc)   Female 5 4.6 109.3 (35.2-255.0) 
Hodgkin Lymphoma            Prostate     
Male 2 1.0 nc (nc-nc)   Male 36 43.8 82.1 (57.5-113.7) 
Female 2 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 8.0 125.0 (59.8-229.9)   Male 2 3.1 nc (nc-nc) 
Female 6 4.2 144.2 (52.7-314.0)   Female 2 1.8 nc (nc-nc) 
Larynx            Testis     
Male 3 2.1 nc (nc-nc)   Male 1 1.9 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 5.4 186.4 (89.2-342.8)   Male 5 3.6 139.9 (45.1-326.5) 
Female 5 3.7 135.7 (43.7-316.8)   Female 10 9.9 101.4 (48.5-186.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 5.0 99.5 (32.1-232.1)             
Female 1 1.5 nc (nc-nc)   Female 15 12.3 122.0 (68.2-201.3) 
Lung and Bronchus            All Sites / Types     
Male 32 23.8 134.7 (92.1-190.2)   Male 191 174.9 109.2 (94.3-125.9) 
Female 35 23.8 147.1 (102.4-204.6)   Female 189 173.0 109.3 (94.2-126.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
289 
Springfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 94 124.8 75.3 (60.9-92.2)   Male 27 82.8 32.6 (21.5-47.5) 
Female 36 48.7 73.9 (51.7-102.3)   Female 26 73.5 35.4 (23.1-51.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 26 27.1 95.8 (62.6-140.4)   Male 22 26.5 83.1 (52.1-125.9) 
Female 22 25.3 87.1 (54.5-131.8)   Female 30 23.2 129.5 (87.3-184.8) 
Breast            Non-Hodgkin Lymphoma     
Male 4 4.5 nc (nc-nc)   Male 73 74.0 98.6 (77.3-124.0) 
Female 526 586.6 89.7 (82.2-97.7)   Female 74 69.6 106.3 (83.4-133.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 73 62.7 116.4 (91.2-146.3) 
Female 37 20.2 183.6 (129.2-253.0)   Female 21 31.1 67.5 (41.8-103.2) 
Colon / Rectum            Ovary     
Male 149 134.5 110.8 (93.7-130.0)             
Female 156 142.6 109.4 (92.9-128.0)   Female 41 50.2 81.6 (58.6-110.7) 
Esophagus            Pancreas     
Male 30 32.5 92.4 (62.3-131.9)   Male 48 46.9 102.4 (75.5-135.7) 
Female 8 9.6 83.0 (35.7-163.5)   Female 49 50.7 96.6 (71.5-127.8) 
Hodgkin Lymphoma            Prostate     
Male 12 11.3 105.9 (54.7-185.0)   Male 310 385.0 80.5 (71.8-90.0) 
Female 14 10.6 131.7 (71.9-220.9)             
Kidney & Renal Pelvis            Stomach     
Male 92 76.1 120.9 (97.5-148.3)   Male 38 29.9 127.3 (90.1-174.7) 
Female 51 46.1 110.7 (82.4-145.6)   Female 20 20.1 99.6 (60.8-153.8) 
Larynx            Testis     
Male 19 18.8 100.8 (60.7-157.4)   Male 12 21.6 55.6 (28.7-97.1) 
Female 9 6.3 143.8 (65.6-273.0)             
Leukemia            Thyroid     
Male 47 54.2 86.7 (63.7-115.2)   Male 15 36.1 41.6 (23.3-68.6) 
Female 36 42.5 84.6 (59.3-117.1)   Female 79 117.6 67.2 (53.2-83.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 59 45.5 129.7 (98.7-167.3)             
Female 17 16.7 101.6 (59.2-162.7)   Female 125 131.2 95.3 (79.3-113.6) 
Lung and Bronchus            All Sites / Types     
Male 244 219.8 111.0 (97.5-125.9)   Male 1524 1645.7 92.6 (88.0-97.4) 
Female 247 258.2 95.7 (84.1-108.4)   Female 1786 1931.8 92.5 (88.2-96.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
290 
Sterling 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 7.0 170.9 (88.2-298.6)   Male 6 4.8 124.4 (45.4-270.8) 
Female 3 3.0 nc (nc-nc)   Female 3 4.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.5 nc (nc-nc)   Male 4 1.5 nc (nc-nc) 
Female 0 1.5 nc (nc-nc)   Female 0 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 7 4.3 162.9 (65.3-335.7) 
Female 45 37.1 121.2 (88.4-162.2)   Female 1 4.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 4.0 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 4 1.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 8.2 85.9 (34.4-177.0)             
Female 3 9.2 nc (nc-nc)   Female 2 3.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 1.9 nc (nc-nc)   Male 4 2.7 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 5 3.2 153.9 (49.6-359.1) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 38 25.0 152.0 (107.5-208.6) 
Female 2 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 4.8 209.5 (100.3-385.4)   Male 2 1.7 nc (nc-nc) 
Female 5 2.9 175.2 (56.5-408.9)   Female 1 1.3 nc (nc-nc) 
Larynx            Testis     
Male 1 1.1 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 3.0 197.1 (72.0-429.1)   Male 2 2.2 nc (nc-nc) 
Female 2 2.6 nc (nc-nc)   Female 8 7.3 110.1 (47.4-216.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 2.8 nc (nc-nc)             
Female 0 1.0 nc (nc-nc)   Female 8 8.1 98.9 (42.6-194.8) 
Lung and Bronchus            All Sites / Types     
Male 10 12.6 79.1 (37.9-145.4)   Male 126 98.6 127.8 (106.5-152.2) 
Female 17 15.8 107.8 (62.7-172.6)   Female 119 120.8 98.5 (81.6-117.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
291 
Stockbridge 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 3.7 nc (nc-nc)   Male 6 2.2 268.2 (97.9-583.8) 
Female 0 1.4 nc (nc-nc)   Female 5 1.6 305.3 (98.4-712.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.6 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 3 2.0 nc (nc-nc) 
Female 11 13.6 80.8 (40.3-144.5)   Female 4 1.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 1.5 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 3.6 137.7 (44.4-321.4)             
Female 6 3.8 157.9 (57.7-343.8)   Female 2 1.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 0.9 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 3 1.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 10 9.9 100.6 (48.2-185.0) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 1.9 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 2 1.2 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Larynx            Testis     
Male 0 0.5 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 1.3 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 1 1.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.2 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 6 3.2 187.1 (68.3-407.3) 
Lung and Bronchus            All Sites / Types     
Male 1 6.5 nc (nc-nc)   Male 43 43.6 98.6 (71.3-132.8) 
Female 4 7.7 nc (nc-nc)   Female 51 48.0 106.3 (79.1-139.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
292 
Stoneham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 32 30.0 106.5 (72.8-150.3)   Male 11 18.0 61.0 (30.4-109.2) 
Female 10 9.9 100.6 (48.1-184.9)   Female 13 13.5 96.2 (51.2-164.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 4.9 141.6 (56.7-291.8)   Male 9 5.8 154.9 (70.7-294.1) 
Female 5 4.3 115.0 (37.1-268.3)   Female 9 4.6 194.1 (88.6-368.4) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.0 nc (nc-nc)   Male 12 15.9 75.6 (39.0-132.1) 
Female 125 108.7 115.0 (95.7-137.0)   Female 13 13.5 96.2 (51.2-164.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 19 12.5 152.1 (91.5-237.5) 
Female 3 3.4 nc (nc-nc)   Female 8 6.0 132.9 (57.2-261.9) 
Colon / Rectum            Ovary     
Male 32 29.7 107.8 (73.7-152.1)             
Female 28 28.2 99.2 (65.9-143.4)   Female 14 9.5 147.6 (80.6-247.6) 
Esophagus            Pancreas     
Male 3 7.1 nc (nc-nc)   Male 8 10.6 75.4 (32.5-148.6) 
Female 1 1.9 nc (nc-nc)   Female 15 10.4 144.5 (80.8-238.3) 
Hodgkin Lymphoma            Prostate     
Male 3 1.8 nc (nc-nc)   Male 55 81.8 67.2 (50.6-87.5) 
Female 0 1.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 15.4 64.9 (31.1-119.3)   Male 10 6.8 148.1 (70.9-272.5) 
Female 12 8.8 136.8 (70.6-239.0)   Female 5 4.0 125.4 (40.4-292.7) 
Larynx            Testis     
Male 5 4.0 124.5 (40.1-290.4)   Male 5 3.2 156.1 (50.3-364.3) 
Female 4 1.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 13 11.3 115.2 (61.3-197.1)   Male 6 6.3 94.6 (34.5-205.9) 
Female 9 7.9 113.4 (51.7-215.2)   Female 30 19.4 154.8 (104.4-221.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 9 9.5 94.5 (43.1-179.3)             
Female 8 3.3 239.4 (103.1-471.7)   Female 35 25.2 138.9 (96.7-193.2) 
Lung and Bronchus            All Sites / Types     
Male 42 50.9 82.5 (59.5-111.6)   Male 327 356.0 91.9 (82.2-102.4) 
Female 55 51.8 106.3 (80.0-138.3)   Female 425 367.0 115.8 (105.1-127.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
293 
Stoughton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 33 35.7 92.4 (63.6-129.8)   Male 15 21.7 69.0 (38.6-113.9) 
Female 14 12.8 109.0 (59.5-182.9)   Female 21 17.5 120.3 (74.4-183.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 6.1 81.5 (26.3-190.1)   Male 10 7.0 141.9 (67.9-261.0) 
Female 6 5.6 107.1 (39.1-233.1)   Female 7 6.0 116.8 (46.8-240.7) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.2 nc (nc-nc)   Male 13 19.3 67.3 (35.8-115.1) 
Female 142 141.4 100.4 (84.6-118.4)   Female 24 17.5 137.1 (87.8-204.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 15.5 70.7 (35.3-126.6) 
Female 2 4.5 nc (nc-nc)   Female 2 7.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 35 35.7 98.2 (68.4-136.5)             
Female 42 36.4 115.5 (83.2-156.1)   Female 12 12.2 98.6 (50.9-172.3) 
Esophagus            Pancreas     
Male 11 8.7 126.6 (63.1-226.6)   Male 10 12.9 77.6 (37.1-142.7) 
Female 3 2.5 nc (nc-nc)   Female 17 13.5 126.0 (73.4-201.8) 
Hodgkin Lymphoma            Prostate     
Male 2 2.3 nc (nc-nc)   Male 91 103.0 88.4 (71.2-108.5) 
Female 6 2.0 297.7 (108.7-647.9)             
Kidney & Renal Pelvis            Stomach     
Male 26 18.9 137.4 (89.7-201.4)   Male 9 8.1 110.8 (50.5-210.3) 
Female 16 11.3 141.2 (80.7-229.3)   Female 5 5.1 97.1 (31.3-226.6) 
Larynx            Testis     
Male 9 5.0 180.9 (82.5-343.4)   Male 6 4.0 151.4 (55.3-329.6) 
Female 3 1.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 13 13.7 94.7 (50.4-161.9)   Male 10 7.9 126.4 (60.5-232.4) 
Female 10 10.2 97.6 (46.7-179.5)   Female 20 25.0 80.1 (48.9-123.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 14 11.9 117.9 (64.4-197.8)             
Female 2 4.3 nc (nc-nc)   Female 25 32.8 76.3 (49.4-112.6) 
Lung and Bronchus            All Sites / Types     
Male 65 60.7 107.1 (82.7-136.5)   Male 428 434.6 98.5 (89.4-108.3) 
Female 55 66.9 82.2 (61.9-106.9)   Female 480 475.2 101.0 (92.2-110.5) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
294 
Stow 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 8.1 147.3 (76.0-257.3)   Male 5 5.2 96.0 (30.9-224.1) 
Female 2 2.5 nc (nc-nc)   Female 3 3.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.5 nc (nc-nc)   Male 1 1.7 nc (nc-nc) 
Female 0 1.3 nc (nc-nc)   Female 3 1.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 4 4.6 nc (nc-nc) 
Female 30 34.2 87.8 (59.2-125.3)   Female 4 3.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 4.0 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 2 1.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 14 8.8 159.0 (86.8-266.7)             
Female 9 7.3 123.7 (56.5-234.9)   Female 5 2.8 178.0 (57.3-415.3) 
Esophagus            Pancreas     
Male 3 2.1 nc (nc-nc)   Male 3 3.0 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 2 2.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 22 25.3 86.8 (54.4-131.4) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 4.8 103.4 (33.3-241.3)   Male 1 1.9 nc (nc-nc) 
Female 1 2.6 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Larynx            Testis     
Male 1 1.2 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 3.3 nc (nc-nc)   Male 4 2.1 nc (nc-nc) 
Female 2 2.1 nc (nc-nc)   Female 8 6.4 125.9 (54.2-248.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.9 nc (nc-nc)             
Female 0 0.9 nc (nc-nc)   Female 8 7.9 101.0 (43.5-199.0) 
Lung and Bronchus            All Sites / Types     
Male 8 13.9 57.7 (24.8-113.6)   Male 98 104.6 93.7 (76.0-114.2) 
Female 8 14.2 56.4 (24.3-111.1)   Female 101 106.4 94.9 (77.3-115.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
295 
Sturbridge 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 13 9.9 131.2 (69.8-224.4)   Male 8 6.6 121.4 (52.3-239.1) 
Female 5 3.7 135.9 (43.8-317.1)   Female 8 5.3 149.7 (64.5-295.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.0 nc (nc-nc)   Male 5 2.1 238.0 (76.7-555.5) 
Female 2 1.7 nc (nc-nc)   Female 2 1.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 7 5.8 120.8 (48.4-249.0) 
Female 35 43.6 80.3 (55.9-111.6)   Female 3 5.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 5.1 nc (nc-nc) 
Female 1 1.5 nc (nc-nc)   Female 2 2.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 9 10.8 83.7 (38.2-158.9)             
Female 11 10.8 101.7 (50.7-181.9)   Female 1 3.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 6 2.6 229.3 (83.7-499.1)   Male 6 3.8 159.0 (58.0-346.0) 
Female 0 0.7 nc (nc-nc)   Female 8 3.9 204.5 (88.1-403.0) 
Hodgkin Lymphoma            Prostate     
Male 3 0.7 nc (nc-nc)   Male 28 32.1 87.4 (58.0-126.3) 
Female 0 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 6.1 114.4 (45.8-235.7)   Male 1 2.4 nc (nc-nc) 
Female 3 3.4 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Larynx            Testis     
Male 2 1.5 nc (nc-nc)   Male 2 1.4 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 4.1 122.8 (39.6-286.5)   Male 0 2.8 nc (nc-nc) 
Female 2 3.1 nc (nc-nc)   Female 7 8.4 83.2 (33.3-171.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 3.8 nc (nc-nc)             
Female 1 1.2 nc (nc-nc)   Female 17 9.7 175.6 (102.2-281.2) 
Lung and Bronchus            All Sites / Types     
Male 24 17.6 136.0 (87.1-202.3)   Male 142 131.6 107.9 (90.9-127.2) 
Female 11 19.4 56.7 (28.3-101.5)   Female 133 143.3 92.8 (77.7-110.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
296 
Sudbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 13 19.8 65.6 (34.9-112.2)   Male 19 13.3 142.8 (85.9-223.0) 
Female 1 6.4 nc (nc-nc)   Female 11 10.0 110.2 (54.9-197.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 4.0 176.6 (70.8-363.9)   Male 4 4.3 nc (nc-nc) 
Female 5 3.2 154.9 (49.9-361.5)   Female 3 3.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.7 nc (nc-nc)   Male 6 11.7 51.2 (18.7-111.5) 
Female 114 83.9 135.9 (112.1-163.2)   Female 12 9.5 126.8 (65.4-221.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 10.6 nc (nc-nc) 
Female 0 2.9 nc (nc-nc)   Female 5 4.3 117.0 (37.7-273.0) 
Colon / Rectum            Ovary     
Male 24 21.9 109.5 (70.1-163.0)             
Female 14 19.3 72.6 (39.6-121.7)   Female 7 7.0 100.6 (40.3-207.3) 
Esophagus            Pancreas     
Male 2 5.3 nc (nc-nc)   Male 10 7.7 130.5 (62.5-239.9) 
Female 2 1.3 nc (nc-nc)   Female 5 6.6 75.3 (24.3-175.8) 
Hodgkin Lymphoma            Prostate     
Male 1 1.3 nc (nc-nc)   Male 68 66.5 102.3 (79.4-129.7) 
Female 2 1.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 12 12.7 94.4 (48.7-164.8)   Male 3 4.8 nc (nc-nc) 
Female 8 6.4 125.9 (54.2-248.0)   Female 3 2.7 nc (nc-nc) 
Larynx            Testis     
Male 2 3.2 nc (nc-nc)   Male 1 2.4 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 8.2 85.8 (34.4-176.7)   Male 7 5.7 123.7 (49.6-254.8) 
Female 5 5.4 92.6 (29.8-216.0)   Female 18 16.1 111.7 (66.2-176.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 7.6 65.6 (21.1-153.1)             
Female 0 2.3 nc (nc-nc)   Female 16 18.7 85.4 (48.8-138.7) 
Lung and Bronchus            All Sites / Types     
Male 14 35.8 39.1 (21.4-65.7)   Male 226 267.6 84.5 (73.8-96.2) 
Female 26 34.5 75.3 (49.2-110.3)   Female 285 265.3 107.4 (95.3-120.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
297 
Sunderland 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 2.6 nc (nc-nc)   Male 1 1.7 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.6 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 17 9.9 171.3 (99.7-274.3)   Female 0 1.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 1.4 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 1 0.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 2.9 nc (nc-nc)             
Female 3 2.6 nc (nc-nc)   Female 2 0.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.7 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 9 8.8 102.7 (46.8-194.9) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.6 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Larynx            Testis     
Male 1 0.4 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 1.2 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 1 2.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.1 nc (nc-nc)             
Female 0 0.3 nc (nc-nc)   Female 5 2.2 227.3 (73.2-530.4) 
Lung and Bronchus            All Sites / Types     
Male 4 4.4 nc (nc-nc)   Male 29 36.0 80.6 (54.0-115.8) 
Female 2 4.6 nc (nc-nc)   Female 37 34.2 108.1 (76.1-149.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
298 
Sutton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 10.9 101.3 (50.5-181.3)   Male 9 6.9 129.5 (59.1-245.8) 
Female 3 2.8 nc (nc-nc)   Female 7 4.6 150.6 (60.3-310.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 2.0 nc (nc-nc)   Male 1 2.2 nc (nc-nc) 
Female 1 1.5 nc (nc-nc)   Female 3 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 9 6.2 145.7 (66.5-276.6) 
Female 38 38.3 99.2 (70.2-136.1)   Female 3 4.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 5.3 nc (nc-nc) 
Female 1 1.4 nc (nc-nc)   Female 3 2.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 11.5 nc (nc-nc)             
Female 10 8.6 115.9 (55.5-213.1)   Female 1 3.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 2.8 nc (nc-nc)   Male 1 4.0 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 3.0 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.7 nc (nc-nc)   Male 33 33.3 99.1 (68.2-139.2) 
Female 0 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 6.4 109.2 (43.7-225.0)   Male 2 2.6 nc (nc-nc) 
Female 6 2.9 209.7 (76.6-456.4)   Female 1 1.2 nc (nc-nc) 
Larynx            Testis     
Male 1 1.6 nc (nc-nc)   Male 3 1.3 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 4.3 162.0 (64.9-333.8)   Male 6 2.8 212.9 (77.7-463.4) 
Female 7 2.5 283.4 (113.5-583.9)   Female 6 7.7 77.7 (28.4-169.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 3.9 nc (nc-nc)             
Female 1 1.0 nc (nc-nc)   Female 15 8.7 172.3 (96.4-284.3) 
Lung and Bronchus            All Sites / Types     
Male 18 18.9 95.4 (56.5-150.8)   Male 130 138.8 93.7 (78.3-111.2) 
Female 15 15.1 99.1 (55.5-163.5)   Female 130 120.9 107.6 (89.9-127.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
299 
Swampscott 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 27 16.8 161.0 (106.1-234.3)   Male 20 10.5 190.0 (116.0-293.5) 
Female 11 6.4 172.4 (85.9-308.5)   Female 16 8.7 184.2 (105.2-299.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 3.0 nc (nc-nc)   Male 0 3.4 nc (nc-nc) 
Female 3 2.8 nc (nc-nc)   Female 5 3.0 168.3 (54.2-392.8) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.6 nc (nc-nc)   Male 17 9.3 183.0 (106.6-293.1) 
Female 75 70.0 107.1 (84.2-134.3)   Female 11 8.7 126.7 (63.2-226.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 7.8 63.8 (20.5-148.8) 
Female 2 2.3 nc (nc-nc)   Female 3 3.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 19 17.4 109.5 (65.9-171.0)             
Female 16 18.4 87.2 (49.8-141.6)   Female 5 6.0 83.4 (26.9-194.7) 
Esophagus            Pancreas     
Male 4 4.2 nc (nc-nc)   Male 6 6.2 97.4 (35.6-211.9) 
Female 2 1.3 nc (nc-nc)   Female 6 6.8 88.6 (32.4-192.9) 
Hodgkin Lymphoma            Prostate     
Male 2 1.0 nc (nc-nc)   Male 62 50.7 122.3 (93.7-156.7) 
Female 4 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 9.5 73.4 (29.4-151.2)   Male 3 3.9 nc (nc-nc) 
Female 4 5.6 nc (nc-nc)   Female 3 2.6 nc (nc-nc) 
Larynx            Testis     
Male 2 2.4 nc (nc-nc)   Male 1 1.8 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 6.6 90.3 (33.0-196.5)   Male 7 4.0 173.5 (69.5-357.6) 
Female 9 5.2 174.1 (79.4-330.5)   Female 23 12.5 184.5 (116.9-276.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 5.9 nc (nc-nc)             
Female 2 2.1 nc (nc-nc)   Female 24 15.9 150.8 (96.6-224.3) 
Lung and Bronchus            All Sites / Types     
Male 27 29.1 92.9 (61.2-135.2)   Male 242 210.8 114.8 (100.8-130.2) 
Female 31 32.7 94.9 (64.5-134.8)   Female 273 235.7 115.8 (102.5-130.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
300 
Swansea 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 23 22.4 102.5 (65.0-153.9)   Male 8 14.0 57.3 (24.7-112.9) 
Female 11 7.5 146.5 (73.1-262.2)   Female 7 9.9 70.6 (28.3-145.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 3.9 154.7 (56.5-336.7)   Male 4 4.6 nc (nc-nc) 
Female 3 3.2 nc (nc-nc)   Female 3 3.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.8 nc (nc-nc)   Male 10 12.3 81.0 (38.8-149.0) 
Female 71 82.2 86.4 (67.5-109.0)   Female 10 10.1 99.3 (47.5-182.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 10.2 nc (nc-nc) 
Female 3 2.5 nc (nc-nc)   Female 4 4.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 22 22.6 97.2 (60.9-147.2)             
Female 18 20.6 87.5 (51.9-138.4)   Female 7 7.0 100.3 (40.2-206.6) 
Esophagus            Pancreas     
Male 3 5.6 nc (nc-nc)   Male 11 8.2 133.6 (66.6-239.0) 
Female 0 1.5 nc (nc-nc)   Female 7 7.7 90.4 (36.2-186.3) 
Hodgkin Lymphoma            Prostate     
Male 3 1.3 nc (nc-nc)   Male 76 67.6 112.5 (88.6-140.8) 
Female 1 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 16 12.5 128.3 (73.3-208.4)   Male 4 5.2 nc (nc-nc) 
Female 7 6.6 105.8 (42.4-218.1)   Female 5 2.9 171.4 (55.2-399.9) 
Larynx            Testis     
Male 2 3.3 nc (nc-nc)   Male 5 2.3 213.9 (68.9-499.2) 
Female 2 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 8.6 nc (nc-nc)   Male 6 5.2 115.6 (42.2-251.7) 
Female 6 5.7 106.0 (38.7-230.8)   Female 12 14.1 84.9 (43.8-148.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 7.8 90.1 (36.1-185.6)             
Female 2 2.4 nc (nc-nc)   Female 13 19.0 68.4 (36.4-117.0) 
Lung and Bronchus            All Sites / Types     
Male 42 39.3 106.7 (76.9-144.3)   Male 285 279.8 101.9 (90.4-114.4) 
Female 37 40.5 91.4 (64.3-126.0)   Female 243 274.9 88.4 (77.6-100.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
301 
Taunton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 54 56.6 95.3 (71.6-124.4)   Male 28 37.5 74.6 (49.6-107.8) 
Female 26 22.4 116.1 (75.8-170.1)   Female 24 31.4 76.4 (48.9-113.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 13 11.5 112.8 (60.0-192.9)   Male 8 12.1 66.1 (28.5-130.2) 
Female 8 10.2 78.5 (33.8-154.8)   Female 11 10.5 105.0 (52.3-187.9) 
Breast            Non-Hodgkin Lymphoma     
Male 4 2.0 nc (nc-nc)   Male 34 33.3 102.1 (70.7-142.7) 
Female 241 250.9 96.1 (84.3-109.0)   Female 30 30.8 97.4 (65.7-139.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 46 29.0 158.8 (116.2-211.8) 
Female 9 8.3 108.0 (49.3-205.0)   Female 13 13.7 94.8 (50.4-162.2) 
Colon / Rectum            Ovary     
Male 65 60.7 107.1 (82.6-136.5)             
Female 73 64.6 113.1 (88.6-142.1)   Female 15 21.7 69.0 (38.6-113.9) 
Esophagus            Pancreas     
Male 20 15.0 133.4 (81.4-206.0)   Male 13 21.5 60.5 (32.2-103.5) 
Female 1 4.4 nc (nc-nc)   Female 24 23.4 102.4 (65.6-152.3) 
Hodgkin Lymphoma            Prostate     
Male 8 4.6 174.4 (75.1-343.7)   Male 134 182.8 73.3 (61.4-86.8) 
Female 4 4.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 36 34.9 103.2 (72.3-142.9)   Male 16 13.6 117.8 (67.3-191.2) 
Female 14 20.1 69.6 (38.0-116.8)   Female 10 9.1 110.5 (52.9-203.2) 
Larynx            Testis     
Male 11 8.8 125.4 (62.5-224.4)   Male 8 8.6 92.6 (39.9-182.5) 
Female 7 2.8 252.4 (101.1-520.0)             
Leukemia            Thyroid     
Male 19 23.6 80.7 (48.5-126.0)   Male 19 15.9 119.5 (71.9-186.6) 
Female 12 18.4 65.0 (33.6-113.6)   Female 61 47.0 129.9 (99.3-166.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 29 21.4 135.8 (90.9-195.0)             
Female 10 7.6 132.4 (63.4-243.4)   Female 58 57.1 101.6 (77.1-131.3) 
Lung and Bronchus            All Sites / Types     
Male 135 101.4 133.1 (111.6-157.5)   Male 766 752.7 101.8 (94.7-109.2) 
Female 123 116.5 105.6 (87.8-126.0)   Female 834 842.6 99.0 (92.4-105.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
302 
Templeton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 11.0 72.8 (31.3-143.4)   Male 5 6.8 73.1 (23.6-170.7) 
Female 4 3.2 nc (nc-nc)   Female 2 4.6 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.9 nc (nc-nc)   Male 3 2.2 nc (nc-nc) 
Female 0 1.5 nc (nc-nc)   Female 2 1.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 2 6.1 nc (nc-nc) 
Female 30 38.5 77.9 (52.6-111.2)   Female 3 4.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 5.2 nc (nc-nc) 
Female 2 1.2 nc (nc-nc)   Female 1 2.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 11.4 61.4 (24.6-126.4)             
Female 7 9.2 76.0 (30.4-156.5)   Female 4 3.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.8 nc (nc-nc)   Male 2 4.1 nc (nc-nc) 
Female 2 0.6 nc (nc-nc)   Female 4 3.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.7 nc (nc-nc)   Male 23 34.6 66.5 (42.1-99.7) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 6.3 111.5 (44.7-229.8)   Male 2 2.6 nc (nc-nc) 
Female 3 3.1 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Larynx            Testis     
Male 0 1.6 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 4.3 117.6 (37.9-274.5)   Male 3 2.6 nc (nc-nc) 
Female 2 2.6 nc (nc-nc)   Female 6 6.9 87.1 (31.8-189.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 3.8 130.1 (41.9-303.6)             
Female 1 1.1 nc (nc-nc)   Female 10 8.9 112.3 (53.8-206.5) 
Lung and Bronchus            All Sites / Types     
Male 20 18.9 105.8 (64.6-163.5)   Male 105 139.3 75.4 (61.6-91.2) 
Female 18 17.8 101.0 (59.8-159.7)   Female 108 125.6 86.0 (70.5-103.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
303 
Tewksbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 36 33.3 108.1 (75.7-149.6)   Male 19 22.0 86.5 (52.0-135.0) 
Female 12 12.8 93.9 (48.5-164.1)   Female 19 17.7 107.2 (64.5-167.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 6.4 124.1 (53.4-244.5)   Male 7 7.0 99.8 (40.0-205.6) 
Female 7 5.8 121.6 (48.7-250.5)   Female 5 5.9 84.1 (27.1-196.2) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.2 nc (nc-nc)   Male 17 19.3 88.0 (51.2-140.9) 
Female 136 146.1 93.1 (78.1-110.1)   Female 21 17.6 119.4 (73.9-182.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 20 16.9 118.5 (72.4-183.1) 
Female 7 4.7 150.0 (60.1-309.0)   Female 9 7.8 115.2 (52.6-218.6) 
Colon / Rectum            Ovary     
Male 34 35.7 95.3 (66.0-133.2)             
Female 32 36.0 88.9 (60.8-125.5)   Female 11 12.4 88.6 (44.2-158.6) 
Esophagus            Pancreas     
Male 13 8.7 149.8 (79.7-256.2)   Male 14 12.6 110.9 (60.6-186.0) 
Female 3 2.5 nc (nc-nc)   Female 11 13.2 83.6 (41.7-149.5) 
Hodgkin Lymphoma            Prostate     
Male 1 2.4 nc (nc-nc)   Male 102 106.0 96.2 (78.5-116.8) 
Female 3 2.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 30 20.3 148.0 (99.8-211.2)   Male 8 8.0 100.4 (43.2-197.8) 
Female 11 11.6 94.9 (47.3-169.7)   Female 3 5.1 nc (nc-nc) 
Larynx            Testis     
Male 4 5.1 nc (nc-nc)   Male 5 4.5 110.9 (35.7-258.9) 
Female 1 1.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 20 13.5 148.0 (90.4-228.7)   Male 11 9.1 121.5 (60.6-217.5) 
Female 12 10.1 118.3 (61.0-206.6)   Female 28 26.4 106.2 (70.6-153.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 12 12.4 96.6 (49.9-168.8)             
Female 2 4.3 nc (nc-nc)   Female 30 33.3 90.2 (60.8-128.7) 
Lung and Bronchus            All Sites / Types     
Male 73 59.8 122.1 (95.7-153.6)   Male 473 437.8 108.0 (98.5-118.2) 
Female 81 68.5 118.3 (93.9-147.0)   Female 483 483.1 100.0 (91.3-109.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
304 
Tisbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 3.1 192.1 (70.2-418.2)   Male 6 2.2 267.2 (97.6-581.6) 
Female 1 1.3 nc (nc-nc)   Female 7 2.0 341.5 (136.8-703.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.7 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 2 2.0 nc (nc-nc) 
Female 25 16.7 149.8 (96.9-221.2)   Female 1 1.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 1.8 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 3.6 nc (nc-nc)             
Female 7 3.7 188.1 (75.4-387.6)   Female 2 1.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.9 nc (nc-nc)   Male 4 1.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 2 1.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 13 11.3 114.9 (61.1-196.5) 
Female 1 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 2.2 nc (nc-nc)   Male 2 0.8 nc (nc-nc) 
Female 2 1.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Larynx            Testis     
Male 1 0.5 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 1.4 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 2 3.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 1.3 nc (nc-nc)             
Female 0 0.5 nc (nc-nc)   Female 3 3.9 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 4 5.9 nc (nc-nc)   Male 56 45.3 123.7 (93.5-160.7) 
Female 11 7.4 148.4 (74.0-265.5)   Female 74 54.1 136.9 (107.5-171.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
305 
Tolland 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 0.8 nc (nc-nc)   Male 2 0.6 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 2.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 0.9 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.2 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 2 3.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.5 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.1 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.3 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 1.5 nc (nc-nc)   Male 9 11.5 78.3 (35.7-148.7) 
Female 1 1.2 nc (nc-nc)   Female 1 8.9 nc (nc-nc) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
306 
Topsfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 3 9.6 nc (nc-nc)   Male 5 5.9 85.3 (27.5-199.2) 
Female 4 3.5 nc (nc-nc)   Female 8 4.3 184.7 (79.5-364.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 1.6 383.2 (139.9-834.1)   Male 0 1.9 nc (nc-nc) 
Female 2 1.4 nc (nc-nc)   Female 3 1.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 6 5.1 117.3 (42.8-255.3) 
Female 36 35.5 101.4 (71.0-140.4)   Female 1 4.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 4.2 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)   Female 3 2.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 9.6 nc (nc-nc)             
Female 6 9.8 61.2 (22.4-133.3)   Female 4 3.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 2.3 nc (nc-nc)   Male 2 3.5 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 3.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.5 nc (nc-nc)   Male 19 28.0 67.8 (40.8-105.8) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 5.2 154.1 (66.3-303.6)   Male 3 2.2 nc (nc-nc) 
Female 2 2.9 nc (nc-nc)   Female 2 1.4 nc (nc-nc) 
Larynx            Testis     
Male 1 1.3 nc (nc-nc)   Male 2 0.8 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 3.6 nc (nc-nc)   Male 2 2.0 nc (nc-nc) 
Female 2 2.7 nc (nc-nc)   Female 4 5.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 3.2 nc (nc-nc)             
Female 1 1.1 nc (nc-nc)   Female 5 7.8 64.2 (20.7-149.8) 
Lung and Bronchus            All Sites / Types     
Male 13 16.9 76.8 (40.8-131.3)   Male 85 116.9 72.7 (58.1-89.9) 
Female 11 17.9 61.4 (30.6-109.9)   Female 105 121.3 86.5 (70.8-104.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
307 
Townsend 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 8.4 166.1 (90.7-278.7)   Male 3 5.9 nc (nc-nc) 
Female 3 2.7 nc (nc-nc)   Female 8 4.5 177.1 (76.3-349.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.9 nc (nc-nc)   Male 0 1.9 nc (nc-nc) 
Female 3 1.5 nc (nc-nc)   Female 2 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 9 5.3 170.8 (77.9-324.3) 
Female 35 37.0 94.5 (65.8-131.5)   Female 2 4.1 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 5.1 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 4 1.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 9.7 103.2 (49.4-189.8)             
Female 17 8.2 206.8 (120.4-331.1)   Female 1 3.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 8 2.5 324.4 (139.7-639.2)   Male 4 3.4 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 1 2.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.8 nc (nc-nc)   Male 23 32.3 71.1 (45.1-106.8) 
Female 2 0.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 10 5.9 168.4 (80.6-309.7)   Male 3 2.1 nc (nc-nc) 
Female 5 2.8 177.8 (57.3-414.9)   Female 2 1.2 nc (nc-nc) 
Larynx            Testis     
Male 1 1.5 nc (nc-nc)   Male 2 1.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 3.7 nc (nc-nc)   Male 3 2.8 nc (nc-nc) 
Female 3 2.4 nc (nc-nc)   Female 9 7.6 118.3 (54.0-224.6) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.6 nc (nc-nc)             
Female 0 1.0 nc (nc-nc)   Female 3 8.4 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 15 15.6 96.2 (53.8-158.7)   Male 130 122.8 105.9 (88.5-125.7) 
Female 16 14.8 108.0 (61.7-175.4)   Female 128 116.9 109.5 (91.3-130.2) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
308 
Truro 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 3.5 nc (nc-nc)   Male 2 2.1 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 4 1.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.5 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 2 0.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 3 1.8 nc (nc-nc) 
Female 13 12.7 102.1 (54.3-174.6)   Female 1 1.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 1.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 3.4 175.4 (64.1-381.8)             
Female 4 2.8 nc (nc-nc)   Female 3 1.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 0.9 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 2 0.2 nc (nc-nc)   Female 2 1.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 7 11.5 60.8 (24.4-125.2) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.9 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Larynx            Testis     
Male 0 0.5 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 1.3 nc (nc-nc)   Male 1 0.7 nc (nc-nc) 
Female 1 0.8 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 1.2 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 2 3.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 6 6.1 97.9 (35.7-213.0)   Male 40 43.5 91.9 (65.7-125.2) 
Female 3 6.3 nc (nc-nc)   Female 46 41.2 111.7 (81.8-149.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
309 
Tyngsborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 8.9 67.3 (24.6-146.6)   Male 5 6.8 73.1 (23.6-170.6) 
Female 7 3.3 215.3 (86.2-443.6)   Female 4 5.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 2.3 nc (nc-nc)   Male 1 2.2 nc (nc-nc) 
Female 2 1.9 nc (nc-nc)   Female 2 1.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 6 6.1 98.3 (35.9-213.9) 
Female 50 46.1 108.4 (80.4-142.9)   Female 3 5.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 6.1 nc (nc-nc) 
Female 1 1.8 nc (nc-nc)   Female 2 2.3 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 12 11.3 105.9 (54.7-185.1)             
Female 6 10.5 57.2 (20.9-124.5)   Female 4 3.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.7 nc (nc-nc)   Male 3 3.8 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 3.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.0 nc (nc-nc)   Male 37 36.4 101.6 (71.5-140.0) 
Female 0 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 7.0 114.1 (49.1-224.8)   Male 5 2.4 209.8 (67.6-489.5) 
Female 3 3.4 nc (nc-nc)   Female 1 1.5 nc (nc-nc) 
Larynx            Testis     
Male 1 1.7 nc (nc-nc)   Male 0 2.0 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 4.1 145.1 (53.0-315.8)   Male 1 3.5 nc (nc-nc) 
Female 5 3.0 164.1 (52.9-383.0)   Female 4 10.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 4.3 nc (nc-nc)             
Female 2 1.2 nc (nc-nc)   Female 11 10.1 109.2 (54.5-195.5) 
Lung and Bronchus            All Sites / Types     
Male 22 16.8 130.7 (81.9-197.9)   Male 139 139.6 99.6 (83.7-117.6) 
Female 22 17.1 128.3 (80.4-194.2)   Female 140 144.5 96.9 (81.5-114.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
310 
Tyringham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 1.0 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.1 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 3 3.1 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 1.0 nc (nc-nc)             
Female 0 0.8 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 1 0.1 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 0 3.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.5 nc (nc-nc)   Male 1 0.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.1 nc (nc-nc)   Male 0 0.0 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.3 nc (nc-nc)             
Female 1 0.1 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 1.9 nc (nc-nc)   Male 5 12.3 40.7 (13.1-94.9) 
Female 0 1.8 nc (nc-nc)   Female 7 10.9 64.5 (25.8-132.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
311 
Upton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 7.2 83.4 (30.4-181.4)   Male 4 5.1 nc (nc-nc) 
Female 2 2.1 nc (nc-nc)   Female 3 3.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.6 nc (nc-nc)   Male 3 1.6 nc (nc-nc) 
Female 2 1.2 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.3 nc (nc-nc)   Male 3 4.5 nc (nc-nc) 
Female 44 30.6 143.8 (104.5-193.0)   Female 5 3.3 153.1 (49.3-357.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 4.3 nc (nc-nc) 
Female 1 1.1 nc (nc-nc)   Female 2 1.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 8.3 72.1 (26.3-156.9)             
Female 3 6.5 nc (nc-nc)   Female 5 2.6 195.4 (63.0-456.0) 
Esophagus            Pancreas     
Male 0 2.1 nc (nc-nc)   Male 2 2.9 nc (nc-nc) 
Female 2 0.4 nc (nc-nc)   Female 6 2.2 276.9 (101.1-602.8) 
Hodgkin Lymphoma            Prostate     
Male 1 0.6 nc (nc-nc)   Male 26 26.4 98.4 (64.3-144.2) 
Female 1 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 5.0 nc (nc-nc)   Male 1 1.8 nc (nc-nc) 
Female 1 2.3 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Larynx            Testis     
Male 0 1.2 nc (nc-nc)   Male 2 1.1 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 3.1 nc (nc-nc)   Male 2 2.3 nc (nc-nc) 
Female 2 1.9 nc (nc-nc)   Female 7 6.4 108.9 (43.6-224.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 3.1 160.5 (51.7-374.6)             
Female 2 0.8 nc (nc-nc)   Female 12 6.9 174.8 (90.2-305.3) 
Lung and Bronchus            All Sites / Types     
Male 14 13.3 105.5 (57.7-177.1)   Male 93 103.4 90.0 (72.6-110.2) 
Female 18 12.0 150.0 (88.9-237.1)   Female 125 94.8 131.8 (109.7-157.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
312 
Uxbridge 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 18 10.1 178.6 (105.8-282.3)   Male 11 7.3 150.0 (74.8-268.4) 
Female 5 5.1 97.4 (31.4-227.3)   Female 4 7.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 2.4 nc (nc-nc)   Male 5 2.3 213.9 (68.9-499.1) 
Female 2 2.5 nc (nc-nc)   Female 4 2.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.4 nc (nc-nc)   Male 8 6.6 122.0 (52.6-240.5) 
Female 64 60.5 105.8 (81.5-135.2)   Female 6 7.2 83.4 (30.5-181.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 16 6.1 261.3 (149.3-424.4) 
Female 0 2.0 nc (nc-nc)   Female 3 3.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 17 11.9 143.0 (83.2-228.9)             
Female 11 15.1 73.0 (36.4-130.6)   Female 9 5.2 173.5 (79.2-329.4) 
Esophagus            Pancreas     
Male 1 2.9 nc (nc-nc)   Male 3 4.1 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 3 5.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 1.0 nc (nc-nc)   Male 51 37.8 134.8 (100.4-177.2) 
Female 1 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 16 7.2 221.5 (126.5-359.7)   Male 3 2.6 nc (nc-nc) 
Female 5 4.8 105.0 (33.9-245.1)   Female 1 2.1 nc (nc-nc) 
Larynx            Testis     
Male 2 1.8 nc (nc-nc)   Male 4 2.0 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 4.6 131.1 (47.9-285.3)   Male 1 3.6 nc (nc-nc) 
Female 5 4.3 116.5 (37.5-271.8)   Female 9 11.4 79.1 (36.1-150.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 4.4 112.6 (36.3-262.9)             
Female 2 1.8 nc (nc-nc)   Female 12 13.7 87.8 (45.3-153.3) 
Lung and Bronchus            All Sites / Types     
Male 26 18.8 138.3 (90.3-202.6)   Male 218 148.9 146.4 (127.6-167.2) 
Female 28 26.9 104.1 (69.2-150.5)   Female 188 199.2 94.4 (81.4-108.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
313 
Wakefield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 27 31.9 84.7 (55.8-123.3)   Male 19 20.1 94.3 (56.8-147.3) 
Female 12 10.1 118.9 (61.4-207.8)   Female 22 14.6 150.3 (94.1-227.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 5.8 138.4 (59.6-272.7)   Male 4 6.5 nc (nc-nc) 
Female 6 4.7 126.6 (46.2-275.6)   Female 4 4.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.1 nc (nc-nc)   Male 11 17.7 62.2 (31.0-111.3) 
Female 127 118.5 107.2 (89.4-127.5)   Female 15 14.1 106.2 (59.4-175.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 15 14.3 105.2 (58.8-173.5) 
Female 2 3.9 nc (nc-nc)   Female 7 6.4 109.5 (43.9-225.6) 
Colon / Rectum            Ovary     
Male 30 32.1 93.4 (63.0-133.3)             
Female 29 29.3 99.0 (66.3-142.2)   Female 7 10.2 68.9 (27.6-142.0) 
Esophagus            Pancreas     
Male 9 7.9 113.7 (51.9-215.8)   Male 11 11.6 94.8 (47.3-169.7) 
Female 0 2.0 nc (nc-nc)   Female 10 10.6 94.8 (45.4-174.3) 
Hodgkin Lymphoma            Prostate     
Male 1 2.2 nc (nc-nc)   Male 53 90.8 58.4 (43.7-76.4) 
Female 1 1.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 11 17.6 62.4 (31.1-111.6)   Male 5 7.4 67.8 (21.8-158.1) 
Female 12 9.3 128.4 (66.3-224.3)   Female 2 4.1 nc (nc-nc) 
Larynx            Testis     
Male 2 4.6 nc (nc-nc)   Male 3 4.1 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 18 12.5 144.1 (85.3-227.7)   Male 8 7.7 103.9 (44.7-204.7) 
Female 7 8.3 83.9 (33.6-172.9)   Female 21 22.6 93.1 (57.6-142.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 8 10.8 73.9 (31.8-145.6)             
Female 3 3.4 nc (nc-nc)   Female 24 27.1 88.5 (56.7-131.6) 
Lung and Bronchus            All Sites / Types     
Male 38 56.5 67.3 (47.6-92.3)   Male 304 394.9 77.0 (68.6-86.1) 
Female 57 53.3 107.0 (81.0-138.6)   Female 396 391.3 101.2 (91.5-111.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
314 
Wales 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 2.3 nc (nc-nc)   Male 0 1.5 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.4 nc (nc-nc)   Male 2 0.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 0 1.3 nc (nc-nc) 
Female 8 8.9 89.4 (38.5-176.2)   Female 0 1.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 1.1 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 2.4 nc (nc-nc)             
Female 7 2.0 352.1 (141.1-725.4)   Female 1 0.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.6 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 5 7.5 66.8 (21.5-155.9) 
Female 1 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.4 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 1 0.4 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.9 nc (nc-nc)   Male 1 0.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 1.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 0.8 nc (nc-nc)             
Female 1 0.2 nc (nc-nc)   Female 5 2.2 230.5 (74.3-538.0) 
Lung and Bronchus            All Sites / Types     
Male 3 4.1 nc (nc-nc)   Male 21 30.3 69.3 (42.9-106.0) 
Female 2 3.7 nc (nc-nc)   Female 30 28.4 105.7 (71.3-150.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
315 
Walpole 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 20 29.2 68.4 (41.8-105.7)   Male 18 18.8 95.5 (56.6-151.0) 
Female 8 10.7 74.8 (32.2-147.4)   Female 12 14.7 81.6 (42.1-142.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 5.4 nc (nc-nc)   Male 7 6.0 116.5 (46.7-240.0) 
Female 6 4.7 126.3 (46.1-275.0)   Female 1 5.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.0 nc (nc-nc)   Male 15 16.6 90.4 (50.5-149.1) 
Female 129 119.4 108.1 (90.2-128.4)   Female 11 14.7 74.6 (37.2-133.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 14.4 62.4 (28.5-118.4) 
Female 3 3.8 nc (nc-nc)   Female 6 6.5 93.0 (34.0-202.4) 
Colon / Rectum            Ovary     
Male 36 31.2 115.6 (80.9-160.0)             
Female 31 31.0 100.1 (68.0-142.0)   Female 15 10.2 146.5 (81.9-241.6) 
Esophagus            Pancreas     
Male 4 7.5 nc (nc-nc)   Male 13 10.9 118.8 (63.2-203.1) 
Female 3 2.1 nc (nc-nc)   Female 11 11.2 98.2 (48.9-175.6) 
Hodgkin Lymphoma            Prostate     
Male 4 2.0 nc (nc-nc)   Male 114 91.1 125.1 (103.2-150.3) 
Female 3 1.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 17 17.2 98.8 (57.5-158.2)   Male 8 6.9 115.7 (49.8-228.0) 
Female 8 9.5 84.5 (36.4-166.5)   Female 4 4.3 nc (nc-nc) 
Larynx            Testis     
Male 4 4.3 nc (nc-nc)   Male 6 3.6 166.3 (60.7-362.0) 
Female 2 1.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 9 11.6 77.4 (35.3-147.0)   Male 4 7.6 nc (nc-nc) 
Female 8 8.6 93.1 (40.1-183.4)   Female 24 21.2 113.2 (72.5-168.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 9 10.6 84.6 (38.6-160.6)             
Female 3 3.5 nc (nc-nc)   Female 21 26.8 78.4 (48.5-119.8) 
Lung and Bronchus            All Sites / Types     
Male 53 50.8 104.4 (78.2-136.5)   Male 389 376.4 103.4 (93.3-114.2) 
Female 50 55.4 90.2 (67.0-119.0)   Female 386 398.4 96.9 (87.5-107.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
316 
Waltham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 56 57.7 97.0 (73.3-126.0)   Male 19 37.0 51.4 (30.9-80.3) 
Female 23 21.4 107.5 (68.2-161.4)   Female 16 29.5 54.3 (31.0-88.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 16 11.6 137.7 (78.7-223.7)   Male 9 11.6 77.6 (35.4-147.3) 
Female 13 10.1 128.2 (68.2-219.2)   Female 6 9.8 61.3 (22.4-133.5) 
Breast            Non-Hodgkin Lymphoma     
Male 2 2.0 nc (nc-nc)   Male 28 33.0 84.8 (56.3-122.5) 
Female 251 223.0 112.6 (99.1-127.4)   Female 30 29.0 103.5 (69.8-147.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 16 26.3 60.8 (34.7-98.8) 
Female 10 7.4 134.8 (64.6-248.0)   Female 9 12.7 70.8 (32.3-134.5) 
Colon / Rectum            Ovary     
Male 67 59.2 113.1 (87.6-143.6)             
Female 65 60.7 107.1 (82.7-136.5)   Female 21 19.9 105.4 (65.2-161.1) 
Esophagus            Pancreas     
Male 9 14.2 63.3 (28.9-120.2)   Male 29 21.0 138.1 (92.5-198.3) 
Female 6 4.1 145.2 (53.0-316.1)   Female 23 22.5 102.4 (64.9-153.7) 
Hodgkin Lymphoma            Prostate     
Male 6 5.5 108.6 (39.6-236.3)   Male 141 166.9 84.5 (71.1-99.6) 
Female 5 4.8 104.3 (33.6-243.4)             
Kidney & Renal Pelvis            Stomach     
Male 36 32.2 111.7 (78.2-154.6)   Male 17 13.4 127.0 (74.0-203.4) 
Female 23 18.4 125.2 (79.3-187.8)   Female 13 8.6 151.4 (80.5-258.9) 
Larynx            Testis     
Male 6 8.2 73.0 (26.7-158.9)   Male 12 11.0 109.4 (56.5-191.1) 
Female 3 2.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 20 23.9 83.6 (51.1-129.2)   Male 23 15.5 148.6 (94.2-223.1) 
Female 16 17.9 89.4 (51.1-145.2)   Female 44 43.8 100.4 (72.9-134.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 22 19.7 111.9 (70.1-169.4)             
Female 4 7.1 nc (nc-nc)   Female 44 51.0 86.3 (62.7-115.8) 
Lung and Bronchus            All Sites / Types     
Male 106 99.9 106.1 (86.8-128.3)   Male 690 729.3 94.6 (87.7-101.9) 
Female 102 109.1 93.5 (76.2-113.5)   Female 774 778.4 99.4 (92.6-106.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
317 
Ware 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 11 11.2 98.2 (48.9-175.7)   Male 4 7.2 nc (nc-nc) 
Female 1 3.8 nc (nc-nc)   Female 5 5.4 93.2 (30.0-217.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.1 nc (nc-nc)   Male 3 2.3 nc (nc-nc) 
Female 0 1.8 nc (nc-nc)   Female 2 1.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 7 6.4 109.0 (43.7-224.7) 
Female 39 45.0 86.6 (61.6-118.3)   Female 7 5.3 133.3 (53.4-274.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 5.6 nc (nc-nc) 
Female 0 1.4 nc (nc-nc)   Female 4 2.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 14 11.9 118.1 (64.5-198.2)             
Female 11 10.7 103.1 (51.4-184.5)   Female 4 3.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 2.9 nc (nc-nc)   Male 8 4.2 189.4 (81.5-373.2) 
Female 1 0.8 nc (nc-nc)   Female 7 3.9 177.7 (71.2-366.2) 
Hodgkin Lymphoma            Prostate     
Male 1 0.8 nc (nc-nc)   Male 24 36.7 65.5 (41.9-97.4) 
Female 0 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 6.7 nc (nc-nc)   Male 2 2.7 nc (nc-nc) 
Female 6 3.6 169.0 (61.7-367.8)   Female 3 1.5 nc (nc-nc) 
Larynx            Testis     
Male 2 1.7 nc (nc-nc)   Male 2 1.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 4.5 nc (nc-nc)   Male 2 2.9 nc (nc-nc) 
Female 3 3.0 nc (nc-nc)   Female 4 8.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 4.1 120.6 (38.9-281.5)             
Female 2 1.3 nc (nc-nc)   Female 12 10.5 114.4 (59.1-199.9) 
Lung and Bronchus            All Sites / Types     
Male 23 19.8 116.1 (73.6-174.2)   Male 134 146.8 91.3 (76.5-108.1) 
Female 20 20.8 96.2 (58.7-148.6)   Female 141 147.1 95.8 (80.7-113.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
318 
Wareham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 39 29.4 132.6 (94.3-181.3)   Male 14 18.2 76.8 (41.9-128.8) 
Female 21 9.6 218.4 (135.2-333.9)   Female 13 13.2 98.6 (52.4-168.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 10 5.1 196.8 (94.2-361.9)   Male 8 5.9 135.7 (58.4-267.4) 
Female 1 4.3 nc (nc-nc)   Female 4 4.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.0 nc (nc-nc)   Male 18 16.1 112.1 (66.4-177.1) 
Female 94 109.3 86.0 (69.5-105.3)   Female 8 13.2 60.5 (26.0-119.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 15 13.0 115.6 (64.7-190.7) 
Female 3 3.4 nc (nc-nc)   Female 9 5.9 152.6 (69.6-289.7) 
Colon / Rectum            Ovary     
Male 33 29.6 111.4 (76.7-156.5)             
Female 36 26.8 134.1 (93.9-185.7)   Female 7 9.4 74.7 (29.9-153.8) 
Esophagus            Pancreas     
Male 9 7.1 126.0 (57.5-239.1)   Male 17 10.6 159.8 (93.0-255.9) 
Female 1 1.9 nc (nc-nc)   Female 17 9.9 172.2 (100.3-275.8) 
Hodgkin Lymphoma            Prostate     
Male 1 1.8 nc (nc-nc)   Male 88 83.3 105.7 (84.8-130.2) 
Female 2 1.6 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 13 15.9 81.6 (43.4-139.5)   Male 3 6.7 nc (nc-nc) 
Female 15 8.8 170.9 (95.6-281.9)   Female 3 3.8 nc (nc-nc) 
Larynx            Testis     
Male 3 4.2 nc (nc-nc)   Male 5 3.1 160.7 (51.8-375.1) 
Female 2 1.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 15 11.3 133.0 (74.4-219.4)   Male 7 6.6 106.6 (42.7-219.6) 
Female 15 7.7 195.9 (109.6-323.1)   Female 20 19.3 103.6 (63.3-160.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 15 9.8 152.7 (85.4-251.9)             
Female 5 3.3 152.3 (49.1-355.5)   Female 24 25.4 94.5 (60.5-140.5) 
Lung and Bronchus            All Sites / Types     
Male 71 51.7 137.4 (107.3-173.3)   Male 418 359.4 116.3 (105.4-128.0) 
Female 74 51.8 143.0 (112.2-179.5)   Female 408 362.4 112.6 (101.9-124.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
319 
Warren 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 5 5.1 98.2 (31.6-229.1)   Male 2 3.4 nc (nc-nc) 
Female 1 1.9 nc (nc-nc)   Female 2 2.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 1.1 nc (nc-nc)   Male 2 1.1 nc (nc-nc) 
Female 1 0.9 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 2 3.1 nc (nc-nc) 
Female 15 21.8 68.7 (38.4-113.4)   Female 2 2.6 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 2.8 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 8 5.7 140.9 (60.7-277.6)             
Female 6 5.5 110.0 (40.2-239.5)   Female 0 1.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 1.4 nc (nc-nc)   Male 4 2.0 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 0 1.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 13 17.9 72.5 (38.6-123.9) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 3.3 nc (nc-nc)   Male 1 1.2 nc (nc-nc) 
Female 1 1.7 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Larynx            Testis     
Male 0 0.8 nc (nc-nc)   Male 3 0.9 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 2.1 nc (nc-nc)   Male 0 1.5 nc (nc-nc) 
Female 1 1.5 nc (nc-nc)   Female 3 4.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.9 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 7 4.7 150.0 (60.1-309.1) 
Lung and Bronchus            All Sites / Types     
Male 8 9.2 87.1 (37.5-171.7)   Male 64 70.4 90.9 (70.0-116.1) 
Female 9 9.7 92.5 (42.2-175.5)   Female 53 71.6 74.1 (55.5-96.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Warwick 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 1.4 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.2 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 3 4.4 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 1.4 nc (nc-nc)             
Female 1 1.0 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.4 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 5 4.1 120.6 (38.9-281.5) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.7 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.5 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.5 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 2.5 nc (nc-nc)   Male 13 17.1 76.1 (40.5-130.1) 
Female 3 2.1 nc (nc-nc)   Female 14 14.4 97.0 (53.0-162.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Washington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 0.9 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.2 nc (nc-nc)   Male 1 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 4 3.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 1.0 nc (nc-nc)             
Female 1 0.7 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.0 nc (nc-nc)   Male 0 3.5 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.6 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.4 nc (nc-nc)             
Female 1 0.1 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 1.7 nc (nc-nc)   Male 5 12.7 39.5 (12.7-92.2) 
Female 2 1.4 nc (nc-nc)   Female 9 9.9 91.3 (41.7-173.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Watertown 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 29 29.4 98.5 (66.0-141.5)   Male 12 19.7 61.0 (31.5-106.6) 
Female 8 12.7 62.9 (27.1-123.9)   Female 21 18.2 115.6 (71.6-176.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 6.3 95.9 (35.0-208.8)   Male 8 6.2 129.4 (55.7-255.0) 
Female 7 5.9 118.7 (47.6-244.7)   Female 5 6.0 83.9 (27.0-195.7) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.1 nc (nc-nc)   Male 13 17.6 74.0 (39.3-126.5) 
Female 160 140.5 113.8 (96.9-132.9)   Female 16 17.6 90.9 (51.9-147.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 12 14.8 81.3 (41.9-142.0) 
Female 9 4.7 192.8 (88.0-366.0)   Female 13 7.8 166.8 (88.7-285.3) 
Colon / Rectum            Ovary     
Male 42 32.2 130.4 (94.0-176.3)             
Female 33 35.5 92.8 (63.9-130.4)   Female 17 12.3 138.6 (80.7-221.9) 
Esophagus            Pancreas     
Male 7 7.6 92.7 (37.1-191.0)   Male 13 11.0 117.7 (62.6-201.4) 
Female 1 2.5 nc (nc-nc)   Female 17 13.3 128.1 (74.6-205.0) 
Hodgkin Lymphoma            Prostate     
Male 4 2.8 nc (nc-nc)   Male 72 90.7 79.4 (62.1-100.0) 
Female 2 2.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 14 18.0 78.0 (42.6-130.8)   Male 10 7.1 141.7 (67.8-260.5) 
Female 3 11.4 nc (nc-nc)   Female 8 5.0 158.9 (68.4-313.2) 
Larynx            Testis     
Male 7 4.4 157.7 (63.2-324.9)   Male 5 5.9 84.8 (27.3-198.0) 
Female 0 1.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 17 12.5 135.7 (79.0-217.2)   Male 9 8.8 102.3 (46.7-194.2) 
Female 13 10.3 125.8 (66.9-215.1)   Female 35 27.5 127.2 (88.6-177.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 10.8 55.5 (20.3-120.9)             
Female 5 4.2 118.4 (38.2-276.3)   Female 27 32.9 82.1 (54.1-119.5) 
Lung and Bronchus            All Sites / Types     
Male 52 51.5 100.9 (75.4-132.4)   Male 373 389.1 95.9 (86.4-106.1) 
Female 60 67.7 88.7 (67.7-114.1)   Female 499 478.1 104.4 (95.4-113.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Wayland 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 17 17.9 95.1 (55.4-152.3)   Male 23 11.3 204.1 (129.4-306.3) 
Female 6 6.4 93.4 (34.1-203.2)   Female 12 8.6 139.6 (72.1-243.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 3.1 nc (nc-nc)   Male 4 3.7 nc (nc-nc) 
Female 4 2.7 nc (nc-nc)   Female 4 3.0 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.6 nc (nc-nc)   Male 8 9.9 80.9 (34.9-159.5) 
Female 77 72.5 106.2 (83.8-132.7)   Female 12 8.7 137.3 (70.9-239.9) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 8.2 60.8 (19.6-141.8) 
Female 3 2.2 nc (nc-nc)   Female 4 3.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 13 18.5 70.3 (37.4-120.2)             
Female 11 18.0 61.2 (30.5-109.4)   Female 4 6.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 4.5 nc (nc-nc)   Male 5 6.6 76.2 (24.5-177.7) 
Female 1 1.2 nc (nc-nc)   Female 8 6.6 121.5 (52.3-239.5) 
Hodgkin Lymphoma            Prostate     
Male 2 1.0 nc (nc-nc)   Male 65 51.9 125.3 (96.7-159.7) 
Female 2 0.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 10.1 69.6 (27.9-143.3)   Male 2 4.2 nc (nc-nc) 
Female 2 5.8 nc (nc-nc)   Female 0 2.5 nc (nc-nc) 
Larynx            Testis     
Male 0 2.6 nc (nc-nc)   Male 3 1.7 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 6 6.9 86.9 (31.7-189.2)   Male 6 4.2 141.7 (51.8-308.5) 
Female 3 4.9 nc (nc-nc)   Female 12 12.2 98.5 (50.8-172.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 6.1 nc (nc-nc)             
Female 0 2.1 nc (nc-nc)   Female 13 16.6 78.4 (41.7-134.2) 
Lung and Bronchus            All Sites / Types     
Male 16 31.4 51.0 (29.1-82.8)   Male 203 221.9 91.5 (79.3-105.0) 
Female 19 34.6 54.9 (33.0-85.8)   Female 210 239.0 87.9 (76.4-100.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Webster 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 25 21.3 117.4 (76.0-173.3)   Male 12 13.0 92.6 (47.8-161.8) 
Female 5 7.2 69.0 (22.2-161.0)   Female 8 9.8 81.6 (35.2-160.9) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 3.6 nc (nc-nc)   Male 4 4.2 nc (nc-nc) 
Female 2 3.2 nc (nc-nc)   Female 6 3.3 180.9 (66.1-393.7) 
Breast            Non-Hodgkin Lymphoma     
Male 3 0.7 nc (nc-nc)   Male 13 11.4 113.8 (60.5-194.6) 
Female 81 76.3 106.2 (84.3-132.0)   Female 11 9.7 113.0 (56.3-202.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 16 9.2 174.3 (99.5-283.0) 
Female 4 2.6 nc (nc-nc)   Female 5 4.3 117.5 (37.9-274.1) 
Colon / Rectum            Ovary     
Male 20 21.5 93.0 (56.8-143.6)             
Female 19 20.9 90.8 (54.6-141.8)   Female 14 6.7 208.6 (113.9-350.0) 
Esophagus            Pancreas     
Male 7 5.1 136.7 (54.8-281.7)   Male 8 7.6 105.2 (45.3-207.3) 
Female 3 1.4 nc (nc-nc)   Female 10 7.6 131.2 (62.8-241.2) 
Hodgkin Lymphoma            Prostate     
Male 2 1.3 nc (nc-nc)   Male 58 59.1 98.2 (74.6-127.0) 
Female 1 1.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 11 11.2 97.9 (48.8-175.1)   Male 2 4.8 nc (nc-nc) 
Female 10 6.2 160.5 (76.8-295.1)   Female 2 2.9 nc (nc-nc) 
Larynx            Testis     
Male 6 2.9 205.3 (75.0-447.0)   Male 3 2.3 nc (nc-nc) 
Female 2 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 8.1 86.3 (34.6-177.8)   Male 5 4.7 107.0 (34.5-249.8) 
Female 6 5.9 101.5 (37.1-221.0)   Female 16 14.3 111.7 (63.8-181.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 10 6.9 145.0 (69.4-266.6)             
Female 5 2.4 212.0 (68.3-494.9)   Female 22 16.8 130.6 (81.8-197.8) 
Lung and Bronchus            All Sites / Types     
Male 49 36.3 134.9 (99.8-178.3)   Male 292 256.2 114.0 (101.3-127.8) 
Female 59 36.9 159.8 (121.7-206.2)   Female 321 262.6 122.3 (109.2-136.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
325 
Wellesley 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 19 30.2 62.9 (37.8-98.2)   Male 35 19.0 183.8 (128.0-255.6) 
Female 8 9.9 80.6 (34.7-158.8)   Female 26 14.3 181.8 (118.7-266.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 5.5 nc (nc-nc)   Male 6 6.2 96.8 (35.3-210.7) 
Female 7 5.1 136.1 (54.5-280.5)   Female 7 4.7 150.5 (60.3-310.1) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.1 nc (nc-nc)   Male 15 16.9 88.6 (49.6-146.2) 
Female 147 117.4 125.2 (105.8-147.2)   Female 7 14.0 50.0 (20.0-103.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 10 14.0 71.7 (34.3-131.8) 
Female 3 4.0 nc (nc-nc)   Female 5 6.2 80.8 (26.0-188.5) 
Colon / Rectum            Ovary     
Male 23 31.3 73.4 (46.5-110.2)             
Female 24 29.2 82.3 (52.7-122.4)   Female 11 9.9 110.6 (55.1-198.0) 
Esophagus            Pancreas     
Male 1 7.5 nc (nc-nc)   Male 8 11.1 72.1 (31.0-142.1) 
Female 1 1.9 nc (nc-nc)   Female 9 10.3 87.3 (39.8-165.7) 
Hodgkin Lymphoma            Prostate     
Male 2 1.8 nc (nc-nc)   Male 113 88.4 127.9 (105.4-153.7) 
Female 3 1.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 15 17.2 87.4 (48.9-144.2)   Male 7 7.0 99.5 (39.8-204.9) 
Female 5 9.2 54.5 (17.6-127.1)   Female 2 4.1 nc (nc-nc) 
Larynx            Testis     
Male 3 4.4 nc (nc-nc)   Male 3 3.2 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 12 12.0 99.9 (51.5-174.4)   Male 7 7.4 95.0 (38.1-195.7) 
Female 9 8.4 106.5 (48.6-202.3)   Female 21 22.4 93.8 (58.0-143.3) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 10.3 58.2 (21.3-126.7)             
Female 1 3.3 nc (nc-nc)   Female 26 25.4 102.5 (66.9-150.1) 
Lung and Bronchus            All Sites / Types     
Male 18 52.5 34.3 (20.3-54.2)   Male 322 377.5 85.3 (76.2-95.2) 
Female 35 52.0 67.3 (46.9-93.6)   Female 387 385.6 100.4 (90.6-110.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Wellfleet 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 4 6.2 nc (nc-nc)   Male 5 3.6 138.6 (44.7-323.5) 
Female 2 2.8 nc (nc-nc)   Female 4 3.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.9 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 2 1.0 nc (nc-nc)   Female 0 1.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 7 3.1 223.8 (89.7-461.1) 
Female 22 25.8 85.4 (53.5-129.3)   Female 1 3.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 2.6 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 7 5.8 121.1 (48.5-249.6)             
Female 4 7.1 nc (nc-nc)   Female 3 2.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 1.5 nc (nc-nc)   Male 0 2.2 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 5 2.9 173.6 (55.9-405.2) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 15 19.0 78.8 (44.1-130.0) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 3 3.2 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 2 2.2 nc (nc-nc)   Female 0 1.0 nc (nc-nc) 
Larynx            Testis     
Male 3 0.9 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 2.2 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 1 1.9 nc (nc-nc)   Female 1 3.2 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 2.0 nc (nc-nc)             
Female 1 0.9 nc (nc-nc)   Female 4 6.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 3 11.3 nc (nc-nc)   Male 63 74.5 84.5 (64.9-108.1) 
Female 10 14.8 67.7 (32.4-124.4)   Female 71 90.5 78.5 (61.3-99.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Wendell 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 1.2 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.2 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 2 4.9 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 1.2 nc (nc-nc)             
Female 0 0.9 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.3 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 2 4.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 0.8 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.5 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 2 0.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.5 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 2 1.2 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 4 2.3 nc (nc-nc)   Male 14 16.8 83.5 (45.6-140.1) 
Female 3 2.1 nc (nc-nc)   Female 11 15.1 73.0 (36.4-130.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
328 
Wenham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 6 5.8 103.9 (38.0-226.3)   Male 6 3.4 176.0 (64.3-383.1) 
Female 1 2.0 nc (nc-nc)   Female 7 2.6 272.2 (109.0-560.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.9 nc (nc-nc)   Male 1 1.1 nc (nc-nc) 
Female 2 1.0 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 5 3.1 162.4 (52.3-379.0) 
Female 27 20.7 130.5 (86.0-189.9)   Female 2 2.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 2.2 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 5.6 nc (nc-nc)             
Female 8 5.7 139.2 (59.9-274.2)   Female 1 1.8 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 1.3 nc (nc-nc)   Male 2 2.0 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 1 2.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 20 14.0 142.9 (87.3-220.7) 
Female 1 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 2 2.8 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 1 1.7 nc (nc-nc)   Female 2 0.8 nc (nc-nc) 
Larynx            Testis     
Male 0 0.8 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 1 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 2.2 nc (nc-nc)   Male 3 1.1 nc (nc-nc) 
Female 1 1.6 nc (nc-nc)   Female 4 3.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.8 nc (nc-nc)             
Female 0 0.7 nc (nc-nc)   Female 6 4.6 131.3 (48.0-285.9) 
Lung and Bronchus            All Sites / Types     
Male 3 9.8 nc (nc-nc)   Male 66 65.8 100.3 (77.6-127.6) 
Female 11 10.1 109.2 (54.4-195.3)   Female 83 71.2 116.6 (92.9-144.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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West Boylston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 17 9.0 187.9 (109.4-300.8)   Male 8 5.9 134.6 (58.0-265.3) 
Female 5 3.1 159.6 (51.4-372.4)   Female 3 3.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 1.9 nc (nc-nc)   Male 1 1.9 nc (nc-nc) 
Female 3 1.2 nc (nc-nc)   Female 2 1.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.3 nc (nc-nc)   Male 3 5.3 nc (nc-nc) 
Female 23 29.8 77.1 (48.9-115.7)   Female 4 4.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 5 4.4 113.4 (36.6-264.7) 
Female 1 0.9 nc (nc-nc)   Female 2 1.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 5 9.5 52.8 (17.0-123.3)             
Female 7 8.8 79.9 (32.0-164.7)   Female 5 2.7 187.2 (60.3-436.9) 
Esophagus            Pancreas     
Male 2 2.3 nc (nc-nc)   Male 3 3.4 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 3 3.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 1.0 nc (nc-nc)   Male 28 28.2 99.3 (66.0-143.5) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 9 5.3 168.3 (76.8-319.5)   Male 0 2.1 nc (nc-nc) 
Female 3 2.5 nc (nc-nc)   Female 1 1.2 nc (nc-nc) 
Larynx            Testis     
Male 1 1.3 nc (nc-nc)   Male 2 1.9 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 3.8 nc (nc-nc)   Male 1 2.6 nc (nc-nc) 
Female 4 2.4 nc (nc-nc)   Female 9 4.7 191.8 (87.5-364.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 3.2 nc (nc-nc)             
Female 0 1.0 nc (nc-nc)   Female 5 6.8 73.4 (23.7-171.3) 
Lung and Bronchus            All Sites / Types     
Male 25 15.9 157.1 (101.6-231.9)   Male 136 118.7 114.6 (96.1-135.5) 
Female 13 15.8 82.4 (43.9-141.0)   Female 108 105.6 102.2 (83.9-123.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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West Bridgewater 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 10 9.6 104.0 (49.8-191.2)   Male 10 5.9 170.8 (81.8-314.2) 
Female 3 2.7 nc (nc-nc)   Female 3 3.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 1.6 nc (nc-nc)   Male 0 1.9 nc (nc-nc) 
Female 2 1.3 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 9 5.2 172.5 (78.7-327.5) 
Female 38 31.5 120.6 (85.4-165.6)   Female 8 3.8 211.2 (90.9-416.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 4.2 167.3 (67.0-344.8) 
Female 1 1.0 nc (nc-nc)   Female 2 1.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 8 9.7 82.3 (35.4-162.2)             
Female 17 7.9 215.2 (125.3-344.5)   Female 2 2.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 4 2.3 nc (nc-nc)   Male 1 3.5 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 3 2.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.6 nc (nc-nc)   Male 21 27.3 76.9 (47.6-117.6) 
Female 0 0.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 5.1 97.9 (31.5-228.4)   Male 3 2.2 nc (nc-nc) 
Female 3 2.5 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Larynx            Testis     
Male 2 1.3 nc (nc-nc)   Male 3 1.0 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 3.7 nc (nc-nc)   Male 2 2.1 nc (nc-nc) 
Female 1 2.2 nc (nc-nc)   Female 11 5.7 192.7 (96.1-344.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 3.2 nc (nc-nc)             
Female 0 0.9 nc (nc-nc)   Female 5 7.2 69.2 (22.3-161.6) 
Lung and Bronchus            All Sites / Types     
Male 18 16.4 110.1 (65.2-174.0)   Male 117 116.6 100.3 (83.0-120.3) 
Female 16 14.1 113.1 (64.6-183.7)   Female 124 104.1 119.1 (99.1-142.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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West Brookfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 5.3 nc (nc-nc)   Male 5 3.3 152.7 (49.2-356.4) 
Female 0 2.1 nc (nc-nc)   Female 1 2.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.9 nc (nc-nc)   Male 0 1.1 nc (nc-nc) 
Female 3 0.8 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 2 2.9 nc (nc-nc) 
Female 16 19.2 83.2 (47.5-135.2)   Female 3 2.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 2.4 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 3 1.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 5.3 nc (nc-nc)             
Female 2 5.8 nc (nc-nc)   Female 4 1.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.3 nc (nc-nc)   Male 0 1.9 nc (nc-nc) 
Female 1 0.4 nc (nc-nc)   Female 2 2.2 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.3 nc (nc-nc)   Male 11 16.2 68.1 (33.9-121.8) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 2.9 169.6 (54.6-395.7)   Male 2 1.2 nc (nc-nc) 
Female 2 1.6 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Larynx            Testis     
Male 0 0.8 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 2.0 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 1.6 nc (nc-nc)   Female 1 3.0 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 1.9 nc (nc-nc)             
Female 0 0.7 nc (nc-nc)   Female 6 4.4 134.9 (49.3-293.6) 
Lung and Bronchus            All Sites / Types     
Male 9 9.2 97.4 (44.5-185.0)   Male 50 66.1 75.7 (56.2-99.8) 
Female 13 10.3 126.1 (67.1-215.6)   Female 61 69.0 88.4 (67.6-113.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
332 
West Newbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 5.3 149.8 (64.5-295.1)   Male 3 3.4 nc (nc-nc) 
Female 0 1.6 nc (nc-nc)   Female 3 2.4 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 1.0 nc (nc-nc)   Male 2 1.1 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.2 nc (nc-nc)   Male 2 3.0 nc (nc-nc) 
Female 22 20.2 108.7 (68.1-164.6)   Female 0 2.3 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 2.7 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 5.7 nc (nc-nc)             
Female 2 4.7 nc (nc-nc)   Female 2 1.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 1.4 nc (nc-nc)   Male 1 2.0 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 1 1.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.3 nc (nc-nc)   Male 23 17.4 132.4 (83.9-198.7) 
Female 0 0.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 7 3.2 219.2 (87.8-451.6)   Male 2 1.3 nc (nc-nc) 
Female 1 1.5 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Larynx            Testis     
Male 0 0.8 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 2.2 nc (nc-nc)   Male 0 1.4 nc (nc-nc) 
Female 1 1.3 nc (nc-nc)   Female 3 3.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 2.0 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 4 4.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 9.3 nc (nc-nc)   Male 66 69.7 94.7 (73.2-120.5) 
Female 4 8.4 nc (nc-nc)   Female 50 64.4 77.7 (57.6-102.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
333 
West Springfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 35 29.4 118.9 (82.8-165.4)   Male 14 19.0 73.9 (40.4-124.0) 
Female 11 11.5 95.5 (47.6-170.8)   Female 9 15.9 56.5 (25.8-107.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 5.8 120.5 (48.3-248.3)   Male 2 6.1 nc (nc-nc) 
Female 9 5.2 172.9 (78.9-328.2)   Female 4 5.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 1.0 nc (nc-nc)   Male 18 17.0 106.1 (62.9-167.8) 
Female 117 127.4 91.8 (75.9-110.0)   Female 16 15.7 102.1 (58.3-165.8) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 18 14.3 125.5 (74.3-198.3) 
Female 8 4.1 193.1 (83.2-380.6)   Female 7 7.0 100.4 (40.2-207.0) 
Colon / Rectum            Ovary     
Male 52 30.7 169.1 (126.3-221.8)             
Female 37 32.9 112.3 (79.1-154.8)   Female 7 11.1 63.2 (25.3-130.3) 
Esophagus            Pancreas     
Male 13 7.6 171.7 (91.3-293.6)   Male 10 11.0 90.8 (43.5-167.1) 
Female 1 2.2 nc (nc-nc)   Female 10 12.0 83.2 (39.9-153.1) 
Hodgkin Lymphoma            Prostate     
Male 1 2.3 nc (nc-nc)   Male 79 91.9 85.9 (68.0-107.1) 
Female 2 2.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 15 17.3 86.9 (48.6-143.4)   Male 5 6.9 72.2 (23.3-168.4) 
Female 13 10.2 126.9 (67.5-217.0)   Female 5 4.6 108.4 (34.9-253.1) 
Larynx            Testis     
Male 2 4.4 nc (nc-nc)   Male 4 4.1 nc (nc-nc) 
Female 2 1.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 12 12.2 98.6 (50.9-172.3)   Male 10 7.7 130.5 (62.5-240.0) 
Female 13 9.4 139.0 (73.9-237.7)   Female 18 23.5 76.5 (45.3-120.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 12 10.8 111.0 (57.3-193.9)             
Female 4 3.9 nc (nc-nc)   Female 27 28.8 93.7 (61.7-136.3) 
Lung and Bronchus            All Sites / Types     
Male 54 51.6 104.6 (78.6-136.5)   Male 389 381.3 102.0 (92.1-112.7) 
Female 82 60.1 136.4 (108.5-169.3)   Female 439 429.1 102.3 (93.0-112.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
334 
West Stockbridge 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 2.1 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 1 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 4 1.1 nc (nc-nc) 
Female 4 7.1 nc (nc-nc)   Female 2 0.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 1.0 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 2 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 2.1 nc (nc-nc)             
Female 1 1.6 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.6 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 6 7.1 84.5 (30.9-184.0) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.2 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 1 0.6 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 0.8 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.8 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 3 1.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 7 3.9 179.9 (72.1-370.7)   Male 27 27.1 99.5 (65.6-144.8) 
Female 0 3.4 nc (nc-nc)   Female 15 23.0 65.1 (36.4-107.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
335 
West Tisbury 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 8 3.1 257.5 (110.9-507.3)   Male 6 1.9 311.3 (113.7-677.6) 
Female 1 1.6 nc (nc-nc)   Female 3 2.2 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 0.6 nc (nc-nc)   Male 2 0.7 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 4 1.7 nc (nc-nc) 
Female 20 18.4 108.8 (66.4-168.1)   Female 4 2.2 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 1.5 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 3.1 nc (nc-nc)             
Female 4 4.6 nc (nc-nc)   Female 2 1.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.9 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 17 11.5 147.6 (85.9-236.3) 
Female 1 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 1.9 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 1.5 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Larynx            Testis     
Male 3 0.5 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.2 nc (nc-nc)   Male 2 0.7 nc (nc-nc) 
Female 0 1.3 nc (nc-nc)   Female 1 2.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 1.2 nc (nc-nc)             
Female 0 0.6 nc (nc-nc)   Female 3 4.7 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 2 5.9 nc (nc-nc)   Male 63 41.6 151.4 (116.3-193.7) 
Female 4 8.3 nc (nc-nc)   Female 49 60.9 80.5 (59.5-106.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Westborough 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 14 18.2 76.8 (41.9-128.8)   Male 14 12.2 114.9 (62.8-192.8) 
Female 7 6.5 107.0 (42.8-220.4)   Female 9 9.7 92.8 (42.3-176.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 3.7 nc (nc-nc)   Male 4 3.9 nc (nc-nc) 
Female 6 3.2 188.6 (68.9-410.4)   Female 2 3.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.7 nc (nc-nc)   Male 8 10.8 73.9 (31.8-145.7) 
Female 87 77.7 112.0 (89.7-138.1)   Female 5 9.2 54.1 (17.4-126.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 9.2 98.0 (44.7-186.0) 
Female 0 2.7 nc (nc-nc)   Female 3 4.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 16 20.1 79.6 (45.5-129.3)             
Female 14 19.5 72.0 (39.3-120.7)   Female 5 6.5 76.6 (24.7-178.8) 
Esophagus            Pancreas     
Male 4 4.7 nc (nc-nc)   Male 8 6.9 116.8 (50.3-230.1) 
Female 3 1.3 nc (nc-nc)   Female 9 6.8 131.5 (60.0-249.6) 
Hodgkin Lymphoma            Prostate     
Male 2 1.5 nc (nc-nc)   Male 59 55.0 107.3 (81.7-138.4) 
Female 3 1.3 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 5 11.2 44.8 (14.4-104.6)   Male 5 4.4 114.0 (36.8-266.1) 
Female 3 6.1 nc (nc-nc)   Female 3 2.8 nc (nc-nc) 
Larynx            Testis     
Male 1 2.7 nc (nc-nc)   Male 5 3.1 158.9 (51.2-370.7) 
Female 0 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 7.6 131.6 (63.0-242.1)   Male 7 5.4 130.6 (52.3-269.2) 
Female 10 5.6 179.6 (86.0-330.3)   Female 14 15.4 91.1 (49.7-152.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 6.6 91.1 (33.3-198.4)             
Female 2 2.2 nc (nc-nc)   Female 22 16.8 130.8 (82.0-198.1) 
Lung and Bronchus            All Sites / Types     
Male 18 31.9 56.4 (33.4-89.1)   Male 222 238.7 93.0 (81.2-106.1) 
Female 32 34.0 94.1 (64.3-132.8)   Female 261 255.4 102.2 (90.2-115.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Westfield 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 44 43.8 100.5 (73.0-134.9)   Male 20 27.7 72.2 (44.1-111.5) 
Female 12 15.8 76.1 (39.3-132.9)   Female 19 21.5 88.2 (53.1-137.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 8.4 nc (nc-nc)   Male 10 9.0 111.3 (53.3-204.8) 
Female 4 7.3 nc (nc-nc)   Female 4 7.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.5 nc (nc-nc)   Male 22 24.7 89.0 (55.8-134.7) 
Female 196 174.8 112.1 (97.0-129.0)   Female 28 21.6 129.7 (86.2-187.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 24 20.5 116.9 (74.9-174.0) 
Female 8 5.5 145.8 (62.8-287.4)   Female 8 9.6 83.4 (35.9-164.3) 
Colon / Rectum            Ovary     
Male 67 45.1 148.7 (115.2-188.8)             
Female 50 44.6 112.1 (83.2-147.8)   Female 19 15.2 125.2 (75.4-195.6) 
Esophagus            Pancreas     
Male 19 11.1 171.4 (103.1-267.7)   Male 13 16.1 80.6 (42.9-137.9) 
Female 4 3.1 nc (nc-nc)   Female 10 16.4 60.9 (29.2-112.1) 
Hodgkin Lymphoma            Prostate     
Male 5 3.2 155.4 (50.1-362.5)   Male 125 132.4 94.4 (78.6-112.4) 
Female 0 2.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 26 24.9 104.3 (68.1-152.9)   Male 12 10.2 117.6 (60.7-205.4) 
Female 7 14.1 49.8 (19.9-102.6)   Female 11 6.3 174.7 (87.1-312.7) 
Larynx            Testis     
Male 5 6.4 78.0 (25.1-182.0)   Male 11 5.6 195.4 (97.4-349.7) 
Female 4 2.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 18 17.8 101.2 (60.0-160.0)   Male 5 10.8 46.1 (14.9-107.6) 
Female 9 12.8 70.4 (32.1-133.6)   Female 23 31.3 73.4 (46.5-110.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 10 15.4 64.8 (31.0-119.1)             
Female 4 5.3 nc (nc-nc)   Female 34 40.2 84.5 (58.5-118.1) 
Lung and Bronchus            All Sites / Types     
Male 86 76.7 112.1 (89.7-138.5)   Male 571 555.8 102.7 (94.5-111.5) 
Female 81 83.1 97.5 (77.5-121.2)   Female 565 587.7 96.1 (88.4-104.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
338 
Westford 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 15 22.3 67.2 (37.6-110.9)   Male 14 15.5 90.6 (49.5-152.0) 
Female 3 7.1 nc (nc-nc)   Female 16 11.6 137.7 (78.7-223.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 8 4.8 168.2 (72.4-331.4)   Male 8 5.0 161.6 (69.6-318.4) 
Female 4 3.8 nc (nc-nc)   Female 2 3.5 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 2 0.8 nc (nc-nc)   Male 13 13.6 95.4 (50.7-163.1) 
Female 114 97.9 116.4 (96.0-139.8)   Female 8 10.6 75.4 (32.5-148.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 12.4 48.4 (17.7-105.4) 
Female 3 3.5 nc (nc-nc)   Female 4 4.9 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 21 25.5 82.5 (51.0-126.1)             
Female 37 21.5 171.9 (121.0-236.9)   Female 5 8.0 62.1 (20.0-145.0) 
Esophagus            Pancreas     
Male 4 6.1 nc (nc-nc)   Male 8 8.7 91.9 (39.5-181.0) 
Female 2 1.4 nc (nc-nc)   Female 5 7.2 69.0 (22.2-161.0) 
Hodgkin Lymphoma            Prostate     
Male 1 1.8 nc (nc-nc)   Male 92 74.7 123.2 (99.3-151.1) 
Female 3 1.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 11 14.9 74.0 (36.9-132.4)   Male 7 5.5 126.4 (50.6-260.4) 
Female 1 7.3 nc (nc-nc)   Female 1 3.0 nc (nc-nc) 
Larynx            Testis     
Male 5 3.6 138.7 (44.7-323.8)   Male 3 3.3 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 9.5 105.3 (50.4-193.7)   Male 10 7.0 142.9 (68.4-262.8) 
Female 7 6.2 113.8 (45.6-234.5)   Female 17 19.8 85.9 (50.0-137.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 8.7 57.4 (18.5-133.9)             
Female 1 2.5 nc (nc-nc)   Female 32 21.5 149.0 (101.9-210.4) 
Lung and Bronchus            All Sites / Types     
Male 26 40.5 64.2 (42.0-94.1)   Male 295 307.2 96.0 (85.4-107.6) 
Female 31 39.0 79.5 (54.0-112.8)   Female 317 304.9 104.0 (92.8-116.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
339 
Westhampton 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 2 2.4 nc (nc-nc)   Male 6 1.6 379.3 (138.5-825.7) 
Female 0 0.7 nc (nc-nc)   Female 1 1.0 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.4 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.4 nc (nc-nc) 
Female 9 8.5 106.0 (48.4-201.2)   Female 0 1.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 0 2.6 nc (nc-nc)             
Female 3 1.9 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.6 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 8 8.1 98.5 (42.4-194.1) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.5 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.7 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.4 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.9 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 0.9 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 1 2.0 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 4 4.4 nc (nc-nc)   Male 25 32.0 78.0 (50.5-115.2) 
Female 2 3.7 nc (nc-nc)   Female 18 26.9 66.8 (39.6-105.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
340 
Westminster 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 7 8.2 85.4 (34.2-175.9)   Male 6 5.5 109.5 (40.0-238.4) 
Female 3 2.2 nc (nc-nc)   Female 7 3.7 189.0 (75.7-389.5) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.6 nc (nc-nc)   Male 0 1.8 nc (nc-nc) 
Female 1 1.2 nc (nc-nc)   Female 1 1.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 6 4.9 123.3 (45.0-268.4) 
Female 42 31.3 134.0 (96.6-181.1)   Female 1 3.4 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 3 4.4 nc (nc-nc) 
Female 2 1.1 nc (nc-nc)   Female 3 1.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 4 9.1 nc (nc-nc)             
Female 7 6.5 108.0 (43.3-222.6)   Female 3 2.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 2.2 nc (nc-nc)   Male 0 3.2 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 2 2.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.6 nc (nc-nc)   Male 22 28.0 78.5 (49.2-118.9) 
Female 1 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 5.2 154.0 (66.3-303.5)   Male 3 2.0 nc (nc-nc) 
Female 4 2.3 nc (nc-nc)   Female 0 0.9 nc (nc-nc) 
Larynx            Testis     
Male 1 1.3 nc (nc-nc)   Male 2 1.2 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 3.4 nc (nc-nc)   Male 1 2.4 nc (nc-nc) 
Female 2 1.9 nc (nc-nc)   Female 9 6.3 143.5 (65.5-272.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 3.2 nc (nc-nc)             
Female 0 0.8 nc (nc-nc)   Female 9 7.4 122.1 (55.7-231.8) 
Lung and Bronchus            All Sites / Types     
Male 8 14.3 56.0 (24.1-110.3)   Male 88 111.2 79.1 (63.5-97.5) 
Female 14 12.3 113.8 (62.2-190.9)   Female 112 97.0 115.5 (95.1-138.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
341 
Weston 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 17 15.4 110.3 (64.2-176.6)   Male 14 9.6 145.4 (79.4-244.0) 
Female 1 5.1 nc (nc-nc)   Female 7 6.9 101.0 (40.4-208.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 2.7 nc (nc-nc)   Male 3 3.1 nc (nc-nc) 
Female 0 2.3 nc (nc-nc)   Female 4 2.4 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.5 nc (nc-nc)   Male 12 8.4 142.2 (73.4-248.3) 
Female 56 57.2 97.9 (73.9-127.1)   Female 3 6.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 7.1 98.8 (39.6-203.6) 
Female 2 1.8 nc (nc-nc)   Female 1 3.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 11 15.6 70.4 (35.1-125.9)             
Female 11 14.6 75.3 (37.5-134.7)   Female 2 4.9 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 3.9 nc (nc-nc)   Male 3 5.7 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 13 5.3 245.6 (130.7-420.1) 
Hodgkin Lymphoma            Prostate     
Male 0 0.9 nc (nc-nc)   Male 45 46.1 97.6 (71.2-130.7) 
Female 0 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 8.7 69.3 (25.3-150.8)   Male 1 3.6 nc (nc-nc) 
Female 0 4.6 nc (nc-nc)   Female 0 2.1 nc (nc-nc) 
Larynx            Testis     
Male 1 2.2 nc (nc-nc)   Male 2 1.4 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)             
Leukemia            Thyroid     
Male 5 6.0 83.3 (26.8-194.3)   Male 5 3.5 141.7 (45.7-330.7) 
Female 5 4.1 120.6 (38.9-281.4)   Female 8 10.0 80.3 (34.6-158.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 5 5.3 94.6 (30.5-220.8)             
Female 1 1.7 nc (nc-nc)   Female 9 12.8 70.1 (32.0-133.0) 
Lung and Bronchus            All Sites / Types     
Male 16 27.2 58.8 (33.6-95.5)   Male 176 192.1 91.6 (78.6-106.2) 
Female 11 26.6 41.4 (20.6-74.0)   Female 145 190.1 76.3 (64.4-89.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
342 
Westport 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 27 22.8 118.3 (77.9-172.1)   Male 13 13.8 94.0 (50.0-160.8) 
Female 4 7.6 nc (nc-nc)   Female 5 10.1 49.6 (16.0-115.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 3.8 nc (nc-nc)   Male 6 4.6 131.7 (48.1-286.7) 
Female 2 3.2 nc (nc-nc)   Female 5 3.6 139.8 (45.1-326.3) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.8 nc (nc-nc)   Male 15 12.3 122.3 (68.4-201.8) 
Female 78 84.2 92.7 (73.3-115.7)   Female 16 10.3 155.0 (88.5-251.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 9.9 71.0 (28.4-146.2) 
Female 2 2.6 nc (nc-nc)   Female 4 4.6 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 23 22.5 102.0 (64.7-153.1)             
Female 21 21.2 98.9 (61.2-151.2)   Female 6 7.1 84.4 (30.8-183.6) 
Esophagus            Pancreas     
Male 8 5.6 142.2 (61.2-280.3)   Male 12 8.2 145.8 (75.3-254.8) 
Female 0 1.5 nc (nc-nc)   Female 11 8.0 136.8 (68.2-244.7) 
Hodgkin Lymphoma            Prostate     
Male 1 1.3 nc (nc-nc)   Male 95 67.6 140.6 (113.7-171.8) 
Female 0 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 12 12.3 97.6 (50.4-170.6)   Male 5 5.2 96.0 (30.9-224.0) 
Female 6 6.7 89.7 (32.8-195.3)   Female 2 3.0 nc (nc-nc) 
Larynx            Testis     
Male 3 3.2 nc (nc-nc)   Male 5 2.2 226.8 (73.1-529.3) 
Female 0 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 8.6 81.2 (32.5-167.3)   Male 6 5.0 120.2 (43.9-261.7) 
Female 5 5.8 85.9 (27.7-200.4)   Female 17 14.0 121.2 (70.6-194.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 7.5 nc (nc-nc)             
Female 1 2.5 nc (nc-nc)   Female 14 19.7 71.1 (38.8-119.2) 
Lung and Bronchus            All Sites / Types     
Male 37 39.8 93.1 (65.5-128.3)   Male 312 279.0 111.8 (99.8-125.0) 
Female 37 40.3 91.8 (64.6-126.5)   Female 259 280.4 92.4 (81.5-104.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
343 
Westwood 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 18 22.5 79.9 (47.3-126.3)   Male 26 13.6 191.6 (125.1-280.7) 
Female 6 7.8 77.2 (28.2-168.0)   Female 15 9.9 151.7 (84.8-250.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 3.6 nc (nc-nc)   Male 11 4.4 250.9 (125.1-448.9) 
Female 4 3.2 nc (nc-nc)   Female 6 3.5 170.7 (62.3-371.6) 
Breast            Non-Hodgkin Lymphoma     
Male 3 0.7 nc (nc-nc)   Male 8 12.0 66.5 (28.6-131.0) 
Female 103 78.8 130.8 (106.7-158.6)   Female 5 10.2 49.0 (15.8-114.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 9.5 73.4 (29.4-151.3) 
Female 2 2.5 nc (nc-nc)   Female 6 4.4 136.5 (49.8-297.1) 
Colon / Rectum            Ovary     
Male 18 22.8 79.0 (46.8-124.8)             
Female 15 22.7 65.9 (36.9-108.8)   Female 7 6.8 102.3 (41.0-210.7) 
Esophagus            Pancreas     
Male 0 5.3 nc (nc-nc)   Male 13 8.1 161.2 (85.7-275.6) 
Female 1 1.5 nc (nc-nc)   Female 2 8.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 3 1.1 nc (nc-nc)   Male 62 60.0 103.3 (79.2-132.4) 
Female 1 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 12 11.6 103.6 (53.5-181.0)   Male 0 5.1 nc (nc-nc) 
Female 6 6.4 94.0 (34.3-204.5)   Female 2 3.2 nc (nc-nc) 
Larynx            Testis     
Male 4 3.0 nc (nc-nc)   Male 6 1.8 329.8 (120.4-717.9) 
Female 1 0.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 10 8.4 119.6 (57.2-219.9)   Male 4 4.7 nc (nc-nc) 
Female 10 6.2 162.3 (77.7-298.4)   Female 20 13.4 149.6 (91.3-231.0) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 7.3 96.4 (38.6-198.6)             
Female 4 2.5 nc (nc-nc)   Female 18 16.8 106.8 (63.3-168.9) 
Lung and Bronchus            All Sites / Types     
Male 25 37.5 66.6 (43.1-98.3)   Male 259 265.3 97.6 (86.1-110.2) 
Female 31 38.4 80.8 (54.9-114.7)   Female 283 271.7 104.2 (92.4-117.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
344 
Weymouth 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 68 59.9 113.5 (88.1-143.9)   Male 43 38.7 111.0 (80.3-149.5) 
Female 37 25.1 147.3 (103.7-203.0)   Female 53 34.3 154.7 (115.9-202.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 9 11.4 78.8 (36.0-149.6)   Male 12 12.4 97.0 (50.1-169.5) 
Female 10 11.0 91.1 (43.6-167.5)   Female 6 11.8 51.0 (18.6-110.9) 
Breast            Non-Hodgkin Lymphoma     
Male 0 2.1 nc (nc-nc)   Male 40 34.2 116.9 (83.5-159.2) 
Female 290 279.3 103.8 (92.2-116.5)   Female 29 34.4 84.3 (56.4-121.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 27 28.4 94.9 (62.5-138.1) 
Female 1 8.8 nc (nc-nc)   Female 23 15.2 150.9 (95.6-226.4) 
Colon / Rectum            Ovary     
Male 70 62.5 112.1 (87.3-141.6)             
Female 68 70.3 96.7 (75.1-122.6)   Female 22 23.9 91.9 (57.6-139.1) 
Esophagus            Pancreas     
Male 19 15.1 125.7 (75.7-196.4)   Male 18 22.2 81.2 (48.1-128.3) 
Female 8 5.0 161.3 (69.4-317.8)   Female 22 26.1 84.1 (52.7-127.4) 
Hodgkin Lymphoma            Prostate     
Male 6 4.5 133.9 (48.9-291.5)   Male 162 178.7 90.6 (77.2-105.7) 
Female 2 4.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 36 34.7 103.7 (72.6-143.5)   Male 14 14.1 99.5 (54.4-167.0) 
Female 28 22.4 125.2 (83.2-180.9)   Female 7 10.0 70.3 (28.2-144.9) 
Larynx            Testis     
Male 17 8.8 192.4 (112.0-308.0)   Male 10 8.5 117.6 (56.3-216.4) 
Female 3 3.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 18 24.2 74.4 (44.1-117.7)   Male 14 15.6 89.6 (48.9-150.4) 
Female 14 19.8 70.7 (38.6-118.6)   Female 44 49.4 89.0 (64.7-119.5) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 20 21.2 94.5 (57.7-145.9)             
Female 9 8.4 107.0 (48.8-203.1)   Female 71 64.9 109.5 (85.5-138.1) 
Lung and Bronchus            All Sites / Types     
Male 134 106.1 126.3 (105.9-149.6)   Male 813 764.0 106.4 (99.2-114.0) 
Female 154 133.1 115.7 (98.2-135.5)   Female 959 934.4 102.6 (96.2-109.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
345 
Whately 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 1.6 nc (nc-nc)   Male 2 1.1 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 1 0.9 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.0 nc (nc-nc) 
Female 5 7.4 67.4 (21.7-157.3)   Female 0 0.9 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 0.9 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 3 1.7 nc (nc-nc)             
Female 0 1.8 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 0.5 nc (nc-nc)   Male 2 0.6 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.7 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 7 6.2 113.5 (45.5-233.8) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 1.1 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.6 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.7 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 1 1.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.7 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 2 1.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 2.9 nc (nc-nc)   Male 25 22.7 110.4 (71.4-162.9) 
Female 3 3.3 nc (nc-nc)   Female 14 24.3 57.7 (31.5-96.8) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
346 
Whitman 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 21 13.3 157.4 (97.4-240.7)   Male 11 9.2 119.6 (59.6-214.0) 
Female 11 4.8 227.9 (113.6-407.8)   Female 14 7.5 186.1 (101.7-312.3) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 2.9 nc (nc-nc)   Male 1 2.9 nc (nc-nc) 
Female 1 2.5 nc (nc-nc)   Female 1 2.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.5 nc (nc-nc)   Male 4 8.1 nc (nc-nc) 
Female 54 60.9 88.6 (66.6-115.6)   Female 4 7.0 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 9 7.2 124.4 (56.8-236.2) 
Female 4 2.1 nc (nc-nc)   Female 4 3.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 17 14.9 114.2 (66.5-182.8)             
Female 15 14.2 105.9 (59.2-174.6)   Female 2 5.2 nc (nc-nc) 
Esophagus            Pancreas     
Male 5 3.6 139.1 (44.8-324.5)   Male 3 5.2 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)   Female 6 5.0 120.7 (44.1-262.8) 
Hodgkin Lymphoma            Prostate     
Male 1 1.2 nc (nc-nc)   Male 43 44.6 96.4 (69.7-129.8) 
Female 0 1.0 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 20 8.7 228.7 (139.6-353.2)   Male 3 3.3 nc (nc-nc) 
Female 3 4.7 nc (nc-nc)   Female 1 2.0 nc (nc-nc) 
Larynx            Testis     
Male 4 2.1 nc (nc-nc)   Male 2 2.3 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)             
Leukemia            Thyroid     
Male 7 5.7 122.4 (49.0-252.1)   Male 5 4.2 120.3 (38.8-280.7) 
Female 4 4.2 nc (nc-nc)   Female 13 12.2 106.3 (56.6-181.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 5.2 nc (nc-nc)             
Female 0 1.7 nc (nc-nc)   Female 6 13.9 43.2 (15.8-93.9) 
Lung and Bronchus            All Sites / Types     
Male 26 24.3 106.8 (69.8-156.5)   Male 195 183.3 106.4 (92.0-122.4) 
Female 43 26.0 165.2 (119.5-222.5)   Female 203 196.9 103.1 (89.4-118.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
347 
Wilbraham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 17 22.3 76.2 (44.4-122.1)   Male 17 13.5 125.9 (73.3-201.7) 
Female 11 7.0 157.1 (78.3-281.1)   Female 9 9.2 98.4 (44.9-186.7) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 3.6 nc (nc-nc)   Male 3 4.4 nc (nc-nc) 
Female 6 2.9 205.2 (74.9-446.5)   Female 3 3.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.7 nc (nc-nc)   Male 8 11.9 67.3 (29.0-132.6) 
Female 81 74.3 109.0 (86.6-135.5)   Female 10 9.3 107.9 (51.6-198.4) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 9.9 111.6 (55.6-199.7) 
Female 1 2.3 nc (nc-nc)   Female 3 4.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 18 22.4 80.4 (47.6-127.0)             
Female 12 20.5 58.7 (30.3-102.5)   Female 10 6.4 157.0 (75.2-288.8) 
Esophagus            Pancreas     
Male 1 5.4 nc (nc-nc)   Male 2 8.1 nc (nc-nc) 
Female 3 1.4 nc (nc-nc)   Female 9 7.5 120.2 (54.9-228.2) 
Hodgkin Lymphoma            Prostate     
Male 2 1.2 nc (nc-nc)   Male 45 65.8 68.4 (49.9-91.6) 
Female 0 0.9 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 9 11.9 75.3 (34.4-143.0)   Male 3 5.1 nc (nc-nc) 
Female 4 5.9 nc (nc-nc)   Female 3 2.9 nc (nc-nc) 
Larynx            Testis     
Male 4 3.1 nc (nc-nc)   Male 1 1.8 nc (nc-nc) 
Female 0 0.8 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 8.3 nc (nc-nc)   Male 5 4.7 106.2 (34.2-247.9) 
Female 6 5.6 107.8 (39.4-234.7)   Female 10 12.6 79.3 (38.0-145.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 7.4 80.8 (29.5-175.9)             
Female 2 2.2 nc (nc-nc)   Female 10 16.4 61.1 (29.3-112.4) 
Lung and Bronchus            All Sites / Types     
Male 26 38.4 67.8 (44.3-99.3)   Male 204 271.5 75.1 (65.2-86.2) 
Female 27 35.2 76.7 (50.5-111.6)   Female 238 251.6 94.6 (82.9-107.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
348 
Williamsburg 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 3.4 nc (nc-nc)   Male 1 2.2 nc (nc-nc) 
Female 0 1.3 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 0.6 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.1 nc (nc-nc)   Male 1 1.9 nc (nc-nc) 
Female 19 14.4 132.2 (79.5-206.4)   Female 1 1.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 1 1.7 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 0.8 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 2 3.5 nc (nc-nc)             
Female 3 3.6 nc (nc-nc)   Female 3 1.3 nc (nc-nc) 
Esophagus            Pancreas     
Male 2 0.9 nc (nc-nc)   Male 1 1.3 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 1.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.2 nc (nc-nc)   Male 5 11.3 44.3 (14.3-103.4) 
Female 0 0.2 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 4 2.0 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 2 1.1 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Larynx            Testis     
Male 1 0.5 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 1.3 nc (nc-nc)   Male 0 0.8 nc (nc-nc) 
Female 1 1.0 nc (nc-nc)   Female 2 2.3 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 1.3 nc (nc-nc)             
Female 0 0.4 nc (nc-nc)   Female 5 3.5 144.1 (46.4-336.2) 
Lung and Bronchus            All Sites / Types     
Male 4 6.3 nc (nc-nc)   Male 28 44.3 63.2 (42.0-91.3) 
Female 3 6.7 nc (nc-nc)   Female 45 47.4 94.9 (69.2-127.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
349 
Williamstown 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 9 9.9 91.3 (41.7-173.3)   Male 7 5.6 125.1 (50.1-257.7) 
Female 3 3.8 nc (nc-nc)   Female 2 4.3 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 1.5 nc (nc-nc)   Male 1 1.8 nc (nc-nc) 
Female 2 1.6 nc (nc-nc)   Female 1 1.7 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.3 nc (nc-nc)   Male 7 5.0 139.8 (56.0-288.1) 
Female 21 33.7 62.4 (38.6-95.4)   Female 3 4.8 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 2 3.7 nc (nc-nc) 
Female 0 0.9 nc (nc-nc)   Female 1 2.1 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 9.3 64.8 (23.7-141.1)             
Female 6 10.5 56.9 (20.8-123.9)   Female 2 3.1 nc (nc-nc) 
Esophagus            Pancreas     
Male 3 2.2 nc (nc-nc)   Male 3 3.4 nc (nc-nc) 
Female 1 0.7 nc (nc-nc)   Female 3 4.1 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.5 nc (nc-nc)   Male 21 25.1 83.8 (51.8-128.1) 
Female 0 0.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 6 4.5 131.9 (48.2-287.2)   Male 3 2.1 nc (nc-nc) 
Female 2 2.9 nc (nc-nc)   Female 0 1.5 nc (nc-nc) 
Larynx            Testis     
Male 1 1.2 nc (nc-nc)   Male 0 0.6 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)             
Leukemia            Thyroid     
Male 0 3.7 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 2 2.9 nc (nc-nc)   Female 3 4.9 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 1 3.0 nc (nc-nc)             
Female 3 1.2 nc (nc-nc)   Female 4 7.8 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 5 16.2 30.8 (9.9-72.0)   Male 83 111.0 74.8 (59.6-92.7) 
Female 16 18.8 85.1 (48.6-138.1)   Female 83 123.8 67.1 (53.4-83.1) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
350 
Wilmington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 24 23.9 100.5 (64.4-149.5)   Male 12 15.4 77.8 (40.2-136.0) 
Female 6 8.6 70.0 (25.6-152.3)   Female 12 12.6 95.4 (49.2-166.6) 
Brain and Other Nervous System            Multiple Myeloma     
Male 5 4.6 107.9 (34.8-251.8)   Male 4 4.9 nc (nc-nc) 
Female 5 4.1 122.9 (39.6-286.7)   Female 4 4.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.8 nc (nc-nc)   Male 10 13.8 72.5 (34.7-133.4) 
Female 121 101.9 118.7 (98.5-141.9)   Female 17 12.1 140.1 (81.6-224.3) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 12 11.6 103.5 (53.4-180.8) 
Female 3 3.4 nc (nc-nc)   Female 4 5.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 23 25.6 89.7 (56.8-134.6)             
Female 29 25.3 114.6 (76.8-164.7)   Female 6 8.7 69.1 (25.2-150.3) 
Esophagus            Pancreas     
Male 3 6.0 nc (nc-nc)   Male 8 8.9 89.9 (38.7-177.1) 
Female 0 1.7 nc (nc-nc)   Female 7 9.0 77.9 (31.2-160.6) 
Hodgkin Lymphoma            Prostate     
Male 4 1.8 nc (nc-nc)   Male 48 72.8 66.0 (48.6-87.4) 
Female 2 1.5 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 20 14.1 141.9 (86.7-219.2)   Male 2 5.6 nc (nc-nc) 
Female 5 8.0 62.8 (20.2-146.6)   Female 5 3.5 140.9 (45.4-328.8) 
Larynx            Testis     
Male 3 3.5 nc (nc-nc)   Male 2 3.4 nc (nc-nc) 
Female 0 1.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 14 9.8 143.3 (78.3-240.4)   Male 8 6.4 124.4 (53.6-245.1) 
Female 5 7.1 70.0 (22.5-163.3)   Female 14 19.4 72.3 (39.5-121.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 8.5 82.5 (33.0-169.9)             
Female 2 2.9 nc (nc-nc)   Female 20 23.0 86.9 (53.1-134.3) 
Lung and Bronchus            All Sites / Types     
Male 43 41.1 104.6 (75.7-140.9)   Male 270 307.1 87.9 (77.7-99.1) 
Female 45 44.8 100.5 (73.3-134.5)   Female 340 334.5 101.6 (91.1-113.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
351 
Winchendon 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 9 11.9 75.6 (34.5-143.5)   Male 1 7.7 nc (nc-nc) 
Female 3 3.8 nc (nc-nc)   Female 3 5.7 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 1 2.3 nc (nc-nc)   Male 3 2.4 nc (nc-nc) 
Female 1 1.8 nc (nc-nc)   Female 1 1.8 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 5 6.8 73.9 (23.8-172.3) 
Female 35 47.3 74.0 (51.5-102.9)   Female 1 5.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 11 5.7 194.6 (97.0-348.2) 
Female 3 1.5 nc (nc-nc)   Female 0 2.5 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 10 12.6 79.4 (38.0-146.1)             
Female 16 11.1 144.4 (82.5-234.6)   Female 4 4.0 nc (nc-nc) 
Esophagus            Pancreas     
Male 5 3.0 167.3 (53.9-390.5)   Male 9 4.4 204.5 (93.3-388.2) 
Female 1 0.7 nc (nc-nc)   Female 4 3.9 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.9 nc (nc-nc)   Male 19 35.1 54.1 (32.5-84.4) 
Female 0 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 6.9 116.6 (50.2-229.7)   Male 1 2.8 nc (nc-nc) 
Female 8 3.7 217.2 (93.5-428.0)   Female 2 1.5 nc (nc-nc) 
Larynx            Testis     
Male 4 1.8 nc (nc-nc)   Male 2 1.7 nc (nc-nc) 
Female 2 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 4.8 nc (nc-nc)   Male 1 3.1 nc (nc-nc) 
Female 1 3.1 nc (nc-nc)   Female 6 8.7 69.0 (25.2-150.1) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 3 4.2 nc (nc-nc)             
Female 1 1.3 nc (nc-nc)   Female 7 10.8 64.7 (25.9-133.2) 
Lung and Bronchus            All Sites / Types     
Male 16 20.8 76.8 (43.8-124.7)   Male 123 151.2 81.4 (67.6-97.1) 
Female 21 20.9 100.5 (62.2-153.7)   Female 129 152.2 84.7 (70.7-100.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
352 
Winchester 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 20 24.8 80.7 (49.3-124.6)   Male 16 16.0 100.0 (57.1-162.3) 
Female 8 9.3 86.0 (37.0-169.4)   Female 13 13.0 100.1 (53.3-171.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 6 4.6 129.8 (47.4-282.5)   Male 6 5.1 117.6 (42.9-256.0) 
Female 4 4.2 nc (nc-nc)   Female 4 4.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.9 nc (nc-nc)   Male 15 14.1 106.2 (59.4-175.2) 
Female 116 106.2 109.3 (90.3-131.1)   Female 14 12.8 109.7 (60.0-184.2) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 7 11.6 60.3 (24.1-124.2) 
Female 2 3.6 nc (nc-nc)   Female 7 5.7 123.4 (49.4-254.2) 
Colon / Rectum            Ovary     
Male 26 26.1 99.7 (65.1-146.1)             
Female 25 27.1 92.4 (59.8-136.4)   Female 9 8.9 101.1 (46.1-192.0) 
Esophagus            Pancreas     
Male 2 6.1 nc (nc-nc)   Male 8 9.2 87.2 (37.5-171.8) 
Female 0 1.8 nc (nc-nc)   Female 9 9.8 91.4 (41.7-173.5) 
Hodgkin Lymphoma            Prostate     
Male 0 1.6 nc (nc-nc)   Male 73 71.3 102.4 (80.2-128.7) 
Female 0 1.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 9 14.4 62.7 (28.6-119.0)   Male 4 5.8 nc (nc-nc) 
Female 16 8.4 191.4 (109.3-310.8)   Female 2 3.8 nc (nc-nc) 
Larynx            Testis     
Male 0 3.6 nc (nc-nc)   Male 0 3.1 nc (nc-nc) 
Female 0 1.2 nc (nc-nc)             
Leukemia            Thyroid     
Male 16 10.0 160.5 (91.7-260.6)   Male 7 6.4 108.6 (43.5-223.8) 
Female 8 7.6 105.3 (45.3-207.5)   Female 20 19.5 102.4 (62.5-158.2) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 6 8.5 70.9 (25.9-154.4)             
Female 2 3.0 nc (nc-nc)   Female 26 23.2 111.8 (73.0-163.9) 
Lung and Bronchus            All Sites / Types     
Male 25 43.4 57.5 (37.2-84.9)   Male 277 311.8 88.8 (78.7-99.9) 
Female 38 48.5 78.3 (55.4-107.5)   Female 356 351.6 101.2 (91.0-112.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
353 
Windsor 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 0 1.3 nc (nc-nc)   Male 0 0.9 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 0 0.5 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 3 0.2 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.0 nc (nc-nc)   Male 1 0.8 nc (nc-nc) 
Female 5 4.5 111.6 (36.0-260.3)   Female 0 0.5 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 6 1.4 414.9 (151.5-903.1)             
Female 2 0.9 nc (nc-nc)   Female 1 0.4 nc (nc-nc) 
Esophagus            Pancreas     
Male 0 0.4 nc (nc-nc)   Male 1 0.5 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.3 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 0 4.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 0 0.8 nc (nc-nc)   Male 1 0.3 nc (nc-nc) 
Female 1 0.3 nc (nc-nc)   Female 0 0.1 nc (nc-nc) 
Larynx            Testis     
Male 0 0.2 nc (nc-nc)   Male 0 0.1 nc (nc-nc) 
Female 0 0.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 1 0.5 nc (nc-nc)   Male 0 0.3 nc (nc-nc) 
Female 0 0.3 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 0 0.5 nc (nc-nc)             
Female 0 0.1 nc (nc-nc)   Female 2 1.1 nc (nc-nc) 
Lung and Bronchus            All Sites / Types     
Male 1 2.4 nc (nc-nc)   Male 15 18.0 83.3 (46.6-137.4) 
Female 3 1.8 nc (nc-nc)   Female 19 13.7 138.3 (83.2-216.0) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
354 
Winthrop 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 19 22.4 84.9 (51.1-132.6)   Male 25 14.2 176.0 (113.9-259.9) 
Female 10 7.6 130.9 (62.7-240.8)   Female 24 10.8 223.2 (143.0-332.2) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 4.1 nc (nc-nc)   Male 7 4.6 151.0 (60.5-311.2) 
Female 3 3.5 nc (nc-nc)   Female 3 3.6 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.8 nc (nc-nc)   Male 9 12.5 71.9 (32.8-136.4) 
Female 84 88.1 95.4 (76.1-118.1)   Female 6 10.6 56.5 (20.6-123.0) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 6 10.5 57.1 (20.8-124.2) 
Female 2 2.8 nc (nc-nc)   Female 5 4.7 106.2 (34.2-247.9) 
Colon / Rectum            Ovary     
Male 29 22.7 127.9 (85.6-183.7)             
Female 26 21.6 120.3 (78.5-176.2)   Female 5 7.6 66.2 (21.3-154.5) 
Esophagus            Pancreas     
Male 9 5.7 157.3 (71.8-298.7)   Male 16 8.3 193.1 (110.3-313.7) 
Female 1 1.5 nc (nc-nc)   Female 5 7.8 63.8 (20.6-149.0) 
Hodgkin Lymphoma            Prostate     
Male 0 1.5 nc (nc-nc)   Male 66 69.0 95.7 (74.0-121.7) 
Female 2 1.4 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 20 12.8 156.6 (95.6-241.9)   Male 7 5.2 134.4 (53.8-276.9) 
Female 8 7.0 114.0 (49.1-224.7)   Female 4 3.0 nc (nc-nc) 
Larynx            Testis     
Male 2 3.3 nc (nc-nc)   Male 2 2.7 nc (nc-nc) 
Female 0 1.0 nc (nc-nc)             
Leukemia            Thyroid     
Male 3 8.8 nc (nc-nc)   Male 9 5.4 167.3 (76.4-317.6) 
Female 9 6.1 146.5 (66.9-278.2)   Female 9 16.2 55.5 (25.3-105.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 7 8.0 87.4 (35.0-180.2)             
Female 2 2.6 nc (nc-nc)   Female 23 20.1 114.3 (72.4-171.5) 
Lung and Bronchus            All Sites / Types     
Male 54 40.1 134.8 (101.3-175.9)   Male 316 284.6 111.0 (99.1-124.0) 
Female 56 41.1 136.1 (102.8-176.8)   Female 307 291.3 105.4 (93.9-117.9) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
355 
Woburn 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 53 43.7 121.4 (90.9-158.8)   Male 31 27.7 111.9 (76.0-158.8) 
Female 23 15.6 147.1 (93.2-220.7)   Female 14 21.4 65.5 (35.8-110.0) 
Brain and Other Nervous System            Multiple Myeloma     
Male 4 8.2 nc (nc-nc)   Male 10 8.7 114.4 (54.8-210.5) 
Female 9 6.9 130.5 (59.5-247.7)   Female 6 7.2 83.4 (30.5-181.5) 
Breast            Non-Hodgkin Lymphoma     
Male 2 1.5 nc (nc-nc)   Male 34 24.5 138.6 (96.0-193.7) 
Female 208 166.2 125.2 (108.7-143.4)   Female 29 21.2 136.9 (91.7-196.7) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 15 19.9 75.3 (42.1-124.3) 
Female 11 5.4 202.8 (101.1-362.9)   Female 6 9.2 65.0 (23.7-141.4) 
Colon / Rectum            Ovary     
Male 56 45.0 124.3 (93.9-161.4)             
Female 53 44.8 118.3 (88.6-154.7)   Female 13 14.6 89.0 (47.3-152.2) 
Esophagus            Pancreas     
Male 11 10.7 103.1 (51.4-184.5)   Male 10 15.9 63.0 (30.2-115.8) 
Female 0 3.0 nc (nc-nc)   Female 15 16.3 91.8 (51.3-151.3) 
Hodgkin Lymphoma            Prostate     
Male 2 3.4 nc (nc-nc)   Male 108 124.6 86.6 (71.1-104.6) 
Female 2 2.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 27 24.3 111.2 (73.3-161.8)   Male 11 10.1 108.9 (54.3-194.9) 
Female 13 13.5 96.2 (51.2-164.5)   Female 7 6.3 110.9 (44.4-228.5) 
Larynx            Testis     
Male 4 6.1 nc (nc-nc)   Male 7 6.7 104.1 (41.7-214.4) 
Female 4 1.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 14 17.6 79.6 (43.5-133.6)   Male 13 11.1 117.0 (62.3-200.2) 
Female 12 12.7 94.3 (48.6-164.7)   Female 38 31.0 122.7 (86.8-168.4) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 18 14.9 121.1 (71.7-191.4)             
Female 2 5.2 nc (nc-nc)   Female 29 37.4 77.4 (51.9-111.2) 
Lung and Bronchus            All Sites / Types     
Male 101 75.2 134.4 (109.4-163.3)   Male 588 544.3 108.0 (99.5-117.1) 
Female 88 80.0 109.9 (88.2-135.4)   Female 634 569.7 111.3 (102.8-120.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
  
  
  
  
  
  
  
356 
Worcester 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 167 163.7 102.0 (87.1-118.7)   Male 73 106.2 68.7 (53.9-86.4) 
Female 60 62.8 95.5 (72.9-123.0)   Female 68 88.8 76.6 (59.5-97.1) 
Brain and Other Nervous System            Multiple Myeloma     
Male 31 33.6 92.2 (62.6-130.8)   Male 29 33.5 86.6 (58.0-124.3) 
Female 22 30.2 72.9 (45.7-110.4)   Female 25 29.0 86.1 (55.7-127.1) 
Breast            Non-Hodgkin Lymphoma     
Male 3 5.7 nc (nc-nc)   Male 96 95.2 100.9 (81.7-123.2) 
Female 634 692.0 91.6 (84.6-99.0)   Female 65 86.2 75.4 (58.2-96.1) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 69 78.3 88.2 (68.6-111.6) 
Female 31 23.2 133.4 (90.6-189.4)   Female 47 38.1 123.2 (90.5-163.9) 
Colon / Rectum            Ovary     
Male 164 174.3 94.1 (80.2-109.6)             
Female 159 181.8 87.4 (74.4-102.1)   Female 52 60.7 85.7 (64.0-112.4) 
Esophagus            Pancreas     
Male 56 40.9 137.1 (103.5-178.0)   Male 66 60.4 109.3 (84.5-139.0) 
Female 16 12.1 132.0 (75.4-214.4)   Female 70 65.8 106.3 (82.9-134.4) 
Hodgkin Lymphoma            Prostate     
Male 13 14.6 88.9 (47.3-152.1)   Male 424 477.3 88.8 (80.6-97.7) 
Female 18 13.1 137.2 (81.2-216.8)             
Kidney & Renal Pelvis            Stomach     
Male 97 94.7 102.5 (83.1-125.0)   Male 39 38.5 101.4 (72.1-138.6) 
Female 66 55.9 118.1 (91.4-150.3)   Female 20 25.5 78.4 (47.9-121.1) 
Larynx            Testis     
Male 22 23.6 93.3 (58.5-141.3)   Male 22 28.3 77.7 (48.7-117.7) 
Female 12 7.7 156.2 (80.6-272.8)             
Leukemia            Thyroid     
Male 70 69.3 101.0 (78.7-127.6)   Male 43 45.0 95.5 (69.1-128.7) 
Female 57 52.9 107.7 (81.5-139.5)   Female 136 135.2 100.6 (84.4-118.9) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 75 57.6 130.2 (102.4-163.2)             
Female 27 20.8 129.6 (85.4-188.5)   Female 176 154.3 114.0 (97.8-132.2) 
Lung and Bronchus            All Sites / Types     
Male 329 280.3 117.4 (105.0-130.8)   Male 2052 2092.8 98.0 (93.9-102.4) 
Female 347 325.0 106.8 (95.8-118.6)   Female 2313 2353.6 98.3 (94.3-102.4) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Worthington 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 1 2.0 nc (nc-nc)   Male 0 1.2 nc (nc-nc) 
Female 2 0.5 nc (nc-nc)   Female 1 0.8 nc (nc-nc) 
Brain and Other Nervous System            Multiple Myeloma     
Male 2 0.3 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.3 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 1 0.1 nc (nc-nc)   Male 3 1.1 nc (nc-nc) 
Female 8 6.6 121.3 (52.2-238.9)   Female 1 0.7 nc (nc-nc) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 0 0.9 nc (nc-nc) 
Female 0 0.2 nc (nc-nc)   Female 0 0.4 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 1 2.0 nc (nc-nc)             
Female 1 1.5 nc (nc-nc)   Female 0 0.6 nc (nc-nc) 
Esophagus            Pancreas     
Male 1 0.5 nc (nc-nc)   Male 0 0.7 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)   Female 1 0.5 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 0 0.1 nc (nc-nc)   Male 1 6.0 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 1 1.1 nc (nc-nc)   Male 0 0.5 nc (nc-nc) 
Female 1 0.5 nc (nc-nc)   Female 0 0.2 nc (nc-nc) 
Larynx            Testis     
Male 0 0.3 nc (nc-nc)   Male 0 0.2 nc (nc-nc) 
Female 0 0.1 nc (nc-nc)             
Leukemia            Thyroid     
Male 2 0.7 nc (nc-nc)   Male 0 0.4 nc (nc-nc) 
Female 0 0.4 nc (nc-nc)   Female 0 1.1 nc (nc-nc) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 2 0.7 nc (nc-nc)             
Female 0 0.2 nc (nc-nc)   Female 6 1.6 371.8 (135.8-809.3) 
Lung and Bronchus            All Sites / Types     
Male 7 3.4 208.2 (83.4-429.1)   Male 23 24.4 94.1 (59.6-141.2) 
Female 0 2.8 nc (nc-nc)   Female 23 21.1 109.1 (69.1-163.6) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Wrentham 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 12 10.3 116.2 (60.0-202.9)   Male 9 7.2 124.4 (56.8-236.1) 
Female 3 4.5 nc (nc-nc)   Female 11 6.4 173.2 (86.3-309.8) 
Brain and Other Nervous System            Multiple Myeloma     
Male 0 2.3 nc (nc-nc)   Male 0 2.3 nc (nc-nc) 
Female 2 2.0 nc (nc-nc)   Female 2 2.1 nc (nc-nc) 
Breast            Non-Hodgkin Lymphoma     
Male 0 0.4 nc (nc-nc)   Male 13 6.4 203.8 (108.4-348.6) 
Female 62 51.5 120.4 (92.3-154.4)   Female 6 6.3 95.8 (35.0-208.6) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 4 5.9 nc (nc-nc) 
Female 2 1.7 nc (nc-nc)   Female 4 2.7 nc (nc-nc) 
Colon / Rectum            Ovary     
Male 18 12.1 148.6 (88.1-234.9)             
Female 13 13.3 98.1 (52.2-167.8)   Female 9 4.4 204.4 (93.3-388.0) 
Esophagus            Pancreas     
Male 4 2.8 nc (nc-nc)   Male 7 4.1 172.2 (69.0-354.9) 
Female 0 0.8 nc (nc-nc)   Female 3 4.6 nc (nc-nc) 
Hodgkin Lymphoma            Prostate     
Male 1 0.8 nc (nc-nc)   Male 56 34.7 161.5 (122.0-209.8) 
Female 0 0.7 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 8 6.9 115.6 (49.8-227.7)   Male 2 2.6 nc (nc-nc) 
Female 5 4.0 123.6 (39.8-288.4)   Female 2 1.9 nc (nc-nc) 
Larynx            Testis     
Male 0 1.7 nc (nc-nc)   Male 1 1.6 nc (nc-nc) 
Female 0 0.5 nc (nc-nc)             
Leukemia            Thyroid     
Male 4 4.5 nc (nc-nc)   Male 8 3.2 246.8 (106.3-486.3) 
Female 3 3.7 nc (nc-nc)   Female 9 9.5 94.7 (43.2-179.8) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 4 4.3 nc (nc-nc)             
Female 2 1.5 nc (nc-nc)   Female 6 11.2 53.4 (19.5-116.2) 
Lung and Bronchus            All Sites / Types     
Male 17 18.6 91.6 (53.3-146.6)   Male 184 143.5 128.2 (110.3-148.1) 
Female 15 22.9 65.5 (36.6-108.1)   Female 170 169.8 100.1 (85.6-116.3) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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Yarmouth 
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2011-2015 
  Obs Exp SIR 95% CI     Obs Exp SIR 95% CI 
Bladder, Urinary            Melanoma of Skin     
Male 50 47.0 106.5 (79.0-140.4)   Male 52 26.1 199.0 (148.6-261.0) 
Female 22 17.4 126.1 (79.0-190.9)   Female 43 19.2 224.5 (162.4-302.4) 
Brain and Other Nervous System            Multiple Myeloma     
Male 7 6.3 111.1 (44.5-228.8)   Male 9 8.5 105.7 (48.2-200.7) 
Female 6 6.1 98.3 (35.9-213.9)   Female 6 7.6 78.7 (28.7-171.2) 
Breast            Non-Hodgkin Lymphoma     
Male 1 1.5 nc (nc-nc)   Male 21 23.1 90.9 (56.3-139.0) 
Female 181 154.6 117.1 (100.6-135.4)   Female 24 21.6 111.2 (71.2-165.5) 
Cervix Uteri            Oral Cavity & Pharynx     
            Male 15 16.1 93.0 (52.0-153.5) 
Female 1 4.1 nc (nc-nc)   Female 17 9.1 186.2 (108.4-298.1) 
Colon / Rectum            Ovary     
Male 37 43.3 85.4 (60.1-117.7)             
Female 39 46.5 83.9 (59.7-114.7)   Female 9 13.7 65.5 (29.9-124.4) 
Esophagus            Pancreas     
Male 19 10.1 188.5 (113.4-294.4)   Male 19 15.8 120.0 (72.2-187.5) 
Female 8 3.3 243.3 (104.8-479.4)   Female 22 18.3 120.2 (75.3-182.0) 
Hodgkin Lymphoma            Prostate     
Male 3 2.0 nc (nc-nc)   Male 137 107.0 128.0 (107.5-151.4) 
Female 3 1.8 nc (nc-nc)             
Kidney & Renal Pelvis            Stomach     
Male 17 20.3 83.6 (48.7-133.9)   Male 6 10.0 59.8 (21.8-130.2) 
Female 11 13.3 82.4 (41.1-147.5)   Female 6 6.6 91.3 (33.4-198.8) 
Larynx            Testis     
Male 3 5.6 nc (nc-nc)   Male 2 3.1 nc (nc-nc) 
Female 2 1.9 nc (nc-nc)             
Leukemia            Thyroid     
Male 32 16.3 196.4 (134.3-277.3)   Male 8 7.4 108.0 (46.5-212.8) 
Female 22 12.6 175.0 (109.6-264.9)   Female 12 21.4 56.0 (28.9-97.7) 
Liver and Intrahepatic Bile Ducts            Uteri Corpus and Uterus, NOS     
Male 21 13.0 161.8 (100.1-247.4)             
Female 9 5.3 169.7 (77.4-322.1)   Female 28 35.5 78.8 (52.4-114.0) 
Lung and Bronchus            All Sites / Types     
Male 73 76.1 95.9 (75.2-120.6)   Male 573 503.7 113.8 (104.6-123.5) 
Female 98 89.2 109.9 (89.2-133.9)   Female 623 558.3 111.6 (103.0-120.7) 
  
          Obs = observed case count; Exp = expected case count; 
          SIR = standardized incidence ratio ( (Obs / Exp) X 100); 
          95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR; 
          Shading indicates the statistical significance of the SIR at 95% level of probability; 
          nc = The SIR and 95% CI were not calculated when Obs < 5; 
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